

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients versus risk of antimicrobial resistance (the ACT-TB Study)

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033999
Article Type:	Protocol
Date Submitted by the Author:	01-Sep-2019
Complete List of Authors:	Divala, Titus; London School of Hygiene and Tropical Medicine, TB Centre; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Fielding, Katherine; London School of Hygiene & Tropical Medicine, TB Centre; University of the Witwatersrand, School of Public Health Sloan, Derek; University of Saint Andrews, School of Medicine French, Neil; University of Liverpool Faculty of Health and Life Sciences, Centre for Global Vaccine Research, Institute of Infection and Global Health Nliwasa, Marriott; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; London School of Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme Kandulu, Chikondi; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Chiume, Lingstone ; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Chilanga, Sanderson ; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Ndaferankhande, Masiye; Malawi Liverpool Wellcome Trust Clinical Research Programme Corbett, Elizabeth ; London School of Hygiene and Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme
Keywords:	trial-of-antibiotics, Tuberculosis < INFECTIOUS DISEASES, TB, antimicrobial resistance, diagnostic performance, antibiotics

1	
3	SCHOLARONE™
5	Manuscripts
7	
9	
11	
12 13	
14 15	
16 17	
18 19	
20	
22	
23	
25 26	
27 28	
29 30	
31 32	
33 34	
35 36	
37 38	
39 40	
41	
43	
44 45	
46 47	
48 49	
50 51	
52 53	
54 55	
56 57	
58 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

TITLE

- spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients
- versus risk of antimicrobial resistance (the ACT-TB Study)

Authors

- Titus H Divala^{1,2,3}, Katherine L Fielding^{1,4}, Derek J Sloan⁵, Neil French⁶, Marriott Nliwasa^{1,2,3},
- Peter MacPherson^{3,7}, Chikondi Kandulu^{2,3}, Lingstone Chiume^{2,3}, Sanderson Chilanga^{2,3},
- Masiye Ndaferankhande³, Elizabeth L Corbett^{1,2,3}

24		
25	9	Author affiliations
26 27	10	1. TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street,
28 29	11	Bloomsbury, London, United Kingdom
30	12	2. Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
31 32	13	Blantyre, Malawi
33 34	14	3. Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
35	15	4. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
36 37	16	5. School of Medicine, University of St Andrews (Derek J Sloan PhD)
38	17	6. Institute of Infection & Global Health, University of Liverpool, Liverpool, United
39 40	18	Kingdom
41	19	7. Liverpool School of Tropical Medicine, Liverpool, United Kingdom
42 43	20	
44 45	21	Correspondence to:
46	22	Dr Titus H Divala
47 48	23	TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury,
49	24	London WC1E 7HT
50 51	25	titus.divala@lshtm.ac.uk
52	26	
53 54	27	KEY WORDS
55 56	28	trial-of-antibiotics, tuberculosis, TB, antimicrobial resistance, AMR, antibiotics, diagnostic
57	29	performance, sensitivity, specificity, randomised controlled clinical trial, randomised, RCT
58 59	30	

Protocol version 3.0, 19 Feb 2019

Page 1 of 29

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

32 ABSTRACT:

33 Introduction

Over 40% of global tuberculosis(TB) case notifications are diagnosed clinically without mycobacteriological confirmation. Standard diagnostic algorithms include "trial-of-antibiotics" -empirical antibiotic treatment given to mycobacteriology-negative individuals to treat infectious causes of symptoms other than tuberculosis, as a "rule-out" diagnostic test for TB. Potentially 26.5 million such antibiotic courses/year are prescribed globally for the 5.3 million/year mycobacteriology-negative patients, making trial-of-antibiotics the most common TB diagnostic, and a global-scale risk for antimicrobial resistance(AMR). Our systematic review found no randomised controlled trial(RCT) to support use of trial-of-antibiotic. The RCT aims to determine the diagnostic and clinical value and AMR consequences of trial-of-antibiotics.

44 Methods and analysis

A three-arm, open-label, RCT randomising(1:1:1) Malawian adults(≥18years) seeking primary care for cough into: a)azithromycin 500mg once daily for 3 days, or b)amoxicillin 1g three times/day for 5 days, or c)standard-of-care(no immediate antibiotic). We will perform Mycobacteriology tests(microscopy, Xpert/MTB/RIF and Mycobacterium-Tuberculosis culture) at baseline. We will use Audio-Computer-Assisted-Self-Interview(ACASI) to assess clinical improvement at day eight. First primary outcome will be proportion of patients reporting day-eight improvement out of those with negative mycobacteriology(specificity). Second primary outcome will be day 29 incidence of a composite endpoint of either death or; hospitalisation or: missed tuberculosis diagnosis or: HIV or tuberculosis treatment non-adherence by day 29. To determine AMR impact we compare incidence of resistant nasopharyngeal Streptococcus pneumoniae isolates on day 29. 400 mycobacteriology-negative participants/arm will be required to detect a $\geq 10\%$ absolute difference in diagnostic

3 4	57
5 6	58
7 8 9	59
10	
11 12	60
13 14 15	61
15 16 17	62
17 18 19	63
20 21 22 23	64
24 25 26	65
27 28 29	66
30 31 32	67
33 34	68
35 36	69
37 38	70
39 40 41	71
41 42 43	72
44 45	73
46 47	74
48 49	75
50 51	76
52 53	77
54 55	78
56 57	
58 50	
59 60	

57 specificity with 80% power. We will estimate measures of effect by comparing outcomes in58 antibiotic arms(combined and individually) to standard-of-care.

59 Ethics and dissemination

60 The study has been reviewed and approved by Malawi College of Medicine Research and

61 Ethics Committee, London School of Hygiene & Tropical Medicine Research Ethics

62 Committee, and Regional Committee for Health and Research Ethics –Norway, and Malawi

63 Pharmacy, Medicines, and Poisons Board.

64 **Registration**

65 Clinicaltrials.gov, NCT03545373

66 Strengths and limitations

- To our knowledge this is the first randomised controlled trial to address benefits and consequences of using antibiotics as an exclusion diagnostic for tuberculosis, a widely used practice that results in millions of antibiotic prescriptions/year.
 - We will also contribute evidence on AMR affecting common antimicrobials used for managing respiratory infections.
 - The use of ACASI for assessing clinical response and adherence to antibiotic treatment which can be used in future studies.
 - Acknowledged weakness include limited power to evaluate safety of deferred antibiotic treatment; conduct subgroup analysis by HIV status; and the possibility that participants randomised to the standard-of-care arm may find alternative access to antibiotics therefore misclassifying exposure/intervention status.

80 INTRODUCTION

The high case-fatality rate for tuberculosis, the leading global infectious cause of death in adults¹ with approximately 10 million cases and 1.6 million deaths in 2017,² in part reflects suboptimal diagnostics.³⁻⁶ To complement diagnostic gap, standard algorithms throughout the world include a "trial-of-antibiotics" (Figure 1). This is a course of broad-spectrum antibiotics, with negligible Mycobacterium tuberculosis activity, given to patients with symptoms such as cough in order to "rule-out" or "rule in" tuberculosis.7-9 In clinical practice and most national guidelines (summarised in figure 1), patients with negative sputum mycobacteriology and who have responded to antibiotic treatment are considered tuberculosis negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations leading on to receiving tuberculosis treatment.7-

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the
need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of

96 tuberculosis in low and middle income countries (based on the WHO GLI model guidelines

97 and as implemented in national guidelines from Ghana, Malawi and South Africa.)

98 We estimate that 26.5 million courses of antibiotics are prescribed in the diagnosis of the 5.3

99 million smear negative tuberculosis registrations recorded annually,¹⁰ making antibiotics the

100 most common diagnostic for tuberculosis.¹¹ The 26.5 million is based on the common

56 101 approach where for every one smear-negative TB case detected, five antibiotics courses are

102 used: the first two courses of antibiotics are those given to patients who end up being

⁶⁰ 103 registered as smear-negative tuberculosis, and the other three courses account for patients

Page 5 of 29

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

whose symptoms resolved and tuberculosis was ruled out.⁴ ¹² This frequency of prescription
of important broad-spectrum antibiotics raises a global-scale risk for antimicrobial resistance
(AMR) which like tuberculosis, is a major crisis, becoming in 2016 one of only four health
topics ever to be discussed at the United Nations General Assembly.¹³⁻¹⁶

We performed a systematic literature review¹⁷ which demonstrated that, despite being in

global and national guidelines for decades, trial-of-antibiotics has limited supporting evidence base with available evidence suggesting there poor diagnostic performance.¹⁸ None of the identified studies was an RCT and most of the observational studies were very small and not primarily designed to assess the benefits and consequences of trial-of-antibiotics. Pooled sensitivity and specificity of trial-of-antibiotics versus mycobacteriology tests were below internationally defined minimum performance profiles for TB diagnostics. To address the evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes of trial-of-antibiotics, we will conduct an RCT (ACT-TB Study) recruiting adult patients with cough presenting to health centres in Blantyre, Malawi. To our knowledge this is the first randomised controlled trial to rigorously address these questions.

121 Study design

METHODS AND ANALYSIS

This is a three-arm individually randomised (1:1:1), open-label controlled clinical trial (RCT) investigating accuracy and broader clinical, and antimicrobial resistance impact of using trialof-antibiotics to rule-out tuberculosis among adults presenting with cough at primary care centres in Malawi (Figure 2). The trial is registered with Clinicaltrials.gov (NCT03545373).

Page 6 of 29

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



127 Study setting

We will screen adults aged at least 18 years presenting to Limbe and Ndirande health
centres in Blantyre, Malawi. Blantyre has an estimated tuberculosis prevalence of 1,014 per
100,000 (95% CI: 486 to 1,542), and an estimated adult HIV prevalence of 12.7% (95% CI:
11.9 to 13.6).¹⁹

132 Eligibility criteria

133 We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

134 Inclusion Criteria

- 135 Ambulatory clinic attendees presenting with cough
- Unwell for at least 14 days
- 137 Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the
 entire study period.

6 140 **Exclusion Criteria**

- Self-reported allergy to study medications
- WHO/Malawi National tuberculosis Program (NTP) danger signs: respiratory rate >
 - 143 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory
 - 144 distress, systolic blood pressure <90 mmHg, inability to walk unassisted
 - Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
 - Tuberculosis treatment or isoniazid preventive therapy within the last 6 months

148 Interventions

149 We will randomise participants, in a ratio of 1:1:1, to the following arms:

Page 8 of 29

1 2		
3 4	150	• Arm 1 (Azithromycin): Azithromycin 500mg taken once daily for 3 days from
5 6	151	enrolment day
7 8	152	• Arm 2 (Amoxicillin): Amoxicillin 500 mg taken once daily for 5 days from enrolment
9 10	153	day.
11 12 13	154	• Arm 3 (Standard of care): No study antibiotic prescription.
14 15	155	Concomitant medication and interaction with other therapies
10 17 18	156	We do not have any restrictions with respect to concomitant medications apart from those
19 20	157	listed in the exclusion criteria.
21 22 23	158	Trial restrictions
24 25	159	We do not require participants to have any dietary restrictions. We will also accept co-
26 27	160	administration with contraception. Our trial interventions can safely be used in pregnancy, so
28 29 30	161	we will include pregnant women should they be eligible.
31 32	162	Assessment of compliance
33 34 35	163	On Day-8, we will document self-reported compliance adherence of study products.
36 37 38	164	Withdraw of interventions
39 40	165	The investigator may also terminate a participant from study product if indicated by an
41 42	166	adverse reaction. If a participant stops taking study product either voluntarily or by
43 44	167	investigator decision, they will be encouraged to remain in follow up and their data will form
45 46 47	168	part of intention to treat analyses.
48 49	169	Timing of interventions
50 51	170	The standard of care in national guidelines for primary care patients presenting with cough
52 53	171	and are otherwise well (no danger signs) is to take sputum x 2 for smear microscopy or
55 56	172	Xpert and ask them to return for results, typically 3 days - 1 week later (Figure 1). The
57 58	173	Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as
59 60	174	trial-of-antibiotics after negative sputum tests are provided to the patient, if they remain

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

> symptomatic. Therefore, the ideal population for randomisation for this study are patients on who already have negative results for smear microscopy or Xpert. However, that may have ethical challenges considering the implications of withholding antibiotics from a symptomatic patient who may benefit from them. The first visit therefore was the most ideal time for randomisation and is in line with recommendations for test interval in investigations evaluating diagnostic tests with respect to the time interval between the index test (trial of antibiotics) and the reference test (mycobacteriology sputum sample collection). The timing also conforms to common clinical practice of prescribing trial-of-antibiotics at the same time as sputum collection to reduce diagnostic delay. The design was discussed with the District Health Office and the national TB program ahead of ethics submission.

186 Study outcomes

187 The following are descriptions of study outcomes:

Primary outcome 1: Specificity of trial-of-antibiotics versus mycobacteriology

This will be specificity of trial-of-antibiotics (the index test) in each arm against mycobacteriology tests (reference test) defined as: proportion of participants classified as tuberculosis negative (defined by self-reported day 8 improvement status of baseline symptoms) out of all who tested tuberculosis negative by mycobacteriology reference standard (smear microscopy, Xpert/MTB/RIF, or MTB culture). The mycobacteriology reference standard will be defined in participants with at least one specimen with a valid result on days 1 and 8 as tuberculosis-positive if there is at least one positive of smear microscopy, Xpert/MTB/RIF, or MTB culture; and as tuberculosis-negative if none of the tests are positive. To minimise bias, the mycobacteriology will be performed by a high-quality research laboratory in the University of Malawi College of Medicine by staff with no access to participant treatment allocation information or symptom results.

On day 8, participants will be asked the following question: on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved? Clinical improvement status will then be defined based on responses as tuberculosis-positive if participants report no change or worsening of illness; and as tuberculosis-negative if they report improvement. To minimise ascertainment bias in evaluation of improvement of baseline symptoms the interview will be conducted using Audio Computer Assisted Self-Interview (ACASI), a platform that allows patients to report their health state directly into a database via an audio questionnaire administered by a tablet device. We developed, piloted, and optimised the ACASI guestionnaire in the study target population. Before proceeding to the self-interview, participants will be oriented using test questions until study staff are sure that they will be able to go through the interview on their own.

> **Reference Result:** any tuberculosis positive sputum result from Day-1 and Day-8 visit samples defines pulmonary tuberculosis positive

(smear microscopy, Gene Xpert, or MTB Culture)

		+ve	-ve
ACASI Response Lack of improvement of from the symptoms they had at baseline documented on Day-8 using	+ve (Did not improve)	а	b
ACASI* defines tuberculosis positive	-ve (Improved)	С	d

Primary outcome: specificity, calculated by d / (b+d)

* ACASI: Audio Computer Assisted Self-Interview

Figure 3: Ascertainment of diagnostic value of trial-of-antibiotics

Page 11 of 29

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

213 Primary outcome 2: Clinical impact of trial-of-antibiotics

We will investigate the overall clinical impact of trial-of-antibiotics by comparing the day 29 risk of any of death, hospitalisation, missed tuberculosis diagnosis (untreated mycobacteriological or radiological tuberculosis identified on Day 29), and non-adherence to HIV or tuberculosis treatment (defined using responses to a questionnaire assessing adherence in the four days leading to the study visit). All these events are potential consequences of trial-of-antibiotics, grouping them as a composite endpoint appropriately represents the effect of the intervention because: 1) there are similarities in the importance patients would attach to each of the components, 2) the components occur with similar frequencies in the patient population, and 3) the direction of effect is anticipated to be the same for all.20

BMJ Open

⁷ 224 Secondary outcome 1: impact of trial-of-antibiotics on antimicrobial resistance

We will assess impact of antibiotic exposure on AMR by comparing risk of acquiring resistant isolates of S. pneumonia in the nasopharynx by day 29. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²¹ S. pneumonia is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²² We will exclude those with resistant isolates on both day-1 and day-29 from the numerator, as they may not truly represent incident resistance. In the denominator, we will include all randomised participants and perform analysis as intention to treat.

49 234 Secondary outcome 2: diagnostic value of trial-of-antibiotics

This will be specificity of trial-of-antibiotics (the index test assessed using ACASI) in each
 arm against mycobacteriology tests (reference test) defined as: proportion of participants
 classified as tuberculosis negative (defined by self-reported day 8 improvement status of
 baseline symptoms) out of all who tested tuberculosis negative by mycobacteriology
 reference standard (smear microscopy, Xpert/MTB/RIF, or MTB culture). Unlike in Primary

Page 12 of 29

Page 15 of 59

BMJ Open

outcome 1, the mycobacteriology reference standard will extend to all study participants regardless of sputum sample availability. Participants unable to provide sputum samples, will be classified as mycobacteriologically negative. Microbiology diagnosis of tuberculosis is mainly based on sputum, therefore being unable to produce it, restricts diagnostic access, which effectively implies a negative test. We have opted to analyse this population because it is significant, can be as high as 13% of symptomatic individuals in the study setting.²³

Secondary outcome 3: Economic evaluation

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions. We will perform a within trial comparison of the three treatment arms to estimate the incremental cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health guality of life (HRQoL) measure.^{24 25} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

Exploratory outcomes

Our exploratory analyses will be comparisons between the azithromycin and amoxicillin arms for all our primary and secondary outcomes.

Planned subgroup analyses

We will perform analysis of primary outcomes stratified by HIV status and by ART status as documented on enrolment day. This is important because the study site has high prevalence of HIV and associated bacterial infections which may be amenable to antibiotics used for trial-of-antibiotics.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

266 Study procedures

Figure 2 and Table 1 presents the study time schedule including a summary of patient
identification, baseline procedures and outcome ascertainment at day 8 and day 29 follow up
visits.

270 Screening

Study staff will approach patients with symptoms of pulmonary tuberculosis (including cough
of any duration, fever, weight loss, and night sweats) with information about the study and
seek written informed consent from all patients who meet eligibility criteria. After consenting,
a participant will be given a unique study identification number confirming enrolment.

275 Randomisation and blinding

 $^{7}_{\circ}$ 276 Randomisation will be in the ratio 1:1:1 to the three arms of the trial, using block-

277 randomisation with variable block sizes, and stratified by study site. An independent

278 statistician will prepare the randomisation list using Ralloc command in Stata software, then

 $\frac{1}{4}$ 279 print each allocation alongside a randomisation number, and seal in opaque envelopes.

280 Upon confirming eligibility and consenting status a designated site staff will open the next

available of sequentially numbered randomisation envelopes and administer the allocated

0 282 study arm.

283 Blinding

284 The study will not use blinding to ensure safety of the participants and allow appropriate

- 285 patient management decision-making which may be related to the trial interventions.
- 286 However, all study outcome assessment will occur without reference to study treatment

allocation.

Page 14 of 29

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
3	2
4	
5	2
6 7	
, 8	2
9	,
10	4
11	2
12 13	-
14	2
15	
16	2
17 18	
19	4
20	2
21	
22	
23 24	4
25	2
26	
27	2
28 29	
30	
31	2
32	
33 24	3
35	
36	3
37	
38	,
39 40	3
41	
42	~
43	
44 45	,
45 46	3
47	
48	3
49	
50 51	
52	4
53	
54	3
55	
50 57	
58	
59	

288 **Baseline procedures**

289 At baseline, we will collect demographic data, clinical history, record vital signs, height and 290 weight. Participants will be requested to provide two sputum samples for Xpert/MTB/RIF and 291 two more sputum samples the following morning for smear microscopy and MTb culture. We 292 will also collect a urine sample for lipoarabamannan antigen detection (TB LAM); and a 293 nasopharyngeal swab for pneumococcal culture and sensitivity testing. We will offer and 294 perform HIV testing according to the national algorithm, and link all who test positive to care. 295 To minimise loss to follow up, we will collect contact phone numbers, a physical address and 296 geolocation information.

297 Participant follow up

On day 8, the first activity (ahead of any other interaction with study staff) will be the ACASI. 298 299 Other activities include providing results for day 1 tuberculosis tests and linking those who 300 test positive to care; collection of another sputum sample for smear microscopy and 301 Mycobacterium tuberculosis (MTB) culture; and management of ongoing symptoms and 302 other illnesses. On visit day 29, the final study visit, we will document participant vital status, 303 hospitalisations, and establish adherence to HIV and tuberculosis treatment. We will also 304 collect nasopharyngeal swab samples from all participants, and sputum from those with 305 tuberculosis symptoms.

306 Participant retention

307 To minimise loss to follow up, we will record geolocation information of participants' place of 308 residence using ePAL android app, a high-resolution mapping system validated in Blantyre. 309 We will also record up to 3 contact phone numbers of the participant and their nominated 310 friends and relatives. We will not replace participants who discontinue study participation or 311 study treatment regardless of reason for withdrawal or discontinuation or the time either of 312 these occurs.

Page 15 of 29

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

We will collect data using TeleForm (paper based system that uses optical character
recognition) and Open Data Kit systems (ODK, an electronic data capture system installed
on android devices). Data will be committed to a secure database located at Malawi-
Liverpool Wellcome Trust (MLW) within 2 days for TeleForm, and 7 days for ODK.

Page 16 of 29

3
4
5
6
7
, Q
0
9
10
11
12
13
14
15
16
17
18
19
20
21
22
22
20
∠4 2⊑
25
26
27
28
29
30
31
32
33
34
35
36
37
20
20
39
40
41
42
43
44
45
46
47
48
49
50
51
52
52
52
54
55
56
57
58
59
60

320

321

319 **Table 1:** key study procedures over the study period

ent Da	Fo	ollow up Day-29
	y-8	Day-29
~ ,		
~ ,		
× >		
~ >		
	x	x
>	ĸ	x
· · · · · · · · · · · · · · · · · · ·	ĸ	
,	ĸ	
		×
		^
	2	
, ,	x 💦	x
, ,	x	5
		×
>	x	x
	nycobacteriology ubmission on Day en clinically indica agnosis (TB LAM ure and sensitivity	X X <td< td=""></td<>

322 Sample size and power

We assume that trial-of-antibiotics (in azithromycin arm or in amoxicillin arm) will correctly classify 60% of mycobacteriology negative participants (Table 2).¹² We have determined that 400 mycobacteriologically negative (true negatives) participants per arm will provide 80% power to detect a 10% absolute difference in proportion of participants without tuberculosis (mycobacteriologically negative) correctly classified as negative by trial-of-antibiotics (amoxicillin arm or by azithromycin arm) (60%) versus standard of care arm (50%) (Table 2). To determine the target enrolment that may be required to achieve 400 mycobacteriologically negative participants per arm, we first assume that 80% of participants randomised will have negative mycobacteriology,²³ requiring 500 participants to yield the 400 per arm. Assuming that 15% will not be able to produce sputum, and that 5% will not return for Day-8 visit, the sample size is increased to 625 per arm or 1,875 for the whole study.

Table 2: Power and sample size estimation for primary outcome 1

True negatives	¹ proportion of tuberculosis	² effect size	power
(mycobacteriology tests	negatives correctly classifie	d	
negative participants) b+d	d/(b+d)		
320	0.60	0.10	69%
400	0.60	0.10	80%
480	0.60	0.10	86%
¹ specificity with either azithromycin o	or amoxicillin trial-of-antibiotics arms		
² risk difference (azithromycin arm ve	rsus standard of care arm; OR amoxic	illin arm versus standar	d of care arm;
OR azithromycin arm combined with	amoxicillin arm versus standard of car	re arm)	

For the clinical impact of trial-of-antibiotics outcome, with the sample size of 625 participants/arm, and a type I alpha of 5%, we will be able to detect the difference between intervention and standard of care with 80% power, if the risk in the intervention arm is 6% or lower.

BMJ Open

For the AMR outcome, we assume that 45% of Day-29 nasopharyngeal swabs will successfully grow S. pneumonia, and that 10% of the isolates will have amoxicillin or azithromycin resistance (expert evidence). Therefore, a study population of 625/arm (accounting for 10% loss to follow up to Day 29), would yield 253 isolates per arm of which 25 would exhibit amoxicillin or azithromycin resistance. For the intention to treat population (the randomised 625 participants/arm) in the standard of care arm the 25 cases of resistant isolates translate into 4% (25/625) risk. With 4% risk in the standard of care group, alpha of 0.05, and using Pearson's Chi-squared test we will be able to detect the impact of the intervention with 85% power if it leads to an increase of risk of resistant isolates from 4% to Pee. 8% (RR of 2).

Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT (Consolidated Standards of Reporting Trials) flow chart. We will describe the study participants by their baseline characteristics, by arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to), adjusting for study site. We will report measures of effect from the following comparisons:

- azithromycin or amoxicillin (combined) versus standard of care i)
- ii) azithromycin versus standard of care
- amoxicillin versus standard of care iii)

For primary outcome 1, and secondary outcome 2, we will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for study site. For each comparison, we will report 95% confidence intervals (CIs) and p-values from the likelihood test. If the GLM model

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

does not converge, we will use logistic regression to estimate the treatment effect using an
odds ratio. If outcomes are rare, we will use logistic regression to model odds and report
odds ratios, their associated 95% CIs, and p-values.

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College station, Texas, USA). The statistical approach will be expanded in a detailed statistical analysis plan, which will be finalised before unblinding the study data.

371 Monitoring and oversight

The trial will be monitored by the Research Support Centre Clinical Trials Unit of the
University of Malawi College of Medicine. An independent Data and Safety Monitoring Board
(DSMB), and a Trial Steering Committee (TSC) have been set up and meet bi-annually.

375 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant,
and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab
work will continue beyond trial closure. The trial may be terminated early by the trial steering
committee upon recommendation of the DSMB. The halting rule for a trial arm is an
unacceptable high level of deaths assessed using an alpha determined at the first DSMB
meeting.

DISCUSSION

The ACT-TB study will investigate the benefits and consequences of "trial-of-antibiotics," a widely promoted approach to many patients with suspected tuberculosis in low- and middleincome countries without solid evidence base. To our knowledge, ACT-TB Study is the first RCT of this kind. Results of our trial will improve efficiency in the approach for detecting tuberculosis (the leading infectious disease killer: ~1.6 million deaths/ year)² and strengthen

BMJ Open

2 3 4	388	our fight against antimicrobial resistance (soon to be leading cause of death: ~10 million
5 6 7	389	deaths/year by 2050). ²⁶
7 8 9	390	Choice of study interventions
10 11 12 13 14	391	We have chosen amoxicillin because it is the first line treatment for outpatient management
	392	of pneumonia in Malawi and is commonly used for trial-of-antibiotics. It also provides data of
15 16 17	393	immediate programmatic relevance and a starting point to investigate exacerbation of pre-
17 18	394	existing AMR pressure. However, amoxicillin may not demonstrate the full benefits for trial-
20 21	395	of-antibiotics because of organisms with intrinsic ("atypicals") or acquired (common in gram-
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	396	negative organisms, and Staphylococcus aureus) penicillin resistance. ²⁷ Oral antibiotics that
	397	may provide the better diagnostic discrimination for bacterial vs mycobacterial causes of
	398	cough are macrolides, such as azithromycin, because of better intrinsic coverage of
	399	"bacterial causes of pneumonia including "atypical" intracellular organisms such as
	400	mycoplasma species, ²⁸⁻³⁰ and low levels of acquired macrolide-resistance in bacterial
	401	isolates in Malawi. ²⁷
	402	ACASI for post-treatment improvement assessment
	403	Our systematic review ¹⁸ did not identify a consistent definition of tuberculosis or no
	404	tuberculosis based on trial-of-antibiotics. A definition of clinical change following antibiotic
43 44	405	treatment is necessary for the trial-of-antibiotics as it determines who get categorised as well
45 46	406	or tuberculosis positive. Approaches that ranged from self-reported improvement, to a
47 48 49 50	407	combination of clinical and radiological assessments are likely to be highly subjective and
50	408	prone to bias, as well as being a potentially avoidable source of heterogeneity between
50 51 52	408 409	prone to bias, as well as being a potentially avoidable source of heterogeneity between studies. In this study, we hope to address these biases (particularly, inter-observer
50 51 52 53 54 55	408 409 410	prone to bias, as well as being a potentially avoidable source of heterogeneity between studies. In this study, we hope to address these biases (particularly, inter-observer variability, and patient/interviewer reporting or ascertainment biases) by using self-rated
50 51 52 53 54 55 56 57	408 409 410 411	prone to bias, as well as being a potentially avoidable source of heterogeneity between studies. In this study, we hope to address these biases (particularly, inter-observer variability, and patient/interviewer reporting or ascertainment biases) by using self-rated change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI
50 51 52 53 54 55 56 57 58 59 60	408 409 410 411 412	prone to bias, as well as being a potentially avoidable source of heterogeneity between studies. In this study, we hope to address these biases (particularly, inter-observer variability, and patient/interviewer reporting or ascertainment biases) by using self-rated change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI (described under outcomes). The ACASI questionnaire, the delivery platform, and the

Page 24 of 59

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

resulting data management can all be replicated in future studies, creating potential for morestandardisation in assessment of clinical response to treatment.

Potential clinical impact of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high, ^{3 31} and is often secondary to severe bacterial infections.³¹⁻³³ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are Streptococcus pneumoniae and non-typhoidal salmonellae: both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active Mycobacterium tuberculosis disease.³¹⁻³³ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected tuberculosis in people living with HIV, then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to tuberculosis treatment decisions. In this context, azithromycin may be the most effective arm, as salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.27

⁰ 429 AMR and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected
tuberculosis has not been investigated before. Previous work has shown that empirical
antibiotics can drive rapid emergence of antimicrobial resistance.^{34 35} Co-trimoxazole
prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal
resistance in bloodstream infections by 2010³⁶. Mass drug administration of azithromycin for
trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*,
but with increased macrolide-resistance 6 months later.^{37 38}

BMJ Open

In this study we have the opportunity to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²¹ S. pneumonia is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²² As exploratory analyses, we will also assess nasopharygeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

445 Important subgroups

Response to trial-of-antibiotic- in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of tuberculosis diagnosis) may relate to multiple super-infections and so this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and commonly identified in patients with suspected tuberculosis in the pre-ART era.^{4 32} More recently, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started tuberculosis treatment on the basis of positive mycobacteriology.²³ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and by subsequent tuberculosis treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

7 456 **ET**

ETHICS AND DISSEMINATION

457 The study has been reviewed and approved by the University of Malawi College of Medicine
458 Research and Ethics Committee (COMREC), the London School of Hygiene & Tropical
459 Medicine Research Ethics Committee, and Regional Committee for Health and Research
460 Ethics, NTNU-Midt, Norway. Regulatory approval has been granted by the Malawi
461 Pharmacy, Medicines, and Poisons Board (PMPB). We will present any future protocol

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

462 modifications to these bodies before implementing. We will submit results for publication in a

463 peer-reviewed journal. We will submit abstracts to relevant national and international

464 conferences. This study will follow the standards set by CONSORT guidelines.

465 AUTHORS' CONTRIBUTIONS

466 THD, KF and ELC are the main contributors to the study design and conception. All authors 467 carefully reviewed and substantially contributed to the development of the protocol. THD 468 developed the first draft of the manuscript. All authors reviewed and contributed to the 469 manuscript. All authors read and approved the final manuscript. THD is the guarantor for this 470 work.

471 FUNDING AND SPONSORSHIP STATEMENT

The clinical trial is funded by the Commonwealth Scholarship Commission and the Helse Nord RHF grant awarded to THD. This work is part of THD's PhD work at London School of Hygiene & Tropical Medicine (LSHTM). LSHTM is the sponsor of this clinical trial (sponsor address: Keppel Street, Bloomsbury, London WC1E 7HT). ELC is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science: WT200901. The funding agencies and the sponsor had no role in the preparation of the protocol or the intention to submit this manuscript for publication.

- 479 COMPETING INTERESTS STATEMENT
 - 480 We have no conflicts of interest to declare.

PATIENT AND PUBLIC INVOLVEMENT

482 Patients were involved in the design of the study especially the audio-computer-assisted
 483 interview (ACASI) used for collecting primary outcome data. Health workers were involved in
 484 the design of study visits and patient flow.

9 485 **BODY WORD COUNT: 4,034**

REFERENCES

1. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. Infectious disease reports 2016;8(2):6570. doi: 10.4081/idr.2016.6570 2. World Health Organization. Global tuberculosis report 2018: World Health Organization 2018. 3. Nliwasa M, MacPherson P, Mukaka M, et al. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. The international journal of tuberculosis and lung disease 2016;20(2):202-10. doi: 10.5588/ijtld.15.0388 4. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. The Lancet 2007;369(9578):2042-49. doi: 10.1016/S0140-6736(07)60284-0 5. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]. The international journal of tuberculosis and lung disease 2013;17(9):1125-38. 6. Siddigi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. The Lancet infectious diseases 2003;3(5):288-96. 7. Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-infection in Ghana. In: Department DCaP, ed. Accra, 2007. 8. Ministry of Health. Malawi National TB Programme Manual. . In: Programme NT, ed. 8 ed. Lilongwe, 2016. 9. National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, ed. Pretoria, 2014. 10. World Health Organization. Global tuberculosis report 2016. 2016 11. McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. The International Journal of Tuberculosis and Lung Disease 2016;20(4):536-43. 12. Wilkinson D, Newman W, Reid A, et al. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. The International Journal of Tuberculosis and Lung Disease 2000;4(6):513-18. [published Online First: 2000/06/23] 13. Holmes AH, Moore LS, Sundsfiord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet 2016;387(10014):176-87. doi: 10.1016/S0140-6736(15)00473-0 14. World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization 2012.

15. World Health Organization. Antimicrobial resistance: global report on surveillance: World Health Organization 2014. 16. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. The Lancet 2016;387(10014):168-75. doi: 10.1016/S0140-6736(15)00474-2 17. Divala TH, Fielding KL, Nliwasa M, et al. Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Systematic reviews 2018;7(1):141. 18. Divala TH. Nliwasa M. Gupta-Wrigh A. et al. Is the current practice of using response to empirical broad-spectrum antibiotic treatment as an exclusion diagnostic for tuberculosis supported by evidence? Systematic review and meta-analysis. 49th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union): Int J Tuberc Lung Dis, 2018. 19. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence Survey, 45th Union World Conference on Lung Health. Barcelona, Spain, 2014. 20. Montori VM, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials. Bmj 2005;330(7491):594-96. 21. Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol 2017;15(5):259-70. doi: 10.1038/nrmicro.2017.14 22. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 2013;32(1):165-79. doi: 10.1016/j.vaccine.2013.08.062 23. Nliwasa M, MacPherson P, Chisala P, et al. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. PloS one 2016;11(5):e0155101. doi: 10.1371/journal.pone.0155101 [published Online First: 2016/05/14] 24. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health policy (Amsterdam, Netherlands) 1990;16(3):199. 25. Maheswaran H, Petrou S, MacPherson P, et al. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. BMC medicine 2016;14(1):34. 26. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016. HM Government and Welcome Trust: UK 2018 27. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. The Lancet Infectious Diseases 2017;17(10):1042-52. doi: 10.1016/s1473-3099(17)30394-8 28. Lubell Y, Turner P, Ashley EA, et al. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics

1 2 2		
$ \begin{array}{c} 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 9 \\ 20 \\ 21 \\ 23 \\ 24 \\ 25 \\ 27 \\ 28 \\ 9 \\ 30 \\ 31 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 9 \\ 41 \\ 42 \\ 44 \\ 45 \\ 47 \\ 48 \\ 9 \\ 51 \\ 52 \\ 56 \\ 57 \\ 58 \\ 9 \\ 60 \end{array} $	565 566 567 568 569	Sensibilité aux macrolides des isolats bactériens provenant des infections acquises dans la communauté en Afrique subsaharienne et en Asie Susceptibilidad a macrólidos de aislados bacterianos provenientes de infecciones adquiridas en la comunidad. <i>Tropical Medicine & International Health</i> 2011;16(10):1192-205. doi: 10.1111/j.1365-3156.2011.02837.x
	570 571 572	 Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely management measures in the first 24 hours. <i>Critical Care</i> 2016;20(1):237. doi: 10.1186/s13054-016-1414-2
	573 574 575	 Lim W, Smith D, Wise M, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. <i>Thorax</i> 2015:thoraxjnl-2015-206881.
	576 577	 Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. <i>Emerging infectious diseases</i> 2009;15(2):258.
	578 579 580	 Bedell RA, Anderson ST, Van Lettow M, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. <i>PLoS One</i> 2012;7(6):e39347. doi: 10.1371/journal.pone.0039347
	581 582 583 584	33. Schleicher G, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. <i>The International Journal of Tuberculosis and Lung Disease</i> 2003;7(12):1207-08.
	585 586	 Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nature medicine 2004;10(12s):S122. doi: 10.1038/nm1145
	587 588 589	35. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. <i>The Lancet</i> 2005;365(9459):579-87.
	590 591 592	36. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. <i>PloS one</i> 2011;6(3):e17765. doi: 10.1371/journal.pone.0017765
	593 594 595 596	37. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. <i>Clinical Infectious Diseases</i> 2013;56(11):1519-26.
	597 598 599 600 601	 38. Mitjà O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. New England Journal of Medicine 2015;372(8):703-10. doi: 10.1056/NEJMoa1408586

602 APPENDIX 1: TRIAL REGISTRATION—DATA SET

NCT Number	NCT03545373
Title	Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
Acronym	ACT-TB
Status	Recruiting
Study Results	No Results Available
Conditions	Tuberculosis Respiratory Tract Infections Pneumonia
Interventions	Drug: Azithromycin Drug: Amoxicillin
Outcome Measures	Diagnostic accuracy of trial-of-antibiotics: Proportion of
	participants correctly classified as PTB negative based on
	report of improvement of baseline symptoms on study Day-8
	against a mycobacteriology reference standard. Overall clinical
	benefit of empirical antibiotic treatment in primary care
	participants with chronic cough: proportion of participants
	experiencing adverse clinical outcomes/Impact of trial-of-
	antibiotics on antimicrobial resistance Diagnostic accuracy of
	trial-of-antibiotics including participants who did not produce
Spanaar/Callaboratora	Sputum Economic analysis of use of that-of-antibiotics
Sponsol/Collaborators	Malawi College of Medicine
Gender	
Phases	Phase 3
Enrollment	1875
Eunded Bys	Other
Study Type	
Study Type Study Designs	Allocation: Randomized
Study Designs	Intervention Model: Parallel Assignment
	Masking: Single (Outcomes Assessor)
	Primary Purpose: Diagnostic
Other IDs	15232
Start Date	February 25, 2019
Primary Completion	Jun-20
Date	
Completion Date	Jun-20
First Posted	June 4, 2018
Results First Posted	
Last Update Posted	August 15, 2019
Locations	University of Malawi College of Medicine, Blantyre, Southern,
	Malawi
Study Documents	
URL	https://ClinicalTrials.gov/show/NCT03545373
	-

1		
2 3 4	605	APPENDIX 2: FULL TRIAL PROTOCOL
5 6 7	606 607	(attached separately)
8 9 10 11	608 609	APPENDIX 3:PATIENT INFORMATION SHEET AND INFORMED CONSENT
12 13 14	610 611	(attached separately)
15 16 17	612	APPENDIX 4: ETHICS AND REGULATORY APPROVALS
17 18 19 20 21 22 32 42 52 62 72 82 93 31 32 33 43 53 63 73 83 940 41 42 34 45 46 47 48 950 51 52 53 45 56 57 859 60	613 614	(attached separately)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

01 September 2019

The Editor in Chief *BMJ Open* BMJ Open Editorial Office BMA House, Tavistock Square London, WC1H 9JR, UK

Dear Editor,

RE: Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients versus risk of antimicrobial resistance (the ACT-TB Study)

We are pleased to submit a clinical trial protocol bearing the above title for consideration for publication in <u>BMJ Open</u>. This clinical trial aims to address a critical, yet ignored, intersection between two major global challenges: 1) the suboptimal nature of Tuberculosis diagnostics, perhaps the key underlying driver for the high mortality in this top killer of all infectious disease; and 2) antimicrobial resistance, which currently kills 700,000 people per year and if left unchecked, it will surpass all killers with deaths from untreatable infections catapulting to 10,000,000 per year by 2050. It is therefore not surprising that Tuberculosis and antimicrobial resistance are two of only five health issues to have ever secured a United Nations High Level Meeting.

Inspired by our recently-submitted, and under-publication-consideration systematic review (*Divala TH, Fielding KL, Nliwasa M, Sloan DJ, Gupta-Wright A, Corbett EL. Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Systematic reviews. 2018 Dec;7(1):141.*), we describe how we will investigate benefits and consequences of the current practice using broad-spectrum antibiotics (such as amoxicillin, macrolides, and others used for treating bacterial pneumonia) as Tuberculosis diagnostics. The use of antibiotics in TB diagnostic algorithms is a practice that is grounded on limited evidence, yet results in prescriptions of approximately 26.5 million antibiotic courses.

Administration of a course of broad spectrum antibiotics as a means of ruling out tuberculosis in coughing patients with negative sputum TB tests, has been part of the TB diagnostic algorithm for over 20 years. In this practice, known as trial-of-antibiotics, response to the antibiotics is interpreted as a negative test for Tuberculosis while failure to respond increases the probability of Tuberculosis, warranting further Tuberculosis diagnostics. Getahun and colleagues (Lancet. 2007;369(9578)]

provide what is perhaps the best description of this approach and extent of use in sub Saharan Africa, but to our knowledge, no comprehensive assessment of diagnostic accuracy of trialof-antibiotics exists. Despite the wide application and potential consequences, no clinical trial or systematic review has been done on the subject.

Our review and meta-analysis has established that the current policy and practice regarding trial-ofantibiotics has weak evidence base, poor diagnostic performance, and worryingly inconsistent choice of antibiotics, number of antibiotic courses, and interpretation of test outcomes. **We believe that this manuscript is appropriate for publication in this special issue because it has potential to 1) drive research forward, 2) help optimize TB diagnostic algorithms with current and new diagnostics, and 3) to improve clinical care and treatment outcomes in the entire TB high burden world.** This work essentially cross-cuts the ideals of the *BMJ Open*.

Ethics and regulatory approvals

The protocol has been reviewed and approved by the following bodies:

- 1. University of Malawi College of Medicine Research and Ethics Committee (COMREC),
- 2. London School of Hygiene & Tropical Medicine Research Ethics Committee
- 3. Regional Committee for Health and Research Ethics, NTNU-Midt, Norway
- 4. The Malawi Pharmacy, Medicines, and Poisons Board (PMPB)
- 5. Annual approvals are granted by 1 and 2

No part of this manuscript has been published or is under consideration for publication elsewhere. We have no conflicts of interest to disclose. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Thank you for considering our manuscript.

Sincerely,

Titus H. Divala MBBS MPH MS

Commonwealth Scholar and Helse Nord RHF Fellow Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel St, London **AND** Helse Nord Tuberculosis Initiative, Department of Pathology, University of Malawi College of Medicine, Blantyre, Malawi

Honorary Lecturer (Epidemiology) Department of Pathology, University of Malawi College of Medicine, Blantyre, Malawi

Mobile: Whatsapp:	+265999478376 (<u>Malawi</u>), +447405231847 (<u>UK</u>) +447405231847
Skype:	tdivala
Email:	titus.divala@lshtm.ac.uk (LSHTM)
	tdivala@umaryland.edu (Other)
Academic Profi	e: http://www.lshtm.ac.uk/aboutus/people/divala.titus



3

4

5 6

7 8

9 10

11

12

13

14

15 16 17

18

35

53 54 55

PARTICIPANT INFORMATION SHEET

Participant information sheet



What is the benefit and unintended consequences of using antibiotic treatment as a way of excluding tuberculosis disease in patients with cough?

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you Protected decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you copyright, including for uses related wish. Take time to decide whether or not to take part.

What is the purpose of the study?

19 Tuberculosis (TB) is a disease that causes a long illness and cough with sputum. Although curable TB is 20 difficult to detect. When they fail to detect TB after testing sputum, clinicians give antibiotic treatment that can 21 cure all other causes of TB symptoms but not TB. In this approach, TB is considered ruled out if patient gets 22 better and it is considered likely if they do not get better. The goal of this research study is to develop 23 understanding of how well the antibiotics help distinguish TB patients from those who do not have it, whether 24 giving antibiotics carries other health benefits, and whether it leads to development of disease causing 25 26 organisms which are resistant to drugs. 27

28 We will learn about this by comparing a group of patients given antibiotics on the first day of the study to 29 another group not given antibiotics. There will be two groups receiving antibiotics as follows: 1) Azithromycin 30 taken as one tablet once a day for 3 days, and 2) Amoxicillin 4 capsules taken three times a day for 5 days. The 31 group you will go into, out of the three, will be decided by chance so you can fall into any group. 32

33 What will be involved if I accept to participate in the study? 34

We are considering you for participation in this study because you told us that you have a cough. Any patient 36 37 who has been coughing for at least 2 weeks, is at least 18 years, and lives within Blantyre, is eligible to 38 participate in this study if they do not have signs consistent with serious illness. Apart from you, we will recruit 39 1,874 other individuals. 40

41 Study activities will be performed the first day, at 1 week (Day 8), and at one month (Day 29). At each of these 42 study visits, we will ask you questions about your contact details, your health, use of medications, and any 43 illnesses or hospitalisations you may have had in between study visits. We will also document relevant details 44 45 from your health passport and other clinical documentation you may have. 46

ining, AI training, and similar technologies 47 On Day 1 and at 1 week, we will ask you to submit sputum and urine samples for TB tests. If you are not able to 48 give sputum on Day 1, we will give you containers so that you can bring them the following morning. Some of 49 the sputum TB tests results will become available after 7 days and we will pass them to health center clinicians 50 who will make a plan for your care, the other results may take up to 4 weeks so you will get them at the 1 month 51 visit. Urine TB test results will not be available for your clinical care. 52

21-May-2019

ref: LSHTM 15232: COMREC P.04/18/238

A copy of this informed consent document to be offered to the participant

56 Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-57 antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi 58 Version & Date: 3.0/28 Feb 2019

59 Principal Investigator: Dr Titus H Divala

Participant Information SheeFor peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 4 60

đ

text

tand

data m


We will also do an HIV test. If the results are confirmed to be HIV positive we will do a viral load test, and at the end of the study activities on Day 1, we will link you to HIV management team here at the health center who will start you on treatment. Should we make a diagnosis of TB or HIV at any other point during the study, we will link you with the responsible health center team for treatment services.

On day 1 and at 1-month visit, we will swab the back of the inside of your nose as shown in this picture to collect germs that live there. We will test the germs for drug resistance. Results of this test are not relevant to your care.

On 1-week visit, we will ask you to report how your health has changed in comparison to how you were on day 1. These 13 questions will be read to you by a computer and you will answer 14 them by choosing various options which it will display during the 16 interview.

The 1 month visit will be the final study visit where we will also

provide you with results for TB culture and ask if you have TB symptoms. If you are in HIV or TB care, we 20 will ask how your follow up is going. The appointment with you at 1 months is very important because it will help you to know the results of the TB tests and it will also help us know the status of your health. 22

The number of clinic visits you will make for this study is at least three. Here we count Day 1, one visit after 24 25 one week, and another visit at one month. If you have not been able to come here for any of the visits, we will 26 remind you by phone call or we will use the permission and information you will give us to visit you at your 27 home. The first visit will take about 60 minutes and the later visits will take about 30 minutes each. 28

29 Will there be any risks involved in this study? 30

31 This study is a low risk study. There are no risks involved in submitting sputum or urine for the study. You 32 may feel some discomfort during swabbing of the back of the nose and during blood collection for HIV and 33 Azithromycin and amoxicillin are already widely used in Malawi and rarely cause viral load tests. 34 35 problems. Rare side effects for azithromycin include feeling nervousness, skin reactions and disturbance of 36 heart function. Rare side-effects for amoxicillin are mental state changes, feeling light-headed, and reactions to 37 sunlight. 38

39 The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If 40 you experience harm or injury as a result of taking part in this study, you may be eligible to claim 41 compensation. 42

43 Will there be any benefits in this study? 44 45

46 The key benefit of this study is that you will have access to a more detailed TB evaluation process than usual. 47 This will help you know if you have TB and to have the opportunity to start TB treatment. The study is also 48 beneficial to health care providers because it will address important questions about use of antibiotics during the 49 TB diagnostic process. ollege OI leaicine 50

53 Will the findings in the study be confidential? 54

21-Mav-2019

55 A copy of this informed consent document to be offered to the participant 56 Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-57 antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi 58 Version & Date: 3.0/28 Feb2019

Principal Investigator: Dr Titus H Divala 59

REC ref: LSHTM 15232; COMREC P.04/18/238 Participant Information SheefFor peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 2 of 4 60





1

2

3

4 5 6

7

8

9

10 11

12

15

17 18

19

21

23

ge 36 of 59 BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, AI training, and similar technologies

Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published for scientific purposes but will not give your name or include any identifiable references to you. Information about TB test result and HIV test results will be recorded using an identification number. However, any records or data obtained as a result of your participation in this study may be used by LSHTM who are sponsoring this study, regulators of health research (COMREC), or by members of the research team. These records will be kept in a locked space in the University of Malawi College of Medicine. Information and samples collected in this study will be retained for up to 10 years after the end of the trial, according to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent.

According to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent. **Can I withdraw from the study anytime and will this affect my treatment?**You are free to choose whether or not to participate in this study. While we would like you to participate in the study to the very end, withdrawing at any point is an option that is freely available to you without any penalty or loss of any entitled benefits. You will be provided with any significant new findings developed during the course of this study that may relate to or influence your willingness to continue participation. **What are the financial benefits of participating in this study?**There will be no payment given to you for participating in the study. The study will provide at least MK8,000 as compensation for your costs of attending the study visits. We will give this money in instalments on scheduled study visits. **Is this study approved by an ethics committee?**The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the College of Medicine Research Ethics Committee (COMREC). **Who do you ask if you have questions regarding the study?**

If you have any questions concerning participation in this study, please feel free to ask me. Alternatively, you can contact the following people by phone or post:

	Name	Telephone	Postal address
Study investigators	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative
		0000/01040	University of Malawi College of
	Dr Marriott	0888681948	Medicine Driverte Dece 200 Chiefaini
	Miiwasa		Private Bag 300, Chichiri, Planturo 3 Malawi
COMREC			Diantyre 5, Malawi
connuc	Administrative	01 877 245	University of Malawi College of
	officer. COMREC	01 877 291	Medicine
	Secretariat		Private Bag 360, Chichiri,
		1	Blantyre 3, Malawi
		1	21-May-2019
tudy title: Randomised cont ntibiotics to evaluate ambula	A copy of this informed c trolled clinical trial of diagno atory adults with prolonged	consent document ostic value, clinical b cough for tuberculo Data: 2.0/28 Eab20	to be offered to the participant enefits and unintended consequences of using trial-of- isis in Malawi
Principal Investigator: Dr T Participant Information Shee	itus H Divala For peer review only - http	o://bmjopen.bmj.c	REC ref: LSHTM 15232; COMREC P.04/18/2381 om/site/about/guidelines.xhtml Page 3 of 4



2 3 4

5



What is the benefit and unintended consequences of using antibiotics treatments as a way of excluding tuberculosis disease in patients with cough?

Patient declaration

Statement			Initial or
			thumbprint
		x 1 1 1	each box
I confirm that I have read the above 1	information sheet for the above named study	v. I have had	
the opportunity to consider the inform	nation, ask questions and have these answer	ed	
Satisfactorily.			
JR have had the information explained	to by study personnel in a language that Lu	nderstand I	
have had the opportunity to consider	the information ask questions and have the	se answered	
satisfactorily	the information, ask questions and have the	se answered	
understand that my participation is	voluntary and that I am free to withdraw at a	any time	
without giving any reason, without m	iv medical care or legal rights being affected	1.	
understand that relevant sections of	my medical notes and data collected during	the study may	
be looked at by authorised individual	s from LSHTM, University of Malawi Coll	ege of	
Medicine, and COMREC, where it is	relevant to my taking part in this research.	Ĭ give	
permission for these individuals to ha	ave access to my records.		
understand that data about me may	be shared via a public data repository or by	sharing directly	
with other researchers, and that I will	l not be identifiable from this information		
understand that the tissue sample co	lected from me will be used to support oth	er research in	
the future and may be shared anonyr	nously with other researchers for their ethic	cally-approved	
projects	nously with other researchers, for then ethic	uny upproved	
agree to take part in the above name	ed study		
Printed name of participant	Signature/thumb print of participant	Date	
		•	
Printed name of impartial witness*	Signature of impartial witness*	Date	
attast that I have explained the study	winformation accurately to		and was
understood to the best of my knowled	dge by the participant and that he/she has fr	eely given their c	_, and was
participate* in the presence of the abo	ove named impartial witness (where applica	ble)	onsent to
	ove hamed impurtait writees (where apprea	010).	the second
			and the second second second second
	Appro	oved by	and the second
	Appr	oved by	
Printed name of staff obtaining conser	nt Signature of staff obtaining consent	Date edici	ne
Printed name of staff obtaining conser	nt Signature of staff obtaining consent	Date edici	ne or them Instead
Printed name of staff obtaining conser *Impartial witness should be someone the partici illiterate participants should use thumbprint in pla	nt Signature of staff obtaining consent pant trusts. The impartial witness can write the participant ace of signature and the impartial witness should go ahead	Date COC	or them. Instead.
Printed name of staff obtaining conser *Impartial witness should be someone the partici lliterate participants should use thumbprint in pla	nt Signature of staff obtaining consent pant trusts. The impartial witness can write the participant ace of signature and the impartial witness should go ahead	Date Date Date Date Date Date Date Date	or them. Instead,
Printed name of staff obtaining conser *Impartial witness should be someone the partici lliterate participants should use thumbprint in pla	nt Signature of staff obtaining consent pant trusts. The impartial witness can write the participant ace of signature and the impartial witness should go ahead	Date CO Date CO name but cannot sign f and sign in designated	or them. Instead,
Printed name of staff obtaining conser *Impartial witness should be someone the participalities and use thumbprint in pla A copy of this i Study title: Bandomised controlled clinical tria	nt Signature of staff obtaining consent pant trusts. The impartial witness can write the participant ace of signature and the impartial witness should go ahead informed consent document to be offered to the participant al of diagnostic value. clinical benefits and unintended	Date Construction Date Construction name but cannot sign f and sign in designated and sign in designated and sign in designated ticipant	for them. Instead, space.
Printed name of staff obtaining conser *Impartial witness should be someone the partici illiterate participants should use thumbprint in pla A copy of this i Study title: Randomised controlled clinical tria antibiotics to evaluate ambulatory adults with	nt Signature of staff obtaining consent pant trusts. The impartial witness can write the participant ace of signature and the impartial witness should go ahead informed consent document to be offered to the participant al of diagnostic value, clinical benefits and unintended of prolonged cough for tuberculosis in Malawi	Date name but cannot sign f and sign in designated ticipant consequences of using	or them. Instead, space.
Printed name of staff obtaining conser *Impartial witness should be someone the partici illiterate participants should use thumbprint in pla A copy of this i Study title: Randomised controlled clinical tria antibiotics to evaluate ambulatory adults with Principal Investigators for Time II Direct	nt Signature of staff obtaining consent pant trusts. The impartial witness can write the participant ace of signature and the impartial witness should go ahead informed consent document to be offered to the part al of diagnostic value, clinical benefits and unintended of prolonged cough for tuberculosis in Malawi Version & Date: 3.0/28 Feb2019	Date name but cannot sign f and sign in designated i ticipant consequences of using	for them. Instead, space.



PARTICIPANT INFORMATION SHEET



Chikalata chofotokozera ofuna kutenga nawo mbali

Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufifuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Chiyambi

Tikukukupemphani kuti mutenge nawo mbali mu kafukufuku. Ndi chifuniro chanu kulowa mu kafukufukuyu. Musanapange chiganizo, mukuyenera kumvetsa chifukwa chimene kafukufukuyu akuchitikira komanso zimene zitadzachitike. M'modzi mwa anthu a gulu logwira ntchito mu kafukufuku awerenga chikalatachi pamodzi ndi inu, ndipo ayankha mafunso ena aliwonse amene mungakhale nawo. Funsani mafunso ngati simukumvetsa zomwe mwawerenga kapena ngati mukufuna uthenga owonjezera. Muli omasuka kulankhula ndi ena zokhudza kafukufukuyu ngati mukufuna. Ganizani mofatsa musanavomereze kutenga nawo mbali kapena ayi.

Kodi cholinga cha kafukufukuyu ndi chiyani?

Chifuwa chachikulu (TB) ndi matenda amene munthu amkhala chidwalire kwa nthawi yaitali. Odwalayo, amapanga makhololo. Ngakhale chili chochizika, chifuwa chachikulu ndi chovuta kuchipeza. Pamene njira zoyeza makholoro zalephera kupeza chifuwa chachikulu, achipatala amapereka mankhwala opha tizirombo toyambitsa matenda amene angathane ndi zonse zimene zimayambitsa zizindikiro za matenda ofanana ndi chifuwa chachikulu. Ngati odwala apeza bwino ndi njira imeneyi amaganiziridwa kuti alibe matenda a chifuwa chachikulu koma ngati sanapeze bwino amaganiziridwa kuti ali ndi chifuwa chachikulu. Cholinga cha kafukufuku ameneyu ndi kufuna kumvetsa za m'mene mankhwala amenewa amathandizira kusiyanitsa odwala matenda a chifuwa chachikulu ndi amene alibe matendawa, ngati mankhwalawa ali ndi phindu lina kwa odwala, komanso ngati kupereka mankhwalawa kukubweretsa tizirombo tosamva makhwala.

Tiphunzira zimenezi pakusiyanitsa gulu la anthu odwala amene apatsidwa mankhwala opha tizirombo toyambitsa matenda patsiku loyamba la kafukufukuyu ndi gulu lina limene silinapatsidwe mankhwalawa. Pakhala magulu awiri olandira mankhwala opha tizirombo motere: 1) Azitrhomycin omwedwa pilisi imodzi kamodzi patsiku kwa masiku atatu, komanso 2) Amoxicillin makapusolo anayi omwedwa katatu patsiku kwa masiku asanu. Gulu limene mulowe, mwa magulu atatuwa, lisankhidwa mwa mayere choncho mukhoza kupezeka mu gulu lina lirilonse.

Kodi chidzachitike ndi chiyani ngati ndingavomereze kutenga nawo mbali mu kafukufukuyu?

Tikukupemphani kuti mutenge nawo mbali mu kafukufukuyu chifukwa mwatiuza kuti muli ndi chifuwa. Odwala wina aliyense amene wakhala akukhosomola kwa masabata osachepera awiri, ali ndi zaka zosachepera 18, ndipo amakhala mu Blantyre muno, atha kutenga nawo mbali mu kafukufukuyu ngati alibe zizindikiro zosonyeza kudwalika kwambiri. Kupatula inu, tilemba anthu ena okwanira 1,874.

Zochitika za kafukufukuyu zidzapangidwa patsiku loyamba, pa sabata imodzi (Tsiku 8), ndi pamwezi umodzi (Tsiku 29). Pa masiku a kafukufuku onsewa, tidzakufunsani mafunso okhudzana ndi m'mene tingalumikizirane nanu, thanzi lanu, kagwiritsidwe ntchito ka mankhwala, ndi matenda ena aliwonse kapena kugonekedwa mu chipatala komwe kungakuchitikireni. Tidzalembahso/zinthulzofunikira

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019



kuchokera mu bukhu lanu la kuchipatala komanso zolembedwa zina za chipatala zimene mungakhale nazo.

Patsiku loyamba ndi pakutha pasabata yoyamba, tidzakufunsani kuti mupereke makhololo komanso mkodzo pofuna kuyeza matenda a chifuwa chachikulu. Ngati simungakwanitse kupereka makhololo patsiku loyamba, tidzakupatsani mabotolo kuti mudzawabweretse m'mawa wa tsiku lotsatira. Zotsatira zina za makhololo zidzatuluka pakutha pa masiku asanu ndi awiri ndipo tidzazipereka kwa matodolo a chipatala chino kuti akuthandizeni, zotsatira zina zidzatenga pafupi-fupi masabata anayi choncho mudzazilandira pa ulendo wa pamwezi umodzi. Zotsatira zanu zoyesa mikodzo ku matenda a chifuwa chachikulu sizidzakhalapo ku nkhani ya chisamaliro chanu cha kuchipatala.

Tidzayezanso kachirombo ka HIV. Ngati zotsatirazi zasonyeza kuti muli ndi kachirombo ka HIV tidzayeza kuchuluka kwa tizirombo ta HIV, komanso kukutumizani kolandilira chithandizo chamatendawa. Ngati tingakupezeni kuti muli ndi matenda a chifuwa chachikulu kapena kachirombo ka HIV panthawi ina iliyonse mkati mwa kafukufukuyu, tidzakutumizani kolandilira zithandizo zamatendawa pompano pachipatala.

Patsiku loyamba komanso pa ulendo wa mwezi woyamba, tidzapukuta kumbuyo kwa mkati mwa mphuno mwanu ngati m'mene zikuonekera pachithunzichi kuti titenge tizirombo timene timakhala m'menemo. Tidzayeza tizirombo timeneti kuti tione ngati tikumva mankhwala. Zotsatira zimenezi sizidzagwiritsidwa ntchito kuchisamaliro chanu chaku chipatala.

Pa ulendo wa sabata yoyamba, tidzakupemphani kuti mutiuze m'mene thanzi lanu lasinthira kuyerekeza ndi

m'mene munaliri patsiku loyamba. Mafunso amenewa adzawerengedwa kwa inu kudzera pa makina a kompyuta ndipo mudzawayankha pakusankha mayankho angapo amene makinawa adzawonetse panthawi yomwe azidzafunsa.

Ulendo wa pa mwezi umodzi udzakhala wotsiriza umene tidzakupatseninso zotsatira za zoyesa za matenda a chifuwa chachikulu komanso tidzakufunsani ngati muli ndi zizindikiro za matenda a chifuwa chachikulu. Ngati panthawiyi mudzakhale kuti mukulandira Thandizo la HIV kapena TB, tidzakufuna kudziwa kuti zikuyenda bwanji. Kukumana ndi inu patatha mwezi umodzi ndikofunikira kwambiri chifukwa zidzakuthandizirani kuti mudziwe zotsatira za zoyeza za matenda a chifuwa chachikulu ndipo zidzatithandiziranso kudziwa zam'mene thanzi lanu liliri.

Maulendo a kuchipatala amene mudzayende a kafukufukuyu ndiwosachepera atatu. Pamenepa tikuwerenga tsiku loyamba, ulendo umodzi pakutha pa sabata imodzi, ndi ulendo umodzi pa mwezi umodzi. Ngati simunakwanitse kubwera kuno pa ulendo wina uliwonse tidzakukumbutsani pokuyimbirani lamya kapena tidzagwiritsa ntchito chilorezo ndi uthenga umene mudzatipatse kuti tikuyendereni kunyumba kwanu. Patsiku loyamba tidzakhala nanu kwa mphindi makumi asanu ndi imodzi, pamene paasiku ena onse, tidzakhala nanu kwa mphindi makumi atatu.

Kodi padzakhala ziopsezo zina zilizonse zochitika mu kafukufukayu?May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Chikalata chofotokozera ofuna kutenga nawo mbali Page 2 of 5



2

3 4

5

6 7

8

9

10

11

12 13

14

15 16

17

18

19 20

21

22

23

24 25

26

27

28

29 30

31

32

33 34

35

36 37

38

39

40

41 42

43

44 45

46

47

48

49

50 51

52

53 54 55

56

57 58

59





Kupanga nawo kafukufukuyu sikuika moyo wanu pa chiopsyezo chochuluka. Palibe chiopsezo pa kupereka makhololo kapena mikozo mu kafukufukuyu. Mukhoza kusamva bwino panthawi yopukuta kumbuyo kwa mphuno komanso panthawi yotenga magazi oyeza za kachirombo ka HIV ndi kuchuluka kwa tizirombo toyambitsa matendawa. Azithromycin ndi amoxicillin ndi mankhwala oti akhala akugwiritsidwa ntchito kwa nthawi yayitali m'Malawi ndipo sikweni-kweni kuyambitsa mavuto. Patalipatali azithromycin amapangitsa kumva nthumazi, ziwengo, komanso kusokonekera kwa kagwiridwe ntchito ka mtima. Patali-patali amoxicillin amapangitsa kusakhazikika mmanganizo, kumva chizungulire, komanso kutuluka ziwengo munthu akakhala padzuwa.

A London School of Hygiene ndi Tropical Medicine ali ndi thumba landalama zachipukuta misozi lokhudzana ndi kafukufukuyu. Ngati mwapweteka kapena kuvulala chifukwa chotenga nawo mbali mu kafukufukuyu, mudzakhale omasuka kupempha chipukuta misonzi.

Kodi padzakhala zopindula zina zilizonse mu kafukufukuyu?

Chopindulitsa chodziwika cha kafukufukuyu ndi chakuti mudzakhala ndi mwayi oyezedwa matenda a chifuwa chachikulu mozama kuposa m'mene zimakhalira nthawi zonse. Zimenezi zidzakuthandizirani kudziwa ngati muli ndi matenda a chifuwa chachikulu komanso kukhala ndi mwayi oyamba kulandira thandizo la mankhwala a chifuwa chachikulu. Kafukufukuyu ndi opindindulitsanso kwa opereka chisamaliro cha kuchipatala chifukwa adzayankha mafunso ofunikira okhudzana ndi kagwiritsidwe ntchito ka mankhwala opha tizirombo toyambitsa matenda panthawi ya ndondomeko yoyeza matenda a chifuwa chachikulu.

Kodi zotsatira za mukafukufukuyu zidzakhala za chinsinsi?

Chizindikiritso chanu mu kafukufukuyu chidzatengedwa kukhala cha chinsinsi. Zotsatira za kafukufukuyu, zikhoza kudzasindikizidwa ndi cholinga cha sayansi koma dzina lanu kapena chizindikiritso chilichonse chokhudzana ndi inu chidzabisidwa. Uthenga okhudza zotsatira zoyesa matenda achifuwa chachikulu kapena HIV zidzalembedwa pogwiritsa ntchito nambala yanu yakafukufuku. Komabe, zina zomwe mungatifotokozere zitha kudzagwiritsidwa ntchito ndi amene ali oyang'anira za kafukufuku wa zaumoyo (COMREC) komanso LSHTM. kapena ndi mamembala a gulu la kafukufukuyu. Zolembedwazi zidzasungidwa mumalo otsekedwa bwino ku sukulu ya ukachenjede ya Malawi College of Medicine. Uthenga ndi zoyesa zotengedwa mu kafukufukuyu zidzassungidwa kwa zaka pafupi-fupi khumi (10) pakutha pakuyesaku, malingana ndi ndondomeko ya bungwe lathu. Zoyesa zotengedwazi ndi mauthenga ena zikhoza kugwiritsidwanso ntchito pa kafukufuku wamtsogolo ngati mutatipatsa chilolezo chimenecho.

Kodi ndikhoza kusiya kafukufukuyu nthawi ina iliyonse ndipo zimenezi zingadzakhudze thandizo langa la mankhwala?

Muli ndi ufulu kusankha kutenga nawo mbali kapena kusatenga nawo mbali mu kafukufukuyu. Ngakhale tingakonde kuti mutenge nawo mbali mu kafukufukuyu mpaka ku mapeto, kutuluka nthawi iliyonse mukafukufuku ndi chisankho chanu popanda chilango chilli chonse kapena kuluza kulandira thandizo lililonse lomwe mukuyenera kulandira. Munthawi yakafukufukuyu, tidzakudziwitsani patati 21-May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Chikalata chofotokozera ofuna kutenga nawo mbali Page 3 of 5 Page 41 of 59



patuluka mauthenga ena a sayansi ofotokoza zinthu zimene zingakupangitseni kuti mulingalirenso 2 zachisamkho chanu chotenga nawo mbali. 3 4 Kodi pali phindu la ndalama lotani pakutenga nawo mbali mu kafukufukuyu? 5 6 Sipadzakhala kupatsidwa malipiro chifukwa chotenga nawo mbali mukafukufukuyu. Ndalama yomwe 7 8 tidzakupatseni ndi yokwana MK8,000. Ndalamayi tizikupatsani pangonopango pamasiku anu 9 akafukufuku.. 10 11 Kodi kafukufukuyu ndiwovomerezeka ndi komiti yowona za ufulu wa anthu mukafukufuku? 12 13 Kafukufukuyu wavomerezedwa ndi London School of Hygiene & Tropical Medicine Research Ethics 14 Committee, ndi College of Medicine Research Ethics Committee (COMREC). 15 16 Kodi mungafunse ndani ngati muli ndi mafunso okhudzana ndi kafukufukuyu? 17 18 Ngati muli ndi mafunso ena aliwonse okhudza kutenga nawo mbali mukafukufukuyu, chonde khalani 19 20 omasuka kundifunsa. Munjira ina, mukhoza kulumikizana ndi anthu otsatirawa pa lamya kapena 21 polemba kalata kumakeyala awa: 22 23 Telephone **Postal address** Name 24 Dzina Lamya Adilesi 25 26 **Study investigators** Dr Titus Divala 0999478376 Helse Nord Tuberculosis Initiative 27 Akulu-akulu 28 University of Malawi College of 29 akafukufuku Medicine 30 Dr Marriott 0888681948 Private Bag 360, Chichiri, 31 Nliwasa Blantyre 3, Malawi 32 **COMREC** 33 01 877 245 University of Malawi College of Administrative 34 01 877 291 officer. COMREC Medicine 35 Private Bag 360, Chichiri, 36 Secretariat 37 Blantyre 3, Malawi 38 39 40 41 42 43 44 45 46 Approved by College of Medicine 47 48 49 50 51 52 21-May-2019 53 54 55 Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira 56 kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani? 57 58 Version & Date: 3.0/28 Feb 2019 59 Mkulu wakafukufuku: Pr Titus H Divala Chikalata chofotokozera ofuna kutenga nawo mbali Page 4 o 60 Page 4 of 5

LONDON



Chitsimikizo cha odwala	
Lembani mubokosi liri kuman	jali mawu oyamba adzina lanu kapena dindani ndi chala
ngati mukuvomereza	
Mfundo yachitsimikizo	
Ndikutsimikiza kuti ndawerenga c m'mwambamu. Ndakhala ndi mw ndayankhidwa mokhutira. KAPENA	chikalata cha uthenga wa kafukufuku amene watchulidwa ayi woganizira za uthengawu, kufunsa mafunso komanso
Ndafotokozeredwa uthengawu ndi ndi mwayi woganizira za uthengay	i akafukufuku mu chilankhulo chimene ndikuchimvetsa. Ndakhala wu kufunsa mafunso komanso ndayankhidwa mokhutira
Ndikumvetsa kuti kutenga nawo n	nbali kwanga ndikosakakamizidwa ndipo ndili ndi ufulu kusiya
panthawi ina iliyonse popanda kup	pereka chifukwa china chilichonse, popanda kukhudza chisamaliro
Ndikumvetsa kuti magawo ofunik	ira a zolembedwa zanga za ku chipatala komanso mu
kafukufukuyu kuwonedwa ndi ant Medicine komanso COMREC, par Ndikupereka chilolezo kwa anthu	hu ovomerezeka aku LSHTM, University of Malawi College of mene kuli kofunika kutenga nawo mbali mukafukufukuyu. amenewa kuti athe kuwona za zolembedwa zanga
Ndikupyetsa kuti zomwe atolere a	akafukufuku zokhudza ine zikhoza kugawilidwa kwa anthu ena
opanga kakafukufuku, ndipo kuti s kwa ine	sipadzakhala chizindikiro chilichonse chosonyeza kuti zinachokera
Ndikumvetsa kuti zoyeza za mthu	pi mwanga zimene zidzatengedwe kwa ine zidzagwiritsidwa
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuyomereza kutenga nawo mb	yovomerezeka ndi malamulo aowona zakafukufuku.
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb	yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu.
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb	yovomerezeka ndi malamulo aowona zakafukufuku. pali mu kafukufuku amene watchulidwa pamwambayu.
ntchito kuthandizira katukutuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb	vini/chidindo cha chala cha wotenga mbali. Tsiku
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa	yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku
ntenito kuthandizira kafukufuku w akafukufuku ena, pa ntehito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa	yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa	Vina mtsogolo, ndipo ziknoza kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali*	Vina mtsogolo, ndipo ziknoza kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Idikutsimikiza kuti ndafotokoza za ut	Jina mtsogolo, ndipo ziknoza kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Idikutsimikiza kuti ndafotokoza za uti inamveka monga mwakudziwa kwang	Vina mtsogolo, ndipo ziknoża kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti a
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za ut inamveka monga mwakudziwa kwang nbali* pamaso pa mboni yopanda mba	Vina mtsogolo, ndipo ziknoża kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti ali imene yatchulidwa pamwambapa (ngati kuli koyenera).
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Idikutsimikiza kuti ndafotokoza za uti inamveka monga mwakudziwa kwang ibali* pamaso pa mboni yopanda mba	Jina mtsogolo, ndipo ziknoża kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti ali imene yatchulidwa pamwambapa (ngati kuli koyenera).
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Idikutsimikiza kuti ndafotokoza za utl inamveka monga mwakudziwa kwang ibali* pamaso pa mboni yopanda mba	Vina mtsogolo, ndipo ziknoża kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti ali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Jdikutsimikiza kuti ndafotokoza za utl inamveka monga mwakudziwa kwang nbali* pamaso pa mboni yopanda mba Dzina la wotenga chilolezo	Ana mtsogolo, ndipo ziknoża kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. ali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti ali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Tsiku okhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba ufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, e ndi chidindo cha chala chake ndipo mboni isayine dzina sayin, pamalo ambone.
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Idikutsimikiza kuti ndafotokoza za uti inamveka monga mwakudziwa kwang ibali* pamaso pa mboni yopanda mba Dzina la wotenga chilolezo Mboni yopanda mbali ikuyenekera kukhala y zina la wotenga chilolezo Mboni yopanda mbali ikuyenekera kukhala y zina la munthu ofuna kutenga nawo mukafuku gati samatha kuwerenga ndi kulemba, asayine Mpatseni oten zina la kafukufuku: Kodi kugwiritsa ntchi	Ana mtsogolo, ndipo ziknoza kudzagawidwa mwachinsinsi ndi yovomerezeka ndi malamulo aowona zakafukufuku. pali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti ali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Tsiku okhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba ufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, e ndi chidindo cha chala chake ndipo mboni isayine dzinandi sayin, panalo ambone.
ntenito kuthandizira kafukufuku w akafukufuku ena, pa ntehito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Vdikutsimikiza kuti ndafotokoza za uti inamveka monga mwakudziwa kwang nbali* pamaso pa mboni yopanda mba Dzina la wotenga chilolezo 'Mboni yopanda mbali ikuyenekera kukhala y zina la munthu ofuna kutenga nawo mukafuku gati samatha kuwerenga ndi kulemba, asayine Dzina la kafukufuku: Kodi kugwiritsa ntehi ufufuza chifuwa chachikulu kuli ndi phindu	Ana misogolo, holpo zikhoza kudzagawidwa mwachinsinsi hol yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali Tsiku sayini ya mboni yopanda mbali Tsiku benga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti a ali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Tsiku okhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba ufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, e ndi chidindo cha chala chake ndipo mboni isoyine dzinanci sojin, papalo ambone. Inga nawo mbali chikalata chimodzi kuti chikhale chake ito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira u kapena kuipa kotani?
ntchito kuthandizira kafukufuku w akafukufuku ena, pa ntchito yawo Ndikuvomereza kutenga nawo mb Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Vdikutsimikiza kuti ndafotokoza za ut inamveka monga mwakudziwa kwang nbali* pamaso pa mboni yopanda mba Dzina la wotenga chilolezo 'Mboni yopanda mbali ikuyenekera kukhala y zina la wotenga chilolezo 'Mboni yopanda mbali ikuyenekera kukhala y zina la munthu ofuna kutenga nawo mukafuku gati samatha kuwerenga ndi kulemba, asayine Vzina la kafukufuku: Kodi kugwiritsa ntchi ufufuza chifuwa chachikulu kuli ndi phindu	Ana misogolo, holpo zikhoza kudzagawidwa mwachinsinsi hol yovomerezeka ndi malamulo aowona zakafukufuku. bali mu kafukufuku amene watchulidwa pamwambayu. yini/chidindo cha chala cha wotenga mbali yini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku henga wa kafukufukuyu molondola kwa ga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti a ali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Tsiku okhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulemba ufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku, ndi chidindo cha chala chimodzi kuti chikhale chake ito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira u kapena kuipa kotani? Version & Date: 3.0/28 Feb 2019



CERTIFICATE OF ETHICS APPROVAL

This is to certify that the College of Medicine Research and Ethics Committee (COMREC) has reviewed and approved a study entitled:

P.04/18/2381 - Accurancy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study) by Titus H Divala

On 03-Jul-18

As you proceed with the implementation of your study, we would like you to adhere to international ethical guidelines, national guidelines and all requirements by COMREC as indicated on the next page

Dr. YB. Mlombe - Chairperson (COMREC)

03-Jul-18

Date

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training and similar technologies.

moni Debeolnwod. 2020 Anew 25 no 99990-203999 no 25 March 2020. Downloaded from

REQUIREMENTS FOR ALL COMREC APPROVED RESEARCH PROTOCOLS

- 1. Pay the research overhead fees as required by the College of Medicine for all approved studies.
- 2. You should note that the COMREC Sub-Committee on Research Participants' Safety will monitor the conduct of the approved protocol and any deviation from the approved protocol may result in your study being stopped.
- 3. You will provide an interim report in the course of the study and an end of study report.
- 4. All COMREC approvals of new applications and progress reports are valid for one year only. Therefore all approved studies running for more than one year are subject to continuing review annually. You are required to submit a progress report to COMREC within 90-30 days before the expiration date. Your current expiration date is 03-Jul-19. Studies shall be considered lapsed and inactive if continuing review application is not received one month after the expiry of the previous approval. In that case, all study related operations should cease immediately except those that are necessary for the welfare of subjects.
- 5. All investigators who are Medical Practitioners must be fully registered with the Medical Council of Malawi.

Enseignement Superieur (ABES) . Protected by copyright, aguipiniar technologiate, text، and tatis, mithing the training and similar technologies.

BMJ Open. first published as 10.1136/bmjopen-2019-09309 on 25 March 2020. Downloaded from http://pmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l



PHARMACY, MEDICINES & POISONS BOARD

Mission: To promote and improve the health of the population of Malawi through the regulation of Pharmacy Personnel, Pharmacy Businesses, Medicines and Allied Substances

ALL CORRESPONDENCE SHOULD BE ADDRESSED TO THE REGISTRAR

Head Office: Off Paul Kagame/ Chilambula Road P.O.Box 30241 Capital City LILONGWE 3, MALAWI Phone: (+265) 01 755 165 Fax : (+265) 01 755 204 Email: <u>info@pmpb.mw</u> Web: <u>www.pmpb.mw</u>

PMPB/CTRC/III/14062018102 DATE: 4th July, 2018

Department of Infectious Disease Epidemiology London School of Hygiene and Tropical Medicine Keppel St London

Attn.: Dr. Titus Divala

RE: ACCURACY AND CONSEQUENCES OF USING TRIAL-OF-ANTIBIOTICS FOR TB DIAGNOSIS (ACT-TB STUDY).

Refer to your application to register the above mentioned clinical trial with the Pharmacy, Medicines and Poisons Board (PMPB).

The Clinical Trial Review Committee (CTRC), at its meeting held on 22nd June, 2018, issued a **No Objection** to the implementation of the trial after members agreed that the nature of the trial was seen to be outside the scope of trials that should be regulated by PMPB through the CTRC.

Please contact the undersigned if there are any issues that need further clarification.

Yours faithfully,

MEDICINES ONS BOARD REGISTRAR M. Kawaye ACTING REGISTRAR TJUL 2018 BOX 30241.LILONGWE



≀egion: ₹EK nord	Saksbehandler:	Telefon:		Vår dato: 06.11.2018 Deres dato: 25.09.2018	Vår referanse: 2018/1964/REK nord Deres referanse:
				Vår referanse må oppgis	ved alle henvendelser
Jon Øyvind	Odland				
Institutt for s	samfunnsmedisin				
2018/1964 eksklusjon	En kontrollert klin sdiagnose i allmenj	nisk studie for å un praksis mot risiko	ndersøke responsen t for antibiotika resist	il bredspekret ant tens	tibiotika som en
Forsknings Prosjektlec	ansvarlig institusj ler: Jon Øyvind Od	o n: UiT Norges ark land	tiske universitet		
Vi viser til s Regional ko er gjort med	søknad om forhånds omité for medisinsk l hjemmel i helsefor	godkjenning av ovo og helsefaglig forsl rskningsloven (hfor	ennevnte forskningspr kningsetikk (REK nor sknl) § 10.	rosjekt. Søknaden b d) i møtet 25.10.20	ble behandlet av 18. Vurderingen
Prosjektled Det skal und kan brukes resistensutv med åpen ir brukermedv mennesker. vedlagt.	lers prosjektomtale dersøkes, ved hjelp o som eksklusjonsdiag ikling knyttet til beh nformasjon undersø virkning og informer Studien skal i sin ho	e av en randomisert, gnose for tuberkulo pandingen. Tre grup kes med standard d t samtykke. Studier elhet foregå i Malav	kontrollert studie om se. Dette skal vurdere oper (625 per gruppe) iagnostisk tilnærming n kan forenkle dignost wi. Alle etiske godkjen	respons til bredspe s opp mot risiko fo individuelt randon . Kun voksne delta ikk og klinikk for et minger fra Malawi	ekret antibiotika r nisert (1:1:1), kere, med full n utsatt gruppe og London er
Komiteen v fvl. § 6.	urderte at Hanne Hu	ısom Haukland var	inhabil og hun fratråd	lte møtet da saken	ble behandlet, jf.
Om prosje l Prosjektet e	ktet r en del av en PhD.	Studenten skal avle	egge sin PhD i Londor	ı.	
Dette er et s Medicine, c	samarbeidsprosjekt 1 og Universitetet i Tro	mellom Universitet omsø.	et i Malawi, London S	School of Hygiene	and Tropical
Prosjektet s	kal gjennomføres i l	Malawi og er et «Ti	uberkulose initiativ» f	ra Helse Nord.	
Det foreligg	ger godkjenning fra	London School of I	Hygiene and Tropical	Medicine, og Univ	versity of Malawi.
Data Det skal he knyttet til ii	entes data fra pasien nfeksjoner og sykehi	tjournal og fra loka istorie.	le poliklinikker. Data	er standard medisi	nske opplysninger
Nye helseoj	pplysninger er respo	ns på behandling a	v infeksjoner.		
Besøksadresse: MH-bygget UiT No	Telefon: 776	46140 Ng@asptitp://bmjop	All post og e-post som inn DEN Baksbehandlinger, bes a	ngår i Hesselitur Berki Ciene Regio	dress all mail and e-mails to nal Ethics Committee, REK

1	
2	
3	
4	
5 6	
7	
8	
9	
10	
12	
13	
14	
15	
16	
17	
19	
20	
21	
22	
23	
25	
26	
27	
28 29	
30	
31	
32	
33	
34 35	
36	
37	
38	
39 40	
40 41	
42	
43	
44	
45 46	
47	
48	

Data avidentifiseres med koblingsnøkkel. Database oppbevares i 5 år i Malawi.

Deltakere/rekruttering

Voksne deltakere fordeles i tre grupper voksne deltakere (625 per gruppe), individuelt randomisert. Deltakere rekrutteres gjennom behandling på poliklinikkene.

REK har ingen innvendinger til prosjektet

Vedtak

REK har gjort en helhetlig forskningsetisk vurdering av alle prosjektets sider og godkjenner det med hjemmel i helseforskningsloven § 10. REK forutsetter at prosjektet også har godkjenning fra Malawi.

Sluttmelding og søknad om prosjektendring

Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 21.03.2022, jf. hfl. § 12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.

Klageadgang

Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK nord. Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til οg h. Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.

Med vennlig hilsen

May Britt Rossvoll sekretariatsleder

Kopi til:jon.oyvind.odland@uit.no

51 52

49

Keppel Street, London WC1E 7HT

United Kingdom

Switchboard: +44 (0)20 7636 8636

www.lshtm.ac.uk



43 44

45

46

47

48

49

50 51

52

53 54

55 56

1

2

3

LSHTM

9 May 2018

Dear Titus,

Study Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

LSHTM ethics ref: 15232

Thank you for your application for the above research, which has now been considered by the Interventions Committee.

Observational / Interventions Research Ethics Committee

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

29	Document Type	File Name	Date	Version
30	Safety Information	ACT_PackageInsertAzithromycin	14/03/2013	JUNE 2013
31 32	Safety Information	ACT_PackageInsertAmoxicillin	21/12/2015	DEC 2015
33	Sponsor Letter	2018-KEP-077_Sponsor Confirmation_13.03.18	13/03/2018	1
34	Other	GCP Cert_LSHTM_TDivala_21.03.18	21/03/2018	1
35	Investigator CV	ACT-CV1_TitusDivala	30/03/2018	1
36 37	Investigator CV	ACT-CV2_KatherineFielding	30/03/2018	1
38	Investigator CV	ACT-CV3_LizCorbett	30/03/2018	1
39	Information Sheet	ACT-20180330InformedConsentEnglish	30/03/2018	1.0
40	Information Sheet	ACT-20180330InformedConsentChichewa	30/03/2018	1.0
41 42	Protocol / Proposal	ACT-20180330Protocol	30/03/2018	1.0

After ethical review

The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review using an Amendment form. Amendments must not be initiated before receipt of written favourable opinion from the committee.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project by submitting a Serious Adverse Event form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk

Additional information is available at: www.lshtm.ac.uk/ethics

Yours sincerely,

<u>ethics@lshtm.ac.uk</u> <u>http://www.lshtm.ac.uk/ethics/</u>

Improving health worldwide

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT

United Kingdom

1

2

3

4

5

6 7

Switchboard: +44 (0)20 7636 8636

www.lshtm.ac.uk





8	Observational / Interventions Research Ethics Committee
9	
10 11	Dr Titus Divala LSHTM
12 13	12/04/2019
14	Dear Titus,
15 16 17	Project Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance
18 19	Project ID: 15232
20	
20	Thank you for your annual report application for the continuation of your research dated 09/04/2019 12:01, which has now been considered by the Chair on behalf of the Ethics Committee.
22	Confirmation of ethical opinion
23 24	This application is approved by the committee for a further year.
25	Conditions of the favourable opinion
26	Approval is dependent on local ethical approval having been received, where relevant.
27	After ethical review
28 29	Any changes to the application must be submitted to the committee via an Amendment form.
30 31	The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reaction (SUSARs) which occur during the project by submitting a SUSAR and Protocol Violation form.
32	An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.
33	At the end of the study, the CI or delegate must notify the committee using an End of Study form.
34 35	All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at http://leo.lshtm.ac.uk.
36	Additional information is available at: www.lshtm.ac.uk/ethics.
37	Yours sincerely,
38	
39	
40	(Mr.
41	
42	Professor John DH Porter Chair
43	
44	ethics@lshtm.ac.uk http://www.lshtm.ac.uk/ethics/
45	
46	
47	Improving health worldwide
48	
49	
50	
51	
52	

Administrative

information

Title

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and

provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold clinical trials. Al training, and simila Page Number FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials.

Ann Intern Med. 2013;158(3):200-207

#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial

acronym

Reporting Item

3	BMJ Open:
27	first published
Protected by copyright 23 23	as 10.1136/bmjopen-2019
c, including for us	-033999 on 25 Ma
23 23 23	rch 2020. Downloaded from
2 2	n http://bmjopen.bmj.com/ on . BES)
19	lune 11, 2025 at Agence Bibliographique de

Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry
Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set
Protocol version	<u>#3</u>	Date and version identifier
Funding	<u>#4</u>	Sources and types of financial, material, and other support
Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol
responsibilities:		contributors
contributorship		
Roles and	<u>#5b</u>	Name and contact information for the trial sponsor
responsibilities:		
sponsor contact		
information		
Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study
responsibilities:		design; collection, management, analysis, and
sponsor and funder		interpretation of data; writing of the report; and the
		decision to submit the report for publication,
		including whether they will have ultimate authority
		over any of these activities
Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the
responsibilities:		coordinating centre, steering committee, endpoint

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1			and other individuals or groups overseeing the
2 3 1			trial, if applicable (see Item 21a for data
- 5 6			monitoring committee)
7 8	Introduction		
9 10	Introduction		
11 12	Background and	<u>#6a</u>	Description of research question and justification
13 14	rationale		for undertaking the trial, including summary of
15 16			relevant studies (published and unpublished)
17 18 10			examining benefits and harms for each
20 21			intervention
22			
23 24	Background and	<u>#6b</u>	Explanation for choice of comparators
25 26 27	rationale: choice of		
27 28 29	comparators		
30 31	Objectives	#7	Specific objectives or hypotheses
32 33			
34 35	Trial design	<u>#8</u>	Description of trial design including type of trial
36 37			(eg, parallel group, crossover, factorial, single
38 39			group), allocation ratio, and framework (eg,
40 41 42			superiority, equivalence, non-inferiority,
42 43 44			exploratory)
45			
47	Methods:		
48 49 50	Participants,		
50 51 52	interventions, and		
53 54	outcomes		
55 56 57 58	Study setting	<u>#9</u>	Description of study settings (eg, community
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1			clinic, academic hospital) and list of countries
2 3			where data will be collected. Reference to where
4 5			list of study sites can be obtained
6 7			
8 9	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If
10 11			applicable, eligibility criteria for study centres and
12 13			individuals who will perform the interventions (eg,
14 15			surgeons, psychotherapists)
16			
18 19	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail
20 21	description		to allow replication, including how and when they
22 23			will be administered
24 25	laten vantievaa.	Щааь	Criteria for discontinuing on modificing allocated
26 27	Interventions:	<u>#11D</u>	Criteria for discontinuing or modifying allocated
28 29	modifications		interventions for a given trial participant (eg, drug
30 31			dose change in response to harms, participant
32 33			request, or improving / worsening disease)
34 35			
36 37	Interventions:	<u>#11C</u>	Strategies to improve adherence to intervention
38 39	adherance		protocols, and any procedures for monitoring
40 41			adherence (eg, drug tablet return; laboratory
42 43			tests)
44 45	Interventione	#114	Polycent concernitent care and interventions that
46 47	interventions.	<u>#110</u>	Relevant concomitant care and interventions that
48 49	concomitant care		are permitted or prohibited during the trial
50 51	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes,
52 53			including the specific measurement variable (eq.
54 55			systolic blood pressure) analysis metric (eq
56 57			change from begeling, final value, time to event
58 59		_	change from baseline, final value, fime to event),
60	l	or peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1			method of aggregation (eg, median, proportion),
2 3 4			and time point for each outcome. Explanation of
5			the clinical relevance of chosen efficacy and harm
7 8			outcomes is strongly recommended
9 10	Participant timeline	#13	Time schedule of enrolment interventions
11 12		<u>// 10</u>	(including any run ins and washouts)
13 14 15			(including any run-ins and washouts),
15 16 17			assessments, and visits for participants. A
17 18 19			schematic diagram is highly recommended (see
20 21			Figure)
22 23	Sample size	<u>#14</u>	Estimated number of participants needed to
24 25			achieve study objectives and how it was
26 27 28			determined, including clinical and statistical
20 29 30			assumptions supporting any sample size
31 32			calculations
33 34			
35 36	Recruitment	<u>#15</u>	Strategies for achieving adequate participant
37 38			enrolment to reach target sample size
39 40 41	Methods:		
41 42 43	Assignment of		
44 45	interventions (for		
46 47	controlled trials)		
48 49			
50 51	Allocation:	<u>#16a</u>	Method of generating the allocation sequence (eg,
52 53	sequence		computer-generated random numbers), and list of
54 55 56	generation		any factors for stratification. To reduce
57 58			predictability of a random sequence, details of any
59 60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00		peer n	enen engen mapin sinjepenisingreoni, site, asoar, galaentesixitani

l

1			related processes to promote data quality (eg,
2 3			duplicate measurements, training of assessors)
4 5 6			and a description of study instruments (eg,
7 8			questionnaires, laboratory tests) along with their
9 10			reliability and validity, if known. Reference to
11 12			where data collection forms can be found, if not in
13 14 15			the protocol
16 17			
17	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and
20	retention		complete follow-up, including list of any outcome
21 22 22			data to be collected for participants who
23 24 25			discontinue or deviate from intervention protocols
26 27 28	Data management	<u>#19</u>	Plans for data entry, coding, security, and
29 30			storage, including any related processes to
31 32			promote data quality (eg, double data entry; range
33 34 35			checks for data values). Reference to where
36 37			details of data management procedures can be
38 39 40			found, if not in the protocol
41 42	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and
43 44			secondary outcomes. Reference to where other
45 46 47			details of the statistical analysis plan can be
48 49			found, if not in the protocol
50 51 52	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg,
52 53 54	analyses		subgroup and adjusted analyses)
55 56			
57 58	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

population and		protocol non-adherence (eq. as randomised		
missing data		analysis) and any statistical methods to handle		
missing data		analysis), and any statistical methods to handle		
		missing data (eg, multiple imputation)		
Methods:				
Monitoring				Protect
Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC);		19by
formal committee		summary of its role and reporting structure;		copyri
		statement of whether it is independent from the		ght, inc
		sponsor and competing interests; and reference		cluding
		to where further details about its charter can be		y for u
		found, if not in the protocol. Alternatively, an		ses rei
		explanation of why a DMC is not needed		ated to
Data manitaring:	#01b	Description of any interim analyzes and stanning	~ 20	o text
Data monitoring:	<u>#210</u>	Description of any interim analyses and stopping	p28	, appendixa
interim analysis		guidelines, including who will have access to		(protocol)a a
		these interim results and make the final decision		ining
		to terminate the trial		Al train
Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and	p28	, appendix
		managing solicited and spontaneously reported		(protocol)
		adverse events and other unintended effects of		lar tec
		trial interventions or trial conduct		hnolog
Auditing	<u>#23</u>	Frequency and procedures for auditing trial	p28	, appendix
		conduct, if any, and whether the process will be		(protocol)
		independent from investigators and the sponsor		
Ethice and				
Ethics and	-			
	For peer i	review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

Page 59 of 59

1 2	dissemination			
3	Research ethics	<u>#24</u>	Plans for seeking research ethics committee /	22
5 6 7	approval		institutional review board (REC / IRB) approval	pupus
8 9 10	Protocol	<u>#25</u>	Plans for communicating important protocol	22 as
11 12	amendments		modifications (eg, changes to eligibility criteria,	Protect
13 14			outcomes, analyses) to relevant parties (eg,	ted by
15 16			investigators, REC / IRBs, trial participants, trial	copyri
17 18 19			registries, journals, regulators)	ight, inc
20 21 22	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from	udin p28 appendix م
23 24			potential trial participants or authorised	consent) الم
25 26 27			surrogates, and how (see Item 32)	seignen s relater
28 29 20	Consent or assent:	<u>#26b</u>	Additional consent provisions for collection and	p28 appendixes
30 31 32	ancillary studies		use of participant data and biological specimens	(consent)d
33 34 25			in ancillary studies, if applicable	r (ABES ata min
35 36 37	Confidentiality	<u>#27</u>	How personal information about potential and	p28 appendix
38 39			enrolled participants will be collected, shared, and	(consent)
40 41 42			maintained in order to protect confidentiality	y, and
43 44			before, during, and after the trial	similar t
45 46 47	Declaration of	<u>#28</u>	Financial and other competing interests for	echnolc 230
48 49	interests		principal investigators for the overall trial and each	ogies. czo ar
50 51 52			study site	Agence
53 54 55	Data access	<u>#29</u>	Statement of who will have access to the final trial	p28, appendix
56 57 58			dataset, and disclosure of contractual agreements	(protocol) april gr
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	e de le

1			that limit such access for investigators	
2 3 4	Ancillary and post	<u>#30</u>	Provisions, if any, for ancillary and post-trial care,	p28, appendix
5 6 7	trial care		and for compensation to those who suffer harm	(protocol)
7 8 9			from trial participation	
10 11 12	Dissemination	<u>#31a</u>	Plans for investigators and sponsor to	Protect 222ct
13 14	policy: trial results		communicate trial results to participants,	ed by
15 16			healthcare professionals, the public, and other	соругі
17 18 19			relevant groups (eg, via publication, reporting in	ght, in
20 21			results databases, or other data sharing	cludin
22 23			arrangements), including any publication	g for u
24 25 26			restrictions	Ises rela
27 28 29	Dissemination	<u>#31b</u>	Authorship eligibility guidelines and any intended	p28, appendixo
30 31 32	policy: authorship		use of professional writers	(protocol) (protocol)
33 34	Dissemination	<u>#31c</u>	Plans, if any, for granting public access to the full	p28, appendix
35 36	policy: reproducible		protocol, participant-level dataset, and statistical	ين بور (protocol) ح
37 38 39	research		code	J trainin
40 41 42	Appendices			g, and si
43 44 45	Informed consent	<u>#32</u>	Model consent form and other related	p28 appendixa
46 47	materials		documentation given to participants and	(consent)
48 49 50			authorised surrogates	ogies.
51 52	Biological	<u>#33</u>	Plans for collection, laboratory evaluation, and	p28 appendix
53 54 55	specimens		storage of biological specimens for genetic or	(consent/protocol)
55 56 57 58			molecular analysis in the current trial and for	
59 60		For peer 1	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2		future use in ancillary studies, if applicable					
- 3 4 5	Not	otes:					
4 5 6 7 8 9 10 11 12 13 14 5 6 7 8 9 10 11 22 23 24 25 26 27 8 9 30 12 23 24 25 26 27 8 9 30 132 33 4 5 36 37 8 9 0 41 42 43 44 56 47 89 50 51 52 53 45 56 57 89 50 51 52 53 54 55 56 57 89 57 57 57 57 57 57 57 57 57 57 57 57 57	•	The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 01. September 2019 using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope ai					
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml					

Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study): protocol for a randomised controlled clinical trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033999.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Jan-2020
Complete List of Authors:	Divala, Titus; London School of Hygiene and Tropical Medicine, TB Centre; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Fielding, Katherine; London School of Hygiene & Tropical Medicine, TB Centre; University of the Witwatersrand, School of Public Health Sloan, Derek; University of Saint Andrews, School of Medicine French, Neil; University of Liverpool Faculty of Health and Life Sciences, Centre for Global Vaccine Research, Institute of Infection and Global Health Nliwasa, Marriott; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; London School of Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme Kandulu, Chikondi; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Chiume, Lingstone ; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Khandar, Sanderson ; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Ndaferankhande, Masiye; Malawi Liverpool Wellcome Trust Clinical Research Programme Corbett, Elizabeth ; London School of Hygiene and Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme
Primary Subject Heading :	Infectious diseases
Secondary Subject Heading:	Diagnostics, Epidemiology, Evidence based practice, General practice / Family practice, HIV/AIDS
Keywords:	trial-of-antibiotics, Tuberculosis < INFECTIOUS DISEASES, TB, antimicrobial resistance, diagnostic performance, antibiotics

1	
2	
3	SCHOLARONE™
5	Manuscripts
6	inditabenip to
7	
9	
10	
11	
12	
13	
15	
16	
17	
19	
20	
21	
22	
24	
25	
26	
27 28	
29	
30	
31 32	
33	
34	
35	
30 37	
38	
39	
40 41	
42	
43	
44	
45 46	
47	
48	
49	
50	
52	
53	
54 55	
56	
57	
58 59	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2 3		
4 5	1	TITLE
6 7		
, 8 9	2	Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study):
9 10 11	3	protocol for a randomised controlled clinical trial
12 13	4	Authors
14 15 16	5	Titus H Divala ^{1,2,3} , Katherine L Fielding ^{1,4} , Derek J Sloan ⁵ , Neil French ⁶ , Marriott Nliwasa ^{1,2,3} ,
17 18	6	Peter MacPherson ^{3,7} , Chikondi Kandulu ^{2,3} , Lingstone Chiume ^{2,3} , Sanderson Chilanga ^{2,3} ,
19 20 21	7	Masiye Ndaferankhande ³ , Elizabeth L Corbett ^{1,2,3}
22 23	8	Author affiliations
24 25	9	1. TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street,
26 27	10	Bloomsbury, London, United Kingdom
28	11	2. Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
29 30	12	Blantyre, Malawi
31	13	3. Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
32 33	14	4. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
34 35	15	5. School of Medicine, University of St Andrews (Derek J Sloan PhD)
36	16	6. Institute of Infection & Global Health, University of Liverpool, Liverpool, United
37 38	17	Kingdom
39	18	7. Liverpool School of Tropical Medicine, Liverpool, United Kingdom
40 41	19	
42 43	20	Correspondence to:
43 44	21	Dr Titus H Divala
45 46	22	TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury,
47	23	London WC1E 7HT
48 49	24	titus.divala@lshtm.ac.uk
50	25	
51	26	KEY WORDS
53 54	27	trial-of-antibiotics, tuberculosis, TB, antimicrobial resistance, AMR, antibiotics, diagnostic
55	28	performance, sensitivity, specificity, randomised controlled clinical trial, randomised, RCT
56 57	29	
58 59 60	30	Protocol version 3.0, 19 Feb 2019

31 ABSTRACT:

32 Introduction

Over 40% of global tuberculosis case notifications are diagnosed clinically without mycobacteriological confirmation. Standard diagnostic algorithms include "trial-of-antibiotics" -empirical antibiotic treatment given to mycobacteriology-negative individuals to treat infectious causes of symptoms other than tuberculosis, as a "rule-out" diagnostic test for tuberculosis. Potentially 26.5 million such antibiotic courses/year are prescribed globally for the 5.3 million/year mycobacteriology-negative patients, making trial-of-antibiotics the most common tuberculosis diagnostic, and a global-scale risk for antimicrobial resistance (AMR). Our systematic review found no randomised controlled trial (RCT) to support use of trial-of-antibiotic. The RCT aims to determine the diagnostic and clinical value and AMR consequences of trial-of-antibiotics.

43 Methods and analysis

A three-arm, open-label, RCT randomising (1:1:1) Malawian adults (≥18years) seeking primary care for cough into: a) azithromycin 500mg once daily for 3 days, or b)amoxicillin 1g three times/day for 5 days, or c) standard-of-care (no immediate antibiotic). We will perform Mycobacteriology tests (microscopy, Xpert/MTB/RIF and Mycobacterium-Tuberculosis culture) at baseline. We will use Audio-Computer-Assisted-Self-Interview (ACASI) to assess clinical improvement at day eight. First primary outcome will be proportion of patients reporting day-eight improvement out of those with negative mycobacteriology (specificity). Second primary outcome will be day 29 incidence of a composite endpoint of either death or; hospitalisation or; missed tuberculosis diagnosis. To determine AMR impact we compare proportion of resistant nasopharyngeal Streptococcus pneumoniaee isolates on day 29. 400 mycobacteriology-negative participants/arm will be required to detect a $\geq 10\%$ absolute

Page 2 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

difference in diagnostic specificity with 80% power. We will estimate measures of effect by
comparing outcomes in antibiotic arms (combined and individually) to standard-of-care.

57 Ethics and dissemination

58 The study has been reviewed and approved by Malawi College of Medicine Research and 59 Ethics Committee, London School of Hygiene &Tropical Medicine (LSHTM) Research Ethics 60 Committee, and Regional Committee for Health and Research Ethics –Norway, and Malawi 61 Pharmacy, Medicines, and Poisons Board (Appendix 1). We will present abstracts at 62 relevant conferences, and prepare a manuscript for publication in a peer-reviewed journal.

Registration

64 Clinicaltrials.gov, NCT03545373

65 Strengths and limitations

- To our knowledge this is the first randomised controlled trial to address benefits and consequences of using antibiotics as an exclusion diagnostic for tuberculosis, a widely used practice that results in millions of antibiotic prescriptions/year.
- We will also contribute evidence on AMR affecting common antimicrobials used for managing respiratory infections.
- The use of ACASI for assessing clinical response and adherence to antibiotic
 treatment which can be used in future studies.
- Acknowledged weaknesses include limited power to evaluate safety of deferred
 antibiotic treatment; conduct subgroup analysis by HIV status; and the possibility that
 participants randomised to the standard-of-care arm may find alternative access to
 antibiotics therefore misclassifying exposure/intervention status.

Page 3 of 31

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

The high case-fatality rate for tuberculosis, the leading global infectious cause of death in adults¹ with approximately 10 million cases and 1.6 million deaths in 2017,² in part reflects suboptimal diagnostics.³⁻⁶ To complement this diagnostic gap, standard algorithms throughout the world include a "trial-of-antibiotics" (Figure 1). This is a course of broad-spectrum antibiotics, with negligible Mycobacterium tuberculosis activity, given to patients with symptoms such as cough in order to "rule-out" or "rule in" tuberculosis.⁷⁻⁹ In clinical practice and most national guidelines (summarised in figure 1), patients who have negative sputum mycobacteriology and have responded to antibiotic treatment are considered tuberculosis-negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations potentially leading on to receiving tuberculosis treatment.7-9

We estimate that 26.5 million courses of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations recorded annually,¹⁰ making antibiotics the most common diagnostic for tuberculosis.¹¹ Our 26.5 million estimate assumes that for every one smear-negative tuberculosis case detected, five antibiotics courses are used: the first two courses being given to patients are ultimately registered as smear-negative tuberculosis, while the other three courses represent patients whose symptoms resolved without starting anti-tuberculosis treatment.^{4 12} This high frequency of prescription of important broad-spectrum antibiotics raises a global-scale risk for antimicrobial resistance (AMR) which like tuberculosis, is a major crisis, becoming in 2016 one of only four health topics ever to be discussed at the United Nations General Assembly.¹³⁻¹⁶

Page 7 of 134

BMJ Open

We performed a systematic literature review¹⁷ which demonstrated that, despite being in global and national guidelines for decades, trial-of-antibiotics has a limited supporting evidence base but with the available evidence suggesting poor diagnostic performance.¹⁸ None of the identified studies was an RCT and most of the observational studies were very small and not primarily designed to assess the benefits and consequences of trial-of-antibiotics. Pooled sensitivity and specificity of trial-of-antibiotics versus mycobacteriology tests were below internationally defined minimum performance profiles for tuberculosis diagnostics.19

We hypothesise that use of antibiotics in the course of evaluating patients for tuberculosis has both benefits and risks that need to be weighed carefully to optimise patient and public health outcomes. We will address evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes of trial-of-antibiotics by conducting an RCT (ACT-TB Study) recruiting adult patients with cough presenting to health centres in Blantyre, Malawi. To our knowledge this is the first randomised controlled trial to rigorously address these questions. Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Page 5 of 31

This is a three-arm individually randomised (1:1:1), open-label controlled clinical trial (RCT)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3 4 5	120
6 7 8 9	121
10 11 12	122
12	123
14 15 16	124
17	125
19 20	126
21 22 23 24	127
25 26 27	128
27	129
29 30	130
31 32 33	131
34 35 36	132
37 38 39 40	133
41 42	134
43 44	135
45 46	136
47 48 40	137
49 50 51	138
52 53	139
55 54 55	140
56 57	141
58 59	
60	

1 2

METHODS AND ANALYSIS

Study design 121

2		
3 4	123	investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-
5 6	124	of-antibiotics to rule-out tuberculosis among adults presenting with cough at primary care
7 8	125	centres in Malawi (Figure 2). The trial is registered with Clinicaltrials.gov (NCT03545373)
9 20 21	126	(Appendix 2). The full trial protocol is provided as Appendix 3.
22 23 24	127	Study setting
26 97	128	We will screen adults aged at least 18 years presenting to Limbe and Ndirande health
28 29	129	centres in Blantyre, Malawi. Blantyre has an estimated tuberculosis prevalence of 1,014 per
80 81	130	100,000 (95% CI: 486 to 1,542), and an estimated adult HIV prevalence of 12.7% (95% CI:
32 33 34	131	11.9 to 13.6). ²⁰
35 36 37	132	Eligibility criteria
89 10	133	We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.
11 12	134	Inclusion Criteria
+3 14 15	135	Ambulatory clinic attendees presenting with cough
16 17	136	Unwell for at least 14 days
19 19	137	Aged at least 18 years
50 51	138	Reside in Blantyre and willing to return to the same clinic for follow up visits over the
52 53	139	entire study period.
54 55	140	Exclusion Criteria
56 57 58 59 50	141	Self-reported allergy to study medications
1 2		
---	-----	--
- 3 4	142	 WHO/Malawi National tuberculosis Program (NTP) danger signs: respiratory rate >
5 6	143	30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory
7 8	144	distress, systolic blood pressure <90 mmHg, inability to walk unassisted
9 10	145	Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
11 12	146	Tuberculosis treatment or isoniazid preventive therapy within the last 6 months
13 14	147	
$\begin{array}{c} 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	148	
60		

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

149 Interventions

150 We will randomise participants, in a ratio of 1:1:1, to the following arms:

• Arm 1 (Azithromycin): Azithromycin 500mg taken once daily for 3 days from enrolment day

Arm 2 (Amoxicillin): Amoxicillin 1g taken three times daily for 5 days from enrolment day.

• Arm 3 (Standard of care): No study antibiotic prescription.

²¹ 156

Rationale for interventions

Amoxicillin was chosen because it is the standard antibiotic used as first line treatment and for trial-of-antibiotics in Malawi. However, amoxicillin may not demonstrate the best performance for trial-of-antibiotics because of increasing resistance, and a narrow coverage for aetiology of community acquired pneumonia and "atypical" organisms. We chose azithromycin to represent the optimal biological specificity of an oral regimen due to more complete coverage of atypical organisms that cause community acquired pneumonia (e.g. mycoplasma and chlamydia), and also the low resistance rates in Malawi where macrolides are rarely used. The dose for Azithromycin is as recommended in the British National Formulary (BNF) as treatment for community acquired pneumonia.²¹ The dose for amoxicillin is the BNF recommendation for severe infections but it is the recommended first line established by the Department of Medicine at Queen Elizabeth Central Hospital (Blantyre, Malawi) based on local microbiology.

⁵¹ 169 **Timing of interventions**

The standard of care in Malawi defined by National Tuberculosis Programme guidelines for
 primary care patients presenting with cough who are otherwise well (no danger signs) is to
 take two sputum specimens for smear microscopy or Xpert and ask patients to return for

Page 8 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

results, typically 3 days - 1 week later (Figure 1). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to patients who remain symptomatic. Therefore, the ideal population for randomisation for this study are patients on who already have negative results for smear microscopy or Xpert. However, that may have ethical challenges considering the implications of withholding treatment (if randomised to reference arm) from a symptomatic patient who, according to guidelines, should be given antibiotics. The first visit therefore was the most ideal time for randomisation and is in line with recommendations for test interval in investigations evaluating diagnostic tests with respect to the time interval between the index test (trial-of-antibiotics) and the reference test (mycobacteriology sputum sample collection). The timing also conforms to common clinical practice of prescribing trial-of-antibiotics at the same time as sputum collection to reduce diagnostic delay. The design was discussed with the District Health Office and the national tuberculosis programme ahead of ethics submission. 02:

Known drug reactions

Azithromycin and amoxicillin have a long registration history, have been widely used globally and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some to subsequently start tuberculosis therapy. Important interactions therefore would be those those between the product and HIV antiretroviral drugs. There is no moderate or

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

198 major interaction between either azithromycin or amoxicillin with the classes of HIV

199 antiretroviral drugs currently used in Malawi.

Trial restrictions

201 We do not require participants to have any dietary restrictions. We will also accept co-

administration with contraception. Azithromycin and amoxicillin are both considered safe in

203 pregnancy, so we will include pregnant women should they be eligible.

204 Assessment of compliance

205 On Day-8, we will document self-reported compliance adherence of study products.

206 Withdraw of interventions

The investigator may also terminate a participant from study product if indicated by an
adverse reaction. If a participant stops taking study product either voluntarily or by
investigator decision, they will be encouraged to remain in follow up and their data will form
part of intention to treat analyses.

211 Study outcomes

The clinical trial has two separately powered, and distinctly assessed primary outcomes, one
for diagnostic evaluation (Primary outcome 1: Day 8) and the other for clinical impact
(Primary outcome 2: Day 29) of the intervention. The following are descriptions of all study
outcomes:

Primary outcome 1: Specificity of day 8 symptom change versus mycobacteriology The investigational test is change in symptoms at Day 8 categorised as: improved or not improved (no change or worsened) in response to the question: on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved?

Page 10 of 31

BMJ Open

2		
3 4	221	As with all self-rated outcomes, social desirability bias (tendency of participants to answer
5 6 7 8 9 10 11 12 13 14 15 16 17 18	222	questions in a manner that will be viewed favourably by healthcare worker), and interviewer
	223	bias (interviewers' subconscious or conscious influencing subject response) may affect the
	224	outcome. To minimise these biases in evaluation of improvement of baseline symptoms the
	225	interview will be conducted using Audio Computer Assisted Self-Interview (ACASI), a
	226	platform that allows patients to report their health state in private and directly into a database
	227	via an audio questionnaire administered by a tablet. The lack of human-to-human interaction
	228	will minimize interviewer, ascertainment, and social desirability biases. Another concern with
19 20 21	229	open-label design is placebo-effect favouring those randomised to antibiotics over the
21 22 23	230	standard of care arm that is however not addressed in our design.
24 25	231	We developed, piloted, and optimised the ACASI questionnaire in the study target population
26 27	232	and arrived at the question: on day 1, you reported that you were unwell: compared to that
28 29 30 31 32 33 34 35 36 37	233	day, has your illness worsened, remained the same, or improved? Before proceeding to the
	234	self-interview, participants will be oriented using test questions until study staff are sure that
	235	they will be able to go through the interview on their own. We will term ACASI interview
	200	autoomo as ACASI test pagative if the participant reports improvement or ACASI test
	230	outcome as ACASI-lest-negative in the participant reports improvement of ACASI-lest-
38 39	237	positive if the participant reports no change or worsening.
40 41	238	The mycobacteriology reference standard will be defined in participants with at least one
42 43	239	valid sputum test result on days 1 and 8 as sputum-test-positive if there is at least one
44 45	240	positive of smear microscopy, Xpert/MTB/RIF, or MTB culture; and as sputum-test-
46 47	241	negative if none of the tests is positive. To minimise bias, the sputum tests will be performed
48 49	242	by a high-quality research laboratory in the University of Malawi College of Medicine by staff
50 51 52	243	with no access to participant treatment allocation information or symptom results.
52 53 54	244	The specificity of day 8 symptom change (the index test measured using ACASI) against
55 56	245	mycobacteriology tests (reference test) is defined as: proportion of sputum-test-negative
57	246	who are ACASI-test-negative
59 60	270	

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3	247	
4 5 6	248	Primary outcome 2: Clinical impact of trial-of-antibiotics
7 8	249	We will investigate the overall clinical impact of trial-of-antibiotics by comparing the day 29
9 10 11	250	risk of any of death, hospitalisation, and "missed tuberculosis" (untreated
12 13	251	mycobacteriological or radiological tuberculosis). All these events can lead to mortality and
14 15	252	are potential consequences of trial-of-antibiotics; therefore, grouping them as a composite
16 17	253	endpoint appropriately represents the effect of the intervention because: 1) there are
18 19	254	similarities in the importance of each of the components, 2) the components occur with
20 21	255	similar frequencies in the patient population, and 3) the direction of effect is anticipated to be
22 23	256	the same for all. ²²
24 25 26	257	The connection between trial-of-antibiotics and risk of hospitalisation and death assumes a
27 28 29 30 31 32 33	258	protective effect of antibiotics. In patients presenting with chronic cough at primary care in
	259	high HIV prevalence settings, frequencies of mortality and hospitalization over a two months
	260	period are similar, ranging from 2 to 6%. ²³
34 35	261	We have included missed tuberculosis diagnosis in our composite clinical outcome because
36 37	262	this too can lead to death. We are defining "missed tuberculosis" as participants who meet
38 39	263	standard mycobacteriological and radiological tuberculosis definitions but are incorrectly
40 41	264	classified as tuberculosis-negative and not vet on tuberculosis treatment by Day 29. Clinical.
42 43	265	radiological, and microbiological evaluation for tuberculosis will be done at Day 8, Day 29, as
44 45	266	well as day between these two for patients who report worsening symptoms.
46 47		
48 49	267	Secondary outcome 1: impact of trial-of-antibiotics on antimicrobial resistance
50 51 52 53 54 55	268	We will use Streptococcus pneumoniae isolated from swabs of the nasopharynx as the
	269	indicator pathogen for AMR evaluation. An ecological niche for many bacterial species, the
	270	upper respiratory tract also presents a convenient window for investigating antimicrobial
56 57	271	resistance. Streptococcus pneumoniae is the organism of choice not only for being an
58 59 60	272	important cause of respiratory tract infections but also because it often colonises the upper
		Page 12 of 31

respiratory tract, acquires resistance readily, and has well documented laboratory investigation procedures in place.24 We will define **AMR positive** as having nasopharyngeal isolates of *Streptococcus* pneumoniae that are resistant to any of the following commonly used antibiotics: ceftriaxone, amoxycillin, cefoxitin, azithromycin, and erythromycin as determined using disc diffusion technique; and AMR negative as either (1) not isolating any Streptococcus pneumoniae or (2) isolating any Streptococcus pneumoniae that is not resistant to any of the assessed antibiotics. For each arm, and at both baseline and day 29, we will report proportion of AMR positive participants. The study outcome will be the proportion of AMR positive participants at day 29. Secondary outcome 2: diagnostic value of trial-of-antibiotics in all patients including those without a valid sputum result The investigational test is as described for primary outcome 1. The mycobacteriology reference standard will be defined as sputum test positive if at least one positive of smear microscopy, Xpert/MTB/RIF, or MTB culture from samples collected on days 1 and 8. The reference test will be sputum-test-negative if none of the tests is positive and where there is no valid sputum test result available. The most likely reason for not having a valid sputum result will be inability to produce sputum, but other explanations will be: lost sample before laboratory analysis, an invalid laboratory reading, or contamination. We have opted to analyse this population because in symptomatic adults of the study setting, failure to

Secondary outcome 3: Economic evaluation

produce sputum can be as high as 13%.²³

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions. We will perform a within trial comparison of the three treatment arms to estimate the incremental

Page 13 of 31

3 4	3
5 6	3
7 8	З
9 10	3
11 12	3
13 14	3
15 16	3
17 18	3
19 20	2
21 22	L.
23 24 25	3
25 26 27	3
27 28 20	3
29 30 21	3
32 32	3
34 35	3
36 37	
38 39	3
40 41	3
42 43	3
44 45	,
46 47	3
48 49	3
50 51	3
52 53	3
54 55	3
56 57	3
58 59	
60	

1 2

cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in
comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health
perspective. Health outcomes will be quantified in QALYs, estimated from participants'
responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL)
measure.^{25 26} We will adopt a time horizon matching the length of participant follow-up to
achieve the within trial evaluation.

307 Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** 308 arms for all our primary and secondary outcomes.

309 Planned subgroup analyses

We will perform analysis of primary outcomes stratified by HIV status and by ART status as documented on enrolment day. This is important because the study site has high prevalence of HIV and associated bacterial infections which may be amenable to antibiotics used for trial-of-antibiotics.

314 Study procedures

Figure 2 and Table 1 presents the study time schedule including a summary of patient
 identification, baseline procedures and outcome ascertainment at day 8 and day 29 follow up
 317 visits.

318 Screening

 $\frac{1}{8}$ 319 Study staff will approach patients with symptoms of pulmonary tuberculosis (including cough

320 of any duration, fever, weight loss, and night sweats) with information about the study and

321 seek written informed consent (Appendix 4) from all patients who meet eligibility criteria.

322 After consenting, a participant will be given a unique study identification number confirming

5 323 enrolment.

Randomisation

1 2 3

5 6	325	Randomisation will be in the ratio 1:1:1 to the three arms of the trial, using block-
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 44 45 44 45 44 45 44 45 46 47 46 47 46 47 47 47 47 47 47 47 47 47 47	326	randomisation with variable block sizes, and stratified by study site. An independent
	327	statistician will prepare the randomisation list using Ralloc command in Stata software, then
	328	print each allocation alongside a randomisation number, and seal in opaque envelopes.
	329	Upon confirming eligibility and consenting status a designated site staff will open the next
	330	available of sequentially numbered randomisation envelopes and administer the allocated
	331	study arm.
	332	Blinding
	333	The study is not placebo controlled because of funding limitations, and so will not use
	334	blinding due to the nature of the study design. However, study team masking will be
	335	maintained with all study outcome assessment occurring without reference to randomisation
	336	arm.
	337	Baseline procedures
	338	At baseline, we will collect demographic data, clinical history, record vital signs, height and
	339	weight. Participants will be requested to provide two sputum samples for Xpert/MTB/RIF and
	340	two more sputum samples the following morning for smear microscopy and MTB culture. We
	341	will also collect a urine sample for lipoarabamannan antigen detection (TB LAM); and a
	342	nasopharyngeal swab for pneumococcal culture and sensitivity testing. We will offer and
46 47	343	perform HIV testing according to the national algorithm, and link all who test positive to care.
48 49 50	344	To minimise loss to follow up, we will collect contact phone numbers, a physical address and
50 51 52	345	geolocation information.
53 54	346	Participant follow up
55 56	347	On day 8, the first activity (ahead of any other interaction with study staff) will be the ACASI.
57 58 59	348	Other activities include providing results for day 1 tuberculosis tests and linking those who
60	349	test positive to care; collection of another sputum sample for smear microscopy and
		Page 15 of 31
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Mycobacterium tuberculosis (MTB) culture; and management of ongoing symptoms and
other illnesses. On visit day 29, the final study visit, we will document participant vital status,
hospitalisations, and establish adherence to HIV and tuberculosis treatment. We will also
collect nasopharyngeal swab samples from all participants, and sputum from those with
tuberculosis symptoms.

355 Participant retention

To minimise loss to follow up, we will record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

362 Data management

We will collect data using TeleForm (paper based system that uses optical character
recognition) and Open Data Kit systems (ODK, an electronic data capture system installed
on android devices). Data will be committed to a secure database located at MalawiLiverpool Wellcome Trust (MLW) within 2 days for TeleForm, and 7 days for ODK.

1

2	
3	
4	
5	
6	
7	
8	
å	
10	
10	
11	
12	
13	
14	
15	
16	
10	
17	
18	
19	
20	
21	
22	
22	
23	
24	
25	
26	
27	
28	
29	
20	
50	
31	
32	
33	
34	
35	
36	
27	
27	
38	
39	
40	
41	
42	
43	
11	
-1-1 // E	
45	
46	
47	
48	
49	
50	
51	
57	
52	
53	
54	
55	
56	
57	
58	
50	
72	

55	
60	

369

Table 1: key study proc	edures over the	study	period

	STUDY PERIO	C		
	Enrolment		Follow up	
TIMEPOINT	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	x			
Informed consent	x			
Allocation	Х			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	×			
Standard of care	x			
ASSESSMENTS:	0			
Demographics	x			
History of antibiotic use	x	x		x
History & examination ¹	x	Х		Х
Sputum collection ²	×	x		
Urine for TB LAM test ³	х	x		
Nasopharyngeal swab for	×	0		v
AMR ⁴	^			^
HIV test	x	7		
Linking to routine care	x	×		Х
ACASI ⁵		x	6	
Clinical events ⁶				Х
Update contact & address		x	1	Х
 For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform 				

2. Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and per mycobacteriology at any time of the study when clinically indicated

3. Urine Lipoarabinomannan for Tuberculosis Diagnosis (TB LAM)

4. Nasopharyngeal swab for Streptococcus pneumoniaeee culture and sensitivity as a way of determining risk of antimicrobial resistance (AMR)

5. Audio Computer Assisted Self-Interview (ACASI) for documenting change of symptoms on Day- 8 versus Day-1

6. Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new tuberculosis diagnosis, death, hospitalisation, missed tuberculosis diagnosis, HIV care loss to follow up, and tuberculosis care loss to follow up

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

370 Statistical approach

 We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT (Consolidated Standards of Reporting Trials) flow chart. We will describe the study participants by their baseline characteristics, by arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to). Analysis for primary outcome 1 will be restricted to participants with a valid sputum test result. We will report measures of effect from the following comparisons:

- ²⁰₂₁ 377 i) Azithromycin or amoxicillin (combined) versus standard of care
 - 378 ii) azithromycin versus standard of care
- ²⁴25 379 iii) amoxicillin versus standard of care

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for study site. For each comparison, we will report 95% confidence intervals (CIs) and p-values from the likelihood test. If outcomes are rare, or the GLM model does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio. We will report the odds ratios with their associated 95% CIs and p-values.

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College
station, Texas, USA). The statistical approach will be expanded in a detailed statistical
analysis plan, which will be finalised before unblinding the study data.

389 Sample size and power

390 We performed power and sample size estimations for the diagnostic impact, clinical impact,
 391 and AMR impact outcomes as described below. Our sample size estimations are based on
 392 planned analysis that will use Chi-squared test for comparing two independent proportions.
 393 We applied a normal-approximation correction for continuity.

Page 18 of 31

3	894	Diagnostic impact outcom	ne			
3	895	We assume that at Day 8, change in well-being from baseline state in trial-of-antibiotics				
3	896	(azithromycin or amoxicillin) arms will correctly classify 60% of all mycobacteriology negative				
3	897	participants (i.e 60%specifi	city of day 8 symptom change in t	rial-of-antibiotics arms). ¹² We		
3	898	wanted to estimate a samp	le size that would provide a discri	minatory power of 80% at a two		
3	899	sided significance level of 5	i%, to detect at least 10% differen	ce in specificity (i.e ≤50%		
4	00	specificity of day 8 symptor	n change in standard of care arm)). The sample sizes will differ by		
4	01	the number of arms being o	compared, we have therefore prov	rided two separate estimates in		
4	02	line with type of comparisor	ns specified under section 7.			
4	03	Sample size for a combin	ation of 2 antibiotic arms again	st standard of care arm		
4	04	The sample size estimates along with assumptions for this comparison are shown in the				
4	05	Table 2A. To achieve the desired 80% discriminatory power, we will need to recruit at least				
4	06	305 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to				
4	07	produce and submit sputum, and loss-to-follow up increases the sample to 472 per arm or				
4	80	1,416 for the whole study.				
4	09	Table 2A: Sample size estimation for the diagnostic impact outcome comparing a				
4	10	combination of two antibiotic arms to standard of care arm				
	Γ	POWER (X2 difference	Effect size (50% SoC vs	Effective sample per arm		
		between independent proportions)	60% amoxycillin or azithromvcin)	(Sputum negative participants needed)		
		0.70	0.10	325		
		0.75	0.10	363		
		0.80	0.10	400		
		0.85	0.10	463		
		0.90	0.10	538		
	Γ	Target power and re	espective sample size estimates b	ased on knowledge of TB risk,		

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2 3 4	412	Sample size for one antibiotic arm against standard of care arm				
5 6 7	413 The sample size estimates along with assumptions for this comparison are shown					
, 8 9	414	Table 2B. To achieve the desired 80% discriminatory power, we will need to recruit at least				
10 11	415 400 sputum-test-negative participants per arm. Accounting for TB prevalence, a					
12 13	416	produce and submit sputum, and loss-to-follow up increases the sample to 625 per arm				
14 15	417 1,875 for the whole study.					
16 17 18	418	Table 2B: Sample size estimation for the diagnostic impact outcome one antibiotic arm to				
19 20 21	419	standard of care arm				
22 23 24 25		POWER (X2 difference between independent proportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)		
26 27	L	0.70	0.10	243		
28 29		0.75	0.10	271		
30 31						
32 33		0.85	0.10	347		
34 35		0.90	0.10	403		
36 37 38		Target power and respect ability to produce and sul	tive sample size estimates bas omit sputum, and loss-to-follow	ed on knowledge of TB risk, up.		
39 40	420		0			
41 42 43	421	Power for clinical impact outcome				
44 45	422	For the clinical impact of trial-of-antibiotics outcome, we assume a 4% baseline risk of				
46 47	423	composite outcome, and a loss to follow up of 10% by Day 29. Using the sample size of 625				
48 49	424	participants per arm (obtained in	Table 2B), and a type I alpha of	of 5%, we will be able to		
50 51	425	detect the difference between arms with 80% power, if the risk in the intervention arm is				
52 53	426	twice that of the standard of care arm. This estimate is applicable to all comparisons shown				
54 55 56 57 58 59 60	427	in section 3.				

428 Power for AMR outcome

Study arms will be compared based proportion of participants with resistant Streptococcus pneumoniae on day 29. We assume that 45% of Day-29 nasopharyngeal swabs will successfully grow Streptococcus pneumoniae, and that 10% of the isolates will meet the definition of resistance (described earlier under outcomes), and that 10% will be lost to follow up by Day 29. Therefore, on day 29, the standard of care arm (of 625 participants) will have 253 Streptococcus pneumoniae isolates, 25 of which would meet the definition of resistance. This translates into a 4% (25/625) risk of AMR positive cases in the standard of care arm. To detect a twofold change in odds of day 29 AMR risk with at least 80% power, using Pearson's Chi-squared test, at 0.05 alpha, we will need at least 431 and 553 participants per arm for the 2:1 and pairwise comparisons respectively.

439 Monitoring and oversight

The trial will be monitored by the Research Support Centre Clinical Trials Unit of the
University of Malawi College of Medicine. An independent Data and Safety Monitoring Board
(DSMB), and a Trial Steering Committee (TSC) have been set up and meet bi-annually.

443 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant,
and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab
work will continue beyond trial closure. The trial may be terminated early by the trial steering
committee upon recommendation of the DSMB. The halting rule for a trial arm is an
unacceptable high level of deaths assessed using an alpha determined at the first DSMB
meeting.

450 PATIENT AND PUBLIC INVOLVEMENT

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

451 Patients were involved in the design of the study especially the audio-computer-assisted
452 interview (ACASI) used for collecting primary outcome data. Health workers were involved in
453 the design of study visits and patient flow.

DISCUSSION

The ACT-TB study will investigate the benefits and consequences of "trial-of-antibiotics," a widely promoted approach to many patients with suspected tuberculosis in low- and middleincome countries without solid evidence base. To our knowledge, ACT-TB Study is the first RCT of this kind. Results of our trial will add to the evidence-base regarding routine diagnosis of tuberculosis in low and middle-income countries and strengthen our fight against AMR. Both tuberculosis and AMR are diseases of major importance globally, with tuberculosis causing an estimated 1.6 million deaths in 2017 and AMR projected to cause

462 10 million deaths per year by 2050.^{2 27}

463 Choice of study interventions

We have chosen amoxicillin because it is the first line treatment for outpatient management
of pneumonia in Malawi and is commonly used for trial-of-antibiotics. It also provides data of
immediate programmatic relevance and a starting point to investigate exacerbation of preexisting AMR pressure. However, amoxicillin may not demonstrate the full benefits for trialof-antibiotics because of organisms with intrinsic ("atypicals") or acquired (common in gramnegative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁸ Oral antibiotics that
may provide the better diagnostic discrimination for bacterial versus mycobacterial causes of
cough are macrolides, such as azithromycin, because of better intrinsic coverage of
"atypical" intracellular organisms such as *mycoplasma* species that cause community
acquired pneumonia,²⁹⁻³¹ and low levels of acquired macrolide-resistance in bacterial isolates
in Malawi.²⁸

ACASI for post-treatment improvement assessment

Our systematic review¹⁸ did not identify a consistent definition of tuberculosis or no tuberculosis based on trial-of-antibiotics. A definition of clinical change following antibiotic treatment is necessary for the trial-of-antibiotics as this determines who get categorised as well or tuberculosis-positive. Approaches that ranged from self-reported improvement to a combination of clinical and radiological assessments are likely to be highly subjective and prone to bias, as well as being a potentially avoidable source of heterogeneity between studies. In this study, we hope to address these biases (particularly, inter-observer variability, and patient/interviewer reporting or ascertainment biases) by using self-rated change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI (described under outcomes). The ACASI questionnaire, the delivery platform, and the resulting data management can all be replicated in future studies, creating potential for more standardisation in assessment of clinical response to treatment.

Potential clinical impact of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high, ^{3 32} and is often secondary to severe bacterial infections.³²⁻³⁴ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are Streptococcus pneumoniaee and non-typhoidal salmonellae: both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active Mycobacterium tuberculosis disease.³²⁻³⁴ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected tuberculosis in people living with HIV, then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to tuberculosis treatment decisions. In this context, azithromycin may be the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

most effective arm, as salmonella infections are highly sensitive to azithromycin, but not to
 amoxicillin.²⁸

502 AMR and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{35 36} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010³⁷. Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of Streptococcus pneumoniaee, but with increased macrolide-resistance 6 months later.38 39 In this study we have the opportunity to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient sampling opportunity for investigating antimicrobial resistance.⁴⁰ Streptococcus pneumoniae is the organism of choice not only for being an important cause of respiratory tract infections but

515 also because it often colonises the upper respiratory tract, acquires resistance readily, and

40 516 has well documented laboratory investigation procedures in place.²⁴ As exploratory

² 517 analyses, we will also assess nasopharygeal colonization and antimicrobial resistance in

⁴ 518 relation to tuberculosis treatment and HIV status.

519 Important subgroups

520 Clinical response to trial-of-antibiotics is possible and indeed well-described in patients with
 521 bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the
 522 perspective of tuberculosis diagnosis) may relate to multiple super-infections.^{4 33} As such,
 523 this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark
 524 of advanced HIV immunosuppression, and are most commonly reported in patients with

BMJ Open

suspected tuberculosis in the pre-ART era. In 2015, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started tuberculosis treatment on the basis of positive mycobacteriology.²³ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and ART coverage, and by subsequent tuberculosis treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

Limitations

The study has several limitations. Firstly, we did not use a placebo-control arm. Secondly, the study is not adequately powered to evaluate safety of deferred antibiotic treatment or conduct subgroup analyses of outcomes by HIV status, both which are important evidence gaps. Other limitations include the possibility that participants randomised to the standard-of-care arm may find alternative access to antibiotics therefore misclassifying exposure/intervention status. There is also a possibility of misclassifying active tuberculosis status because of the suboptimal nature of the available tests.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

ETHICS AND DISSEMINATION

The study has been reviewed and approved by the University of Malawi College of Medicine Research and Ethics Committee (COMREC; registration number P.04/18/2381), the London School of Hygiene & Tropical Medicine Research Ethics Committee (LSHTM EC; registration number 15232), and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (REK nord; registration number 208/1964). Regulatory approval has been granted by the Malawi Pharmacy, Medicines, and Poisons Board (PMPB; registration number CTRC/III/14062018102). We will present any future protocol modifications to these bodies before implementing. We will submit results for publication in a peer-reviewed journal. We will submit abstracts to relevant national and international conferences. This work will also

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

form part of a PhD thesis for TD, which he will submit to the LSHTM. This study will followthe standards set by CONSORT guidelines.

551 AUTHORS' CONTRIBUTIONS

THD, KF and ELC are the main contributors to the conception, and design of the study. DS, MN and PM contributed to the general study planning and clinical design. NF contributed to the general study planning and antimicrobial resistance design. CK, LC, SC, and MF contributed to the design, piloting, and refining of study and clinical procedures. THD developed the first draft of the manuscript. All authors carefully reviewed and substantially contributed to the development of the trial protocol and this manuscript. All authors read and approved the final manuscript. THD is the guarantor for this work.

559 FUNDING AND SPONSORSHIP STATEMENT

560 The clinical trial is funded by the Commonwealth Scholarship Commission and the Helse 561 Nord RHF grant awarded to THD. This work is part of THD's PhD work at London School of 562 Hygiene & Tropical Medicine (LSHTM). LSHTM is the sponsor of this clinical trial (sponsor 563 address: Keppel Street, Bloomsbury, London WC1E 7HT). ELC is funded by a Wellcome 564 Trust Senior Research Fellowship in Clinical Science: WT200901. The funding agencies and 565 the sponsor had no role in the preparation of the protocol or the intention to submit this 566 manuscript for publication.

567 COMPETING INTERESTS STATEMENT

568 We have no conflicts of interest to declare.

- 569 BODY WORD COUNT: 4,034
 - **REFERENCES**

1 2		
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	571 572	 Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. <i>Infectious disease reports</i> 2016;8(2):6570. doi: 10.4081/idr.2016.6570
	573 574	 World Health Organization. Global tuberculosis report 2018: World Health Organization 2018.
	575 576 577	 Nliwasa M, MacPherson P, Mukaka M, et al. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. <i>The international</i> <i>journal of tuberculosis and lung disease</i> 2016;20(2):202-10. doi: 10.5588/ijtld.15.0388
	578 579 580 581	 Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. <i>The Lancet</i> 2007;369(9578):2042-49. doi: 10.1016/S0140-6736(07)60284-0
19 20 21 22 23	582 583 584 585	5. Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]. <i>The international journal of tuberculosis and lung disease</i> 2013;17(9):1125-38.
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 90 31 32 33 34 35 36 37 38 90 41 42 43 44 45 46 47 48 90 51 52 54 55 56 57 58 90	586 587 588	 Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. <i>The Lancet infectious</i> <i>diseases</i> 2003;3(5):288-96.
	589 590	 Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co- infection in Ghana. In: Department DCaP, ed. Accra, 2007.
	591 592	 Ministry of Health. Malawi National TB Programme Manual In: Programme NT, ed. 8 ed. Lilongwe, 2016.
	593 594	 National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, ed. Pretoria, 2014.
	595	10. World Health Organization. Global tuberculosis report 2016. 2016
	596 597 598	 McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. <i>The International Journal of</i> <i>Tuberculosis and Lung Disease</i> 2016;20(4):536-43.
	599 600 601 602	 Wilkinson D, Newman W, Reid A, et al. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. <i>The</i> <i>International Journal of Tuberculosis and Lung Disease</i> 2000;4(6):513-18. [published Online First: 2000/06/23]
	603 604 605	 Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. <i>The Lancet</i> 2016;387(10014):176-87. doi: 10.1016/S0140- 6736(15)00473-0
	606 607	 World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization 2012.
	608 609	 World Health Organization. Antimicrobial resistance: global report on surveillance: World Health Organization 2014.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

- 16. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. The Lancet 2016;387(10014):168-75. doi: 10.1016/S0140-6736(15)00474-2
 - 17. Divala TH, Fielding KL, Nliwasa M, et al. Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Systematic reviews 2018;7(1):141.
 - 18. Divala TH, Nliwasa M, Gupta-Wrigh A, et al. Is the current practice of using response to empirical broad-spectrum antibiotic treatment as an exclusion diagnostic for tuberculosis supported by evidence? Systematic review and meta-analysis. 49th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union): Int J Tuberc Lung Dis, 2018.
 - 19. World Health Organization. High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland: World Health Organization, 2014.
 - 20. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014.
 - 21. Joint Formulary Committee. British national formulary (BNF) 78: Pharmaceutical Press 2019.
 - 22. Montori VM, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials. Bmj 2005;330(7491):594-96.
 - 23. Nliwasa M, MacPherson P, Chisala P, et al. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. PloS one 2016;11(5):e0155101. doi: 10.1371/journal.pone.0155101 [published Online First: 2016/05/14]

 - 24. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 2013;32(1):165-79. doi: 10.1016/j.vaccine.2013.08.062
 - 25. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health policy (Amsterdam, Netherlands) 1990;16(3):199.
 - 26. Maheswaran H, Petrou S, MacPherson P, et al. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. BMC medicine 2016;14(1):34.
 - 27. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016. HM Government and Welcome Trust: UK 2018
 - 28. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. The Lancet Infectious Diseases 2017;17(10):1042-52. doi: 10.1016/s1473-3099(17)30394-8
 - 29. Lubell Y, Turner P, Ashley EA, et al. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics

2 3 4 5 6 7 8	651 652 653 654 655	Sensibilité aux macrolides des isolats bactériens provenant des infections acquises dans la communauté en Afrique subsaharienne et en Asie Susceptibilidad a macrólidos de aislados bacterianos provenientes de infecciones adquiridas en la comunidad. <i>Tropical Medicine & International Health</i> 2011;16(10):1192-205. doi: 10.1111/j.1365-3156.2011.02837.x
9 10 11 12	656 657 658	 Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely management measures in the first 24 hours. <i>Critical Care</i> 2016;20(1):237. doi: 10.1186/s13054-016-1414-2
13 14 15 16	659 660 661	 Lim W, Smith D, Wise M, et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. <i>Thorax</i> 2015:thoraxjnl-2015-206881.
17 18 19 20	662 663	 Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. <i>Emerging infectious diseases</i> 2009;15(2):258.
20 21 22 23 24 25 26 27 28 29	664 665 666	33. Bedell RA, Anderson ST, Van Lettow M, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. <i>PLoS One</i> 2012;7(6):e39347. doi: 10.1371/journal.pone.0039347
	667 668 669 670	34. Schleicher G, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. <i>The International Journal of Tuberculosis and Lung Disease</i> 2003;7(12):1207-08.
30 31 32	671 672	 Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. <i>Nature medicine</i> 2004;10(12s):S122. doi: 10.1038/nm1145
33 34 35 36	673 674 675	36. Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. <i>The Lancet</i> 2005;365(9459):579-87.
37 38 39 40	676 677 678	 Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. <i>PloS one</i> 2011;6(3):e17765. doi: 10.1371/journal.pone.0017765
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	679 680 681 682	38. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. <i>Clinical Infectious Diseases</i> 2013;56(11):1519-26.
	683 684 685	 Mitjà O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. New England Journal of Medicine 2015;372(8):703-10. doi: 10.1056/NEJMoa1408586
	686 687 688 689 690 691	40. Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. <i>Nat Rev Microbiol</i> 2017;15(5):259-70. doi: 10.1038/nrmicro.2017.14

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

692	LEGENDS FOR FIGURES
693	1. Legend for figure 1
694 [*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the
695	need for a third clinic visit to complete the algorithm.
696	Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of
697	tuberculosis in low and middle income countries (based on the 2018 WHO GLI model
698	guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)
699	
700	2. Legend for figure 2
701	ART = antiretroviral treatment for HIV
702	NTP = Malawi National Tuberculosis Program
703	TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis
704	VL = HIV Viral load
705	Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi
706	1
707	3. Legend for figure 3
708	Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8
709	
710	APPENDIX 1: ETHICS AND REGULATORY APPROVALS
711	(attached separately)
712	APPENDIX 2: TRIAL REGISTRATION—DATA SET
713 714	(attached separately)
715	APPENDIX 3: FULL TRIAL PROTOCOL

1 ว		
2 3 4 5	716 717	(attached separately)
6 7 8	718 719	APPENDIX 4:PATIENT INFORMATION SHEET AND INFORMED CONSENT
/ 8 9 10 1 12 13 14 15 16 7 18 9 20 20 20 20 20 20 20 20 20 20 20 20 20	719 720 721 722	(attached separately)
57 58 59		
60		
		Dago 24 of 24





*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the 2018 WHO GLI model guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)



ART = antiretroviral treatment for HIV NTP = Malawi National Tuberculosis Program TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis VL = HIV Viral load

Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi



Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8

366x222mm (96 x 96 DPI)



CERTIFICATE OF ETHICS APPROVAL

This is to certify that the College of Medicine Research and Ethics Committee (COMREC) has reviewed and approved a study entitled:

P.04/18/2381 - Accurancy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study) by Titus H Divala

On 03-Jul-18

As you proceed with the implementation of your study, we would like you to adhere to international ethical guidelines, national guidelines and all requirements by COMREC as indicated on the next page

Dr. YB. Mlombe - Chairperson (COMREC)

03-Jul-18

Date

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training and similar technologies.

moni Debeolnwod. 2002 Anew 25 no 99990-203999 no 25 March 2020. Downloaded from

REQUIREMENTS FOR ALL COMREC APPROVED RESEARCH PROTOCOLS

- 1. Pay the research overhead fees as required by the College of Medicine for all approved studies.
- 2. You should note that the COMREC Sub-Committee on Research Participants' Safety will monitor the conduct of the approved protocol and any deviation from the approved protocol may result in your study being stopped.
- 3. You will provide an interim report in the course of the study and an end of study report.
- 4. All COMREC approvals of new applications and progress reports are valid for one year only. Therefore all approved studies running for more than one year are subject to continuing review annually. You are required to submit a progress report to COMREC within 90-30 days before the expiration date. Your current expiration date is 03-Jul-19. Studies shall be considered lapsed and inactive if continuing review application is not received one month after the expiry of the previous approval. In that case, all study related operations should cease immediately except those that are necessary for the welfare of subjects.
- 5. All investigators who are Medical Practitioners must be fully registered with the Medical Council of Malawi.

Enseignement Superieur (ABES) . Protected by copyright, agluding for tests seignement Superieur (ABES) . Protected by copyright, agluding for tests seigned for test and all and a the protected by test and a large seign

BMJ Open. first published as 10.1136/bmjopen-2019-09309 on 25 March 2020. Downloaded from http://pmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l



PHARMACY, MEDICINES & POISONS BOARD

Mission: To promote and improve the health of the population of Malawi through the regulation of Pharmacy Personnel, Pharmacy Businesses, Medicines and Allied Substances

ALL CORRESPONDENCE SHOULD BE ADDRESSED TO THE REGISTRAR

Head Office: Off Paul Kagame/ Chilambula Road P.O.Box 30241 Capital City LILONGWE 3, MALAWI Phone: (+265) 01 755 165 Fax : (+265) 01 755 204 Email: <u>info@pmpb.mw</u> Web: <u>www.pmpb.mw</u>

PMPB/CTRC/III/14062018102 DATE: 4th July, 2018

Department of Infectious Disease Epidemiology London School of Hygiene and Tropical Medicine Keppel St London

Attn.: Dr. Titus Divala

RE: ACCURACY AND CONSEQUENCES OF USING TRIAL-OF-ANTIBIOTICS FOR TB DIAGNOSIS (ACT-TB STUDY).

Refer to your application to register the above mentioned clinical trial with the Pharmacy, Medicines and Poisons Board (PMPB).

The Clinical Trial Review Committee (CTRC), at its meeting held on 22nd June, 2018, issued a **No Objection** to the implementation of the trial after members agreed that the nature of the trial was seen to be outside the scope of trials that should be regulated by PMPB through the CTRC.

Please contact the undersigned if there are any issues that need further clarification.

Yours faithfully,

MEDICINES ONS BOARD REGISTRAR M. Kawaye ACTING REGISTRAR TJUL 2018 BOX 30241.LILONGWE



REK nord	Saksbehandler:	Telefon:	V; 06 D: 25	år dato: 6.11.2018 eres dato: 5.09.2018	Vår referanse: 2018/1964/REK n Deres referanse:
			Va	år referanse må op	pgis ved alle henvendelser
Jon Øyvind C	Odland				
Institutt for sa	amfunnsmedisin				
2018/1964 E eksklusjonso	En kontrollert klin liagnose i allmenp	iisk studie for å un oraksis mot risiko f	dersøke responsen til b for antibiotika resistens	redspekret S	antibiotika som e
Forskningsa Prosjektlede	n svarlig institusj o er: Jon Øyvind Odl	on: UiT Norges arkt and	iske universitet		
Vi viser til sø Regional kor er gjort med	øknad om forhånds nité for medisinsk (hjemmel i helsefor	godkjenning av ove og helsefaglig forsk skningsloven (hfors	nnevnte forskningsprosj ningsetikk (REK nord) i knl) § 10.	ekt. Søknade møtet 25.10	en ble behandlet av).2018. Vurderinge
Det skal und kan brukes se resistensutvil med åpen inf brukermedvi mennesker. S vedlagt.	ersøkes, ved hjelp o om eksklusjonsdiag kling knyttet til beh ormasjon undersøk rkning og informer Studien skal i sin he	av en randomisert, k mose for tuberkulos andingen. Tre grup kes med standard did t samtykke. Studien Hhet foregå i Malaw	ontrollert studie om resp e. Dette skal vurderes op per (625 per gruppe) ina agnostisk tilnærming. Ku kan forenkle dignostikk vi. Alle etiske godkjennin	pons til bred op mot risika lividuelt ran un voksne de og klinikk fo ger fra Mala	spekret antibiotika o for domisert (1:1:1), ltakere, med full r en utsatt gruppe awi og London er
Komiteen vu fvl. § 6.	rderte at Hanne Hu	ısom Haukland var i	inhabil og hun fratrådte i	møtet da sak	en ble behandlet, j
Om prosjek Prosjektet er	tet en del av en PhD. S	Studenten skal avleg	gge sin PhD i London.		
Dette er et sa Medicine, og	marbeidsprosjekt r Universitetet i Tro	nellom Universitete omsø.	t i Malawi, London Scho	ool of Hygie	ne and Tropical
Prosjektet sk	al gjennomføres i N	Malawi og er et «Tu	berkulose initiativ» fra H	Helse Nord.	
Det foreligge	er godkjenning fra I	London School of H	lygiene and Tropical Me	dicine, og U	niversity of Malav
Data Det skal hen knyttet til inf	tes data fra pasient eksjoner og sykehi	journal og fra lokale storie.	e poliklinikker. Data er s	tandard mec	lisinske opplysnin

BMJ Open

1	Data avidentifiseres med koblingsnøkkel. Database oppbevares i 5 år i Malawi.
2	
3	Deltakere/rekruttering
4	voksne denakere fordeles i tre grupper voksne denakere (625 per gruppe), individuelt randomisert.
5	Detakere rekrutteres gjennom benandning på ponkninkkere.
6	PEK har ingen innvendinger til prosiektet
7	KER har nigen hinvendniger en prosjektet
8	Vedtak
9	REK har viort en helhetlig forskningsetisk vurdering av alle prosjektets sider og vodkienner det med
10	hjemmel i helseforskningsloven § 10. REK forutsetter at prosjektet også har godkjenning fra Malawi.
10	
11	
12	Sluttmelding og søknad om prosjektendring
13	Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 21.03.2022, jf. hfl. §
14	12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige
15	endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.
16	
17	Klageadgang
18	Du kan klage på komiteens vedtak, jl. torvaltningstoven § 28 fig. Klagen sendes til REK nord. Klagen sidera til
19	Den nacionale forskningsetiske komité for medisin og belsefag for endelig vurdering
20	Den nasjonale forskningsetiske konnte for medisin og neiserag for endeng vurdering.
20	
21	Med vennlig hilsen
22	May Dwitt Descruell
23	May bill Rossvoll
24	sekretariatsieder
25	
26	
27	Kopi til:jon.oyvind.odland@uit.no
28	
29	
30	
31	
27	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
12	
45	
44 45	
45	
46	
47	
48	
49	For peer review only - http://bmiopen.bmi.com/site/about/quidelines.xhtml
50	

LONDON

&TROPICAL

HOOLof

٧E

NE

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT

United Kingdom

Switchboard: +44 (0)20 7636 8636

www.lshtm.ac.uk

26

27

43 44

45

46

47

48

49

50 51

52

53 54

55 56

1

2

3

Dr Titus Divala

LSHTM

9 May 2018

Dear Titus,

Study Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

LSHTM ethics ref: 15232

Thank you for your application for the above research, which has now been considered by the Interventions Committee.

Observational / Interventions Research Ethics Committee

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document Type	File Name	Date	Version			
Safety Information	ACT_PackageInsertAzithromycin	14/03/2013	JUNE 2013			
Safety Information	ACT_PackageInsertAmoxicillin	21/12/2015	DEC 2015			
Sponsor Letter	2018-KEP-077_Sponsor Confirmation_13.03.18	13/03/2018	1			
Other	GCP Cert_LSHTM_TDivala_21.03.18	21/03/2018	1			
Investigator CV	ACT-CV1_TitusDivala	30/03/2018	1			
Investigator CV	ACT-CV2_KatherineFielding	30/03/2018	1			
Investigator CV	ACT-CV3_LizCorbett	30/03/2018	1			
Information Sheet	ACT-20180330InformedConsentEnglish	30/03/2018	1.0			
Information Sheet	ACT-20180330InformedConsentChichewa	30/03/2018	1.0			
Protocol / Proposal	ACT-20180330Protocol	30/03/2018	1.0			

After ethical review

The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review using an Amendment form. Amendments must not be initiated before receipt of written favourable opinion from the committee.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project by submitting a Serious Adverse Event form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk

Additional information is available at: www.lshtm.ac.uk/ethics

Yours sincerely,

<u>ethics@lshtm.ac.uk</u> <u>http://www.lshtm.ac.uk/ethics/</u>

BMJ Open

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT

United Kingdom

Switchboard: +44 (0)20 7636 8636

www.lshtm.ac.uk





Observational / Interventions Research Ethics Committee				
Dr Titus Divala LSHTM	•			
12/04/2019				
Dear Titus,	Pro			
Project Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance	otected			
Project ID: 15232	d by c			
Thank you for your annual report application for the continuation of your research dated 09/04/2019 12:01, which has now been considered by the Chair on behalf of the Ethics Committee.	opyrig			
Confirmation of ethical opinion	Jht,			
This application is approved by the committee for a further year.	incl			
Conditions of the favourable opinion	udir			
Approval is dependent on local ethical approval having been received, where relevant.	ום fo			
After ethical review	u u			
Any changes to the application must be submitted to the committee via an Amendment form.	Ens			
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reaction (SUSARs) which occur during the project by submitting a SUSAR and Protocol Violation form.	eignei relate			
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.	nd to			
At the end of the study, the CI or delegate must notify the committee using an End of Study form.	o tey			
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at http://leo.lshtm.ac.uk.	uper tt an			
Additional information is available at: www.lshtm.ac.uk/ethics.	ieu d d			
Yours sincerely,	r (AB ata m			
	ES) . Nining, A			
Professor John DH Porter	l tra			
ethics@lshtm.ac.uk http://www.lshtm.ac.uk/ethics/	aining, and			
Improving health worldwide	d similar			
	tech			
	lout			
	logi			
	es			
APPENDIX 1: TRIAL REGISTRATION—DATA SET

NCT Number	NCT03545373
Title	Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
Acronym	ACT-TB
Status	Recruiting
Study Results	No Results Available
Conditions	Tuberculosis Respiratory Tract Infections Pneumonia
Interventions	Drug: Azithromycin Drug: Amoxicillin
Outcome Measures	Diagnostic accuracy of trial-of-antibiotics: Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 against a mycobacteriology reference standard. Overall clinical benefit of empirical antibiotic treatment in primary care participants with chronic cough: proportion of participants experiencing adverse clinical outcomes Impact of trial-of- antibiotics on antimicrobial resistance Diagnostic accuracy of trial-of-antibiotics including participants who did not produce sputum Economic analysis of use of trial-of-antibiotics
Sponsor/Collaborators	London School of Hygiene and Tropical Medicine University of Malawi College of Medicine
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	1875
Funded Bys	Other
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Diagnostic
Other IDs	15232
Start Date	February 25, 2019
Primary Completion Date	Jun-20
Completion Date	Jun-20
First Posted	June 4, 2018
Results First Posted	
Last Update Posted	August 15, 2019
Locations	University of Malawi College of Medicine, Blantyre, Southern, Malawi
Study Documents	
URL	https://ClinicalTrials.gov/show/NCT03545373

Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primary care adult patients versus risk of antimicrobial resistance (AMR)

Short title: Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis

Acronym: ACT-TB Study

Trial registration:

Protocol version: 3.0, 19 Feb 2019

Chief Investigator:	Titus H Divala
	London School of Hygiene & Tropical Medicine
	Keppel Street, London WC1E 7HT
	Tel: +44 740 523 1847
	Email: titus.divala@lshtm.ac.uk
Co-Investigators:	Katherine L Fielding, Neil French, Derek J Sloan, Elizabeth L Corbett
Collaborators:	Marriott Nliwasa, Augustine Choko, Ankur Gupta-Wright, Jennifer Cornic,
	Jon Øyvind Odland, Chisomo Msefula, Hendramoorthy Maheswaran
Sponsor:	London School of Hygiene & Tropical Medicine is the main research sponso
	for this study. For further information regarding the sponsorship conditions,
	please contact the Research Governance and Integrity Office:
	London School of Hygiene & Tropical Medicine
	Keppel Street, London WC1E 7HT
	Tel: +44 207 927 2626
	Email: RGIO@lshtm.ac.uk
Funding:	Helse Nord RHF
	Tromsø, Norway; Tel: +47 97065144
	Email: Hanne.Husom.Haukland@helse-nord.no
Study Coordination	University of Malawi College of Medicine
Centre:	Private Bag 360
	Chichiri, Blantyre, Malawi
	Tel: +2651871911
	Email: rscdirector@medcol.mw

This trial will adhere to the principles outlined in the International Council for Harmonisation Good Clinical Practice (ICH GCP) guidelines, protocol and all applicable local regulations.

2	
3	
4	
5	
6 7	
/	
0 0	
9 10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
20	
28	
20	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42 42	
45 44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
50 57	
57 20	
50 50	
60	
00	

Table of contents

I AL	brevi	ations	6
2 St	udy S	ummary	8
3 Int	roduc	tion	11
3.1	Ba	ckground	11
3.2	Sys	stematic literature review	13
3.3	Pla	nned study	15
3.4	Rat	tionale for current study	16
3.4	4.1	Accuracy of trial-of-antibiotics	
3.4	4.2	Antimicrobial resistance and trial-of-antibiotics	
3.4	4.3	Potential benefits of antibiotics	17
3.4	4.4	Important subgroups	
3.5	Ch	oice of study interventions	19
3.6	Na	sopharyngeal pneumococcus for AMR	20
3.7	Ob	jectives and outcomes	20
4 St	udy d	esign, participants, and statistical approach	23
4 Str 4.1	udy d <mark>Stu</mark>	esign, participants, and statistical approach	
4 Str 4.1 4.2	udy de Stu Stu	esign, participants, and statistical approach dy design dy setting	23 23 23 23
4 Str 4.1 4.2 4.3	udy de Stu Stu Sta	esign, participants, and statistical approach Idy design Idy setting	23 23 23 23 23 23
4 Str 4.1 4.2 4.3 4.4	udy d Stu Stu Sta Elig	esign, participants, and statistical approach udy design udy setting undard of care	23 23 23 23 23 23 25
4 Str 4.1 4.2 4.3 4.4 4.4	udy d Stu Stu Sta Elig 4. 1	esign, participants, and statistical approach Idy design Idy setting Indard of care gibility criteria Inclusion Criteria	23 23 23 23 23 23 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4	udy d Stu Stu Sta Elig 4.1 4.2	esign, participants, and statistical approach ady design ady setting andard of care gibility criteria Inclusion Criteria Exclusion Criteria	23 23 23 23 23 23 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Inte	esign, participants, and statistical approach ady design ady setting andard of care gibility criteria Inclusion Criteria Exclusion Criteria erventions	23 23 23 23 23 23 23 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.5 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Into 5. 1	esign, participants, and statistical approach ady design ady setting andard of care gibility criteria Inclusion Criteria Exclusion Criteria Exclusion Criteria Name and description of intervention arms	23 23 23 23 23 23 25 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.4 4.5 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Into 5. 1 5. 2	esign, participants, and statistical approach ady design ady setting andard of care	23 23 23 23 23 23 23 25 25 25 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Inta 5. 1 5. 2 5. 3	esign, participants, and statistical approach ady design ady setting andard of care gibility criteria. Inclusion Criteria. Exclusion Criteria. Exclusion Criteria. Exclusion Criteria. Exclusion Criteria. Summary of Product Characteristics.	23 23 23 23 23 23 23 25 25 25 25 25 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.5 4.5 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Inta 5. 1 5. 2 5. 3 5. 4	esign, participants, and statistical approach Idy design Idy setting	23 23 23 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.5 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Inta 5. 1 5. 2 5. 3 5. 4 5. 5	esign, participants, and statistical approach idy design idy setting indard of care gibility criteria. Inclusion Criteria. Exclusion Criteria. Exclusion Criteria. Name and description of intervention arms. Legal status of drugs used in intervention arms. Summary of Product Characteristics. Drug Storage and Supply Preparation and labelling of study drugs.	23 23 23 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.5 4.5 4.5	udy d Stu Stu Sta Elig 4.1 4.2 Into 5.1 5.2 5.3 5.4 5.5 5.6	esign, participants, and statistical approach Idy design Indy setting Indard of care gibility criteria Inclusion Criteria Exclusion Criteria Name and description of intervention arms Legal status of drugs used in intervention arms Summary of Product Characteristics Drug Storage and Supply Preparation and labelling of study drugs Known drug reactions (adverse events)	23 23 23 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25
4 Str 4.1 4.2 4.3 4.4 4.4 4.4 4.4 4.5 4.5 4.5 4.5 4.5 4.5	udy d Stu Stu Sta Elig 4. 1 4. 2 Inta 5. 1 5. 2 5. 3 5. 4 5. 5 5. 6 5. 7	esign, participants, and statistical approach idy design	23 23 23 23 23 23 25 25 25 25 25 25 25 25 25 25 25 25 25

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
3
4
5
c
6
7
8
0
9
10
11
10
12
13
14
15
15
16
17
18
10
19
20
21
22
23
24
25
25
26
27
28
20
29
30
31
27
52
33
34
35
22
36
37
38
20
39
40
41
12
42
43
44
45
16
46
47
48
10
50
51
52
52
22
54
55
56
50
57
58
59
<u> </u>
ъU

	4.5.	9 Assessment of compliance	26
	4.5.	10 Withdraw of interventions	27
	4.6	Statistical approach	27
	4.6.	1 Primary outcome	27
	4.6.	2 Secondary outcomes	30
	4.6.	3 Exploratory outcome	30
	4.6.	4 Planned subgroup analyses	30
	4.7	Sample size and power	31
	4.7.	1 Primary outcome 1: specificity of trial-of-antibiotics versus mycobacteriology	31
	4.7.	2 Primary outcome 2: Incidence of adverse clinical outcome at Day-29	31
	4.7.	3 Secondary outcomes	32
	4.7.	4 Exploratory outcomes	32
F	Dila		22
Ð	PIIO		აა
	5.1	Specific objectives of the pilot study	33
	5.2	Population for the pilot study	34
	5.3	Pilot study procedures	34
	5.4	Data analysis	35
6	Stud	dy procedures	37
	6.1	Screening	37
	6.2	Informed consent	37
	6.3	Baseline procedures	37
	6.4	Assignment of interventions	38
	0.4	Diadiag	
	0.5	Binding	40
	6.6	Participant follow up	40
	6.6.	1 Day-8 activities	
	6.6.	2 Day-29 activities	41
	6.7	Laboratory methods	42
	6.7.	1 Tuberculosis mycobacteriology	42
	6.7.	2 Urine antigen testing for lipoarabamannan and other MTB antigens	42
	6.7.	3 Antimicrobial resistance testing	42

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2
2
3
4
5
6
7
, 0
8
9
10
11
12
12
13
14
15
16
17
17
18
19
20
21
22
22
23
24
25
26
27
27
28
29
30
31
27
22
33
34
35
36
27
27
38
39
40
41
יי ⊿ר
42
43
44
45
46
17
47
48
49
50
51
52
52
55
54
55
56
57
57
20
59
60

6.9	Trial closure
6.10	Summary schedule for study procedures43
7 Saf	ety reporting
7.1	Definitions45
7.2	DMID grading for AEs46
7.3	Grading for expected events46
7.4	Causality48
7.5	Reporting Procedures
7.5	5.1 Non-serious Adverse Events (AEs)
7.5	5.2 Serious Adverse Events (SAEs)
8 Ecc	onomic evaluation
8.1	Objective
8.2	Outcomes
8.3	Data collection
8.4	Data analysis
8.5	Missing data
9 Dat	a management
9.1	Source Data
9.2	Data collection methods
9.3	Data management
9.4	Quality control and quality assurance
9.5	Access to data
10 C	Data monitoring and quality assurance
10.1	Data monitoring
10.2	Audits and Inspections54
10.3	Data Safety and Monitoring Board (DSMB)54
10.4	Trial Management Group (TMG)54
10.5	Trial Investigational Team55

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
20	
20	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	

1 2

11	Ethics and dissemination
11.1	Risk assessment
11.2	Research ethics approval56
11.3	Indemnity
11.4	Sponsor
11.5	Declaration of interests
11.6	Cost of participation, ancillary and post-trial care
11.7	Dissemination policy
12	References
13	Appendix 1: Informed consent
14	Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table 62
15	Appendix 3: Package insert for Azithromycin and amoxicillin74

thromycin .

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ACASI	Audio Computer Assisted Self-Interview
AE	Adverse Event
AMR	Antimicrobial Resistance
AR	Adverse Reaction
ART	Antiretroviral Therapy
CD4	Cluster of Differentiation 4
CEACs	Cost-Effectiveness Acceptability Curves
COMREC	University of Malawi College of Medicine Research and Ethics Committee
CXR	Chest X-Ray
DMID	Division of Microbiology and Infectious Diseases
DSMB	Data Safety and Monitoring Board
GLM	Generalised Linear Model
HIV	Human Immunodeficiency Virus
HRQoL	Health Quality of Life
LAM	Urine Lipoarabinomannan Assay
LJ	Lowenstein-Jensen
LSHTM	London School of Hygiene & Tropical Medicine
MDA	Mass Drug Administration
MGIT	Mycobacteria Growth Indicator Tube

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

MIB or M.tb	Mycobacterium tuberculosis
NMBs	Net Monetary Benefits
NTM	Non-Tuberculous Mycobacteria
NTP	National Tuberculosis Control Program
NTS	Non-Typhoidal Salmonellae
PCP	Pneumocystis Jiroveci
PLHIV	People Living With HIV
PTB	Pulmonary Tuberculosis
QALY	Quality-Adjusted Life Year
RCT	Randomized Controlled Trial
SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SOC	Standard of Care
STGG	Skim Milk Tryptone Glucose Glycerol
SUSAR	Suspected Unexpected Serious Adverse Reaction
ТВ	Tuberculosis
TMG	Trial Management Group
WHO	World Health Organization
WTP	Willingness to Pay

Title	Randomised controlled clinical tr	ial investigating benefits of using response to broad					
	spectrum antibiotics as an exclusion	sion diagnostic for tuberculosis (TB) in primary care					
	adult patients versus risk of antir	nicrobial resistance (AMR)					
Desian	Three arm (625 per arm) individually randomised (1:1:1) open-label controlled clinical						
_ • • • · g · ·	trial investigating standard care of	diagnostic approach for tuberculosis. The trial will not					
	use any unlicensed products.	5 11					
Objective		Outcomes					
Primary							
1. To establ	ish the diagnostic value of trial-of-	Proportion of participants correctly classified as PTB					
antibiotics for	or excluding pulmonary	negative based on report of improvement of baseline					
tuberculosis	(PTB) in adults with prolonged	symptoms on study Day-8 (i.e. after a trial-of-					
cough at pri	imary care level in Malawi	antibiotics if in azithromycin or amoxicillin arms, or					
oougn at ph		without antibiotics if in standard of care arm) against a					
		mycobacteriology reference standard, among					
		participants submitting at least one sputum specimen					
2. To deterr	nine the overall clinical benefit of	Proportion of participants experiencing at least one of					
giving empi	rical antibiotic treatment in primary	the following adverse outcomes by Day 29:					
care particip	pants with chronic cough.	1) death					
		2) hospitalisation					
		3) missed TB diagnosis					
		4) HIV care loss to follow up					
		5) TB care loss to follow up					
Secondary							
3. To evalua	ate using nasopharyngeal	Risk of acquiring nasopharyngeal Streptococcus					
Streptococo	cus pneumonia, the effect of a trial-	pneumonia isolates resistant to any of the commonly					
of-antibiotic	s on selection for antimicrobial	used groups of antimicrobials by Day-29.					
resistance.							
4. To establ	ish the diagnostic value of trial-of-	Proportion of participants correctly classified as PTB					
antibiotics for	or excluding pulmonary	negative based on report of improvement of baseline					
tuberculosis	(PTB) in adults with prolonged	symptoms on study Day-8 (i.e. after a trial-of-					
cough at pri	mary care level in Malawi.	antibiotics if in azithromycin or amoxicillin arms, or					
		without antibiotics if in standard of care arm) against a					

		randomised participants, with those who could not				
		provide sputum classified as mycobacteriologically				
		negative.				
C To optimized	- the increase the lagest					
5. To estimat	e the incremental cost-	Incremental cost per quality adjusted life year				
effectiveness	of trial-of-antibiotics using	gained				
azithromycin	and trial-of-antibiotics using	Total direct medical costs per participant over				
	comparison to standard of care,	56 days				
and to each o	other.	Eq-5D utility score				
Exploratory						
Our explorate	ory analyses will be comparisons be	etween the azithromycin and amoxicillin arms for all ou				
primary and s	secondary outcomes.					
Population	Adults presenting to primary care	centres in Malawi reporting cough.				
	Inclusion criteria:					
	Ambulatory clinic attended	es presenting with cough for \geq 14 days				
	Aged at least 18 years					
	Reside in Blantyre and wi	illing to return to the same clinic for follow up visits over				
	the entire study period.					
	Exclusion criteria:					
	 Self-reported allergy to study medications Acute danger signs defined in national TB treatment guidelines Tuberculosis treatment or isoniazid preventive therapy in the last 6 months Treated with antibiotics, other than co-trimoxazole prophylaxis, for the current 					
	illness or within the past 14 days					
Treatment	Arm 1: Azithromycin 500mg once	e daily for 3 days commencing on randomization day.				
	Arm 2: Amoxicillin 1 g 3 times da	ily for 5 days commencing on randomization day.				
	Arm 3: Standard of care in curren	nt national guidelines for patients presenting with cough				
	and without danger signs (No trea	atment until re-evaluation with sputum TB test results)				
Duration	We will give treatments on the ra	ndomisation day (Day-1) and perform follow up				
	activities on days 8 and 29	· · ·				

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

3 Introduction

3.1 Background

Antimicrobial resistance is a growing crisis, becoming in 2016 one of only four health topics ever to be discussed at the United Nations General Assembly.¹⁻⁴ Tuberculosis is the leading global infectious cause of death in adults,⁵ with approximately 10.4 million cases and 1.8 million deaths in 2015.⁶ The high case-fatality rate in part reflects suboptimal diagnostics(Figure 2).⁷⁻¹⁰



Figure 2: method of diagnosis for TB notifications globally (A) and in Blantyre, Malawi (B)

To complement the suboptimal diagnostics, standard diagnostic algorithms in resource-limited settings include a "trial-of-antibiotics" (Figure 3). This is a course of broad-spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients with symptoms such as cough in order to "rule-out" or "rule in" tuberculosis.¹¹⁻¹³ Patients with negative sputum mycobacteriology and responded to antibiotic treatment are considered tuberculosis negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations leading on to receiving tuberculosis treatment.



Figure 3: Implementation of trial-of-antibiotics (marked with red boxes) in Malawi TB diagnostic algorithm, National TB control program (NTP)

 Approximately 26.5 million course of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations per annum (Figure 4).⁶ This estimate is based on an average of 5 antibiotic courses per sputum-negative treatment initiation, with 2 courses given to the patients before tuberculosis treatment,⁸ and the other 3 courses accounting for patients whose symptoms resolved and tuberculosis was ruled out.¹⁴.

Wilkinson et al¹⁴ prescribed 120 + 74 courses of trial-of-antibiotics to diagnose 40 smear-negative TB patients (a typical ratio of ~1:5).⁸ If generalizable, then for 5.3 million annual smearnegative TB registrations globally ~5 x 5.3 million trial-of-antibiotics courses (26.5 million) will have been prescribed.

Enrolled	280	
TB smear microscopy positive		160
Given trial-of-antibiotics (amoxicillin)	120	
Improved, declared TB negative		46
Given trial-of-antibiotics (erythromycin)	74	
Improved, declared TB negative		34
Treated for smear negative TB	40	
Wilkinson et.al Int J Tuberc Lung Dis.	2000	

Figure 4: Quantifying number of trial-of-antibiotics courses prescribed per year using data from Wilkinson et.al and WHO TB Report 2016

Despite this widespread use, there is no randomised controlled trial evidence supporting the diagnostic accuracy of trial-of-antibiotics. There is also a dearth of evidence on their impact on antimicrobial resistance or patient clinical outcomes.

3.2 Systematic literature review

We performed a systematic literature review to determine the sensitivity and specificity of using a trial-of-antibiotics compared to sputum mycobacteriology for diagnosis of PTB. We also wanted to describe how trial-of-antibiotics tits into TB diagnostic algorithms: timing of prescription; type, duration, and number of antibiotic prescriptions; and how response to treatment is measured. We searched MEDLINE, Embase, and Global Health using the Ovid platform to identify studies meeting the following criteria:

2
3
1
4
5
6
7
Q
0
9
10
11
12
12
13
14
15
16
17
17
18
19
20
21
ר <u>∼</u> ו בר
22
23
24
25
25
20
27
28
29
20
50
31
32
33
34
24
35
36
37
38
20
39
40
41
42
12
44
45
46
47
т/ 40
40 40
49
50
51
52
52
53
54
55
56
55
57
58
59

60

Population	Adult patients with symptoms suggestive of pulmonary tuberculosis
Intervention	Routinely prescribed broad-spectrum oral antibiotics without MTB activity,
	and given as part of evaluation of pulmonary TB
Outcome	sensitivity and specificity of the intervention in comparison with any
	mycobacteriology test
Study design	Any design with prospective component allows evaluation of the outcome
	of the intervention
Time frame	Studies published after WHO declaration of TB as a 'global emergency'
	(1993)
Language	English, lack of translation capacity

We identified 7,064 articles from a systematic search on MEDLINE, Embase, and Global Health using the Ovid platform. Of these studies, 12 were eligible for narrative synthesis and seven had suitable data for meta-analysis. None of the studies was an RCT and all the observational studies were small and not primarily designed to address the benefits and consequences of trial-of-antibiotics. Unlike our proposed RCT, most of the published work was from hospital setting or in specialised clinics. Most studies used amoxicillin and some studies prescribed a subsequent course of antimicrobials either before or after assessing for improvement. The definition of improvement from baseline clinical state was largely subjective: it was based on self-report, clinical examination, radiological assessment or a combination.

There is no consensus on the sensitivity and specificity of trial-of-antibiotics across studies with estimates ranging from 43% to 91% for sensitivity and 41% to 82% for specificity (shown below).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
1
4
5
6
7
8
9
10
11
11
12
13
14
15
16
17
10
10
19
20
21
22
23
24
25
25
20
27
28
29
30
31
32
33
31
24 25
35
36
37
38
39
40
41
10
-⊤∠ //?
45
44
45
46
47
48
49
50
50
51
52
53
54
55
56
57
58
50

60

1

Population, Study		Sensitivi	ty, 95% (CI	Specificity, 95% Cl			
237	Wilkinson et al 1997	0.5	0.37	0.64	0.82	0.76	0.87	
120	Wilkinson et al 2000	0.83	0.71	0.91	0.56	0.44	0.67	
204	Kudjawu et al 2006	0.91	0.83	0.96	0.65	0.56	0.73	
1000	Kamran et al 2006	0.72	0.62	0.8	0.41	0.38	0.44	
264	Soto et al 2011	0.43	0.32	0.55	0.68	0.63	0.72	
439	Soto et al 2013	0.46	0.34	0.58	0.6	0.53	0.66	
440	Padmapriyadarsini et al 2	0.7	0.55	0.8	0.69	0.64	0.73	

We could not identify any RCT, the current literature only has small studies, with trial-of-antibiotics not being the primary focus of investigation in most cases. There is limited data for primary care settings as most of the work was in hospital setting. None of the studies addressed AMR. Therefore, despite widespread use, the approach, the value and consequences of having trial-of-antibiotics in TB diagnostic algorithms, remains to be established.

3.3 Planned study

To address the evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes), we propose to conduct a randomised controlled clinical trial recruiting adult patients presenting to primary care centres in Blantyre, Malawi with history of cough for at least 2 weeks. After excluding those with danger signs we will randomise participants to receiving or not receiving trial-of-antibiotics (azithromycin or amoxicillin) from Day-1 to determine diagnostic accuracy (specificity) against mycobacteriology reference standard (smear microscopy, Xpert/MTB/RIF and culture).

For secondary outcomes, we will also compare between arms differences in antimicrobial resistance and clinical outcomes (risk of death, hospitalisation, TB misdiagnosis, and loss to HIV or TB care follow up) at Day-29. To our knowledge this will be the first randomised controlled trial to address these questions in over 20 years of systematic use of trial-of-antibiotics without strong evidence base.

3.4 Rationale for current study

3.4.1 Accuracy of trial-of-antibiotics

As an approach that is being used on such a large scale, trial-of-antibiotics should ideally have a strong evidence-base (supported by reference mycobacteriology) of how much diagnostic and/or clinical improvement it brings to the TB diagnostic algorithm.^{15,16} This will be among the most important considerations when deciding whether it is worth the trade-off with potential for AMR. Such evidence could come from an RCT or a well-designed prospective study.¹⁵⁻¹⁷ However, despite being in use for more than 20 years, we have not identified any such clinical trial, and even the observational evidence is highly limited and of insufficient quality and quantity to definitively address the question.

There is also no guidance on antibiotic choice beyond a recommendation to avoid those with antituberculosis activity (like fluoroquinolones). Another key area that lacks clarity is lack of a clear definition for clinical resolution when determining the outcome of trial-of-antibiotics. Clinical resolution is the basis for decisions that follow (i.e. discontinue follow up or proceed Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance can be either intrinsic or acquired. The risk of acquired resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been previously investigated, although previous work has shown that empirical antibiotics can drive rapid emergence of AMR.^{18,19} For example, co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010.²⁰ Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

In our study, the AMR risks of empirical antibiotic prescriptions (azithromycin and amoxicillin arms of the RCT) are justified because of the widespread use of this approach for amoxicillin, and the low potential clinical impact and short-lived effects of use of azithromycin on AMR, given the limited use of macrolides in Malawi. Mathematical modelling work suggests that macrolide resistance can successfully be eliminated by intra-species competition alone (fitness cost) within 5 years of last use.²³

3.4.2 Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{18,19} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010²⁰ also shown in Table 1. Mass drug administration of azithromycin for trachoma control initially

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolideresistance 6 months later.^{21,22}

We will investigate antimicrobial resistance in nasopharyngeal *S. pneumonia* by randomisation arm and cumulative antibiotic exposure to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²⁴ *S. pneumonia* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²⁵ As exploratory analyses, we will also assess nasopharygeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

 Table 1 Resistance patterns of common aetiologies of pneumonia to commonly used

 antimicrobials in Blantyre, Malawi

		Gram positive		Gram negative			
Ormoniom		Streptococcus	Staphylococcu	Haemophilu	Klebsiella	Escherichia	Pseudomona
Organism		pneumoniae	s aureus	s influenzae	pneumoniae	coli	s aeruginosa
Prevalence		15.6%	6.6%	0.9%	4.4%	0.1%	1.5%
	amoxicillin	*	*	58%	100%	94%	100%
	penicillin	21%	*	*	*	*	*
	co-trimoxazole	98%	40%	100%	92%	94%	75%
Resistance	chloramphenicol	21%	2%	92%	48%	61%	100%
percentage	Erythromycin	2%	30%	*	*	*	*
	tetracycline	38%	35%	*	*	*	*
	Ceftriaxone	*	*	0%	90%	30%	100%
	Ciprofloxacin	*	*	NA	705	31%	24%
*not routinely	tested						

2016 data from hospitalised febrile patients at Queen Elizabeth central hospital (Blantyre, Malawi) as reported by the MLW Clinical research laboratory (unpublished).

3.4.3 Potential benefits of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high, ^{7,26} and is often secondary to severe bacterial infections.²⁶⁻²⁸ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae (NTS): both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active *Mycobacterium tuberculosis* (*M.tb*) disease.²⁶⁻²⁸ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected TB in people living with HIV (PLHIV), then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to TB treatment decisions. In this context,

BMJ Open

azithromycin may be the most effective arm, as Salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.²⁹

3.4.3.1 Measures of clinical benefit of trial-of-antibiotics

In this study, we will investigate the overall clinical benefit of trial-of-antibiotics by comparing the risk of any of death, hospitalisation, missed TB diagnosis, and loss to HIV or TB care follow up by Day 29. Although all these events are potential consequences of trial-of-antibiotics, grouping them as a single composite endpoint may only appropriately represent the effect of the intervention 1) there are similarities in the importance patients would attach to each of its components and 2) the components occur with similar frequencies in the patient population.³⁰

The impact of antibiotics on hospitalisation and mortality causing illnesses is as described above. Both these outcomes are important with their similarity hinged on the fact that hospitalisation event predicts mortality. In patients with chronic cough, frequencies of mortality and that of hospitalization over a two months period are similar, ranging from 2 to 6%.³¹

TB misdiagnosis becomes a concern because of the potential for misclassification in either direction –false positive or false negative. False positive diagnosis in the context of trial-of-antibiotics would occur when the underlying pathology for the respiratory symptoms is not responding to the antibiotic, which can be secondary to either AMR or the illness not being of bacterial origin. On the other hand, patients would be prone to a false negative result had both TB and a susceptible bacterial infection. If the symptoms were largely driven by the susceptible bacterial infection, their symptoms will improve and would be declared TB negative. TB is a life-threatening illness, missing its diagnosis can therefore lead to death which is more important to an individual patient than taking TB chemotherapy with a false positive TB diagnosis. We will therefore include only missed TB diagnoses in the composite clinical outcome. Unpublished data from Blantyre shows that the frequency of missed TB diagnosis under routine care settings is approximately 5% which is similar to that of death and hospitalisation.

Experiencing respiratory symptoms prompts care seeking which often leads to TB and HIV diagnosis and respective long-term treatment and follow up going way beyond resolution of initial symptoms. We hypothesize that giving antibiotics and curing the respiratory illness that prompted them to seek diagnosis, reduces care-seeking motivation. Care seeking is often driven by having symptoms and perceivable benefits of care often fade away as symptoms shed off. We will estimate the frequency of HIV and TB care loss to follow up at 1 month during the pilot study. The pilot study will also assess the combined risk of all the five components of the clinical benefit outcome.

3.4.4 Important subgroups

Response to trial-of-antibiotic- in patients with bacteriologically confirmed tuberculosis (i.e. falsenegatives/low sensitivity from the perspective of TB diagnosis) may relate to multiple superinfections and so this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and commonly identified in patients with suspected TB in the pre-ART era.^{8,27} More recently, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started TB treatment on the basis of positive mycobacteriology.³¹ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and by subsequent TB treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

3.5 Choice of study interventions

 Our trial will compare azithromycin and amoxicillin to standard of care. We propose 2 different antibiotic arms for the following reasons: -

- a) Macrolides, including azithromycin, are rarely used in Malawi because of their higher manufacturing costs. However, they do provide a more effective treatment of communityacquired pneumonia than the standard antibiotic by Ministry of Health for trial-of-antibiotic (amoxicillin), because of low levels of acquired macrolide-resistance in bacterial isolates in Malawi,²⁹ reflecting low rates of past exposure to this class of drugs, and also better intrinsic coverage of "bacterial cause of pneumonia including "atypical" intracellular organisms such as *mycoplasma* species.
- Although viral pneumonias, *Pneumocystis jiroveci* (PCP) and non-infectious causes of cough will still not be expected to respond to azithromycin, this arm should then provide the highest possible diagnostic discrimination for bacterial vs mycobacterial causes of cough. The starting point of low pre-existing (acquired) resistance will also facilitate investigation of AMR acquired during trial-of-antibiotics. However, the trial will have limited national relevance in Malawi without comparison to an antibiotic in programmatic use.
- b) Amoxicillin is low cost option that is still a recommended treatment for community-acquired pneumonia in most settings, including UK, despite potential treatment failure from bacterial pneumonia due to organisms with intrinsic ("atypicals") or acquired (common in gram-negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁹ This arm reflects the true standard of care (SOC) currently in widespread use in Malawi and many other low-income countries, and so provides data of immediate programmatic relevance and also a starting point to investigate exacerbation of pre-existing AMR pressure. If there is a marked difference between

BMJ Open

the azithromycin and amoxicillin arms, then there will also be important health economic considerations of relevance to many national TB programmes beyond Malawi.

Azithromycin provides effective treatment for community-acquired pneumonia³²⁻³⁴ and has negligible activity against *M.tb.*^{35,36} As discussed above, macrolides are not commonly used in Malawi. Azithromycin has an excellent safety profile and is used for mass drug administration (MDA) in communities prone to trachoma. Azithromycin used for MDA in Ethiopia reduced inter-current infections^{21,37} and death in children,^{38,39} supporting the safety of using this drug for our trial.⁷

Amoxicillin is the first line treatment for outpatient management of pneumonia in Malawi and is commonly used for trial-of-antibiotics. We anticipate higher specificity for azithromycin than amoxicillin, due to broader coverage of "atypical pneumonia" organisms, and salmonella species, but with the 2 antibiotics arms having "equipoise" due to lack of previous head-to-head comparison.²⁷

3.6 Nasopharyngeal pneumococcus for AMR

Streptococcus pneumonia is a major cause of morbidity and mortality in children and adults.^{20,29,40,41} Asymptomatic nasopharyngeal carriage of *S. pneumoniae* is common and a prerequisite for the occurrence and transmission of invasive pneumococcal disease.^{42,43} Since carriage is more common than the invasive *S. pneumoniae* disease it forms a basis for establishing circulating serotypes, resistance patterns, and evaluation of vaccine effectiveness.

The other key advantage is the existence of globally accepted laboratory procedures for assessing and interpreting pneumococcal resistance. Our laboratory (in Malawi-Liverpool Wellcome Trust) has carried out pneumococcal work for decades with outstanding quality assurance reputation.

3.7 Objectives and outcomes

In Table 2 below, we present study objectives together with corresponding outcomes. We have clarified the outcomes with detailed definitions and planned analyses under "statistical approach" section.

Objective	Outcome
Primary	
1. To establish the diagnostic value of	Proportion of participants correctly classified as PTB
trial-of-antibiotics for excluding pulmonary tuberculosis (PTB) in adults	negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

with prolonged cough at primary care	antibiotics if in azithromycin or amoxicillin arms, or
level in Malawi.	without antibiotics if in standard of care arm) against a
	mycobacteriology reference standard, among
	participants submitting at least one sputum specimen
2. To determine the overall clinical	Proportion of participants experiencing at least one of
benefit of giving empirical antibiotic	the following adverse outcomes by Day 29:
treatment in primary care participants	1) death
with chronic cough.	2) hospitalisation
	3) missed TB diagnosis
	4) HIV care loss to follow up
	5) TB care loss to follow up
Secondary	
3. To evaluate using nasopharyngeal	Risk of acquiring nasopharyngeal Streptococcus
Streptococcus pneumonia, the effect of	pneumonia isolates resistant to any of the commonly
a trial-of-antibiotics on selection for	used groups of antimicrobials by Day-29.
antimicrobial resistance.	K
4. To establish the diagnostic value of	Proportion of participants correctly classified as PTB
trial-of-antibiotics for excluding	negative based on report of improvement of baseline
pulmonary tuberculosis (PTB) in adults	symptoms on study Day-8 (i.e. after a trial-of-
with prolonged cough at primary care	antibiotics if in azithromycin or amoxicillin arms, or
level in Malawi.	without antibiotics if in standard of care arm) against a
	mycobacteriology reference standard, among all
	randomised participants, with those who could not
	provide sputum classified as mycobacteriologically
	negative.
5. To estimate the incremental cost-	Incremental cost per quality adjusted life year
effectiveness of trial-of-antibiotics using	gained
azithromycin and trial-of-antibiotics	Total direct medical costs per participant over
using amoxicillin in comparison to	56 days
standard of care, and to each other.	Eq-5D utility score
Exploratory	
Our exploratory analyses will be comparis	sons between the azithromycin and amoxicillin arms for
all our primary and secondary outcomes.	
<u>L</u>	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

4 Study design, participants, and statistical approach

4.1 Study design

This is a three arm (625 per arm) individually randomised (1:1:1), open-label controlled clinical trial investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-ofantibiotics to "rule out" tuberculosis among adults presenting with cough at primary care centres in Malawi.

4.2 Study setting

We will screen adults aged at least 18 presenting to primary care centres in Blantyre, Malawi. Blantyre has an estimated adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6) and an estimated tuberculosis prevalence of 1,014 per 100,000 (95% CI: 486 to 1,542).⁴⁴

4.3 Standard of care

The standard of care in national guidelines from the NTP for primary care patients presenting with cough and are otherwise well (no danger signs) is to take sputum x 2 for smear microscopy or Xpert and ask them to return for results, typically 3 days - 1 week later (Figure 3 and 5). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to the patient, if they remain symptomatic.

However, more commonly this algorithm is adapted in the outpatient setting to combine prescription of antibiotics (usually amoxicillin) with sputum collection at the first visit, to save the patient from making separate visits: thus, our amoxicillin arm is the most common standard-of-care in Malawi, while the no-antibiotic arm is the NTP recommended standard-of-care.







Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

4.4 Eligibility criteria

We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

4.4.1 Inclusion Criteria

- Ambulatory clinic attendees presenting with cough for at least 14 days
- No previous formal consultation for current illness (initial presentation)
- Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period.

4.4.2 Exclusion Criteria

- Self-reported allergy to study medications
- Danger signs (WHO/Malawi NTP): respiratory rate > 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- TB treatment or Isoniazid preventive therapy within the last 6 months

4.5 Interventions

We will have two active study arms receiving trial-of-antibiotics at enrolment (azithromycin and amoxicillin) and a standard of care arm of no trial-of-antibiotics. In this study, the goal is to investigate the role of these antibiotics as they are used in TB diagnostic algorithms, as "trial-of-antibiotics," to exclude TB in symptomatic patients. The study is likely to be underpowered to detect differences between the 2 antibiotic arms will only be compared for exploratory outcomes.

4.5.1 Name and description of intervention arms

The study will have three arms as follows:

- Arm 1: Immediate trial-of-antibiotics with Azithromycin 500mg once daily for 3 days.
- Arm 2: Immediate trial-of-antibiotics with Amoxicillin 500 mg 3 times daily for 5 days.
- Arm 3: Standard of care

4.5.2 Legal status of drugs used in intervention arms

Both azithromycin and amoxicillin are registered for use in Malawi and United Kingdom, with both Arms 1 and 2 regimens being UK-recommended community-acquired pneumonia treatment.

4.5.3 Summary of Product Characteristics

 BMJ Open

Appendix 3 includes current versions of package insets for azithromycin and amoxicillin. We will review and update (when applicable) the package inserts annually with each ethics continuing review.

4.5.4 Drug Storage and Supply

We will procure study products from Durbin PLC (DURBIN PLC 180 Northolt Road South Harrow Middlesex HA2 0LT). Azithromycin will be manufactured by Sandoz limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Amoxicillin will be manufactured by Medopharm private limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Both azithromycin and amoxicillin are stable at room temperature. We will therefore ship and store in ambient conditions.

4.5.5 Preparation and labelling of study drugs

Study products will be stored at Malawi Liverpool Wellcome Trust Pharmacy. The pharmacy team will be responsible for packing and labelling.

4.5.6 Known drug reactions (adverse events)

Azithromycin and amoxicillin are already widely used in Malawi and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

4.5.7 Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some may subsequently start tuberculosis therapy. Important interactions therefore would be those with HIV antiretroviral drugs and tuberculosis therapy. There is no moderate or major interaction between either azithromycin or amoxicillin with the classes of HIV antiretroviral drugs, tuberculosis therapy, and antimalarial drugs used in Malawi.

4.5.8 Trial restrictions

We do not require participants to have any dietary restrictions. We will also accept co-administration with contraception. Our trial interventions can safely be used in pregnancy, so we will include pregnant women should they be eligible.

4.5.9 Assessment of compliance

On Day-8, we will document self-reported compliance adherence of study products.

4.5.10 Withdraw of interventions

 The investigator may also terminate a participant from study product if indicated by an adverse reaction. If a participant stops taking study product either voluntarily or by investigator decision, they will be encouraged to remain in follow up and their data will form part of intention to treat analyses.

4.6 Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT flow chart. We will describe the study participants by their baseline characteristics which we will report for each arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to), adjusting for centre. We will make the following comparisons:

- i) azithromycin or amoxicillin versus standard of care
- ii) azithromycin versus standard of care
- iii) amoxicillin versus standard of care

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College station, Texas, USA).

The following are descriptions of each outcome and corresponding statistical approach. The statistical approach will be expanded in a detailed statistical analysis plan, separate to the protocol, which will be finalised before unblinding the study data.

4.6.1 Primary outcome

4.6.1.1 Primary outcome 1: Specificity of trial-of-antibiotics versus mycobacteriology

Outcome definition

Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 ACASI against a mycobacteriology reference standard (b+d in Figure 6).

To minimise ascertainment bias in ascertaining this endpoint, the evaluation of improvement of baseline symptoms will be captured using a self-interview platform: Audio Computer Assisted Self-Interview (ACASI). After orientation, the participant will be left alone in the room to interact with the computer. ACASI on Day-8 will precede all other interaction with research staff and clinical assessment/decision making.

Mycobacteriology reference standard will be defined in participants with at least one specimen with a valid result on days 1 and 8 as:

- **TUBERCULOSIS-POSITIVE**: if at least one positive smear microscopy, Xpert/MTB/RIF, or MTB culture on sputum samples taken.
 - **TUBERCULOSIS-NEGATIVE**: none of the day 1 and day 8 sputum samples are positive on smear microscopy, GeneXpert MTB/RIF, or MTB culture.

To minimise bias, the mycobacteriology will be performed by a high-quality research laboratory in the University of Malawi College of Medicine by staff with no access to participant treatment allocation information or ACASI results.

ACASI Response interpretation

The responses of participants during the ACASI interview will be classified as:

- TUBERCULOSIS-POSITIVE: participant reports lack of improvement of symptoms they had on Day 1.
- TUBERCULOSIS-NEGATIVE: participant reports improvement of symptoms they had on
 Day 1.



Primary outcome: a comparison of **d / (b+d)** proportions in treatment versus standard of care as follows:

- i) azithromycin or amoxicillin versus standard of care
- ii) azithromycin versus standard of care and
- iii) amoxicillin versus standard of care

* Audio Computer Assisted Self-Interview (ACASI) validated during a pilot study. Figure 6: Ascertainment of diagnostic value of trial-of-antibiotics

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. In pre-specified

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

subgroup analysis, we will estimate the treatment effects stratifying by baseline HIV status. If the GLM model does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio.

Participants without mycobacteriology

Primary analyses will be limited to participants who have at least one valid sputum sample result from all samples collected on visits Day-1 and Day-8. However, in real-life, ~15% fail to produce sputum, we will as a secondary outcome, perform all the analyses described for primary outcome with these participants defined as mycobacteriology negative. Further sensitivity analyses with urine lipoarabamannan antigen (LAM) results will include them in mycobacteriology definition.

4.6.1.2 Primary outcome 2: Clinical benefit of trial-of-antibiotics

Outcome definition

Proportion of participants experiencing at least one of the following adverse outcomes: death, hospitalisation, TB misdiagnosis, HIV care loss to follow up, TB care loss to follow up. The definitions of the components of this composite clinical outcome are defined in the table below:

Outcome component	Definition
death	Proportion of deaths by Day 29
hospitalisation	Proportion hospitalised for any cause by Day 29
missed TB diagnosis	Day 29 proportion of participants meeting standard
	mycobacteriological and radiological TB definitions but
	incorrectly classified as TB negative and not yet on TB
	treatment by Day 29.
HIV care loss to follow up	Proportion of newly identified (Day 1) HIV positive participants
	not continuing with care by Day 29
TB care loss to follow up	Proportion of newly identified (Day 1/Day 8) TB positive
	participants who were put on treatment but were not
	continuing with treatment and follow up by Day 29

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for primary care center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. If the

 BMJ Open

outcome is rare or if GLM does not converge, we will use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.2 Secondary outcomes

Outcome definitions

- 1) Risk of acquiring nasopharyngeal Streptococcus pneumonia isolates resistant to any of the commonly used groups of antimicrobials by Day-29. We will exclude those with resistant isolates on both Day-1 and Day-29 from the numerator, as they may not truly represent incident resistance. In the denominator, we will include all randomised participants and perform analysis as intention to treat.
- 2) Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology reference standard, among all randomised participants, with those who could not provide sputum classified as mycobacteriologically negative.

Estimation of measures of effect

Our secondary outcomes are anticipated to be rare, we will therefore use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% Cls and p-values.

4.6.3 Exploratory outcome

Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** arms for all our primary and secondary outcomes.

4.6.4 Planned subgroup analyses

We will perform subgroup analysis for the primary outcome. The important subgroups based on rationale detailed under section 2.4.4, include HIV status, ART status, and PTB treatment. HIV and ART status will be as documented on Day-1 while PTB treatment will be either as:

- TB treatment commenced based on positive baseline (Day-1 and Day-8) mycobacteriology, or
- TB treatment commenced within 29 days of enrolment in patients with negative Day1 and Day-8 bacteriology.

The 29 days cut off for clinical decision to treat is to ensure that we only capture TB disease that was present at baseline. 29 days is a reasonable because: TB is a slowly progressing disease

which if positive at Day-29, must have been incident on Day-1; and in routine care setting it can take over a month from presentation to diagnosis of TB.⁸

4.7 Sample size and power

4.7.1 Primary outcome 1: specificity of trial-of-antibiotics versus mycobacteriology

We assume that trial-of-antibiotics (in azithromycin arm or in amoxicillin arm) will correctly classify 60% of mycobacteriology negative participants.¹⁴ We have determined that 400 mycobacteriologically negative (true negatives) participants per arm will provide 80% power to detect a 10% difference in proportion of participants correctly classified as negative by amoxicillin arm or by azithromycin arm (60%) versus standard of care arm (50%). See table 3. We assume that 80% of participants randomised will have negative mycobacteriology,³¹ requiring 500 participants to yield the 400 per arm. Assuming that 15% will not be able to produce sputum, and that 5% will not return for Day-8 visit, the sample size is increased to 625 per arm or 1,875 for the whole study.

 Table 3: Power and sample size estimation for primary outcome 1

True negatives (mycobacteriology tests negative participants) b+d	¹ p (negatives correctly classified) d/(b+d)	² effect size	power (X difference between independent proportions)			
320	0.60	0.10	69%			
400	0.60	0.10	80%			
480	0.60	0.10	86%			
¹ specificity with either azithromycin or amoxicillin trial-of-antibiotics arms						
² risk difference (azithromycin arm- standard of care arm)						

4.7.2 Primary outcome 2: Incidence of adverse clinical outcome at Day-29

We will use a pilot study to determine the standard of care risk of at least one of death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up. The pilot study is described in section 5.0.

For now, we will assume that there is a 10% risk of experiencing this composite adverse outcome in the standard of care arm, and that loss to follow up by Day-29 will be 10%. With the sample size of 625 participants per arm (based on the primary outcome 1 sample size calculation), and alpha of 0.05, we will be able to detect the difference between intervention and standard of care with 80% power, if the risk in intervention arm is 6% or lower (Table 4).

Table 4: Sample size estimation for clinical benefit outcome

Participants per arm <u>based on primary</u>	625	
10% loss to follow up by Day-29	562	
Outcome risk in standard of care arm	0.10	
Desired power	0.80	
Alpha	0.05	
Required intervention arm risk	0.06	

4.7.3 Secondary outcomes

1) Incidence of resistant S. pneumonia on Day-29

We assume 10% loss to follow up by Day-29, and the rate of *S. pneumonia* isolation from nasopharyngeal swabs in this population is expected to be ~45% at Day-29. The sample size based on the primary outcome (625 per arm) will provides ~253 *S. pneumonia* isolates/arm. In the standard of care arm, with 10% risk of resistant isolates, this translates into 25 cases. For the intention to treat population (the randomised 625 participants/arm) in the standard of care arm the 21 cases of resistant isolates translate into 4% (25/625) risk. With 4% risk in the standard of care group, alpha of 0.05, and using Pearson's Chi-squared test we will be able to detect the impact of the intervention with 85% power if it leads to an increase of risk of resistant isolates from 4% to 8% (or RR of 2, risk difference of 4%) (Table 5).

Table 5: Sample size estimation for AMR outcome

Participants per arm <u>based on primary</u>	625
10% loss to follow up by Day-29	563
45% isolation rate for <i>S. pneumonia</i>	253
Resistance: 10% of all isolates	25
Overall proportion in standard of care (25/625)	0.04
Effect size (RR =2, or RD=4%)	0.04 to 0.08
Power	0.85

4.7.4 Exploratory outcomes

We anticipate that our sample size will be enough for hypothesis generation around our exploratory objectives but may not be enough to provide discriminatory power for comparison of outcomes between arms.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

5 Pilot study

This area of research has limited evidence to guide the precise determination of sample size and the practical aspects of the clinical trial making a pilot study an invaluable tool. We have identified the following as key knowledge gaps which require exploration using a pilot study:

- 1) Among the adult patients presenting to primary care centres with cough for at least 2 weeks what proportion gets antibiotics:
 - a. before clinic presentation?
 - **b.** on first clinic visit?
 - c. on follow up clinic visit after mycobacteriology results?
- 2) Following antibiotic treatment, how do patients report their clinical response? What are the best questions to ask patients post-antibiotic treatment to determine if they have improved or not? How best can we deliver these questions via Audio Computer Assisted Self-Interview (ACASI)? How well do these responses correlate with mycobacteriology and radiology?
- 3) What is the best timing for nasopharyngeal swabs for evaluating AMR in patients who receive a course of antibiotics during TB investigations?
- 4) In the standard of care setting, what proportion of adult patients presenting to primary care centres with cough for at least 2 weeks experience the following adverse outcomes (as defined under the clinical benefit composite endpoint)?
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.1 Specific objectives of the pilot study

- 1) To determine the proportion of adults with prolonged cough who
 - a. present to primary care having already had antibiotics for the index clinical complaints.
 - b. receive antibiotics before sputum mycobacteriology results at first presentation
 - c. receive antibiotics after negative mycobacteriology



- 2) To establish an objective way of documenting response to antibiotic treatment using Audio Computer Assisted Self Interview (ACASI). Assessing ACASI responses against clinical signs, outcomes of TB mycobacteriology and chest radiography.
- **3)** To determine:
 - a. the prevalence of Streptococcus pneumonia;
 - b. the prevalence of resistant *Streptococcus pneumonia* isolates;
 - c. the optimal specimen collection timing for evaluating impact of antibiotic use on prevalence of *Streptococcus pneumonia* isolates resistant to common antibiotics
- 4) To establish standard of care rates of the following adverse clinical outcomes:
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.2 Population for the pilot study

This exploratory study will include up to 400 adult (≥18 years old) patients presenting to primary care centres with cough for at least 14 days. We will exclude patients not meeting the eligibility criteria of the clinical trial.

5.3 Pilot study procedures

The pilot study procedures are outlined in the flow chart below. Following pilot study informed consent, we will use a baseline assessment questionnaire to collect clinical history, and antibiotic use for the index illness prior to the clinic visit. Throughout follow up, we will record all antibiotic use from any source. We will collect sputum samples for mycobacteriology from all participants on Day1 and Day 8.

We will establish HIV and TB diagnosis throughout the study, link participants to care services, and follow their adherence to follow up. For TB we will use a combination of Xpert, smear and culture on Day 1, 8 and whenever symptomatic suggestions of TB arise. We will also perform a chest x-ray on Day 8 and a follow up film on Day 29.

We will collect nasopharyngeal swab samples, for antimicrobial resistance assessment using *Streptococcus pneumonia* culture and sensitivity, on Day 1, Day 8, and Day 29. We will assess change in symptoms and well-being from Day 1 to Day 8, by using various combinations of questions and answers delivered via Audio Computer Assisted Self Interview (ACASI) on Day 8. We

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

will ask participants which sets of questions they found easy to understand. We will also collect clinical information on all study visits including illness events, hospitalisations and vital status.



Pilot study flow diagram, summarizing the study procedures at each visit.

5.4 Data analysis

We will report the proportions of participants who used any antibiotics prior to primary care and during work-up for Tuberculosis. We will determine the best ACASI question and response combinations by participant reported ease of use, and by assessing correlation with clinical findings,
mycobacteriology and radiological outcomes. The optimal time for assessing AMR will be determined by comparing incidence of resistant *Streptococcus pneumonia* isolates at days 8 and 29.

We will comparing participants exposed to antibiotics to those not exposed to antibiotics by estimating and reporting relative risk and 95% confidence intervals for:

- 1) Day 8 and Day 29 of resistant Streptococcus pneumonia
- 2) Composite adverse outcome of experiencing any of: death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ACT-TB Study Protocol V3.0, 19 Feb 2019

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

6 Study procedures

6.1 Screening

 At the designated primary health care centres, study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study. Those willing to be screened for eligibility will be assessed against the study inclusion and exclusion criteria.

6.2 Informed consent

We will seek written informed consent (Appendix 1) from all patients who meet eligibility criteria before any trial-specific procedures. Screening for tuberculosis symptoms will not be considered as part of the study procedures, as it is already a fundamental component of the routine clinical assessment and history taking. A member of the study team will hand an informed consent form to a potential participant in their preferred language (Chichewa or English) detailing background, procedures, risks, benefits and participant expectations should they choose to join the study. The consent form will also state that the participant is free to withdraw from the trial at any time for any reason without prejudice to future care, and no obligation to give reason for the withdrawal.

If they choose to join as a study participant, we will then request them to sign two copies of informed consent form. If a potential participant does not know how to read or write, we will perform the informed consent process in the presence of a witness. In such cases, if they agree to participate in the study, we will ask them to sign using a thumb-print in the presence of their witness and a study team member. We will keep one copy of the signed informed consent forms and hand the participant the other copy.

6.3 Baseline procedures

After consenting, we will on the same visit request participants to provide 2 on the spot sputum samples for smear microscopy, Xpert and culture collected at least one hour apart. Those unable to spontaneously produce sputum will be instructed in the physiotherapy manoeuvre of "huffing" (forced expiration technique) for inducing mucus clearance from the airways.

Patients still unable to provide at least one mucoid sputum sample of >1 ml will initially will be given a sputum container and asked to return it the next day. If they do not manage to produce sputum at home, their mycobacteriology results will be treated as missing. We expect ~15% of participants to fall in this category³¹ and have accounted for them in the sample size estimation. For participants who produce less than the needed quantity of sputum, we will process them for the planned tests in the following priority order: 1) Xpert MTB/RIF, 2) MTB culture, 3) smear microscopy. The Xpert MTB/RIF

BMJ Open

is the single most important guide for immediate clinical diagnosis and the MTB culture is the single most accurate reference diagnostic.

We will also collect a urine sample which we will store for subsequent lipoarabamannan antigen detection (LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing to estimate prevalent antimicrobial resistance. We will also perform HIV tests according to the national algorithm, and if positive we will do HIV viral load. After completing all Day-1 visit procedures, we will link the newly tested positive participants to routine HIV care and will document when they start ART (Malawi National Program provides same-Day-ART initiation to all newly-diagnosed or untreated HIV-positive patients). After the sample collections, we will collect the following information:

- Demographic data, including precise geographic locator information using ePAL geolocation software (to aid follow-up). The locator information will also include phone numbers for the participant and for up to 3 family, or friends they nominate as alternative contacts.
- Clinical history including information on tuberculosis symptoms and health care seeking for HIV and tuberculosis care services including ART, cotrimoxazole, isoniazid preventive therapy, and past TB treatment.
- Vital signs including height and weight

After completing all these baseline procedures, we will randomise the participants to the three study arms.

6.4 Assignment of interventions

Step 1: An independent statistician based at LSHTM and without contact with participants or the study staff that see participants, will use the ralloc command in Stata (StataCorp LLC, College Station, Texas USA. Release 15.0) to prepare a random allocation sequence in advance of study recruitment efforts. Randomisation will be 1:1:1 to the three arms of the trial, block-randomised with variable block sizes, and stratified by primary care centre.

Step 2: Each treatment allocation will be printed alongside a randomisation number onto a pdf document.

Step 3: The statistician will email the pdf document to an independent designee within university of Malawi who will print and place the randomisation assignments in envelopes labelled with randomisation numbers. The independent designee will hand the envelopes directly to the study pharmacist who will also receive a shipment of study medications. The pharmacist will store the envelopes in a secure location within the pharmacy.

Step 5: The pharmacist will pre-pack 625 each of protocol doses of azithromycin and amoxycillin without any reference to the allocation sequence. There is no need to refer to the allocation sequence for this step because the dosage for both treatments is the same and the total number of allocation for each treatment is known.

Step 6: At the beginning of each working week and upon request from study site, the study pharmacist will hand to site coordinators of each primary care center, a recruitment-rate-driven daily working stock of 1) the sequentially numbered sealed opaque envelopes containing randomization numbers and corresponding treatment allocations, and 2) study drugs.

Step 7: Study staff from each site will conduct patient eligibility assessments. Patients meeting the quick criteria of age and cough for ≥14 days, will be assigned screening IDs before being taken through the full eligibility criteria and consenting process. Participants will be considered eligible and ready for randomisation after they meet all criteria and sign consent.

Step 8: Upon signing consent, the participant will be taken to the site-coordinators (nurse or clinical officer) who will assign them the next available study ID number and document it on their paper and electronic eligibility checklist and enrolment CRF. The study ID number will be the number on the treatment allocation envelope plus a site-specific code. They will then open the envelope, document the treatment assignment, to the participant's enrolment paper and electronic case report forms as well as on a study card that will be pasted in the participant personal health profile book.

Step 9: The coordinator will double-check to ensure that the enrolment number and the treatment assignment are recorded correctly. They will then record screening date, screening ID, randomisation date, study ID, and randomisation arm on an enrolment log. They will then administer the allocated treatment. Administering study medications will not be considered as prescribing considering that prescription to all eligible participants will have already been done by the study protocol.

Step 10: When the stock of either envelopes or study drugs runs out,, the nurse-coordinators will reorder a from the study pharmacist.

Additional details

All steps of receipt, and utilization of the allocations and study drugs are elaborated in a detailed SOP. The SOP guides implementation of the above plan as far as possible and in line with site conditions.

BMJ Open

The study drugs will be pre-packed blindly without any reference to treatment allocations ensuring that neither the pharmacist nor the nurse-coordinator know the treatment allocations until just before assigning to a participant.

6.5 Blinding

We will mask the treatments as far as possible. The study pharmacist will remain blinded as they will use the randomly- allocated label numbers to prepare and pack the correctly dosed study medications in opaque packaging. Study outcome assessment will occur without reference to study treatment allocation. All laboratory forms for mycobacteriology and nasopharyngeal pneumococcal work will have no reference to participant treatment allocation. On Day-8, assessment of improvement from baseline symptoms will utilize audio computer-assisted self-interview (ACASI) to minimise potential for social-mediated reporting and ascertainment biases (see Procedures Section of the protocol). All clinical endpoints assessment case report forms will bear no reference to treatment arm. However, we will keep participants, research coordinators, and routine care staff unmasked to ensure safety of the participants and allow appropriate patient management decision-making which may be related to the trial interventions.

6.6 Participant follow up

Following enrolment and completion of baseline procedures we will ask participants to return for follow up visits on days 8, and 29. They will be given 1 sputum collection bottle when leaving the clinic on Day-1 to bring with them sputum for mycobacteriology planned for Day-8 ("morning" specimen) followed by collection of one further "spot" sputum on Day-8, 2 sputum samples in total). We will also collect a second urine sample for storage for subsequent LAM antigen testing. Patients unable to produce at least one mucoid sputum sample of >1ml on Day-8 will be assumed for purposes of analysis to be mycobacterially negative for the Day-8 sputum samples. We are performing two sets of sputum examinations (Day-1 and Day-8) for each participant to strengthen the accuracy of the reference standard. Considering that TB progresses very slowly, making a diagnosis on Day-8 is not different from that made on Day-1.

We will advise participants that their sputum TB test results will start becoming available from 48 working hours after collection, but with the last test (MTB culture) taking up to 4 weeks. Patients will be advised that they will not be routinely contacted if positive TB test results become available before their Day-8 appointment (as is standard for outpatient management without danger signs in Malawi), and so will be advised to report promptly back to the clinic (with refund of transportation given) if they experience any clinical deterioration during Days 2 to 7.

In the circumstances where TB treatment is commenced before completion of antibiotics prescribed for trial-of-antibiotics (amoxicillin and azithromycin), we will ask them to carry on with their allocated intervention together with the TB treatment.

6.6.1 Day-8 activities

 On Day-8, the first activity before the participants undergo all other evaluations will be documentation of self-reported improvement of baseline (Day 1) TB symptoms using a pilot-validated set of questions and answer options delivered via Audio Computer Assisted Self Interview (ACASI). We will use ACASI with the goal of eliminating inter-observer variability and patient/interviewer reporting or ascertainment biases. After a "how to use" orientation and testing session, the participant will be left alone in the room to interact with the computer. A pre-recorded interviewer will ask the participant questions related to how their symptoms have changed on that day compared to how they were on Day-1 and will offer categorised voice-recorded responses with touch screen response buttons. The ACASI questionnaire will also include questions about adherence to study arm drugs and any other medical care (including traditional medicine) sought during the previous week.

Other activities for all participants on Day-8 include:

- collection of a second sputum sample for mycobacteriology tests.
- providing participants with Day 1 smear and Xpert results linking those with positive tests, ongoing symptoms and other illnesses with routine care for appropriate management.
- clinical history detailing clinical events since enrolment.
- documentation of any medications including antimicrobials and traditional medicine outside
 the study
- providing a study Day-29 appointment card

For participants with negative Day-1 mycobacteriology results we will perform clinical evaluation after ACASI and will inform the patient that any positive Day-8 sputum mycobacteriology results will be reported actively (via telephone or house visit) as soon as quality-assured results become available (within 48 working hours for microscopy and Xpert). Patients who have not had complete resolution of symptoms will be referred with all available results to routine primary care management.

6.6.2 Day-29 activities

Day-29 will be the final study visit. We will on this visit, collect data on clinical impact of antibiotic treatment and risk of AMR. In line with the second primary endpoint (composite clinical impact), we will document:

- 1) vital status
- 2) hospitalisations
- **3)** identify missed TB diagnosis by using culture results from Day 1 and Day 8 sputum, any chest X-rays performed in follow up, and repeat mycobacteriology if symptomatic
- 4) perform HIV tests for those with unknown status and eligible for routine HIV test.
- 5) establish the status of HIV care and follow up
- 6) establish the status of TB care and follow up

We will first collect information on clinical events prior to and at the visit and communicate all available sputum culture results and the final reported CXR results.

After collecting the clinical information, we will collect nasopharyngeal swab sample for assessing antimicrobial resistance. To collect the sample, a trained study staff will swab the participants' nasopharynx and place the swab in a tube containing skim milk tryptone glucose glycerol (STGG).

6.7 Laboratory methods

6.7.1 Tuberculosis mycobacteriology

We will process mycobacteriology tests at the Malawi College of Medicine TB laboratory, a reference laboratory located in Blantyre. For sputum samples collected on Day-1, we will perform smear microscopy, Xpert MTB/RIF and MTB culture. For sputum samples collected on Day-8, we will perform smear microscopy and MTB culture. We will use Mycobacteria Growth Indicator Tube (MGIT) and Lowenstein-Jensen (LJ) culture methods for TB culture. Once isolated, we will perform speciation as *Mycobacteria tuberculosis* (MTB) or non-tuberculous mycobacteria (NTM) using MBP84 antigen testing, microscopic cording and, if necessary, morphology and growth characteristics at different temperatures and on solid (LJ) media containing p-nitrobenzoic acid (PNB).

6.7.2 Urine antigen testing for lipoarabamannan and other MTB antigens

Urine will be collected and stored as two 1 ml aliquots at -20°C from each participant on both Day-1 and Day-8 for subsequent mycobacterial antigen testing. No appropriate product is available for immediate use, but we anticipate that a commercial product with sufficiently high analytic accuracy for use in ambulant outpatients (sensitivity and specificity) may become available during the course of, or soon after, the study. If ongoing evaluations of the FIND-sponsored FujiFilm product⁴⁵ meet or exceed pre-specified requirements for clinical utility in the outpatient context, then point-of-care LAM testing at Day-1 and Day-8 will be added to the mycobacteriological definition of TB and patient management as soon as kits have been obtained and evaluated in Malawi.

6.7.3 Antimicrobial resistance testing

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

We will store swabs in STGG at minus 80°C. At a later stage we will thaw them in batches, and plate them onto selective media and culture colonies consistent with *S. pneumoniae*. We will determine Minimal inhibitory concentrations (MICs) using E-test strips (azithromycin and amoxicillin), and Kirby Bauer Disc diffusion testing (azithromycin, rifampicin, tetracycline, ceftriaxone, chloramphenicol, co-trimoxazole, erythromycin and penicillin) and define resistance by EUCAST breakpoints.

We will store isolates and remaining STGG at minus 80°C to allow genotypic characterization, isolation and susceptibility testing of other key respiratory pathogens, FTD 33 respiratory pathogen diagnostic panel, metagenomics analysis, and microarrays to detect multiple carriage and macrolide resistance genes in a broader range of pathogens at a later stage.

6.8 Loss to follow-up

To minimise loss to follow up, we will at enrolment record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. Should a participant miss a study visit, we will contact them by phone or by visiting them at home to encourage them to attend the study visit before expiry of prescribed visit window.

We anticipate a loss to follow-up of 5% by Day-8, and 10% by Day-29. We have accounted for these assumptions in the sample size calculation. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

6.9 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

6.10 Summary schedule for study procedures

In Table 6 below, we have summarised all key study procedures over the study period.

		STUDY PER	RIOD	
	Enrolment		Follow ι	р
TIMEPOINT**	Day-1	Day-8		Day-29
ENROLMENT:				
- Eligibility screen	Х			
Informed consent	Х			
Allocation	x			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	X			
Standard of care	x			
ASSESSMENTS:				
Demographics	x	4		
History of antibiotic use	Х	x		Х
*History & examination	X	x		х
**Sputum collection	X	x		
Urine for TB I AM test	х	x		
Nasophanyngeal swah	X		O,	Х
	Х		2	х
	х	x		x
		x		
***Clinical events		Х		х
		x		x
<i>Give sputum bottles at end of the symptomatic participants, Date of the sputum bottles at end of Date of the sputum bottles at end of the sputum sputum of the sputum spu</i>	y-8 sputum mycoba X-ray should be pe ay-1 visit for submiss the study when clinica	L cteriology should be formed and interpre sion on Day-8. Also ally indicated	i l fast-track ted in real collect spu	ed to inform -time. itum and per

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

7 Safety reporting

7.1 Definitions

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence in a participant to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product.
	An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.
Adverse Reaction (AR)	Any untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant.
	The phrase "response to an investigational medicinal product" means that a causal relationship between a trial medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out.
	All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the trial medication qualify as adverse reactions.
Serious Adverse Event (SAE)	 A serious adverse event is any untoward medical occurrence that: Results in death Is life-threatening Requires inpatient hospitalisation or prolongation of existing hospitalisation Results in persistent or significant disability/incapacity
	 Consists of a congenital anomaly or birth defect
	Other 'important medical events' may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences.
Serious Adverse Reaction (SAR)	An adverse event that is both serious and, in the opinion of the reporting investigator, believed with reasonable probability to be due to one of the trial treatments, based on the information provided.
Suspected Unexpected Serious Adverse Reaction (SUSAR)	A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out:
	 In the case of a product with a marketing authorisation, in the summary of product characteristics (SmPC) for that product.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

7.2 DMID grading for AEs

We will adopt the events grading criteria prepared by the Division of Microbiology and Infectious Diseases (DMID) of the USA National Institutes of Health as shown in the table below.

1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
Transient or mild discomfort (< 48 hours); no medical intervention required	Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention required	Marked limitation in activity, some assistance usually required; medical intervention required, hospitalizations possible	Extreme limitation in activity, significant assistance required; significant medical intervention required, hospitalization probable

7.3 Grading for expected events

The following table provides guidance for grading known important or frequent side effects of azithromycin (based on the AE grading criteria provided in the BREATHE Trial Protocol, also investigating azithromycin) and amoxicillin graded on the DMID scale. All events not mentioned here or in Appendix 2, will be graded using the DMID grading for AEs table presented above.

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE- THREATENING
Side-effects	1	2	3	4
Acute Allergic Reaction	Localized urticaria (wheals) with no medical intervention indicated	Localized urticaria with intervention indicated OR Mild angioedema with no intervention indicated	Generalized urticaria OR Angioedema with intervention indicated OR Symptoms of mild bronchospasm	Acute anaphylaxis OR Life-threatening bronchospasm OR Laryngeal oedema
Rash Specify type, if applicable	Localized rash	Diffuse rash OR Target lesions	Diffuse rash AND Vesicles or limited number of bullae or superficial ulcerations of mucous membrane limited to one site	Extensive or generalized bullous lesions OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Stevens-Johnson syndrome OR Toxic epidermal necrolysis
Mental state changes	mild anxiety or depression	moderate anxiety or depression; therapy required;	severe mood changes requiring therapy; or suicidal ideation;	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE- THREATENING
Photosensitivity	Painless erythema covering <10% body surface area	change in normal routine Tender Erythema covering 10 - 30% body surface area	or aggressive ideation Erythema covering >30% body surface area and erythema with blistering, requiring intervention	Life-threatening consequences; urgent intervention indicated
Arrhythmia (by ECG or physical examination) Specify type, if applicable	No symptoms AND No intervention indicated	No symptoms AND Non-urgent intervention indicated	Non-life- threatening symptoms AND Non-urgent intervention indicated	Life-threatening arrhythmia OR Urgent intervention indicated
Prolonged QTc Interval	0.45 to 0.47 seconds	> 0.47 to 0.50 seconds	> 0.50 seconds OR ≥ 0.06 seconds above baseline	Life-threatening consequences (e.g., Torsade de pointes, other associated serious ventricular dysrhythmia)
Diarrhea ≥ 1 year of age	Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline per 24-hour period	Persistent episodes of unformed to watery stools OR Increase of 4 to 6 stools over baseline per 24-hour period	Increase of ≥ 7 stools per 24- hour period OR IV fluid replacement indicated	Life-threatening consequences (e.g., hypotensive shock)
Tinnitus	Symptoms causing no or minimal interference with usual social & functional activities with intervention not indicated	Symptoms causing greater than minimal interference with usual social & functional activities with intervention indicated	Symptoms causing inability to perform usual social & functional activities	NA
Nausea	Transient (< 24 hours) or intermittent AND No or minimal	Persistent nausea resulting in decreased oral intake for 24 to 48 hours	Persistent nausea resulting in minimal oral intake for > 48 hours OR Rehydration	Life-threatening consequences (e.g., hypotensive shock)

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE- THREATENING
	interference with oral intake		indicated (e.g., IV fluids)	
Vomiting	Transient or intermittent AND No or minimal interference with oral intake	Frequent episodes with no or mild dehydration	Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated (e.g., IV fluids)	Life-threatening consequences (e.g., hypotensive shock)
Laboratory	1	2	3	4
ALT or SGPT, High	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Report only one				
Creatinine Clearance or eGFR, Low <i>Report only one</i>	NA	< 90 to 60 ml/min or ml/min/1.73 m2 OR 10 to < 30% decrease from baseline	< 60 to 30 ml/min or ml/min/1.73 m2 OR ≥ 30 to < 50% decrease from baseline	< 30 ml/min or ml/min/1.73 m2 OR ≥ 50% decrease from baseline or dialysis needed

7.4 Causality

When reporting on serious adverse events, the trial investigator will state whether they believe that the event is causally associated with any of the trial treatments and the strength of the causal relationship. They will also state whether the adverse event was expected and what if any action was taken.

Relationship	Description
Unrelated	There is no evidence of any causal relationship
Unlikely	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatment).
Possible	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g. the participant's clinical condition, other concomitant treatments).
Probable	There is evidence to suggest a causal relationship and the influence of other factors is unlikely.

Definitely	There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.
Not assessable	There is insufficient or incomplete evidence to make a clinical judgement of the causal relationship.

7.5 Reporting Procedures

7.5.1 Non-serious Adverse Events (AEs)

Adverse events will be ascertained from patient follow-up visits or reports from relatives or guardian if patient cannot be contacted for follow-up. Study clinicians will be responsible for recording of details of the event including a description of the event, date of onset, severity, assessment of relatedness to trial interventions. Adverse events will be recorded in case report forms and uploaded into the study database.

7.5.2 Serious Adverse Events (SAEs)

All serious adverse events (SAEs) will be recorded on the relevant study CRFs and reported immediately to the Principal Investigator who will ensure that they are compiled in aggregate form and reported to COMREC and the DSMB once every 6 months. The DSMB will review SAE reports at their 6 monthly meetings and issue recommendations which will be shared with ethics committees. Events relating to a pre-existing condition or any planned hospitalisations for elective treatment of a pre-existing condition will not be reported as SAEs.

8 Economic evaluation

8.1 Objective

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions.

8.2 Outcomes

We will perform a within trial comparison of the three treatment arms to estimate the incremental cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) measure.^{46,47} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

8.3 Data collection

The health economic data collection will be undertaken alongside planned clinical data collections. We will administer the Chichewa version of the EQ-5D-3L to all trial participants at baseline (Day1), Day 8 and Day 29. The Chichewa EQ-5D-3L was prepared in accordance with international and EuroQoL guidelines. The EQ-5D uses a descriptive system and a visual analogue scale (VAS). HRQoL on the day of response is defined using the descriptive system in terms of the following dimensions: 1) mobility, 2)self care, 3)usual activities, 4)pain/discomfort, and 5) anxiety or depression. The responses are then split into the following ordinal levels: 1) no problems; 2) some or moderate problems; and 3) severe or extreme problems.

The EQ-5D has 243 health states to which each response is allocated and converted to an EQ-5D utility score using a tariff. Tariff sets are derived from national surveys and currently no Malawian EQ-5D tariff exists. Zimbabwe, a setting similar to Malawi, has EQ-5D tariff set. In this study, we will use the Zimbabwean set to derive EQ-5D utility scores⁴⁸ an acceptable practice considering the similarities in how the two populations value health.⁴⁹ The EQ-5D utility scores in the Zimbabwean tariff, range from 1.0 (which means no problems in the five dimensions) to -0.29 (defined as severe problems in all five dimension).

We will capture all healthcare resources used by trial participants from recruitment into the trial till Day 29. This will be undertaken on Day 1, Day 8 and Day 29. Healthcare resources will be translated into direct medical costs using previously estimated costs^{47,50,51} and the wider literature.

BMJ Open

Drug prices will be based on International market prices.⁵² The health resource use questionnaire will at a minimum capture:

- Outpatient clinic visits
- Days of inpatient hospital care
- Medications

• Investigations and procedures

8.4 Data analysis

Our primary analysis will focus on direct intervention and the broader healthcare costs. We will define direct intervention costs as the costs associated with the application of the interventions. We will plot health state values measured by the EQ-5D-3L against time assuming that the health states reported at each time point are linearly connected. We will estimate QALYs associated with participant health profile by area under the plotted curve as calculated using the trapezium rule.

We will use a range of analytical methods depending on whether baseline covariates (EQ-5D utility values) are balanced between the trial arms or not. If they are balanced, we can obtain unbiased cost-effectiveness estimates by using non-parametric bootstrap approaches; if imbalance exists regression methods will be the approach of choice.

We will explore a range of estimators and undertake model diagnostics to determine the optimal model because the distributions of costs and QALYs are commonly skewed, often bimodal, or truncated. We will estimate mean costs and outcomes for each intervention together with respective mean incremental cost-effectiveness ratio. We will for each estimate report respective measures of uncertainty (standard errors and confidence intervals). We will also estimate the net monetary benefits (NMBs) for a range of different willingness to pay (WTP) thresholds. To identify the optimal intervention at different WTP thresholds, we will construct cost-effectiveness acceptability curves (CEACs) based on the NMB framework.

8.5 Missing data

For each participant we will collect complete data as far as possible but in cases of missing values, a common occurrence in trials, we will perform additional analyses to explore the impact of and account for the missingness.

9 Data management

9.1 Source Data

We will consider a document as source if it is where data were first recorded, and from which we obtained participants' case report forms (CRF) data. These will include hospital records, health center records, participant health passport, laboratory and pharmacy records, diaries, radiographs, and correspondence. We will consider CRF entries as source data if the CRF is the site of the original recording.

We will on all study-specific documents, other than study ID code list, the signed consent forms household locator form and, refer to the participant by their trial participant identification number, not by name. We will keep study ID code list, consent and locator forms separate from the rest of the participant file to avoid linkage between participant name and the study ID.

9.2 Data collection methods

We will collect data using standardised, pre-tested CRFs in two forms:

- programmed into android tablets using Open Data Kit (ODK) platform (opendatakit.org) with paper back-ups.
- optical mark recognition readable forms read and extracted using TELEFORM system (Cardiff Software, Inc., Vista, CA), an optical-character-recognition software.

9.3 Data management

Any participants' identifiable data collected by the Study Coordination Centre will be stored securely and their confidentiality protected in accordance with the Data Protection Act 1998.

To ensure data security and maintenance of participant confidentiality, we will take several strict measures. All the study data collection tablets and computers will be encrypted, password protected and stored in a fireproof lockable cabinet inside a locked room. The principal investigator, study coordinator and data manager will be responsible for the maintenance of the tablets as well as all other computers, and their security from viruses and theft. All users will check in with the study coordinator and sign for data entry tablets every time they are taken out to for data entry and upon return. Whenever not in use, the devices will be kept in their locked cabinet.

We will keep all paper records in a locked space only be accessible to the principal investigator, coinvestigators and delegated study staff. Study databases will be encrypted, password protected and will be stored on dedicated servers within the University of Malawi College of Medicine. We will keep all electronic and paper records securely for up to 10 years after the end of the trial in accordance with LSHTM Records Retention & Disposal Schedule guidelines.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

9.4 Quality control and quality assurance

We will apply quality control at each stage of data handling in accordance with GCP requirements to ensure that all data are reliable and have been processed correctly. We will manual review all paper CRFs for completeness, accuracy and legibility before scanning. Our ODK data entry system will include automatic pre-programmed real-time data validation. The TELEFORM system will also have pre-programmed automatic data validation capabilities. We will perform data quality assurance (QA) on a random 10% of all participant files. The QA process will involve examining database entries and for paper source documents, verification of database entries and source.

9.5 Access to data

We will upon request, provide direct access to authorised representatives from the Sponsor, host institution and the regulatory authorities to allow smooth running of trial-related monitoring, audits and inspections.

10 Data monitoring and quality assurance

10.1 Data monitoring

Site monitoring for safety will be conducted to ensure human subject protection. The study will be monitored just before commencing enrolment, then once every 6 months by a monitoring team from the University of Malawi College of Medicine. The objective will be to ensure that study procedures, study products administration, and data collection processes are of high quality and meet ethical and regulatory guidelines. The regular monitoring will focus on the following areas: 1) protocol adherence, 2) informed consent documentation, 3) trial endpoints, 4) treatment discontinuation, 5) regulatory documents, 6) compare source documents and case report forms for accuracy, and 7) documentation practices in general.

10.2 Audits and Inspections

The study will be subject audit by the London School of Hygiene & Tropical Medicine under their remit as sponsor, the Study Coordination Centre and other regulatory bodies to ensure adherence to GCP.

10.3 Data Safety and Monitoring Board (DSMB)

We will set up a DSMB before commencing trial activities. The DSMB will provide independent review of the study conduct, progress and findings. It will comprise 3 members including a chairperson who will be responsible for collating and communicating the views of the DSMB. The DSMB will consist of an independent statistician and two clinicians, at least one of them a physician, with research experience and expertise in the management of tuberculosis and HIV in Africa. The proposed data safety monitoring plan will be discussed in a teleconference including the DSMB members and the key investigators prior to the study starting.

The proposed meeting schedule is 6 monthly. Two weeks before a 6 monthly DSMB meeting, the study team will prepare a report covering study progress, study approvals, any obstacles, and recruitment statistics, adverse events, withdrawals and trial outcome measures. The DSMB will, through its chairperson, provide written feedback to the principal investigator who will be responsible for passing it on to ethics committees.

10.4 Trial Management Group (TMG)

A Trial Management Group (TMG) will be appointed and will be responsible for overseeing the progress of the trial. The day-to-Day-management of the trial will be co-ordinated through the University of Malawi College of Medicine.

10.5 Trial Investigational Team

Our investigational team includes expertise in diagnosis and management of TB; clinical evaluation of TB diagnostics; design and conduct of large randomised controlled trials; laboratory TB and AMR diagnostics; data management and analysis.

Chief investigator

 Dr Titus H Divala: the chief investigator and PhD student will be responsible for protocol development, coordination and conduct of the trial, governance, data management, data analysis and results dissemination. Dr Divala is a clinician with a career interest in clinical trials. Apart from medical training, he holds MPH and Masters of Science in epidemiology and preventive medicine. He has managed two large GCP, US-NIH-funded clinical trials, one of which was IND as the local PI supervising over 40 study staff at two sites in different cities. He has worked as a clinician for over 8 years in Malawi, a period when identifying TB cases and putting them on treatment was a daily job. This topic therefore falls in area of great personal interest above and beyond the potential benefit it has towards improving patient care in Malawi and all low and middle-income countries where 95% of the TB burden lies, where this approach is the standard.

Co-investigators and members of PhD supervisory team

<u>Prof Katherine L Fielding</u>: a seasoned TB statistician and clinical trialist, and PhD supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

<u>Prof Elizabeth L Corbett</u>: a seasoned TB clinical epidemiologist and PhD co-supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

Co-investigators and members of PhD advisory committee

Dr Derek J Sloan: clinician with detailed local clinical and research experience, will be responsible for protocol development, trial implementation and data dissemination.

<u>Prof Neil French</u>: a seasoned pneumococcal expert, will be responsible for protocol development, oversee all aspects of AMR work, and data dissemination.

Collaborators

<u>Dr Marriott Nliwasa</u>: clinician, with experience conducting studies in the study setting. He will be support the conduct of the study, linkage with the national program, and data dissemination.

<u>Mr Augustine Choko</u>: statistician, with expertise and experience in using ACASI. He will support ACASI development, data management and development of analysis plan.

<u>Dr Ankur Gupta-Wright</u>: clinician, will provide clinical input in protocol development and clinical consultation support to research coordinators during study implementation..

<u>Dr Jennifer Cornick</u>: microbiologist, will be support protocol development, and AMR laboratory methods and analysis, and data dissemination.

<u>Prof Jon Øyvind Odland</u>: Epidemiologist and honorary professor at University of Malawi College of Medicine, responsible for seeking ethical approvals from the funder appointed ethics committee.

11 Ethics and dissemination

We will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki and in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice E6 (R2) of November 2016.

11.1 Risk assessment

This is a low risk study as it is using already licensed antibiotics with good safety profile in a population defined by national clinical guidelines as clinically stable and not requiring other intervention but TB investigations. Our work complements standard of care by bringing in detailed TB diagnostics. In our study, the standard of care equivalent of the antibiotics we will prescribed on Day-1 to those randomised to either azithromycin or amoxicillin arms, are in standard of care prescribed on Day-8 only to mycobacteriology negative symptomatic patients (similar to the no antibiotic or standard of care arm of our trial). So, participants randomised to no antibiotic at Day-1 will not be receiving inadequate care but the recommended standard management of withholding antibiotics until after the TB results are available (Figure 1). To maintain participant safety and continuity of their care while on study interventions, we will not blind routine care clinical team and they will be free to manage the participants on their clinical judgement and national guidelines.

11.2 Research ethics approval

We will seek ethical approval for the trial protocol, informed consent forms, participant information sheet, any advertising material, and amendments to any of these documents, from the University of Malawi College of Medicine Research and Ethics Committee (COMREC), the LSHTM Research Ethics Committee, and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (on behalf of the funder). We will seek regulatory approval from the Malawi Pharmacy, Medicines, and Poisons Board (PMPB). Every year when the trial is active, we will seek continuous ethical review and approval before expiry of previous year's approval. In the event of an amendment, the changes will only be implemented upon ethical and regulatory approval.

11.3 Indemnity

London School of Hygiene & Tropical Medicine holds Public Liability ("negligent harm") and Clinical Trial ("non-negligent harm") insurance policies which apply to this trial.

11.4 Sponsor

London School of Hygiene & Tropical Medicine will act as the main sponsor for this study. Delegated responsibilities will be assigned locally.

11.5 Declaration of interests

The study team declares that they have no conflict of interest in conducting this clinical trial.

11.6 Cost of participation, ancillary and post-trial care

During the study, participant will benefit from frequent interaction with clinical study staff and associated optimised management of illnesses. There are minimal risks including discomfort associated with collection of nasopharygeal samples, and side-effects of study interventions. We will reimburse participant transport for attending study visits.

11.7 Dissemination policy

This work will form part of a PhD thesis for Titus Divala, which he will submit to the London School of Hygiene & Tropical Medicine (LSHTM). All publications and presentations relating to the study will be authorised by the Trial Management Group. The first publication of the trial results will be in the name of the Trial Management Group, if this does not conflict with the journal's policy. If there are named authors, these will include at least the trial's Chief Investigator, Statistician and Trial Coordinator.

Members of the TMG and the DSMB will be listed and contributors will be cited by name if published in a journal where this does not conflict with the journal's policy

	-
12	References
1	Holmes AH, Moore LS, Sundsfiord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Pi
••	I Understanding the mechanisms and drivers of antimicrobial resistance. The Lance
~	2016; 387 (10014): 176-87.
2.	World Health Organization. The evolving threat of antimicrobial resistance: options for
	action: Geneva: World Health Organization; 2012.
3.	World Health Organization. Antimicrobial resistance: global report on surveillance: Wo
	Health Organization; 2014.
4.	Laxminaravan R. Matsoso P. Pant S. Brower C. Røttingen J-A. Klugman K. Davies S
	Access to effective antimicrobials: a worldwide challenge. The Lancet 2016: 387(100)
	168-75
5	Revialione M. Sulis G. Tuberculosis 2015: burden, challenges and strategy for contro
0.	elimination Infectious disease reports 2016: 8(2): 6570
6	World Health Organization, Clobal tuberoulogic report 2016, 2016
0. 7	Wond Health Organization. Global tuberculosis report 2010. 2010.
1.	Nilwasa M, MacPherson P, Mukaka M, Mdolo A, Mwapasa M, Kaswaswa K, Msefula
	Chipungu G, Mwandumba H, Corbett E. High mortality and prevalence of HIV and
	tuberculosis in adults with chronic cough in Malawi: a cohort study. The international
	of tuberculosis and lung disease 2016; 20 (2): 202-10.
8.	Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonar
	tuberculosis in people with HIV infection or AIDS in resource-constrained settings: inf
	urgent policy changes. The Lancet 2007; 369 (9578): 2042-9.
9.	Corbett E. MacPherson P. Tuberculosis screening in high human immunodeficiency
•	prevalence settings: turning promise into reality [State of the art series. Active case
	finding/screening. Number 5 in the series] The international journal of tuberculosis a
	disease 2013: 17 (0): 1125-38
10	Siddigi K Lombort M L Wollow L Clinical diagnosis of amour pagative pulmonary
10.	Sidulqi K, Lambert W-L, Walley J. Cillical diagnosis of sineal-negative pullionary
	2003; 3 (5): 288-96.
11.	Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-infe
	Ghana. In: Department DCaP, editor. Accra; 2007.
12.	Ministry of Health. Malawi National TB Programme Manual In: Programme NT, edit
	ed. Lilongwe; 2016.
13.	National Department of Health. South Africa National Tuberculosis Management Guid
	2014. In: Coordination TDS, editor. Pretoria; 2014.
14.	Wilkinson D, Newman W, Reid A, Squire S, Sturm A, Gilks C. Trial-of-antibiotic algori
	the diagnosis of tuberculosis in a district hospital in a developing country with high HI
	prevalence. The International Journal of Tuberculosis and Lung Disease 2000. 4(6).
15	Whiting PF, Ruties AW, Westwood MF, Mallett S, Deeks JJ, Reitsma JB, Leeflang M
	Sterne JA Bossuvt PM QUADAS-2: a revised tool for the quality assessment of diag
	accuracy studies Annals of internal medicine 2011: 155(8): 520-36
16	Rychatnik I. Frommer M. Hawe D. Shiell A. Critoria for avaluating avidance on public
10.	interventions Leurnal of Enidemialogy & Community Leadth 2000, EC(0), 440.07
4-	Interventions. Journal of Epidemiology & Community Health 2002; 56 (2): 119-27.
17.	Schunemann HJ, Oxman AD, Brozek J, Glaszlou P, Jaeschke R, Vist GE, Williams J
	Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, Group GW. Grading quality of e
	and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336(
	1106-10.
18.	Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and resp
	Nature medicine 2004; 10 (12s): S122.
19	Goossens H. Ferech M. Vander Stichele R. Elseviers M. Group FP. Outpatient antibio
	in Furope and association with resistance: a cross-national database study. The Land
	2005 365(9459) 579-87
20	Everett DR Mukaka M Denis R Cordon SR Carrol ED van Oosterbout LL Molynou
∠0.	Molynoux M. Eronob N. Hoyderman DS. Ton years of surveillance for investig
	woryneux w, French w, neyderman KS. Ten years of surveillance for invasive

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

3		Streptococcus pneumon
4		prophylaxis in Malawi. P
5	21.	Coles CL. Mabula K. Se
6		Mass distribution of azith
7		azithromycin resistant S
8		aziti i oniyon-resistant S
9		treatment. Clinical Infect
10	22.	Mitjá O, Houinei W, Mos
11		Grice T. Mass treatment
12		Medicine 2015; 372(8): 7
12	23.	Maher MC, Alemavehu \
13	20.	TM Porco TC The fitne
14		from the field PLoS One
15	24	Man Mul de Steenbuije
16	24.	Man WH, de Steennuijse
17		gatekeeper to respirator
18	25.	Satzke C, Turner P, Viro
19		Restrepo AM, Leach AJ,
20		respiratory carriage of S
21		World Health Organization
22		165 70
23	20	Coin KD An altheorem
24	20.	Cain KP, Anekinananon
25		Sattayawutnipong W, Ta
25		who have tuberculosis,
20	27.	Bedell RA, Anderson ST
27		Heyderman RS, Zachari
28		bloodstream infections in
29		Malawi PLoS One 2012
30	20	Schloichar C. Foldman (
31	20.	Mussiche stariums tub snoul
32		Mycobacterium tubercul
33		pneumonia. The Interna
34		8.
35	29.	Musicha P, Cornick JE,
36		Gordon MA. Msefula CL
37		resistance in bloodstrea
38		a surveillance study The
30	20	Montori VM Dormonyor
40	50.	Drivent D. Alense I. Akl
40		Bryant D, Alonso J, Aki i
41		clinical trials. <i>Bmj</i> 2005;
42	31.	Nliwasa M, MacPherson
43		Msefula C, Sohn H, Flac
44		Amplification (LAMP) as
45		Malawi, PloS one 2016;
46	32	Lubell Y Turner P Ashle
47	02.	acquired infections in su
48		Modicino 8 International
49	00	
50	33.	Phua J, Dean NC, Guo
51		pneumonia: timely mana
52		237.
53	34.	Lim W, Smith D, Wise M
54		pneumonia quideline an
55		2015 thoraxinl-2015-20
56	35	van der Paardt Δ_F \//ilf
50	55.	dor Worf TS Kastariak
57		
58		against multidrug-resista
59		46 (2): 444-55.
60		

1 2

- 21. Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. *Clinical Infectious Diseases* 2013; **56**(11): 1519-26.
- 22. Mitjà O, Houinei W, Moses P, Kapa A, Paru R, Hays R, Lukehart S, Godornes C, Bieb SV, Grice T. Mass treatment with single-dose azithromycin for yaws. *New England Journal of Medicine* 2015; **372**(8): 703-10.
- Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC. The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. *PLoS One* 2012; **7**(1): e29407.
- Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol* 2017; **15**(5): 259-70.
- Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* 2013; **32**(1): 165-79.
- 26. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK. Causes of death in HIV-infected persons who have tuberculosis, Thailand. *Emerging infectious diseases* 2009; **15**(2): 258.
 - 27. Bedell RA, Anderson ST, Van Lettow M, Åkesson A, Corbett EL, Kumwenda M, Chan AK, Heyderman RS, Zachariah R, Harries AD. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. *PLoS One* 2012; **7**(6): e39347.
- Schleicher G, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease* 2003; **7**(12): 1207-8.
- 29. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, Kennedy N, Mallewa J, Gordon MA, Msefula CL, Heyderman RS, Everett DB, Feasey NA. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. *The Lancet Infectious Diseases* 2017; **17**(10): 1042-52.
- 30. Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E. Validity of composite end points in clinical trials. *Bmj* 2005; **330**(7491): 594-6.
- 31. Nliwasa M, MacPherson P, Chisala P, Kamdolozi M, Khundi M, Kaswaswa K, Mwapasa M, Msefula C, Sohn H, Flach C. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. *PloS one* 2016; **11**(5): e0155101.
- 32. Lubell Y, Turner P, Ashley EÁ, White NJ. Susceptibility of bacterial isolates from communityacquired infections in sub-Saharan Africa and Asia to macrolide antibiotics. *Tropical Medicine & International Health* 2011; **16**(10): 1192-205.
- 33. Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. Severe community-acquired pneumonia: timely management measures in the first 24 hours. *Critical Care* 2016; **20**(1): 237.
- 34. Lim W, Smith D, Wise M, Welham S. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. *Thorax* 2015: thoraxjnl-2015-206881.
- 35. van der Paardt A-F, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar J-WC. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. *European Respiratory Journal* 2015;
 46(2): 444-55.

1		
2		
3	36.	Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of
4		macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother
5		2005 [.] 49 (4) [.] 1447-54
6	37	Fry A Jha H Lietman T Chaudhary JP Bhatta R Elliott J Hyde T Schuchat A Gaynor B
7	07.	Dowell S. Adverse and beneficial secondary effects of mass treatment with azithromycin to
8		Dowell S. Adverse and beneficial secondary effects of mass freathered diseases 2000; 25(4): 205
9		eliminate bindness due to trachoma in Nepal. <i>Clinical infectious diseases</i> 2002; 35 (4): 395-
10		402.
11	38.	Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ,
12		Emerson P. Effect of mass distribution of azithromycin for trachoma control on overall
13		mortality in Ethiopian children: a randomized trial. <i>Jama</i> 2009; 302 (9): 962-8.
13	39.	Keenan JD. Avele B. Gebre T. Zerihun M. Zhou Z. House JI. Gavnor BD. Porco TC.
15		Emerson PM Lietman TM. Childhood mortality in a cohort treated with mass azithromycin
15		for trachoma Clin Infect Dis 2011: 52(7): 883-8
10	40	Muchar DM Thornor AP. Community acquired pnoumonia. N Engl / Mod 2014: 371 /17):
1/	40.	Musher Divi, momer AR. Community-acquired priedmoma. <i>IN Engl 5 Med</i> 2014, 37 1 (17).
18		
19	41.	Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA, Machili CE, Gilks CF, Boeree
20		MJ, Kampondeni S, Read RC, Molyneux ME. Pneumococcal disease in HIV-infected
21		Malawian adults: acute mortality and long-term survival. <i>AIDS</i> 2002; 16 (10): 1409-17.
22	42.	Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that
23		control pneumococcal carriage. PLoS pathogens 2017; 13(12): e1006665.
24	43.	Goldblatt D. Hussain M. Andrews N. Ashton L. Virta C. Melegaro A. Pebody R. George R.
25	-	Solution A Edmunds I Gav N Kayhty H Miller F Antibody responses to nasopharyngeal
26		carriage of Streptococcus preumoniae in adults: a longitudinal household study. Unfect Dis
27		
28		2000, 192(0). 307-95.
29	44.	National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence
30		Survey. 45 ^{er} Union World Conference on Lung Health. Barcelona, Spain, 2014.
31	45.	Global Health Innovative Technology Fund. Highly Sensitive POC TB-LAM Rapid Diagnostic
32		Test. 2017. https://www.ghitfund.org/impact/portfolio/awpdetail/detail/78 (accessed 28 Feb
33		2018).
34	46.	EuroQol G. EuroQola new facility for the measurement of health-related guality of life.
35		Health policy (Amsterdam, Netherlands) 1990; 16 (3); 199.
36	47	Maheswaran H. Petrou S. MacPherson P. Choko AT. Kumwenda F. Lalloo DG. Clarke A
37		Corbett EL Cost and quality of life analysis of HIV self-testing and facility-based HIV testing
20		and acupabiling in Plantura, Malawi, <i>PMC madiaina</i> 2016; 1 /(1): 24
20	40	and coursening in Diantyre, Malawi. <i>Divic medicine</i> 2010, 14(1). 54.
39 40	48.	Jeisma J, Hansen K, De Weerdt W, De Cock P, Kind P. How do Zimbabweans value nealth
40		states? Population health metrics 2003; 1(1): 11.
41	49.	Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the
42		economic evaluation of health care programmes: Oxford university press; 2015.
43	50.	Maheswaran H, Petrou S, MacPherson P, Kumwenda F, Lalloo DG, Corbett EL, Clarke A.
44		Economic costs and health-related quality of life outcomes of HIV treatment after self-and
45		facility-based HIV testing in a cluster randomized trial. Journal of acquired immune
46		deficiency syndromes (1999) 2017: 75 (3): 280
47	51	Maheswaran H. Petrou S. Cohen D. MacPherson P. Kumwenda F. Lalloo DG. Corbett Fl
48	51.	Clarke A. Economic costs and bealth related quality of life outcomes of beanitalized nationts
49		with high LIV providence: A presentative beautiful schort study in Malawi, DLOS ONE 2010;
50		with high miv prevalence: A prospective nospital conort study in Malawi. PLOS ONE 2018;
51		13 (3): e0192991.
52	52.	Frye JE. International Medical Products price indicator guide: Management Sciences for
53		Health, 2015.
54		
55		
56		
57		
58		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

13 Appendix 1: Informed consent

Included as a separate document on headed pages.

to peer teriew only

14 Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table

TABLE VERSION: November 2007

ABBREVIATIONS: Abbreviations utilized in the Table:

ULN = Upper Limit of Normal LLN = Lower Limit of Normal R_x = Therapy Red	q = Required
---	--------------

Mod = Moderate IV = Intravenous ADL = Activities of Daily Living Dec = Decreased

ESTIMATING SEVERITY GRADE

For abnormalities NOT found elsewhere in the Toxicity Tables use the scale below to estimate grade of severity:

GRADE 1 Mild Transient or mild discomfort

(< 48 hours); no medical intervention/therapy required

GRADE 2 Moderate Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required

GRADE 3SevereMarked limitation in activity, some assistance usually required;medical intervention/therapy required, hospitalizations possible

GRADE 4 Life-threatening Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable

SERIOUS OR LIFE-THREATENING AEs

ANY clinical event deemed by the clinician to be serious or life-threatening should be considered a grade 4 event. Clinical events considered to be serious or life-threatening include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, severe depression.

COMMENTS REGARDING THE USE OF THIS TABLE

- Standardized and commonly used toxicity tables (Division of AIDS, NCI's Common Toxicity Criteria (CTC), and World Health Organization (WHO)) have been adapted for use by the Division of Microbiology and Infectious Diseases (DMID) and modified to better meet the needs of participants in DMID trials.
- For parameters not included in the following Toxicity Tables, sites should refer to the "Guide for Estimating Severity Grade" located above.

• Criteria are generally grouped by body system.

• Some protocols may have additional protocol specific grading criteria, which will supersede the use of these tables for specified criteria.

HEMATOLOGY				
	Grade 1	Grade 2	Grade 3	Grade 4
Hemoglobin	9.5 - 10.5 gm/d L	8.0 - 9.4gm/dL	6.5 - 7.9 gm/d L	< 6.5 gm/dL
Absolute Neutrophil Count	1000-1500/ mm ³	750-999/ mm ³	500-749/ mm ³	<500/ mm ³
Platelets	75,000-	50,000-	20,000-49,999/	<20,000/ mm ³
	99,999/ mm³	74,999/ mm³	mm ³	
WBCs	11,000-13,000/	13,000-	15,000-	>30,000 or
	mm ³	15,000 / mm³	30,000/ mm³	<1,000 / mm³
% Polymorphonuclear	> 80%	90 – 95%	>95%	
Leucocytes + Band Cells				
Abnormal Fibrinogen	Low:	Low:	Low:	Fibrinogen
	100-200 mg/dL	<100 mg/dL	< 50 mg/dL	associated with
		4		gross bleeding
	High:	High:		
	400-600 ma/dL	>600 ma/dL		disseminated
				coagulation
Fibrin Split Product	20-40 mcg/ ml	41-50 mcg/ ml	51-60 mcg/ ml	> 60 mcg/ ml
Prothrombin Time (PT)	1.01 - 1.25 x ULN	1.26-1.5 x ULN	1.51 -3.0 x ULN	>3 x ULN
Activated Partial	1.01 -1.66 x ULN	1.67 - 2.33 x	2.34 - 3 x ULN	> 3 x ULN
Thromboplastin (APPT)		ULN		
Methemoglobin	5.0 - 9.9 %	10.0 - 14.9 %	15.0 - 19.9%	> 20.0 %

	Grade 1	Grade 2	Grade 3	Grade 4
Hyponatremia	130-135 mEq/ L	123-129	116-122 mEq/ L	< 116 mEq/ L abnormal
		mEq/ L		sodium <i>with</i> mental
				status change or seizures
Hypernatremia	146-150 mEq/ L	151-157 mEq/ L	158-165 mEq/ L	> 165 mEq/ L abnormal sodium with mental status change or seizures
Hypokalemia	3.0 - 3.4 mEq/ L	2.5 - 2.9 mEq/ L	2.0 - 2.4 mEq/ L or intensive replacement therapy or hospitalization required	< 2.0 mEq/ L abnormal potassium <i>wit</i> paresis, ileus life-threatenin arrhythmia
Hyperkalemia	5.6 - 6.0 mEq/ L	6.1 - 6.5 mEq/ L	6.6 - 7.0 mEq/l	> 7.0 mEq/ L abnormal potassium <i>wit</i> life-threatenin arrhythmia
Hypoglycemia	55-64 mg/dL	40-54 mg/dL	30-39 mg/dL	<30 mg/d L or abnormal glucose <i>with</i> mental

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

				status changes
				or coma
Hyperglycemia	116 - 160 mg/dL	161- 250	251 - 500 mg/dL	> 500 mg/d L or
(nonfasting and no prior		ma/d l		abnormal
diabetes)		ing/a L		glucose <i>with</i>
				ketoacidosis or
				seizures
Hypocalcemia (corrected	8.4 - 7.8 mg/dL	7.7 - 7.0 mg/dL	6.9 - 6.1 mg/dL	< 6.1 mg/dL or
for albumin)				abnormal
				calcium <i>with</i> life
	6			threatening
				arrhythmia or
	No.			tetany
Hypercalcemia (correct for	10.6 - 11.5 mg/d	11.6 - 12.5	12.6 - 13.5 mg/d L	> 13.5 mg/dL or
albumin)	L	ma/d l		abnormal
		IIIg/d L		calcium <i>with</i> life
		4.		threatening
		Q.		arrhythmia
Hypomagnesemia	1.4 - 1.2 mEq/ L	1.1 - 0.9 mEq/	0.8 - 0.6 mEq/ L	< 0.6 mEq/ L or
		L		abnormal
				magnesium <i>with</i>
			21	life-threatening
			1	arrhythmia
Hypophosphatemia	2.0 - 2.4 mg/dL	1.5 -1.9 mg/dL	1.0 -1.4 mg/dL	< 1.0 mg/dL or
		or	intensive therapy	abnormal
		replacement	or hospitalization	phosphate <i>with</i>
		Rx required	required	life-threatening
				arrhythmia
Hyperbilirubinemia (when	1.1 - <1.25 x ULN	1.25 - <1.5 x	1.5 – 1.75 x ULN	> 1.75 x ULN
a second second second data a second	1	LU NI	1	1

increase in other liver				
function test)				
Hyperbilirubinemia (when	1.1 - <1.5 x ULN	1.5 - <2.0 x	2.0 – 3.0 x ULN	> 3.0 x ULN
other liver function are in		ULN		
the normal range)				
BUN	1.25 - 2.5 x ULN	2.6 - 5 x ULN	5.1 - 10 x ULN	> 10 x ULN
Hyperuricemia (uric acid)	7.5 – 10.0 mg/dL	10.1 – 12.0	12.1 – 15.0 mg/d	>15.0 mg/d L
		mg/d L	L	
Creatinine	1.1 - 1.5 x ULN	1.6 - 3.0 x ULN	3.1 - 6 x ULN	> 6 x ULN or
				dialysis required
EN ZYMES			<u> </u>	<u> </u>
	Grade 1	Grade 2	Grade 3	Grade 4
AST (SGOT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
ALT (SGPT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
GGT	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
Alkaline Phosphatase	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
Amylase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
Lipase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
URINALYSIS				
	Grade 1	Grade 2	Grade 3	Grade 4
Proteinuria	1+	2-3+	4+	nephrotic
	or	or	or	syndrome
	200 mg - 1 gm	1- 2 gm	2-3.5 gm loss/day	or
	loss/day	loss/day		> 3.5 gm
				loss/day

ACT-TB Study Protocol V3.0, 19 Feb 2019

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3
4
5
6
0
/
8
9
10
11
12
13
14
15
16
17
10
10
עו 20
∠∪ ⊃1
21
22
23
24
25
26
27
28
29
30
31
27
32 22
33
34
35
36
37
38
39
40
41
42
43
44
15
75 16
-10 //7
47
48
49
50
51
52
53
54
55
56
57
58
50
27
υU

1 2

Hematuria	microscopic only	aross no clots	aross with or	obstructive or
		9.000, 110 0.010	without clots OR	required
	<10 rbc/hpf	>10 rbc/hpf	red blood cell	
			casts	transfusion
			00515	
CARDIOVASCULAR				
	Grade 1	Grade 2	Grade 3	Grade 4
Cardiac Rhythm		asymptomatic,	recurrent/persiste	unstable
			nt;	
C		transient signs,	symptomatic Rx	dysrythmia;
		no	required	hospitalization
	6	Rx required		and treatment
	Ň.			required
Hypertension	transient increase	recurrent,	acute treatment	end organ
	> 20 mm/ Ha: no	chronic	roquirod	damaga ar
	reatment	increase	required,	
	liealment	> 20mm/ Ha	treatment or	nospitalization
		20mm/rig.		required
		/treatment	hospitalization	
		required	possible	
			\mathbf{O}	
Hypotension	transient	symptoms due	requires IV fluids;	mean arterial
	orthostatic	to orthostatic	no hospitalization	pressure
	hypotension with	hypotension or	required	<60mm/ Hg or
	heart rate	BP decreased		end organ
	increased by <20	by <20 mm Hg		damage or
	beat/min or	systolic;		shock; requires
	decreased by <10	correctable		hospitalization
	mm Hg systolic	with oral flu id		and vasopressor
	BP, No treatment	treatment		treatment
	required			

Pericarditis Hemorrhage, Blood Loss	minimal effusion microscopic/occul	mild/ moderate asymptomatic effusion, no treatment mild, no	symptomatic effusion; pain; EKG changes gross blood loss;	tamponade; pericardiocentes is or surgery required massive blood
	t	transfusion	1-2 units transfused	loss; > 3 units transfused
RESPIRATORY				
C	Grade 1	Grade 2	Grade 3	Grade 4
Cough	transient- no treatment	persistent cough; treatment responsive	Paroxysmal cough; uncontrolled with treatment	
Bronchospasm, Acute	transient; no treatment; 70% - 80% FEV ₁ of peak flow	requires treatment; normalizes with bronchodilator; FEV ₁ 50% - 70% (of peak flow)	no normalization with bronchodilator; FEV ₁ 25% - 50% of peak flow; or retractions present	cyanosis: FEV ₁ < 25% of peak flow or intubation necessary
Dyspnea	dyspnea on exertion	dyspnea with normal activity	dyspnea at rest	dyspnea requiring Oxygen therapy
GASTROINTESTINAL				
	Grade 1	Grade 2	Grade 3	Grade 4

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
<u>с</u>
4
5
6
7
,
8
9
10
11
12
12
13
14
15
16
17
17
18
19
20
21
22
22 22
23
24
25
26
27
27
28
29
30
31
32
22
33
34
35
36
37
20
38
39
40
41
42
-⊤∠ ∕\?
43
44
45
46
47
10
40
49
50
51
52
53
55
54
55
56
57
58
50
72
6 ()

1

Nausea	mild or transient;	moderate	no significant	hospitalization
	maintains	discomfort;	intake; requires IV	required;
	reasonable intake	intake	flu ids	
		decreased		
		significantly:		
		some activity		
		limited		
Vomiting	1 episode in 24	2-5 episodes in	>6 episodes in 24	physiologic
	hours	24 hours	hours or needing	consequences
			IV fluids	requiring
	-			hospitalization
				or requiring
				parenteral
				nutrition
Constinution	requiring stool	requiring	obstination	obstruction or
			obstipation	
	softener or	laxatives	requiring manual	toxic megacolon
	dietary		evacuation or	
	modification		enema	
Diarrhea	mild or transient;	moderate or	>7 loose	hypotensive
	3-4 loose	persistent; 5-7	stools/day	shock or
	stools/Day-or mild	loose	or bloody	physiologic
	bloolo, Day of Thia	stools/Day-or	diarrhea: or	consequences
	diarrhea last < 1	diarrhea	orthostatic	requiring
	week	lasting >1	hypotension or	hospitalization
		week	electrolvte	
			imbalance or >2L	
			IV fluids required	
Oral Discomfort/Dysphagia	mild discomfort;		eating/talking very	unable to drink
	no difficulty	eating/drinking		tiu ids; requires
	swallowing		swallow solid	IV fluids
			IOOAS	
NEUROLOGICAL	L	I	I	

	Grade 1	Grade 2	Grade 3	Grade 4
Neuro-Cerebellar	slight incoordination	intention tremor,	locomotor ataxia	incapacitated
	dysdiadochokines	dysmetria,		
	13	slurred		
		speech;		
		nystagmus		
Psychiatric	mild anxiety or	moderate	severe mood	acute psychosis
	depression	anxiety or	changes requiring	requiring
	4	depression;	therapy; or	hospitalization;
		therapy	suicidal ideation;	or suicidal
		required;	or aggressive	gesture/attempt
		change in	ideation	or hallucinations
	9	normal routine		
Muscle Strength	subjective	mild objective	objective	paralysis
	weakness no objective	signs/symptom s no decrease	weakness function limited	
	symptoms/ signs	in function		
Paresthesia (burning,	mild discomfort;	moderate	severe discomfort;	incapacitating;
tingling, etc.)	no treatment	discomfort;	or narcotic	or not
	required	non-narcotic analgesia required with symptor improvemen	analgesia	responsive to
			required	narcotic
			with symptomatic	analgesia
			improvement	
Neuro-sensory	mild impairment	moderate	severe	sensory loss
	in sensation	impairment	impairment	involves limbs
	(decreased	(mod	(decreased or	and trunk;
	sensation, e.g., vibratory, pinprick, hot/cold in great toes) in	decreased sensation, e.g., vibratory, pinprick,	loss of sensation to knees or wrists) or loss of sensation of at	paralysis; or seizures
	,	hot/cold to		

ACT-TB Study Protocol V3.0, 19 Feb 2019

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	-		L	
	focal area or	ankles) and/or	least mod degree	
	symmetrical	joint position or	in multiple	
	distribution; or	mild	different body	
	change in taste,	impairment	areas (i.e., upper	
	smell, vision	that	and lower	
	and/or hearing	is not	e xtremities)	
		symmetrical		
MUSCULOSKELATEL				
	Grade 1	Grade 2	Grade 3	Grade 4
Arthrolaio (isist sais)	mild poin not	modorato nair		diophing roin
Arthraigia (joint pain)	mild pain not	moderale pain,	severe pain; pain	disabiing pain
			and/or analgesics	
	function	and/or pain	interfering with	
		interfering with	activities of daily	
		function but	living	
		not with		
		activities		
		of daily living		
Arthritis	mild pain with	moderate pain	severe pain with	permanent
	inflammation,	with	inflammation,	and/or disabling
	erythema or joint		erythema or joint	joint
		inflammation,		distruction
	swelling – but not	erythema or	swelling –and	
	interfering with	joint swellina —	interfering with	
	function	interferina with	activities of dailv	
		tunction, but	living	
		not with		
		activities of		
		daily living		
Myalgia	myalgia with no	muscle	severe muscle	frank

ACT-TB Study Protocol V3.0, 19 Feb 2019

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
	limitation of activity	tenderness (at other than injection site) or with moderate impairment of activity	tenderness with marked impairment of activity	myonecrosis
SKIN				
	Grade 1	Grade 2	Grade 3	Grade 4
Mucocutaneous	erythema; pruritus	diffuse, maculo- papular	vesiculation or	exfoliative
		rash, dry desquamation	moist desquamation or	dermatitis, mucous
			ulceration	membrane involvement or erythema,
			3,	multiforme or suspected
			2	Stevens-
				necrosis
				requiring surgery
Induration	< 15mm	15-30 mm	>30mm	
Erythema	< 15mm	15-30 mm	>30mm	
	1	1		

ACT-TB Study Protocol V3.0, 19 Feb 2019

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2
3
1
4
5
6
7
,
8
9
10
11
11
12
13
1/
14
15
16
17
10
18
19
20
21
21
22
23
24
25
25
26
27
28
20
29
30
31
21
52
33
34
35
20
36
37
38
30
72
40
41
42
42
45
44
45
46
17
47
48
49
50
50
51
52
53
51
J4
55
56
57
57
SQ
59

Rash at Injection Site	< 15mm	15-30 mm	>30mm	
Pruritus	slight itching at	moderate	itching over entire	
	injection site	itching at	body	
		injection		
		extremity		
SYSTEMIC	I	L	L	L
	Grade 1	Grade 2	Grade 3	Grade 4
Allergic Reaction	pruritus without	localized	generalized	anaphylaxis
	rash	urticaria	urticaria;	
			angioedema	
Headache	mild, no treatment	transient,	severe; responds	intractable;
	required	moderate;	to initial narcotic	requires
	Ó'	treatment	therapy	repeated
		reauired		narcotic therapy
Fever: oral	37.7 - 38.5 C or	38.6 - 39.5 C	39.6 - 40.5 C or	> 40 C or
	100.0 - 101.5 F	or 101.6 -	103 - 105 F	> 105 F
		102.9 F		
Fatigue	normal activity	normal activity	normal activity	unable to care
	reduced < 48	decreased 25-	decreased > 50%	for self
	hours	50% > 48	can't work	
		hours	2	
			5	•

ACT-TB Study Protocol V3.0, 19 Feb 2019

15 Appendix 3: Package insert for Azithromycin and amoxicillin

Included as separate attachments.

to beet terien only

ACT-TB Study Protocol V3.0, 19 Feb 2019



3

4

5 6

7 8

9 10

11

12

13

14

15 16 17

18

35

53 54 55

PARTICIPANT INFORMATION SHEET

Participant information sheet



What is the benefit and unintended consequences of using antibiotic treatment as a way of excluding tuberculosis disease in patients with cough?

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you Protected decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

19 Tuberculosis (TB) is a disease that causes a long illness and cough with sputum. Although curable TB is 20 difficult to detect. When they fail to detect TB after testing sputum, clinicians give antibiotic treatment that can 21 cure all other causes of TB symptoms but not TB. In this approach, TB is considered ruled out if patient gets 22 better and it is considered likely if they do not get better. The goal of this research study is to develop 23 understanding of how well the antibiotics help distinguish TB patients from those who do not have it, whether 24 giving antibiotics carries other health benefits, and whether it leads to development of disease causing 25 26 organisms which are resistant to drugs. 27

28 We will learn about this by comparing a group of patients given antibiotics on the first day of the study to 29 another group not given antibiotics. There will be two groups receiving antibiotics as follows: 1) Azithromycin 30 taken as one tablet once a day for 3 days, and 2) Amoxicillin 4 capsules taken three times a day for 5 days. The 31 group you will go into, out of the three, will be decided by chance so you can fall into any group. 32

33 What will be involved if I accept to participate in the study? 34

We are considering you for participation in this study because you told us that you have a cough. Any patient 36 37 who has been coughing for at least 2 weeks, is at least 18 years, and lives within Blantyre, is eligible to 38 participate in this study if they do not have signs consistent with serious illness. Apart from you, we will recruit 39 1,874 other individuals. 40

41 Study activities will be performed the first day, at 1 week (Day 8), and at one month (Day 29). At each of these 42 study visits, we will ask you questions about your contact details, your health, use of medications, and any 43 illnesses or hospitalisations you may have had in between study visits. We will also document relevant details 44 45 from your health passport and other clinical documentation you may have. 46

47 On Day 1 and at 1 week, we will ask you to submit sputum and urine samples for TB tests. If you are not able to 48 give sputum on Day 1, we will give you containers so that you can bring them the following morning. Some of 49 the sputum TB tests results will become available after 7 days and we will pass them to health center clinicians 50 who will make a plan for your care, the other results may take up to 4 weeks so you will get them at the 1 month 51 visit. Urine TB test results will not be available for your clinical care. 52

21-May-2019

A copy of this informed consent document to be offered to the participant

56 Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-57 antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi 58 Version & Date: 3.0/28 Feb 2019

59 Principal Investigator: Dr Titus H Divala

ref: LSHTM 15232: COMREC P.04/18/238 Participant Information SheeFor peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 4 60



We will also do an HIV test. If the results are confirmed to be HIV positive we will do a viral load test, and at the end of the study activities on Day 1, we will link you to HIV management team here at the health center who will start you on treatment. Should we make a diagnosis of TB or HIV at any other point during the study, we will link you with the responsible health center team for treatment services.

On day 1 and at 1-month visit, we will swab the back of the inside of your nose as shown in this picture to collect germs that live there. We will test the germs for drug resistance. Results of this test are not relevant to your care.

Page 121

1

2

3

4 5 6

7

8

9

10

18

19

21

51 52

11 On 1-week visit, we will ask you to report how your health has 12 changed in comparison to how you were on day 1. These 13 questions will be read to you by a computer and you will answer 14 15 them by choosing various options which it will display during the 16 interview. 17

The 1 month visit will be the final study visit where we will also

provide you with results for TB culture and ask if you have TB symptoms. If you are in HIV or TB care, we 20 will ask how your follow up is going. The appointment with you at 1 months is very important because it will help you to know the results of the TB tests and it will also help us know the status of your health. 22

23 The number of clinic visits you will make for this study is at least three. Here we count Day 1, one visit after 24 25 one week, and another visit at one month. If you have not been able to come here for any of the visits, we will 26 remind you by phone call or we will use the permission and information you will give us to visit you at your 27 home. The first visit will take about 60 minutes and the later visits will take about 30 minutes each. 28

29 Will there be any risks involved in this study? 30

31 This study is a low risk study. There are no risks involved in submitting sputum or urine for the study. You 32 may feel some discomfort during swabbing of the back of the nose and during blood collection for HIV and 33 Azithromycin and amoxicillin are already widely used in Malawi and rarely cause viral load tests. 34 35 problems. Rare side effects for azithromycin include feeling nervousness, skin reactions and disturbance of 36 heart function. Rare side-effects for amoxicillin are mental state changes, feeling light-headed, and reactions to 37 sunlight. 38

39 The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If 40 you experience harm or injury as a result of taking part in this study, you may be eligible to claim 41 compensation. 42

43 Will there be any benefits in this study? 44 45

46 The key benefit of this study is that you will have access to a more detailed TB evaluation process than usual. 47 This will help you know if you have TB and to have the opportunity to start TB treatment. The study is also 48 beneficial to health care providers because it will address important questions about use of antibiotics during the 49 TB diagnostic process. ollege OI leaicine 50

53 Will the findings in the study be confidential? 54

21-Mav-2019

55 A copy of this informed consent document to be offered to the participant 56 Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-57 antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi 58 Version & Date: 3.0/28 Feb2019

59 Principal Investigator: Dr Titus H Divala

REC ref: LSHTM 15232; COMREC P.04/18/238 Participant Information SheefFor peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 2 of 4 60



122 of 134 BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, AI training, and similar technologies

Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published for scientific purposes but will not give your name or include any identifiable references to you. Information about TB test result and HIV test results will be recorded using an identification number. However, any records or data obtained as a result of your participation in this study may be used by LSHTM who are sponsoring this study, regulators of health research (COMREC), or by members of the research team. These records will be kept in a locked space in the University of Malawi College of Medicine. Information and samples collected in this study will be retained for up to 10 years after the end of the trial, according to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent.

According to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent. **Can I withdraw from the study anytime and will this affect my treatment?**You are free to choose whether or not to participate in this study. While we would like you to participate in the study to the very end, withdrawing at any point is an option that is freely available to you without any penalty or loss of any entitled benefits. You will be provided with any significant new findings developed during the course of this study that may relate to or influence your willingness to continue participation. **What are the financial benefits of participating in this study?**There will be no payment given to you for participating in the study. The study will provide at least MK8,000 as compensation for your costs of attending the study visits. We will give this money in instalments on scheduled study visits. **Is this study approved by an ethics committee?**The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the College of Medicine Research Ethics Committee (COMREC). **Who do you ask if you have questions regarding the study?**

If you have any questions concerning participation in this study, please feel free to ask me. Alternatively, you can contact the following people by phone or post:

	Name	Telephone	Postal address
Study investigators	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative University of Malawi College of
	Dr Marriott	0888681948	Medicine
	Nliwasa		Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC			
	Administrative	01 877 245	University of Malawi College of
	officer, COMREC	01 877 291	Medicine por over by
	Secretariat		Private Bag 360, Chichiri, Blantyre 3, Malawi
		-	21-May-2019
Study title: Randomised cont intibiotics to evaluate ambula Principal Investigator: Dr T Participant Information Sheet	A copy of this informed c crolled clinical trial of diagno atory adults with prolonged Version & itus H Divala For peer review only - http	onsent document ostic value, clinical b cough for tuberculo Date: 3.0/28 Feb20 p://bmjopen.bmj.c	to be offered to the participant enefits and unintended consequences of using trial-of- osis in Malawi 19 REC ref: LSHTM 15232; COMREC P.04/18/2381 om/site/about/guidelines.xhtml Page 3 of 4

Page 123 of 134 ACT

2 3 4

5



What is the benefit and unintended consequences of using antibiotics treatments as a way of excluding tuberculosis disease in patients with cough?

Patient declaration

Statement		Initial or
		thumbprir
		each box
I confirm that I have read the above	e information sheet for the above named study.	I have had
the opportunity to consider the info	ormation, ask questions and have these answere	ed
satisfactorily.		
OR		
I have had the information explained	ed to by study personnel in a language that I un	derstand. I
have had the opportunity to consid	er the information, ask questions and have thes	e answered
satisfactorily.		
I understand that my participation i	is voluntary and that I am free to withdraw at an	ny time
without giving any reason, without	t my medical care or legal rights being affected.	the study may
i understand that relevant sections	of my medical notes and data collected during	me study may
Medicine and COMREC where it	is relevant to my taking part in this research	ge ui
nermission for these individuals to	have access to my records	
I understand that data about me ma	by be shared via a nublic data repository or by s	haring directly
with other researchers and that I w	yill not be identifiable from this information	
and that I w		
I understand that the tissue sample	collected from me will be used to support othe	r research in
the future, and may be shared anon	nymously with other researchers, for their ethica	ally-approved
projects		
I agree to take part in the above nat	med study	
8 1	inea stady	
0 1		
Printed name of narticinant	Signature/thumb print of participant	Date
Printed name of participant	Signature/thumb print of participant	Date
Printed name of participant	Signature/thumb print of participant	Date
Printed name of participant	Signature/thumb print of participant	Date
Printed name of participant Printed name of impartial witnes	Signature/thumb print of participant Signature of impartial witness*	Date
Printed name of participant Printed name of impartial witnes	Signature/thumb print of participant Signature of impartial witness*	Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to	Date Date, and was
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applied)	Date Date, and was ely given their consent to le)
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applicab	Date Date, and was ely given their consent to ble).
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Udy information accurately toledge by, the participant and that he/she has free above named impartial witness (where applicab	Date Date, and was ely given their consent to ble).
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my know participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab	Date Date, and was ely given their consent to le).
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent	Date Date, and was ely given their consent to le). Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *	Signature/thumb print of participant Signature of impartial witness* udy information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent	Date Date , and was ely given their consent to le). Date COME
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participant should be someone the part	Signature/thumb print of participant Signature/thumb print of participant ss* Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applicab sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant in place of signature and the impartial witness chard does also does	Date Date, and was ely given their consent to le). Date Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in	Signature/thumb print of participant Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant n place of signature and the impartial witness should co ahead and applicable	Date Date Date, and was ely given their consent to ble). Date Date Date Date Date Date Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in	Signature/thumb print of participant ss* Signature of impartial witness* udy information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant m place of signature and the impartial witness should go ahead and the should be an and the impartial witness should go ahead and the impar	Date Date Date, and was ely given their consent to le). Date Date Date Date Date Date Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in A copy of the	Signature/thumb print of participant Signature/thumb print of participant ss* Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant n place of signature and the impartial witness should go ahead at is informed consent document to be offered to the part	Date Date Date, and was ely given their consent to le). Date Date Date Date Date Date Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in A copy of thi Study title: Randomised controlled clinical antibilaties to avaluate ambulatery adults of	Signature/thumb print of participant Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant n place of signature and the impartial witness should co ahead a is informed consent document to be offered to the part trial of diagnostic value, clinical benefits and unintended co	Date Date Date Date , and was ely given their consent to ele). Date Date Date Date Date Date Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part Iliterate participants should use thumbprint in A copy of thi Study title: Randomised controlled clinical antibiotics to evaluate ambulatory adults wi	Signature/thumb print of participant Signature/thumb print of participant Signature of impartial witness* Use Signature of impartial witness* Use Signature of staff obtaining consent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant n place of signature and the impartial witness should co ahead a sis informed consent document to be offered to the part trial of diagnostic value, clinical benefits and unintended co ith prolonged cough for tuberculosis in Malawi Version & Date: 3.0/28 Feb2019	Date Date Date, and was ely given their consent to le). Date Date
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in A copy of thi Study title: Randomised controlled clinical antibiotics to evaluate ambulatory adults wi Principal Investigator: Dr Titus H Divala	Signature/thumb print of participant Signature/thumb print of participant Signature of impartial witness* Ady information accurately to ledge by, the participant and that he/she has fre above named impartial witness (where applicab sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant n place of signature and the impartial witness should co ahead a sis informed consent document to be offered to the part trial of diagnostic value, clinical benefits and unintended co ith prolonged cough for tuberculosis in Malawi Version & Date: 3.0/28 Feb2019 REC ref: LSHTM 1.	Date Date Date, and was ely given their consent to le). Date Date, and was ely given their consent to leb. Date



PARTICIPANT INFORMATION SHEET



Chikalata chofotokozera ofuna kutenga nawo mbali

Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufifuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Chiyambi

1

2

3 4

5 6

7 8

9 10

11

12

13

14

15 16

17

18 19

20 21

22

23

24

25 26

27

28

29

30

31

32 33

34 35

36

37

38

39

40 41

42 43 44

45

46

47

48 49

50

51

52 53

54 55

56

57 58

59

60

Tikukukupemphani kuti mutenge nawo mbali mu kafukufuku. Ndi chifuniro chanu kulowa mu kafukufukuyu. Musanapange chiganizo, mukuyenera kumvetsa chifukwa chimene kafukufukuyu akuchitikira komanso zimene zitadzachitike. M'modzi mwa anthu a gulu logwira ntchito mu kafukufuku awerenga chikalatachi pamodzi ndi inu, ndipo ayankha mafunso ena aliwonse amene mungakhale nawo. Funsani mafunso ngati simukumvetsa zomwe mwawerenga kapena ngati mukufuna uthenga owonjezera. Muli omasuka kulankhula ndi ena zokhudza kafukufukuyu ngati mukufuna. Ganizani mofatsa musanavomereze kutenga nawo mbali kapena ayi.

Kodi cholinga cha kafukufukuyu ndi chiyani?

Chifuwa chachikulu (TB) ndi matenda amene munthu amkhala chidwalire kwa nthawi yaitali. Odwalayo, amapanga makhololo. Ngakhale chili chochizika, chifuwa chachikulu ndi chovuta kuchipeza. Pamene njira zoyeza makholoro zalephera kupeza chifuwa chachikulu, achipatala amapereka mankhwala opha tizirombo toyambitsa matenda amene angathane ndi zonse zimene zimayambitsa zizindikiro za matenda ofanana ndi chifuwa chachikulu. Ngati odwala apeza bwino ndi njira imeneyi amaganiziridwa kuti alibe matenda a chifuwa chachikulu koma ngati sanapeze bwino amaganiziridwa kuti ali ndi chifuwa chachikulu. Cholinga cha kafukufuku ameneyu ndi kufuna kumvetsa za m'mene mankhwala amenewa amathandizira kusiyanitsa odwala matenda a chifuwa chachikulu ndi amene alibe matendawa, ngati mankhwalawa ali ndi phindu lina kwa odwala, komanso ngati kupereka mankhwalawa kukubweretsa tizirombo tosamva makhwala.

Tiphunzira zimenezi pakusiyanitsa gulu la anthu odwala amene apatsidwa mankhwala opha tizirombo toyambitsa matenda patsiku loyamba la kafukufukuyu ndi gulu lina limene silinapatsidwe mankhwalawa. Pakhala magulu awiri olandira mankhwala opha tizirombo motere: 1) Azitrhomycin omwedwa pilisi imodzi kamodzi patsiku kwa masiku atatu, komanso 2) Amoxicillin makapusolo anayi omwedwa katatu patsiku kwa masiku asanu. Gulu limene mulowe, mwa magulu atatuwa, lisankhidwa mwa mayere choncho mukhoza kupezeka mu gulu lina lirilonse.

Kodi chidzachitike ndi chiyani ngati ndingavomereze kutenga nawo mbali mu kafukufukuyu?

Tikukupemphani kuti mutenge nawo mbali mu kafukufukuyu chifukwa mwatiuza kuti muli ndi chifuwa. Odwala wina aliyense amene wakhala akukhosomola kwa masabata osachepera awiri, ali ndi zaka zosachepera 18, ndipo amakhala mu Blantyre muno, atha kutenga nawo mbali mu kafukufukuyu ngati alibe zizindikiro zosonyeza kudwalika kwambiri. Kupatula inu, tilemba anthu ena okwanira 1,874.

Zochitika za kafukufukuyu zidzapangidwa patsiku loyamba, pa sabata imodzi (Tsiku 8), ndi pamwezi umodzi (Tsiku 29). Pa masiku a kafukufuku onsewa, tidzakufunsani mafunso okhudzana ndi m'mene tingalumikizirane nanu, thanzi lanu, kagwiritsidwe ntchito ka mankhwala, ndi matenda ena aliwonse kapena kugonekedwa mu chipatala komwe kungakuchitikireni. Tidzalembahso/zinthulzofunikira

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: ԹՇՇֈեսջ ի Divala only - http://bmjopen.bmj.com/sitePaSouf/JSHJCH14523RtmpMREC P.04/18/238 Chikalata chofotokozera ofuna kutenga nawo mbali Page 1 of 5



kuchokera mu bukhu lanu la kuchipatala komanso zolembedwa zina za chipatala zimene mungakhale nazo.

Patsiku loyamba ndi pakutha pasabata yoyamba, tidzakufunsani kuti mupereke makhololo komanso mkodzo pofuna kuyeza matenda a chifuwa chachikulu. Ngati simungakwanitse kupereka makhololo patsiku loyamba, tidzakupatsani mabotolo kuti mudzawabweretse m'mawa wa tsiku lotsatira. Zotsatira zina za makhololo zidzatuluka pakutha pa masiku asanu ndi awiri ndipo tidzazipereka kwa matodolo a chipatala chino kuti akuthandizeni, zotsatira zina zidzatenga pafupi-fupi masabata anayi choncho mudzazilandira pa ulendo wa pamwezi umodzi. Zotsatira zanu zoyesa mikodzo ku matenda a chifuwa chachikulu sizidzakhalapo ku nkhani ya chisamaliro chanu cha kuchipatala.

Tidzayezanso kachirombo ka HIV. Ngati zotsatirazi zasonyeza kuti muli ndi kachirombo ka HIV tidzayeza kuchuluka kwa tizirombo ta HIV, komanso kukutumizani kolandilira chithandizo chamatendawa. Ngati tingakupezeni kuti muli ndi matenda a chifuwa chachikulu kapena kachirombo ka HIV panthawi ina iliyonse mkati mwa kafukufukuyu, tidzakutumizani kolandilira zithandizo zamatendawa pompano pachipatala.

Patsiku loyamba komanso pa ulendo wa mwezi woyamba, tidzapukuta kumbuyo kwa mkati mwa mphuno mwanu ngati m'mene zikuonekera pachithunzichi kuti titenge tizirombo timene timakhala m'menemo. Tidzayeza tizirombo timeneti kuti tione ngati tikumva mankhwala. Zotsatira zimenezi sizidzagwiritsidwa ntchito kuchisamaliro chanu chaku chipatala.

Pa ulendo wa sabata yoyamba, tidzakupemphani kuti mutiuze m'mene thanzi lanu lasinthira kuyerekeza ndi

m'mene munaliri patsiku loyamba. Mafunso amenewa adzawerengedwa kwa inu kudzera pa makina a kompyuta ndipo mudzawayankha pakusankha mayankho angapo amene makinawa adzawonetse panthawi yomwe azidzafunsa.

Ulendo wa pa mwezi umodzi udzakhala wotsiriza umene tidzakupatseninso zotsatira za zoyesa za matenda a chifuwa chachikulu komanso tidzakufunsani ngati muli ndi zizindikiro za matenda a chifuwa chachikulu. Ngati panthawiyi mudzakhale kuti mukulandira Thandizo la HIV kapena TB, tidzakufuna kudziwa kuti zikuyenda bwanji. Kukumana ndi inu patatha mwezi umodzi ndikofunikira kwambiri chifukwa zidzakuthandizirani kuti mudziwe zotsatira za zoyeza za matenda a chifuwa chachikulu ndipo zidzatithandiziranso kudziwa zam'mene thanzi lanu liliri.

Maulendo a kuchipatala amene mudzayende a kafukufukuyu ndiwosachepera atatu. Pamenepa tikuwerenga tsiku loyamba, ulendo umodzi pakutha pa sabata imodzi, ndi ulendo umodzi pa mwezi umodzi. Ngati simunakwanitse kubwera kuno pa ulendo wina uliwonse tidzakukumbutsani pokuyimbirani lamya kapena tidzagwiritsa ntchito chilorezo ndi uthenga umene mudzatipatse kuti tikuyendereni kunyumba kwanu. Patsiku loyamba tidzakhala nanu kwa mphindi makumi asanu ndi imodzi, pamene paasiku ena onse, tidzakhala nanu kwa mphindi makumi atatu.

Kodi padzakhala ziopsezo zina zilizonse zochitika mu kafukufukayu?May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Chikalata chofotokozera ofuna kutenga nawo mbali Page 2 of 5







Kupanga nawo kafukufukuyu sikuika moyo wanu pa chiopsyezo chochuluka. Palibe chiopsezo pa kupereka makhololo kapena mikozo mu kafukufukuyu. Mukhoza kusamva bwino panthawi yopukuta kumbuyo kwa mphuno komanso panthawi yotenga magazi oyeza za kachirombo ka HIV ndi kuchuluka kwa tizirombo toyambitsa matendawa. Azithromycin ndi amoxicillin ndi mankhwala oti akhala akugwiritsidwa ntchito kwa nthawi yayitali m'Malawi ndipo sikweni-kweni kuyambitsa mavuto. Patalipatali azithromycin amapangitsa kumva nthumazi, ziwengo, komanso kusokonekera kwa kagwiridwe ntchito ka mtima. Patali-patali amoxicillin amapangitsa kusakhazikika mmanganizo, kumva chizungulire, komanso kutuluka ziwengo munthu akakhala padzuwa.

A London School of Hygiene ndi Tropical Medicine ali ndi thumba landalama zachipukuta misozi lokhudzana ndi kafukufukuyu. Ngati mwapweteka kapena kuvulala chifukwa chotenga nawo mbali mu kafukufukuyu, mudzakhale omasuka kupempha chipukuta misonzi.

Kodi padzakhala zopindula zina zilizonse mu kafukufukuyu?

Chopindulitsa chodziwika cha kafukufukuyu ndi chakuti mudzakhala ndi mwayi oyezedwa matenda a chifuwa chachikulu mozama kuposa m'mene zimakhalira nthawi zonse. Zimenezi zidzakuthandizirani kudziwa ngati muli ndi matenda a chifuwa chachikulu komanso kukhala ndi mwayi oyamba kulandira thandizo la mankhwala a chifuwa chachikulu. Kafukufukuyu ndi opindindulitsanso kwa opereka chisamaliro cha kuchipatala chifukwa adzayankha mafunso ofunikira okhudzana ndi kagwiritsidwe ntchito ka mankhwala opha tizirombo toyambitsa matenda panthawi ya ndondomeko yoyeza matenda a chifuwa chachikulu.

Kodi zotsatira za mukafukufukuyu zidzakhala za chinsinsi?

Chizindikiritso chanu mu kafukufukuyu chidzatengedwa kukhala cha chinsinsi. Zotsatira za kafukufukuyu, zikhoza kudzasindikizidwa ndi cholinga cha sayansi koma dzina lanu kapena chizindikiritso chilichonse chokhudzana ndi inu chidzabisidwa. Uthenga okhudza zotsatira zoyesa matenda achifuwa chachikulu kapena HIV zidzalembedwa pogwiritsa ntchito nambala yanu yakafukufuku. Komabe, zina zomwe mungatifotokozere zitha kudzagwiritsidwa ntchito ndi amene ali oyang'anira za kafukufuku wa zaumoyo (COMREC) komanso LSHTM. kapena ndi mamembala a gulu la kafukufukuyu. Zolembedwazi zidzasungidwa mumalo otsekedwa bwino ku sukulu ya ukachenjede ya Malawi College of Medicine. Uthenga ndi zoyesa zotengedwa mu kafukufukuyu zidzassungidwa kwa zaka pafupi-fupi khumi (10) pakutha pakuyesaku, malingana ndi ndondomeko ya bungwe lathu. Zoyesa zotengedwazi ndi mauthenga ena zikhoza kugwiritsidwanso ntchito pa kafukufuku wamtsogolo ngati mutatipatsa chilolezo chimenecho.

Kodi ndikhoza kusiya kafukufukuyu nthawi ina iliyonse ndipo zimenezi zingadzakhudze thandizo langa la mankhwala?

Muli ndi ufulu kusankha kutenga nawo mbali kapena kusatenga nawo mbali mu kafukufukuyu. Ngakhale tingakonde kuti mutenge nawo mbali mu kafukufukuyu mpaka ku mapeto, kutuluka nthawi iliyonse mukafukufuku ndi chisankho chanu popanda chilango chilli chonse kapena kuluza kulandira thandizo lililonse lomwe mukuyenera kulandira. Munthawi yakafukufukuyu, tidzakudziwitsani patati 21-May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Chikalata chofotokozera ofuna kutenga nawo mbali Page 3 of 5



Page 127 of 13 patuluka mauthenga ena a sayansi ofotokoza zinthu zimene zingakupangitseni kuti mulingalirenso 2 zachisamkho chanu chotenga nawo mbali. 3 4 Kodi pali phindu la ndalama lotani pakutenga nawo mbali mu kafukufukuyu? 5 6 Sipadzakhala kupatsidwa malipiro chifukwa chotenga nawo mbali mukafukufukuyu. Ndalama yomwe 7 8 tidzakupatseni ndi yokwana MK8,000. Ndalamayi tizikupatsani pangonopango pamasiku anu 9 akafukufuku.. 10 11 Kodi kafukufukuyu ndiwovomerezeka ndi komiti yowona za ufulu wa anthu mukafukufuku? 12 13 Kafukufukuyu wavomerezedwa ndi London School of Hygiene & Tropical Medicine Research Ethics 14 Committee, ndi College of Medicine Research Ethics Committee (COMREC). 15 16 Kodi mungafunse ndani ngati muli ndi mafunso okhudzana ndi kafukufukuyu? 17 18 Ngati muli ndi mafunso ena aliwonse okhudza kutenga nawo mbali mukafukufukuyu, chonde khalani 19 20 omasuka kundifunsa. Munjira ina, mukhoza kulumikizana ndi anthu otsatirawa pa lamya kapena 21 polemba kalata kumakeyala awa: 22 23 Telephone **Postal address** Name 24 Dzina Lamya Adilesi 25 26 **Study investigators** Dr Titus Divala 0999478376 Helse Nord Tuberculosis Initiative 27 Akulu-akulu 28 University of Malawi College of 29 akafukufuku Medicine 30 Dr Marriott 0888681948 Private Bag 360, Chichiri, 31 Nliwasa Blantyre 3, Malawi 32 **COMREC** 33 01 877 245 University of Malawi College of Administrative 34 01 877 291 officer. COMREC Medicine 35 Private Bag 360, Chichiri, 36 Secretariat 37 Blantyre 3, Malawi 38 39 40 41 42 43 44 45 46 Approved by College of Medicine 47 48 49 50

21-May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

51 52

53 54 55

56

57 58

59

60

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Pr Titus H Divala Chikalata chofotokozera ofuna kutenga nawo mbali Page 4 o Page 4 of 5



MEDICINE Kodi pali phindu lotani komanso zotsatira zosayembekezereka zotani pogwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ngati njira yothana ndi matenda a chifuwa chachikulu mu anthu amene ali ndi chifuwa?

Chitsimikizo cha odwala

 Lembani mubokosi liri kumanjali mawu oyamba adzina lanu kapena dindani ndi chala

ngati mukuvomereza			
Mfundo yachitsimikizo			
Ndikutsimikiza kuti ndawerenga	hikalata cha uthenga wa kaf	fukufuku amene	e watchulidwa
m'mwambamu. Ndakhala ndi mwavi woganizira za uthengawu, kufunsa mafunso komanso			
ndavankhidwa mokhutira.		,	
KAPFNA			
Ndafotokozeredwa uthengawu nd	akafukufuku mu chilankhu	lo chimene ndik	uchimvetsa Ndakhala
ndi mwavi waganizira za uthenga	akarukuruku mu cimankinu	no enimene nark	uominiveisa. Tuakiiaia
Ndilumyataa luuti luutanga nawa	hali luwan aa ndilaaalaalaan	iso nuayankinuv	ki ndi ufulu lausiyo
Noikumvelsa kuli kulenga nawo i	ibali kwanga nulkosakakam	lizidwa ndipo nd	1111 ndi ululu kusiya
pantnawi ina inyonse popanda ku	ereka chilukwa china chinc	enonse, popanda	kukhudza chisamaliro
cha kuchipatala kapena ufulu war	za.	1 1 • . 1 1	
Ndikumvetsa kuti magawo ofunik	ra a zolembedwa zanga za l	ku chipatala kon	nanso mu
kafukufukuyu kuwonedwa ndi an	hu ovomerezeka aku LSHT	M, University of	f Malawi College of
Medicine komanso COMREC, pa	nene kuli kofunika kutenga	nawo mbali mu	kafukufukuyu.
Ndikupereka chilolezo kwa anthu	amenewa kuti athe kuwona	za zolembedwa	zanga.
Ndikumvetsa kuti zomwe atolere	kafukufuku zokhudza ine z	ikhoza kugawili	dwa kwa anthu ena
opanga kakafukufuku, ndipo kuti	ipadzakhala chizindikiro ch	nilichonse choso	nyeza kuti zinachokera
kwa ine.			
Ndikumvetsa kuti zoveza za mthu	oi mwanga zimene zidzaten	gedwe kwa ine z	zidzagwiritsidwa
ntchito kuthandizira kafukufuku y	ina mtsogolo, ndipo zikhoz	a kudzagawidwa	a mwachinsinsi ndi
akafukufuku ena na ntchito yawa	vovomerezeka ndi malamul	lo aowona zakaf	ukufuku
N 1'1 1 1 1	jevennerezerka nar maramar	ie uewena	anarana.
Ndikiivomereza kiitenga nawo ml	ali mu kafukufuku amene w	vatchulidwa nam	wamhayu
Ndikuvomereza kutenga nawo m	ali mu kafukufuku amene w	vatchulidwa pam	iwambayu.
Ndikuvomereza kutenga nawo mi	ali mu kafukufuku amene w	vatchulidwa pam	iwambayu.
Ndikuvomereza kutenga nawo m	ali mu kafukufuku amene w	vatchulidwa pam	iwambayu.
Ndikuvomereza kutenga nawo ml	ali mu kafukufuku amene w	vatchulidwa pam	iwambayu.
Dzina la wotenga nawo mbali Sa	ali mu kafukufuku amene w	vatchulidwa pam wotenga mbali	iwambayu. Fsiku
Dzina la wotenga nawo mbali Sa	ali mu kafukufuku amene w yini/chidindo cha chala cha v	watchulidwa pam	iwambayu. Fsiku
Dzina la wotenga nawo mbali Sa	ali mu kafukufuku amene w yini/chidindo cha chala cha v	watchulidwa pam	iwambayu. Fsiku
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali*	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop	wotenga mbali	iwambayu. Tsiku Tsiku
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali*	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop	wotenga mbali	Tsiku
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor	wotenga mbali manda mbali ndola kwa	iwambayu. Fsiku Tsiku
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko	wotenga mbali wotenga mbali manda mbali ndola kwa	Iwambayu. Fsiku Tsiku Ka chilolezo chawo kuti :
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko ili imene yatchulidwa pamwan	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere nbapa (ngati kuli	wambayu. Tsiku Tsiku cka chilolezo chawo kuti : koyenera).
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko ili imene yatchulidwa pamwan	wotenga mbali wotenga mbali ndola kwa omanso kuti apere mbapa (ngati kuli	Tsiku Tsiku Tsiku Ka chilolezo chawo kuti s koyenera).
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan	wotenga mbali manda mbali ndola kwa omanso kuti apere nbapa (ngati kuli	Tsiku Tsiku Ka chilolezo chawo kuti s koyenera).
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko ili imene yatchulidwa pamwan Sayini ya wotenga ch	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere mbapa (ngati kuli hilolezo	Tsiku Tsiku Ka chilolezo chawo kuti : koyenera).
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko ili imene yatchulidwa pamwan Sayini ya wotenga ch	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere nbapa (ngati kuli hilolezo	Tsiku Tsiku Tsiku Tsiku Tsiku Tsiku Tsiku Tsiku
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofina kutenga nawo mukafuk	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kute fukuyo koma sijngasayine mmalo m	wotenga mbali wotenga mbali manda mbali mdola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuma	Tsiku Tsiku Ka chilolezo chawo kuti s koyenera). Tsiku fukuyo. Mboni ikhoza kulemba
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba. asavin	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kuto fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo n	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isavine dzinam	Tsiku Tsiku Ka chilolezo chawo kuti s koyenera). Tsiku fukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku,
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kute fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo r	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isayine dzinan	Tsiku Tsiku Ka chilolezo chawo kuti skoyenera). Tsiku fukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku, di sayin, panalo ambone.
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oten	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kuto fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo r	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere nbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isayihe dyhan zi kuti chikhale cha	Tsiku Tsiku Ka chilolezo chawo kuti a koyenera). Tsiku fukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku, gi sayin, panalo ambone. hke
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oten Dzina la kafukufuku: Kodi kugwiritsa ntch	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kuta fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo r ga nawo mbali chikalata chimoda to mankhwala opha tizirombo toya	wotenga mbali wotenga mbali manda mbali mdola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isayine dzina n zi kuti chikhale cha ambitsa matenda en	Tsiku Tsiku Tsiku Tsiku Tsiku Tsiku Tukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku, di sogin, pagalo ambone. Tuku
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oter Dzina la kafukufuku: Kodi kugwiritsa ntch kufufuza chifuwa chachikulu kuli ndi phind	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kuto fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo r ga nawo mbali chikalata chimode to mankhwala opha tizirombo toya kapena kuipa kotani?	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isayihe dyhan zi kuti chikhale cha ambitsa matenda ei	Tsiku Tsiku Tsiku Ka chilolezo chawo kuti a koyenera). Tsiku fukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku, di sa (n), panalo ambone. Ike na ngati njira yothandizira
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oter Dzina la kafukufuku: Kodi kugwiritsa ntch kufufuza chifuwa chachikulu kuli ndi phind	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kute fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo r ga nawo mbali chikalata chimoda to mankhwala opha tizirombo toya kapena kuipa kotani?	wotenga mbali wotenga mbali manda mbali ndola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isayine dzina p zi kuti chikhale cha ambitsa matenda en	Tsiku Tsiku Tsiku Ka chilolezo chawo kuti s koyenera). Tsiku fukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku, di sayin, panalo ambone.
Ndikuvomereza kutenga nawo ml Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oten Dzina la kafukufuku: Kodi kugwiritsa ntch kufufuza chifuwa chachikulu kuli ndi phind	ali mu kafukufuku amene w yini/chidindo cha chala cha v Sayini ya mboni yop nenga wa kafukufukuyu molor ga ndi, wotenga nawo mbali ko li imene yatchulidwa pamwan Sayini ya wotenga ch okhulupiridwa ndi munthu ofuna kuta fukuyo koma siingasayine mmalo m ndi chidindo cha chala chake ndipo r ga nawo mbali chikalata chimodi to mankhwala opha tizirombo toya kapena kuipa kotani? Version & Date: 3.0/28 Feb 20	wotenga mbali wotenga mbali manda mbali mdola kwa omanso kuti apere mbapa (ngati kuli hilolezo enga nawo mukafuku wake. Munthu ofuna mboni isayine dyna n zi kuti chikhale cha ambitsa matenda eu	Tsiku Tsiku Tsiku Ka chilolezo chawo kuti a koyenera). Tsiku fukuyo. Mboni ikhoza kulemba kutenga nawo mukafukufuku, di sayin, panalo ambone. Ke na ngati njira yothandizira 232: COMREC P.04/18/238

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	<u>#1</u>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	30
Protocol version	<u>#3</u>	Date and version identifier	1
Funding	<u>#4</u>	Sources and types of financial, material, and other support	26
	For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

U	0		54
			BMJ Open: first published
	Protected by copyright, includ		as 10.1136/bmjopen-2019-033999
•	ing for uses related to text and da	Enseignement Superieur	on 25 March 2020. Downloaded fr
	ta mining, Al training	(ABES) .	om http://bmjopen.bi
	, and similar techn		nj.com/ on June 11
	ologies.		, 2025 at Agen
			ce Bibliographique de l

1 2 3 4 5	Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	26
6 7 8 9 10 11 12	Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	26
13 14 15 16 17 18 19 20 21 22	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	26
22 23 24 25 26 27 28 29 30 31	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	21
32 33	Introduction			
34 35 36 37 38 39 40 41 42	Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
43 44 45 46 47	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	4, 8, 22
48 49	Objectives	<u>#7</u>	Specific objectives or hypotheses	5, 10
50 51 52 53 54 55 56 57 58	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5, 6
5 9 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

60

1 2 3 4 5 6	Methods: Participants, interventions, and outcomes		
7 8 9 10 11 12 13	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
14 15 16 17 18 19 20	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
21 22 23 24 25	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
41 42 43 44	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial
45 46 47 48 49 50 51 52 53 54 55 56 57 58	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
59 60	Fo	or peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4 5 6 7 8	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
9 10 11 12 13 14 15 16	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
17 18 19 20	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size
21 22	Methods:		
23	Assignment of		
24	interventions (for		
25 26 27	controlled trials)		
28 20	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence
30	generation		(eg, computer-generated random numbers),
31 22			and list of any factors for stratification. To
33			reduce predictability of a random sequence,
34			details of any planned restriction (eq, blocking)
35 36			should be provided in a separate document that
37			is unavailable to those who enrol participants or
38			assign interventions
39 40			assign interventions
41	Allocation	<u>#16b</u>	Mechanism of implementing the allocation
42 43	concealment		sequence (eq, central telephone; sequentially
44	mechanism		numbered, opaque, sealed envelopes).
45			describing any steps to conceal the sequence
46 47			until interventions are assigned
48			
49 50	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who
51	implementation		will enrol participants, and who will assign
52			participants to interventions
55 54			
55	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to
оо 57			interventions (eg, trial participants, care
58			
59 60	Fo	r peer rev	/iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2			providers, outcome assessors, data analysts), and how
3 4 5 6 7 8 9	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial
10 11 12	Methods: Data		
12 13 14	collection,		
14 15 16	analysis		
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
56 57 58 59 60	Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5 6 7	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	19
, 8 9 10	Methods: Monitoring			
11 12 13 14 15 16 17 18 19 20 21 22 22 23	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	21 21
24 25 26 27 28 29 30	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	P30, appendix ser related to text
31 32 33 34 35 36 27	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	P30, appendix data (protocol) an nining, A
37 38 39 40 41 42	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	P30, appendix fraining (protocol) and si
43 44 45 46	Ethics and dissemination			nilar tech
47 48 49	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	22 22
50 51 52 53 54 55 56 57 58 59 59	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	22

1 2 3 4 5	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	30 appendix (consent)
6 7 8 9 10	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	30 appendix (consent)
11 12 13 14 15 16 17	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	30 appendix (consent) by copyrig
18 19 20 21 22	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	ht, including fo
23 24 25 26 27 28 29	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	30, appendix s (protocol) f to tex
30 31 32 33 34	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	30, appendix and data (protocol) data min
55 36 37 38 39 40 41 42 43 44 43 44 45 46	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	ing, Al training, and similar tech
47 48 49	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	25, and 28 og appendix (protocol)
50 51 52 53 54 55	Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	25, and 28 appendix (protocol)
56 57 58	Appendices			
59 60		For peer rev	/iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtm	I

Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and	30 appendix (consent)
		authorised surrogates	
Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	30 appendix (consent/protocol)
Notes:			
 The SPIRIT chec CC-BY-ND 3.0. ⁻ <u>https://www.good</u> <u>Penelope.ai</u> 	cklist is d This chec <u>dreports.</u>	Istributed under the terms of the Creative Commor cklist was completed on 01. September 2019 using org/, a tool made by the <u>EQUATOR Network</u> in col	laboration with
	For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtm	1

Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study): protocol for a randomised controlled clinical trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033999.R2
Article Type:	Protocol
Date Submitted by the Author:	20-Feb-2020
Complete List of Authors:	Divala, Titus; London School of Hygiene and Tropical Medicine, TB Centre; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Fielding, Katherine; London School of Hygiene & Tropical Medicine, TB Centre; University of the Witwatersrand, School of Public Health Sloan, Derek; University of Saint Andrews, School of Medicine French, Neil; University of Liverpool Faculty of Health and Life Sciences, Centre for Global Vaccine Research, Institute of Infection and Global Health Nliwasa, Marriott; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; London School of Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme Kandulu, Chikondi; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Chiume, Lingstone ; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative Malawi Liverpool Wellcome Trust Clinical Research Programme; University of Malawi College of Medicine, Helse Nord Tuberculosis Initiative; Malawi Liverpool Wellcome Trust Clinical Research Programme Ndaferankhande, Masiye; Malawi Liverpool Wellcome Trust Clinical Research Programme Corbett, Elizabeth ; London School of Hygiene and Tropical Medicine; Malawi Liverpool Wellcome Trust Clinical Research Programme
Primary Subject Heading :	Infectious diseases
Secondary Subject Heading:	Diagnostics, Epidemiology, Evidence based practice, General practice / Family practice, HIV/AIDS
Keywords:	trial-of-antibiotics, Tuberculosis < INFECTIOUS DISEASES, TB, antimicrobial resistance, diagnostic performance, antibiotics

1	
2	
3 4	SCHOLARONE™
5	Manuscripts
6	inditabenip to
7	
9	
10	
11	
12	
13	
15	
16	
17	
19	
20	
21	
22 23	
24	
25	
26	
27 28	
29	
30	
31 32	
33	
34	
35	
30 37	
38	
39	
40 41	
42	
43	
44	
45 46	
47	
48	
49	
50	
52	
53	
54 55	
56	
57	
58 50	
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

2 3		
4 5	1	TITLE
6		
7 8 9	2	<u>A</u> ccuracy and <u>C</u> onsequences of using <u>Trial-of-antibiotics</u> for <u>TB</u> diagnosis (ACT-TB Study):
10 11	3	protocol for a randomised controlled clinical trial
12 13 14	4	Authors
15 16 17	5	Titus H Divala ^{1,2,3} , Katherine L Fielding ^{1,4} , Derek J Sloan ⁵ , Neil French ⁶ , Marriott Nliwasa ^{1,2,3} ,
17 18 10	6	Peter MacPherson ^{3,7} , Chikondi Kandulu ^{2,3} , Lingstone Chiume ^{2,3} , Sanderson Chilanga ^{2,3} ,
20 21	7	Masiye Ndaferankhande ³ , Elizabeth L Corbett ^{1,2,3}
22 23	8	Author affiliations
24 25	9	1. TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street,
26 27	10	Bloomsbury, London, United Kingdom
28	11	2. Helse Nord Tuberculosis Initiative, University of Malawi College of Medicine,
29 30	12	Blantyre, Malawi
31	13	3. Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi
32 33	14	4. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
34 35	15	5. School of Medicine, University of St Andrews (Derek J Sloan PhD)
35 36	16	6. Institute of Infection & Global Health, University of Liverpool, Liverpool, United
37 38	17	Kingdom
39	18	7. Liverpool School of Tropical Medicine, Liverpool, United Kingdom
40 41	19	
42	20	Correspondence to:
43 44	21	Dr Titus H Divala
45 46	22	TB Centre, London School of Hygiene & Tropical Medicine, Keppel Street, Bloomsbury,
40 47	23	London WC1E 7HT
48 49	24	titus.divala@lshtm.ac.uk
50	25	
51 52	26	KEY WORDS
53	27	trial-of-antibiotics, tuberculosis, TB, antimicrobial resistance, AMR, antibiotics, diagnostic
54 55	28	performance, sensitivity, specificity, randomised controlled clinical trial, randomised, RCT
56 57	29	
58 59 60	30	Protocol version 4.0, 27 Jan 2020

31 ABSTRACT:

32 Introduction

Over 40% of global tuberculosis case notifications are diagnosed clinically without mycobacteriological confirmation. Standard diagnostic algorithms include "trial-of-antibiotics" -empirical antibiotic treatment given to mycobacteriology-negative individuals to treat infectious causes of symptoms other than tuberculosis, as a "rule-out" diagnostic test for tuberculosis. Potentially 26.5 million such antibiotic courses/year are prescribed globally for the 5.3 million/year mycobacteriology-negative patients, making trial-of-antibiotics the most common tuberculosis diagnostic, and a global-scale risk for antimicrobial resistance (AMR). Our systematic review found no randomised controlled trial (RCT) to support use of trial-of-antibiotic. The RCT aims to determine the diagnostic and clinical value and AMR consequences of trial-of-antibiotics.

43 Methods and analysis

A three-arm, open-label, RCT randomising (1:1:1) Malawian adults (≥18years) seeking primary care for cough into: a) azithromycin 500mg once daily for 3 days, or b)amoxicillin 1g three times/day for 5 days, or c) standard-of-care (no immediate antibiotic). We will perform Mycobacteriology tests (microscopy, Xpert/MTB/RIF and Mycobacterium-Tuberculosis culture) at baseline. We will use Audio-Computer-Assisted-Self-Interview (ACASI) to assess clinical improvement at day eight. First primary outcome will be proportion of patients reporting day-eight improvement out of those with negative mycobacteriology (specificity). Second primary outcome will be day 29 incidence of a composite endpoint of either death or; hospitalisation or; missed tuberculosis diagnosis. To determine AMR impact we compare proportion of resistant nasopharyngeal Streptococcus pneumoniaee isolates on day 29. 400 mycobacteriology-negative participants/arm will be required to detect a $\geq 10\%$ absolute

Page 2 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

difference in diagnostic specificity with 80% power. We will estimate measures of effect by
comparing outcomes in antibiotic arms (combined and individually) to standard-of-care.

57 Ethics and dissemination

58 The study has been reviewed and approved by Malawi College of Medicine Research and 59 Ethics Committee, London School of Hygiene &Tropical Medicine (LSHTM) Research Ethics 60 Committee, and Regional Committee for Health and Research Ethics –Norway, and Malawi 61 Pharmacy, Medicines, and Poisons Board (Appendix 1). We will present abstracts at 62 relevant conferences, and prepare a manuscript for publication in a peer-reviewed journal.

Registration

64 Clinicaltrials.gov, NCT03545373

65 Strengths and limitations

- To our knowledge this is the first randomised controlled trial to address benefits and consequences of using antibiotics as an exclusion diagnostic for tuberculosis, a widely used practice that results in millions of antibiotic prescriptions/year.
- We will also contribute evidence on AMR affecting common antimicrobials used for managing respiratory infections.
- The use of ACASI for assessing clinical response and adherence to antibiotic
 treatment which can be used in future studies.
- Acknowledged weaknesses include limited power to evaluate safety of deferred
 antibiotic treatment; conduct subgroup analysis by HIV status; and the possibility that
 participants randomised to the standard-of-care arm may find alternative access to
 antibiotics therefore misclassifying exposure/intervention status.

Page 3 of 31

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

INTRODUCTION

The high case-fatality rate for tuberculosis, the leading global infectious cause of death in adults¹ with approximately 10 million cases and 1.6 million deaths in 2017,² in part reflects suboptimal diagnostics.³⁻⁶ To complement this diagnostic gap, standard algorithms throughout the world include a "trial-of-antibiotics" (Figure 1). This is a course of broad-spectrum antibiotics, with negligible Mycobacterium tuberculosis activity, given to patients with symptoms such as cough in order to "rule-out" or "rule in" tuberculosis.⁷⁻⁹ In clinical practice and most national guidelines (summarised in figure 1), patients who have negative sputum mycobacteriology and have responded to antibiotic treatment are considered tuberculosis-negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations potentially leading on to receiving tuberculosis treatment.7-9

We estimate that 26.5 million courses of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations recorded annually,¹⁰ making antibiotics the most common diagnostic for tuberculosis.¹¹ Our 26.5 million estimate assumes that for every one smear-negative tuberculosis case detected, five antibiotics courses are used: the first two courses being given to patients are ultimately registered as smear-negative tuberculosis, while the other three courses represent patients whose symptoms resolved without starting anti-tuberculosis treatment.^{4 12} This high frequency of prescription of important broad-spectrum antibiotics raises a global-scale risk for antimicrobial resistance (AMR) which like tuberculosis, is a major crisis, becoming in 2016 one of only four health topics ever to be discussed at the United Nations General Assembly.¹³⁻¹⁶

Page 7 of 134

BMJ Open

We performed a systematic literature review¹⁷ which demonstrated that, despite being in global and national guidelines for decades, trial-of-antibiotics has a limited supporting evidence base but with the available evidence suggesting poor diagnostic performance.¹⁸ None of the identified studies was an RCT and most of the observational studies were very small and not primarily designed to assess the benefits and consequences of trial-of-antibiotics. Pooled sensitivity and specificity of trial-of-antibiotics versus mycobacteriology tests were below internationally defined minimum performance profiles for tuberculosis diagnostics.19

We hypothesise that use of antibiotics in the course of evaluating patients for tuberculosis has both benefits and risks that need to be weighed carefully to optimise patient and public health outcomes. We will address evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes of trial-of-antibiotics by conducting an RCT (ACT-TB Study) recruiting adult patients with cough presenting to health centres in Blantyre, Malawi. To our knowledge this is the first randomised controlled trial to rigorously address these questions. Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Page 5 of 31

This is a three-arm individually randomised (1:1:1), open-label controlled clinical trial (RCT)

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3 4 5	120
6 7 8 9	121
10 11 12	122
12	123
14 15 16	124
10 17 19	125
19 20	126
21 22 23 24	127
25 26 27	128
27	129
29 30	130
31 32 33	131
34 35 36	132
37 38 39 40	133
41 42	134
43 44	135
45 46	136
47 48 40	137
49 50 51	138
52 53	139
54 55	140
56 57	141
58 59	
60	

1 2

METHODS AND ANALYSIS

Study design 121

2		
3 4	123	investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-
5 6	124	of-antibiotics to rule-out tuberculosis among adults presenting with cough at primary care
7 8	125	centres in Malawi (Figure 2). The trial is registered with Clinicaltrials.gov (NCT03545373)
9 20 21	126	(Appendix 2). The full trial protocol is provided as Appendix 3.
22 23 24	127	Study setting
26 97	128	We will screen adults aged at least 18 years presenting to Limbe and Ndirande health
28 29	129	centres in Blantyre, Malawi. Blantyre has an estimated tuberculosis prevalence of 1,014 per
80 81	130	100,000 (95% CI: 486 to 1,542), and an estimated adult HIV prevalence of 12.7% (95% CI:
32 33 34	131	11.9 to 13.6). ²⁰
35 36 37	132	Eligibility criteria
89 10	133	We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.
11 12	134	Inclusion Criteria
+3 14 15	135	Ambulatory clinic attendees presenting with cough
16 17	136	Unwell for at least 14 days
19 19	137	Aged at least 18 years
50 51	138	Reside in Blantyre and willing to return to the same clinic for follow up visits over the
52 53	139	entire study period.
54 55	140	Exclusion Criteria
56 57 58 59 50	141	Self-reported allergy to study medications

1 2		
3 4	142	 WHO/Malawi National tuberculosis Program (NTP) danger signs: respiratory rate >
5 6	143	30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory
7 8	144	distress, systolic blood pressure <90 mmHg, inability to walk unassisted
9 10	145	Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
11 12	146	Tuberculosis treatment or isoniazid preventive therapy within the last 6 months
13 14	147	
$\begin{array}{c} 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ 60\\ \end{array}$	147	
50 51 52 53 54 55 56 57 58 59 60		

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

149 Interventions

150 We will randomise participants, in a ratio of 1:1:1, to the following arms:

• Arm 1 (Azithromycin): Azithromycin 500mg taken once daily for 3 days from enrolment day

• **Arm 2** (Amoxicillin): Amoxicillin 1g taken three times daily for 5 days from enrolment day.

• Arm 3 (Standard of care): No study antibiotic prescription.

²¹ 156

Rationale for interventions

Amoxicillin was chosen because it is the standard antibiotic used as first line treatment and for trial-of-antibiotics in Malawi. However, amoxicillin may not demonstrate the best performance for trial-of-antibiotics because of increasing resistance, and a narrow coverage for aetiology of community acquired pneumonia and "atypical" organisms. We chose azithromycin to represent the optimal biological specificity of an oral regimen due to more complete coverage of atypical organisms that cause community acquired pneumonia (e.g. mycoplasma and chlamydia), and also the low resistance rates in Malawi where macrolides are rarely used. The dose for Azithromycin is as recommended in the British National Formulary (BNF) as treatment for community acquired pneumonia.²¹ The dose for amoxicillin is the BNF recommendation for severe infections but it is the recommended first line established by the Department of Medicine at Queen Elizabeth Central Hospital (Blantyre, Malawi) based on local microbiology.

⁵¹ 169 **Timing of interventions**

The standard of care in Malawi defined by National Tuberculosis Programme guidelines for
 primary care patients presenting with cough who are otherwise well (no danger signs) is to
 take two sputum specimens for smear microscopy or Xpert and ask patients to return for

Page 8 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

results, typically 3 days - 1 week later (Figure 1). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to patients who remain symptomatic. Therefore, the ideal population for randomisation for this study are patients on who already have negative results for smear microscopy or Xpert. However, that may have ethical challenges considering the implications of withholding treatment (if randomised to reference arm) from a symptomatic patient who, according to guidelines, should be given antibiotics. The first visit therefore was the most ideal time for randomisation and is in line with recommendations for test interval in investigations evaluating diagnostic tests with respect to the time interval between the index test (trial-of-antibiotics) and the reference test (mycobacteriology sputum sample collection). The timing also conforms to common clinical practice of prescribing trial-of-antibiotics at the same time as sputum collection to reduce diagnostic delay. The design was discussed with the District Health Office and the national tuberculosis programme ahead of ethics submission. 02:

Known drug reactions

Azithromycin and amoxicillin have a long registration history, have been widely used globally and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some to subsequently start tuberculosis therapy. Important interactions therefore would be those those between the product and HIV antiretroviral drugs. There is no moderate or

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

198 major interaction between either azithromycin or amoxicillin with the classes of HIV

199 antiretroviral drugs currently used in Malawi.

Trial restrictions

201 We do not require participants to have any dietary restrictions. We will also accept co-

administration with contraception. Azithromycin and amoxicillin are both considered safe in

203 pregnancy, so we will include pregnant women should they be eligible.

204 Assessment of compliance

205 On Day-8, we will document self-reported compliance adherence of study products.

206 Withdraw of interventions

The investigator may also terminate a participant from study product if indicated by an
adverse reaction. If a participant stops taking study product either voluntarily or by
investigator decision, they will be encouraged to remain in follow up and their data will form
part of intention to treat analyses.

211 Study outcomes

The clinical trial has two separately powered, and distinctly assessed primary outcomes, one
for diagnostic evaluation (Primary outcome 1: Day 8) and the other for clinical impact
(Primary outcome 2: Day 29) of the intervention. The following are descriptions of all study
outcomes:

Primary outcome 1: Specificity of day 8 symptom change versus mycobacteriology The first primary outcome is the proportion of patients without tuberculosis (by sputum tests) who report improvement of their baseline illness when asked 7 days after randomisation (Day 8 study visit). This outcome can be thought of as diagnostic specificity if you take

sputum test results as a reference standard and *change in symptoms at Day 8* as the

Page 10 of 31

BMJ Open

2 3 4	221
4 5 6	222
7 8	223
9 10	224
11 12	
13	225
14 15	226
16 17	227
18 19	228
20 21	229
22 23	230
24 25	231
26 27	232
28 29	233
30 31	200
32	234
33 34	235
35 36	236
37 38	237
39 40	238
41 42	239
43 44	200
45 46	240
47 48	241
49 50	242
50 51 52	243
53	244
54 55	- · ·
56 57	240
58 59	246
60	247

investigational test (Figure 3). In this case the possible results of the investigational test are
improvement and no improvemet (no change or worsened) in response to the question: *on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved?*

As with all self-rated outcomes, social desirability bias (tendency of participants to answer questions in a manner that will be viewed favourably by healthcare worker), and interviewer bias (interviewers' subconscious or conscious influencing subject response) may affect the outcome. To minimise these biases in evaluation of improvement of baseline symptoms the interview will be conducted using Audio Computer Assisted Self-Interview (ACASI), a platform that allows patients to report their health state in private and directly into a database via an audio questionnaire administered by a tablet. The lack of human-to-human interaction will minimize interviewer, ascertainment, and social desirability biases. Another concern with open-label design is placebo-effect favouring those randomised to antibiotics over the standard of care arm that is however not addressed in our design.

We developed, piloted, and optimised the ACASI questionnaire in the study target population and arrived at the question: *on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved?* Before proceeding to the self-interview, participants will be oriented using test questions until study staff are sure that they will be able to go through the interview on their own. We will term ACASI interview outcome as ACASI-test-negative if the participant reports improvement or ACASI-testpositive if the participant reports no change or worsening (Figure 3).

The mycobacteriology reference standard will be defined in participants with at least one
valid sputum test result on days 1 and 8 as **sputum-test-positive** if there is at least one
positive of smear microscopy, Xpert/MTB/RIF, or MTB culture; and as **sputum-test- negative** if none of the tests is positive. To minimise bias, the sputum tests will be performed
by a high-quality research laboratory in the University of Malawi College of Medicine by staff
with no access to participant treatment allocation information or symptom results.

Page 11 of 31

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

The specificity of day 8 symptom change (the index test measured using ACASI) against
mycobacteriology tests (reference test) is defined as: proportion of sputum-test-negative
who are ACASI-test-negative.

252 Primary outcome 2: Clinical impact of trial-of-antibiotics

We will investigate the overall clinical impact of trial-of-antibiotics by comparing the day 29 risk of any of death, hospitalisation, and "missed tuberculosis" (untreated mycobacteriological or radiological tuberculosis). All these events can lead to mortality and are potential consequences of trial-of-antibiotics; therefore, grouping them as a composite endpoint appropriately represents the effect of the intervention because: 1) there are similarities in the importance of each of the components, 2) the components occur with similar frequencies in the patient population, and 3) the direction of effect is anticipated to be the same for all.²²

The connection between trial-of-antibiotics and risk of hospitalisation and death assumes a protective effect of antibiotics. In patients presenting with chronic cough at primary care in high HIV prevalence settings, frequencies of mortality and hospitalization over a two months period are similar, ranging from 2 to 6%.²³

We have included missed tuberculosis diagnosis in our composite clinical outcome because this too can lead to death. We are defining "missed tuberculosis" as participants who meet standard mycobacteriological and radiological tuberculosis definitions but are incorrectly classified as tuberculosis-negative and not yet on tuberculosis treatment by Day 29. Clinical, radiological, and microbiological evaluation for tuberculosis will be done at Day 8, Day 29, as well as day between these two for patients who report worsening symptoms.

5 271 Secondary outcome 1: impact of trial-of-antibiotics on antimicrobial resistance

⁵⁷ 272 We will use *Streptococcus pneumoniae* isolated from swabs of the nasopharynx as the

⁵⁹ 273 indicator pathogen for AMR evaluation. An ecological niche for many bacterial species, the

Page 12 of 31

BMJ Open

upper respiratory tract also presents a convenient window for investigating antimicrobial
resistance. *Streptococcus pneumoniae* is the organism of choice not only for being an
important cause of respiratory tract infections but also because it often colonises the upper
respiratory tract, acquires resistance readily, and has well documented laboratory
investigation procedures in place.²⁴

We will define **AMR positive** as having nasopharyngeal isolates of *Streptococcus* pneumoniae that are resistant to any of the following commonly used antibiotics: ceftriaxone, amoxycillin, cefoxitin, azithromycin, and erythromycin as determined using disc diffusion technique; and AMR negative as either (1) not isolating any Streptococcus pneumoniae or (2) isolating any Streptococcus pneumoniae that is not resistant to any of the assessed antibiotics. For each arm, and at both baseline and day 29, we will report proportion of AMR positive participants. The study outcome will be the proportion of AMR positive participants at day 29.

2 287 Secondary outcome 2: diagnostic value of trial-of-antibiotics in all patients including 3 4 288 those without a valid sputum result

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

In this analysis, all will remain as described for primary outcome 1 except for the denominator, which will now include those without a valid sputum test result. The mycobacteriology reference standard for secondary outcome 2 will be defined as sputum test positive if at least one positive of smear microscopy, Xpert/MTB/RIF, or MTB culture from samples collected on days 1 and 8. The reference test will be sputum-test-negative if none of the tests is positive and where there is no valid sputum test result available. The most likely reason for not having a valid sputum result will be inability to produce sputum, but other explanations will be: lost sample before laboratory analysis, an invalid laboratory reading, or contamination. We have opted to analyse this population because in symptomatic adults of the study setting, failure to produce sputum can be as high as 13%.²³

Page 13 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3
4
5
6
7
/
8
9
10
11
12
13
14
15
16
17
10
10
19
20
21
22
23
24
25
26
27
28
20
20
50 21
31
32
33
34
35
36
37
38
30
10
- 1 0 // 1
41
42
43
44
45
46
47
48
49
50
51
52
52
55
54 57
55
56
57
58
59
60

1 2

299 Secondary outcome 3: Economic evaluation

300 The objective of the economic evaluation is to undertake a cost-utility analysis to estimate 301 the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-302 antibiotics using amoxicillin in comparison to standard of care, and to each other. We will 303 systematically compare costs and consequences associated with the interventions. We will 304 perform a within trial comparison of the three treatment arms to estimate the incremental 305 cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in 306 comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health 307 perspective. Health outcomes will be quantified in QALYs, estimated from participants' 308 responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) 309 measure.^{25 26} We will adopt a time horizon matching the length of participant follow-up to 310 achieve the within trial evaluation.

⁹ 311 *Exploratory outcomes*

312 Our exploratory analyses will be comparisons between the azithromycin and amoxicillin
 313 arms for all our primary and secondary outcomes.

⁶ 314 **Planne**o

Planned subgroup analyses

⁸ 315 We will perform analysis of primary outcomes stratified by HIV status and by ART status as ⁰ 316 documented on enrolment day. This is important because the study site has high prevalence ² 317 of HIV and associated bacterial infections which may be amenable to antibiotics used for ⁴ trial-of-antibiotics.

² 319 Study procedures

Figure 2 and Table 1 presents the study time schedule including a summary of patient
identification, baseline procedures and outcome ascertainment at day 8 and day 29 follow up
visits.

Page 14 of 31

1 2		
- 3 4	323	Screening
5 6	324	Study staff will approach patients with symptoms of pulmonary tuberculosis (including cough
7 8	325	of any duration, fever, weight loss, and night sweats) with information about the study and
9 10	326	seek written informed consent (Appendix 4) from all patients who meet eligibility criteria.
11 12	327	After consenting, a participant will be given a unique study identification number confirming
13 14 15	328	enrolment.
16 17	329	Randomisation
18 19	330	Randomisation will be in the ratio 1:1:1 to the three arms of the trial, using block-
20 21	331	randomisation with variable block sizes, and stratified by study site. An independent
22 23	332	statistician will prepare the randomisation list using Ralloc command in Stata software, then
24 25 26	333	print each allocation alongside a randomisation number, and seal in opaque envelopes.
20 27 28	334	Upon confirming eligibility and consenting status a designated site staff will open the next
20 29 30	335	available of sequentially numbered randomisation envelopes and administer the allocated
31 32	336	study arm.
33 34	337	Blinding
35 36 27	338	The study is not placebo controlled because of funding limitations, and so will not use
37 38 39	339	blinding due to the nature of the study design. However, study team masking will be
40 41	340	maintained with all study outcome assessment occurring without reference to randomisation
42 43 44 45	341	arm.
40 47 48	342	Baseline procedures
49 50	343	At baseline, we will collect demographic data, clinical history, record vital signs, height and
51 52	344	weight. Participants will be requested to provide two sputum samples for Xpert/MTB/RIF and
53 54	345	two more sputum samples the following morning for smear microscopy and MTB culture. We
55 56	346	will also collect a urine sample for lipoarabamannan antigen detection (TB LAM); and a
57 58	347	nasopharyngeal swab for pneumococcal culture and sensitivity testing. We will offer and
59 60	348	perform HIV testing according to the national algorithm, and link all who test positive to care.

Page 15 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

To minimise loss to follow up, we will collect contact phone numbers, a physical address andgeolocation information.

351 Participant follow up

On day 8, the first activity (ahead of any other interaction with study staff) will be the ACASI. Other activities include providing results for day 1 tuberculosis tests and linking those who test positive to care; collection of another sputum sample for smear microscopy and Mycobacterium tuberculosis (MTB) culture; and management of ongoing symptoms and other illnesses. On visit day 29, the final study visit, we will document participant vital status, hospitalisations, and establish adherence to HIV and tuberculosis treatment. We will also collect nasopharyngeal swab samples from all participants, and sputum from those with tuberculosis symptoms.

360 Participant retention

To minimise loss to follow up, we will record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

367 Data management

We will collect data using TeleForm (paper based system that uses optical character
recognition) and Open Data Kit systems (ODK, an electronic data capture system installed
on android devices). Data will be committed to a secure database located at MalawiLiverpool Wellcome Trust (MLW) within 2 days for TeleForm, and 7 days for ODK.

Page 16 of 31

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2	
3	
4	
5	
6	
7	
8	
9	~
1	0
1	ן ר
1	2
1	5 ∧
1	4
1	5 6
1	7
1	י 8
1	g
2	0 0
2	1
2	2
2	3
2	4
2	5
2	6
2	7
2	8
2	9
3	0
3	1
3	2
3	3
3	4
3	5
3	6
3	7
3	8
3	9
4	0
4	1
4	2
4	3
4	4
4	5
4	6
4	0
4	0
4	2
5	1
5	י כ
5	∠ २
5	4
5	5
5	6
5	7
5	8

374

Table 1: key study procedures over the study period

	STUDY PERIO	C		
	Enrolment	Follow up		ow up
TIMEPOINT	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	x			
Informed consent	x			
Allocation	x			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	x			
Standard of care	x			
ASSESSMENTS:				
Demographics	x			
History of antibiotic use	x	x		Х
History & examination ¹	x	Х		x
Sputum collection ²	x	x		
Urine for TB LAM test ³	x	x		
Nasopharyngeal swab for		0		v
AMR ⁴	X			X
HIV test	x	1		
Linking to routine care	x	Х		Х
ACASI ⁵		Х	3	
Clinical events ⁶				x
Update contact & address		Х		x
 For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated 				

3. Urine Lipoarabinomannan for Tuberculosis Diagnosis (TB LAM)

4. Nasopharyngeal swab for Streptococcus pneumoniaeee culture and sensitivity as a way of determining risk of antimicrobial resistance (AMR)

5. Audio Computer Assisted Self-Interview (ACASI) for documenting change of symptoms on Day- 8 versus Day-1

6. Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new tuberculosis diagnosis, death, hospitalisation, missed tuberculosis diagnosis, HIV care loss to follow up, and tuberculosis care loss to follow up

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

375 Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT (Consolidated Standards of Reporting Trials) flow chart. We will describe the study participants by their baseline characteristics, by arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to). Analysis for primary outcome 1 will be restricted to participants with a valid sputum test result. We will report measures of effect from the following comparisons:

- 382 i) Azithromycin or amoxicillin (combined) versus standard of care
 - 383 ii) azithromycin versus standard of care
- 25 384 iii) amoxicillin versus standard of care

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for study site. For each comparison, we will report 95% confidence intervals (CIs) and p-values from the likelihood test. If outcomes are rare, or the GLM model does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio. We will not perform adjustments for multiple comparisons but will report all effect sizes with their 95% CIs and p-values to facilitate appropriate interpretation of our results.

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College
 station, Texas, USA). The statistical approach will be expanded in a detailed statistical
 analysis plan, which will be finalised before unblinding the study data.

395 Sample size and power

We performed power and sample size estimations for the diagnostic impact, clinical impact,
and AMR impact outcomes as described below. Our sample size estimations are based on
planned analysis that will use Chi-squared test for comparing two independent proportions.

2	
_ 3 ⊿	399
5	400
0 7	401
o 9 10	402
10 11 12	403
12 13	404
14 15 16	405
10 17 10	405
18 19 20	406
21 22	407
23 24	408
25 26	409
27 28	410
29 30 21	411
31 32 33	412
34 35	413
36 37	
38 39	
40 41	
42 43	
44 45	
46 47	
48 49	
50 51	
52 53	414
54 55	415
56 57	-
58 59	416
60	417

9 Diagnostic impact outcome

We assume that at Day 8, change in well-being from baseline state in trial-of-antibiotics
(azithromycin or amoxicillin) arms will correctly classify 60% of all mycobacteriology negative
participants (i.e 60%specificity of day 8 symptom change in trial-of-antibiotics arms).¹² We
wanted to estimate a sample size that would provide a discriminatory power of 80% at a twosided significance level of 5%, to detect at least 10% difference in specificity (i.e ≤50%
specificity of day 8 symptom change in standard of care arm).

406 Sample size for a combination of 2 antibiotic arms against standard of care arm

407 The sample size estimates along with assumptions for this comparison are shown in the

408 Table 2A. To achieve the desired 80% discriminatory power, we will need to recruit at least

409 290 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to

410 produce and submit sputum, and loss-to-follow up increases the sample to 453 per arm or

411 1,359 for the whole study.

412 **Table 2A:** Sample size estimation for the *diagnostic impact outcome* comparing a

413 combination of two antibiotic arms to standard of care arm (2:1 comparison)

OWER (X2 difference etween independent roportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)
0.80	0.10	290
0.85	0.10	332
0.90	0.10	388
Target power and r ability to produce a Stata code: power tw	espective sample size estimates nd submit sputum, and loss-to-fo	based on knowledge of TB risk, llow up.

415 Sample size for one antibiotic arm against standard of care arm

416 The sample size estimates along with assumptions for this comparison are shown in the

⁰ 417 Table 2B. To achieve the desired 80% discriminatory power, we will need to recruit at least

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

418 388 sputum-test-negative participants per arm. Accounting for TB prevalence, ability to

419 produce and submit sputum, and loss-to-follow up increases the sample to 606 per arm or

420 1,819 for the whole study (The ethics approved protocol uses an older calculation that yields

421 625 per arm, and 1875 for whole study).

Table 2B: Sample size estimation for the *diagnostic impact outcome* one antibiotic arm to

423 standard of care arm (pairwise comparison)

	POWER (X2 difference between independent proportions)	Effect size (50% SoC vs 60% amoxycillin or azithromycin)	Effective sample per arm (Sputum negative participants needed)			
1	0.80	0.10	388			
	0.85	0.10	443			
	0.90	0.10	519			
	Target power and respension ability to produce and s	ective sample size estimates bas ubmit sputum, and loss-to-follow	ed on knowledge of TB risk, y up.			
124	Power for clinical impact out					
+24		come				
425	For the clinical impact of trial-o	f-antibiotics outcome, we assum	e a 4% baseline risk of			
426	composite outcome, and a loss to follow up of 10% by Day 29. Using the sample size of 625					
427	participants per arm (obtained in Table 2B), and a type I alpha of 5%, we will be able to					
428	detect the difference between arms with 80% power, if the risk in the intervention arm is					
429	twice that of the standard of care arm. This estimate is applicable to all comparisons shown					
430	in section 3.					
431	Power for AMR outcome					
432	Study arms will be compared b	ased proportion of participants v	vith resistant Streptococcus			
433	pneumoniae on day 29. We assume that 45% of Day-29 nasopharyngeal swabs will					
434	successfully grow Streptococc	<i>us pneumoniae,</i> and that 10% of	the isolates will meet the			
435	definition of resistance (describ	bed earlier under outcomes), and	I that 10% will be lost to follow			
436	up by Day 29. Therefore, on da	ay 29, the standard of care arm (of 625 participants) will have			

BMJ Open

437 253 *Streptococcus pneumoniae* isolates, 25 of which would meet the definition of resistance.
438 This translates into a 4% (25/625) risk of AMR positive cases in the standard of care arm. To
439 detect a twofold change in odds of day 29 AMR risk with at least 80% power, using
440 Pearson's Chi-squared test, at 0.05 alpha, we will need at least 431 and 553 participants per
441 arm for the 2:1 and pairwise comparisons respectively.

442 Monitoring and oversight

The trial will be monitored by the Research Support Centre Clinical Trials Unit of the
University of Malawi College of Medicine. An independent Data and Safety Monitoring Board
(DSMB), and a Trial Steering Committee (TSC) have been set up and meet bi-annually.

446 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant,
and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab
work will continue beyond trial closure. The trial may be terminated early by the trial steering
committee upon recommendation of the DSMB. The halting rule for a trial arm is an
unacceptable high level of deaths assessed using an alpha determined at the first DSMB
meeting.

3 453 l

PATIENT AND PUBLIC INVOLVEMENT

454 Patients were involved in the design of the study especially the audio-computer-assisted
455 interview (ACASI) used for collecting primary outcome data. Health workers were involved in
456 the design of study visits and patient flow.

DISCUSSION

458 The ACT-TB study will investigate the benefits and consequences of "trial-of-antibiotics," a

459 widely promoted approach to many patients with suspected tuberculosis in low- and middle-

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

income countries without solid evidence base. To our knowledge, ACT-TB Study is the first
RCT of this kind. Results of our trial will add to the evidence-base regarding routine
diagnosis of tuberculosis in low and middle-income countries and strengthen our fight
against AMR. Both tuberculosis and AMR are diseases of major importance globally, with
tuberculosis causing an estimated 1.6 million deaths in 2017 and AMR projected to cause

C

Choice of study interventions

10 million deaths per year by 2050.227

We have chosen amoxicillin because it is the first line treatment for outpatient management of pneumonia in Malawi and is commonly used for trial-of-antibiotics. It also provides data of immediate programmatic relevance and a starting point to investigate exacerbation of pre-existing AMR pressure. However, amoxicillin may not demonstrate the full benefits for trial-of-antibiotics because of organisms with intrinsic ("atypicals") or acquired (common in gram-negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁸ Oral antibiotics that may provide the better diagnostic discrimination for bacterial versus mycobacterial causes of cough are macrolides, such as azithromycin, because of better intrinsic coverage of "atypical" intracellular organisms such as mycoplasma species that cause community acquired pneumonia,²⁹⁻³¹ and low levels of acquired macrolide-resistance in bacterial isolates in Malawi.28

478 ACASI for post-treatment improvement assessment

479 Our systematic review¹⁸ did not identify a consistent definition of tuberculosis or no
480 tuberculosis based on trial-of-antibiotics. A definition of clinical change following antibiotic
481 treatment is necessary for the trial-of-antibiotics as this determines who get categorised as
482 well or tuberculosis-positive. Approaches that ranged from self-reported improvement to a
483 combination of clinical and radiological assessments are likely to be highly subjective and
484 prone to bias, as well as being a potentially avoidable source of heterogeneity between

Page 25 of 134

BMJ Open

studies. In this study, we hope to address these biases (particularly, inter-observer
variability, and patient/interviewer reporting or ascertainment biases) by using self-rated
change of illness (on day 8) recorded using a self-completed questionnaire, the ACASI
(described under outcomes). The ACASI questionnaire, the delivery platform, and the
resulting data management can all be replicated in future studies, creating potential for more
standardisation in assessment of clinical response to treatment.

Potential clinical impact of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high, 3 32 and is often secondary to severe bacterial infections.³²⁻³⁴ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are Streptococcus pneumoniaee and non-typhoidal salmonellae: both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active Mycobacterium tuberculosis disease.³²⁻³⁴ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected tuberculosis in people living with HIV, then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to tuberculosis treatment decisions. In this context, azithromycin may be the most effective arm, as salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.28

505 AMR and trial-of-antibiotics

506 Antimicrobial resistance relating to antibiotic use during evaluation for suspected
 507 tuberculosis has not been investigated before. Previous work has shown that empirical
 508 antibiotics can drive rapid emergence of antimicrobial resistance.^{35 36} Co-trimoxazole
 509 prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

resistance in bloodstream infections by 2010³⁷. Mass drug administration of azithromycin for
trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniaee*,
but with increased macrolide-resistance 6 months later.^{38 39}

In this study we have the opportunity to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient sampling opportunity for investigating antimicrobial resistance.⁴⁰ Streptococcus pneumoniae is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract, acquires resistance readily, and has well documented laboratory investigation procedures in place.²⁴ As exploratory analyses, we will also assess nasopharygeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

522 Important subgroups

Clinical response to trial-of-antibiotics is possible and indeed well-described in patients with bacteriologically confirmed tuberculosis (i.e. false-negatives/low sensitivity from the perspective of tuberculosis diagnosis) may relate to multiple super-infections.^{4 33} As such, this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and are most commonly reported in patients with suspected tuberculosis in the pre-ART era. In 2015, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started tuberculosis treatment on the basis of positive mycobacteriology.²³ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and ART coverage, and by subsequent tuberculosis treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

534 Limitations

The study has several limitations. Firstly, we did not use a placebo-control arm. Secondly, the study is not adequately powered to evaluate safety of deferred antibiotic treatment or conduct subgroup analyses of outcomes by HIV status, both which are important evidence gaps. Other limitations include the possibility that participants randomised to the standard-ofcare arm may find alternative access to antibiotics therefore misclassifying exposure/intervention status. There is also a possibility of misclassifying active tuberculosis status because of the suboptimal nature of the available tests.

ETHICS AND DISSEMINATION

The study has been reviewed and approved by the University of Malawi College of Medicine Research and Ethics Committee (COMREC; registration number P.04/18/2381), the London School of Hygiene & Tropical Medicine Research Ethics Committee (LSHTM EC; registration number 15232), and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (REK nord; registration number 208/1964). Regulatory approval has been granted by the Malawi Pharmacy, Medicines, and Poisons Board (PMPB; registration number CTRC/III/14062018102). We will present any future protocol modifications to these bodies before implementing. We will submit results for publication in a peer-reviewed journal. We will submit abstracts to relevant national and international conferences. This work will also form part of a PhD thesis for TD, which he will submit to the LSHTM. This study will follow the standards set by CONSORT guidelines.

¹⁷ 554

AUTHORS' CONTRIBUTIONS

51 555 THD, KF and ELC are the main contributors to the conception, and design of the study. DS,
 53 556 MN and PM contributed to the general study planning and clinical design. NF contributed to
 54 557 the general study planning and antimicrobial resistance design. CK, LC, SC, and MJN
 558 contributed to the design, piloting, and refining of study and clinical procedures. THD
 559 developed the first draft of the manuscript. All authors carefully reviewed and substantially

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

560 contributed to the development of the trial protocol and this manuscript. All authors read and561 approved the final manuscript. THD is the guarantor for this work.

562 FUNDING AND SPONSORSHIP STATEMENT

The clinical trial is funded by the Commonwealth Scholarship Commission and the Helse Nord RHF grant awarded to THD. This work is part of THD's PhD work at London School of Hygiene & Tropical Medicine (LSHTM). LSHTM is the sponsor of this clinical trial (sponsor address: Keppel Street, Bloomsbury, London WC1E 7HT). ELC is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science: WT200901. The funding agencies and the sponsor had no role in the preparation of the protocol or the intention to submit this manuscript for publication.

- 570 COMPETING INTERESTS STATEMENT
 - 571 We have no conflicts of interest to declare.

BODY WORD COUNT: 4,034

REFERENCES

- 574 1. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. *Infectious disease reports* 2016;8(2):6570. doi: 10.4081/idr.2016.6570
- 5 576 2. World Health Organization. Global tuberculosis report 2018: World Health Organization 2018.
- 578 3. Nliwasa M, MacPherson P, Mukaka M, et al. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. *The international journal of tuberculosis and lung disease* 2016;20(2):202-10. doi: 10.5588/ijtld.15.0388
- 581
 4. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *The Lancet* 2007;369(9578):2042-49. doi: 10.1016/S0140-6736(07)60284-0

1 2		
3 4 5 6 7 8 9	587 588	finding/screening. Number 5 in the series]. <i>The international journal of tuberculosis and lung disease</i> 2013;17(9):1125-38.
	589 590 591	 Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. <i>The Lancet infectious</i> <i>diseases</i> 2003;3(5):288-96.
10 11 12	592 593	 Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co- infection in Ghana. In: Department DCaP, ed. Accra, 2007.
13 14 15	594 595	8. Ministry of Health. Malawi National TB Programme Manual In: Programme NT, ed. 8 ed. Lilongwe, 2016.
16 17 18	596 597	 National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, ed. Pretoria, 2014.
19 20	598	10. World Health Organization. Global tuberculosis report 2016. 2016
21 22 23 24 25	599 600 601	 McDowell A, Pai M. Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. <i>The International Journal of</i> <i>Tuberculosis and Lung Disease</i> 2016;20(4):536-43.
26 27 28 29 30 31 32 33 34	602 603 604 605	 Wilkinson D, Newman W, Reid A, et al. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. <i>The</i> <i>International Journal of Tuberculosis and Lung Disease</i> 2000;4(6):513-18. [published Online First: 2000/06/23]
	606 607 608	 Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. <i>The Lancet</i> 2016;387(10014):176-87. doi: 10.1016/S0140- 6736(15)00473-0
35 36 37	609 610	 World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization 2012.
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 	611 612	15. World Health Organization. Antimicrobial resistance: global report on surveillance: World Health Organization 2014.
	613 614 615	 Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. <i>The Lancet</i> 2016;387(10014):168-75. doi: 10.1016/S0140- 6736(15)00474-2
	616 617 618	 Divala TH, Fielding KL, Nliwasa M, et al. Sensitivity and specificity of using trial-of- antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Systematic reviews 2018;7(1):141.
	619 620 621 622 623	18. Divala TH, Nliwasa M, Gupta-Wrigh A, et al. Is the current practice of using response to empirical broad-spectrum antibiotic treatment as an exclusion diagnostic for tuberculosis supported by evidence? Systematic review and meta-analysis. 49th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union): Int J Tuberc Lung Dis, 2018.
56 57 58 59 60	624 625 626	 World Health Organization. High priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting, 28-29 April 2014, Geneva, Switzerland: World Health Organization, 2014.

20. National Tuberculosis Control programme. Malawi Nationwide Tuberculosis Prevalence Survey. 45th Union World Conference on Lung Health. Barcelona, Spain, 2014. 21. Joint Formulary Committee. British national formulary (BNF) 78: Pharmaceutical Press 2019. 22. Montori VM, Permanyer-Miralda G, Ferreira-González I, et al. Validity of composite end points in clinical trials. Bmj 2005;330(7491):594-96. 23. Nliwasa M, MacPherson P, Chisala P, et al. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. PloS one 2016:11(5):e0155101. doi: 10.1371/journal.pone.0155101 [published Online First: 2016/05/14] 24. Satzke C, Turner P, Virolainen-Julkunen A, et al. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. Vaccine 2013;32(1):165-79. doi: 10.1016/j.vaccine.2013.08.062 25. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health policy (Amsterdam, Netherlands) 1990;16(3):199. 26. Maheswaran H, Petrou S, MacPherson P, et al. Cost and guality of life analysis of HIV self-testing and facility-based HIV testing and counselling in Blantyre, Malawi. BMC medicine 2016;14(1):34. 27. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. 2016. HM Government and Welcome Trust: UK 2018 28. Musicha P, Cornick JE, Bar-Zeev N, et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. The Lancet Infectious Diseases 2017;17(10):1042-52. doi: 10.1016/s1473-3099(17)30394-8 29. Lubell Y, Turner P, Ashley EA, et al. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics Sensibilité aux macrolides des isolats bactériens provenant des infections acquises dans la communauté en Afrique subsaharienne et en Asie Susceptibilidad a macrólidos de aislados bacterianos provenientes de infecciones adquiridas en la comunidad. Tropical Medicine & International Health 2011;16(10):1192-205. doi: 10.1111/j.1365-3156.2011.02837.x 30. Phua J, Dean NC, Guo Q, et al. Severe community-acquired pneumonia: timely management measures in the first 24 hours. Critical Care 2016;20(1):237. doi: 10.1186/s13054-016-1414-2 31. Lim W. Smith D. Wise M. et al. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax 2015:thoraxjnl-2015-206881. 32. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerging infectious diseases 2009;15(2):258.

2		
3 4 5 6	667 668 669	 Bedell RA, Anderson ST, Van Lettow M, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. <i>PLoS One</i> 2012;7(6):e39347. doi: 10.1371/journal.pone.0039347
7 8 9 10 11	670 671 672 673	34. Schleicher G, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. <i>The International Journal of Tuberculosis and Lung Disease</i> 2003;7(12):1207-08.
12 13 14	674 675	 Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. <i>Nature medicine</i> 2004;10(12s):S122. doi: 10.1038/nm1145
15 16 17 18	676 677 678	 Goossens H, Ferech M, Vander Stichele R, et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. <i>The Lancet</i> 2005;365(9459):579-87.
19 20 21 22	679 680 681	37. Everett DB, Mukaka M, Denis B, et al. Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. <i>PloS one</i> 2011;6(3):e17765. doi: 10.1371/journal.pone.0017765
23 24 25 26 27 28	682 683 684 685	38. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. <i>Clinical Infectious Diseases</i> 2013;56(11):1519-26.
29 30 31 32	686 687 688	 Mitjà O, Houinei W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. New England Journal of Medicine 2015;372(8):703-10. doi: 10.1056/NEJMoa1408586
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 	689 690 691 692 693 694	40. Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. <i>Nat Rev Microbiol</i> 2017;15(5):259-70. doi: 10.1038/nrmicro.2017.14

3 4	695
5 6	696
7 8	697
9	698
10 11	
12 13	699
13 14 15	700
16 17	701
18 19	702
20 21 22	703
23 24 25	704
26 27 28	705
28 29 30	706
31 32 33	707
34 35	708
36 37 38	709
39 40 41	710
42 43 44	711
45 46 47	712
47 48 49	713
50 51	714
52 53	715
54	-
55 56	716 717
57 58	- / -
59 60	718

LEGENDS FOR FIGURES

6 1. Legend for figure 1

697 698	*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.
699	Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of
700	tuberculosis in low and middle income countries (based on the 2018 WHO GLI model
701	guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)
702	
703	2. Legend for figure 2
704	ART = antiretroviral treatment for HIV
705	NTP = Malawi National Tuberculosis Program
706	TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis
707	VL = HIV Viral load
708	Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi
709	4
710	3. Legend for figure 3
711	Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8
712	
713	APPENDIX 1: ETHICS AND REGULATORY APPROVALS
714	(attached separately)
715	APPENDIX 2: TRIAL REGISTRATION—DATA SET
716 717	(attached separately)
718	APPENDIX 3: FULL TRIAL PROTOCOL

719 (attached separately) 721 APPENDIX 4:PATIENT INFORMATION SHEET AND INFORMED 722 CONSENT 723 (attached separately) 724 (attached separately) 725 (attached separately) 724 (attached separately) 725 (attached separately) 726 (attached separately) 727 (attached separately) 728 (attached separately) 729 (attached separately) 724 (attached separately) 725 (attached separately) 726 (attached separately) 727 (attached separately) 728 (attached separately) 729 (attached separately) <	1 2		
721 APPENDIX 4:PATIENT INFORMATION SHEET AND INFORMED 722 (attached separately) 724 725	2 3 4 5	719 720	(attached separately)
723 (attached separately) 724 725 725	6 7 8	721 722	APPENDIX 4:PATIENT INFORMATION SHEET AND INFORMED CONSENT
	8 9 10 11 23 14 15 16 17 8 9 20 21 22 32 42 52 62 7 8 9 30 31 23 34 35 36 37 83 9 40 41 42 34 45 46 47 48 9 50 51 52 54 55 67 58 960	722 723 724 725	(attached separately)





BMJ Open

*The common clinical practice is that outpatients start antibiotics at the time of submitting sputum, to avoid the need for a third clinic visit to complete the algorithm.

Figure 1: The position of trial-of-antibiotics in standard algorithms for diagnosis of tuberculosis in low and middle income countries (based on the 2018 WHO GLI model guidelines and as implemented in national guidelines e.g Ghana, Malawi and South Africa.)



ART = antiretroviral treatment for HIV NTP = Malawi National Tuberculosis Program TB LAM = Urine Lipoarabinomannan for Tuberculosis Diagnosis VL = HIV Viral load Figure 2: Flow diagram for the clinical trial in Blantyre, Malawi



Figure 3: Assessing the diagnostic value of a change in symptoms from baseline to day 8

366x222mm (96 x 96 DPI)



BMJ Open

CERTIFICATE OF ETHICS APPROVAL

This is to certify that the College of Medicine Research and Ethics Committee (COMREC) has reviewed and approved a study entitled:

P.04/18/2381 - Accurancy and Consequences of using Trial-of-antibiotics for TB diagnosis (ACT-TB Study) by Titus H Divala

On 03-Jul-18

As you proceed with the implementation of your study, we would like you to adhere to international ethical guidelines, national guidelines and all requirements by COMREC as indicated on the next page

Dr. YB. Mlombe - Chairperson (COMREC)

03-Jul-18

Date

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training and similar technologies.

moni Debeolnwod. 2020 Anew 25 no 99990-203999 no 25 March 2020. Downloaded from

REQUIREMENTS FOR ALL COMREC APPROVED RESEARCH PROTOCOLS

- 1. Pay the research overhead fees as required by the College of Medicine for all approved studies.
- 2. You should note that the COMREC Sub-Committee on Research Participants' Safety will monitor the conduct of the approved protocol and any deviation from the approved protocol may result in your study being stopped.
- 3. You will provide an interim report in the course of the study and an end of study report.
- 4. All COMREC approvals of new applications and progress reports are valid for one year only. Therefore all approved studies running for more than one year are subject to continuing review annually. You are required to submit a progress report to COMREC within 90-30 days before the expiration date. Your current expiration date is 03-Jul-19. Studies shall be considered lapsed and inactive if continuing review application is not received one month after the expiry of the previous approval. In that case, all study related operations should cease immediately except those that are necessary for the welfare of subjects.
- 5. All investigators who are Medical Practitioners must be fully registered with the Medical Council of Malawi.

Enseignement Superieur (ABES) . Protected by copyright, agluding for tests seignement Superieur (ABES) . Protected by copyright, agluding for tests seigned for test and all and a the protected by test and a large seign

BMJ Open. first published as 10.1136/bmjopen-2019-09309 on 25 March 2020. Downloaded from http://pmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de l



PHARMACY, MEDICINES & POISONS BOARD

Mission: To promote and improve the health of the population of Malawi through the regulation of Pharmacy Personnel, Pharmacy Businesses, Medicines and Allied Substances

ALL CORRESPONDENCE SHOULD BE ADDRESSED TO THE REGISTRAR

Head Office: Off Paul Kagame/ Chilambula Road P.O.Box 30241 Capital City LILONGWE 3, MALAWI Phone: (+265) 01 755 165 Fax : (+265) 01 755 204 Email: <u>info@pmpb.mw</u> Web: <u>www.pmpb.mw</u>

PMPB/CTRC/III/14062018102 DATE: 4th July, 2018

Department of Infectious Disease Epidemiology London School of Hygiene and Tropical Medicine Keppel St London

Attn.: Dr. Titus Divala

RE: ACCURACY AND CONSEQUENCES OF USING TRIAL-OF-ANTIBIOTICS FOR TB DIAGNOSIS (ACT-TB STUDY).

Refer to your application to register the above mentioned clinical trial with the Pharmacy, Medicines and Poisons Board (PMPB).

The Clinical Trial Review Committee (CTRC), at its meeting held on 22nd June, 2018, issued a **No Objection** to the implementation of the trial after members agreed that the nature of the trial was seen to be outside the scope of trials that should be regulated by PMPB through the CTRC.

Please contact the undersigned if there are any issues that need further clarification.

Yours faithfully,

MEDICINES ONS BOARD REGISTRAR M. Kawaye ACTING REGISTRAR TJUL 2018 BOX 30241.LILONGWE



REK nord	Saksbehaldler.	Telefon:		Vár dato: 06.11.2018 Deres dato: 25.09.2018	Vår referanse: 2018/1964/REK n Deres referanse:
				Vår referanse må op	pgis ved alle henvendelser
Jon Øyvind C	dland				
Institutt for sa	mfunnsmedisin				
2018/1964 E eksklusjonso	En kontrollert klin liagnose i allmenp	nisk studie for å un praksis mot risiko i	dersøke responsen for antibiotika resis	til bredspekret stens	antibiotika som e
Forskningsa Prosjektlede	nsvarlig institusjo r: Jon Øyvind Odl	o n: UiT Norges ark land	tiske universitet		
Vi viser til sø Regional kon er gjort med l	oknad om forhånds nité for medisinsk hjemmel i helsefor	godkjenning av ove og helsefaglig forsk skningsloven (hfors	ennevnte forskningsp ningsetikk (REK no sknl) § 10.	prosjekt. Søknade ord) i møtet 25.10	en ble behandlet av 0.2018. Vurderinge
Det skal unde kan brukes se resistensutvil med åpen inf brukermedvi mennesker. S vedlagt.	ersøkes, ved hjelp o om eksklusjonsdiag kling knyttet til beh ormasjon undersøk kning og informer tudien skal i sin he	av en randomisert, i gnose for tuberkulos andingen. Tre grup kes med standard di t samtykke. Studien lhet foregå i Malav	kontrollert studie om se. Dette skal vurder per (625 per gruppe jagnostisk tilnærmin, kan forenkle dignos vi. Alle etiske godkje	a respons til bred es opp mot risika e) individuelt ran g. Kun voksne de tikk og klinikk fo nninger fra Mala	spekret antibiotika o for domisert (1:1:1), ltakere, med full r en utsatt gruppe awi og London er
Komiteen vu fvl. § 6.	rderte at Hanne Hu	ısom Haukland var	inhabil og hun fratrå	ådte møtet da sak	en ble behandlet, j
Om prosjek t Prosjektet er	t et en del av en PhD.	Studenten skal avle	gge sin PhD i Londo	on.	
Dette er et sa Medicine, og	marbeidsprosjekt r Universitetet i Tro	nellom Universitete omsø.	et i Malawi, London	School of Hygie	ne and Tropical
Prosjektet sk	al gjennomføres i N	Malawi og er et «Tu	ıberkulose initiativ»	fra Helse Nord.	
Det foreligge	r godkjenning fra l	London School of H	Iygiene and Tropica	l Medicine, og U	niversity of Malav
Data Det skal hen knyttet til inf	tes data fra pasient eksjoner og sykehi	journal og fra lokal istorie.	e poliklinikker. Data	a er standard med	lisinske opplysninį

BMJ Open

1	Data avidentifiseres med koblingsnøkkel. Database oppbevares i 5 år i Malawi.
2	
3	Deltakere/rekruttering
4	voksne denakere fordeles i fre grupper voksne denakere (625 per gruppe), individuelt randomisert.
5	Detakere rekrutteres gjennom benandning på ponkninkkere.
6	PEK har ingen innvendinger til prosiektet
7	KER har nigen hinvendniger en prosjektet
8	Vedtak
9	REK har viort en helhetlig forskningsetisk vurdering av alle prosjektets sider og vodkienner det med
10	hjemmel i helseforskningsloven § 10. REK forutsetter at prosjektet også har godkjenning fra Malawi.
10	
11	
12	Sluttmelding og søknad om prosjektendring
13	Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 21.03.2022, jf. hfl. §
14	12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige
15	endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.
16	
17	Klageadgang
18	Du kan klage på komiteens vedtak, jl. torvaltningstoven § 28 fig. Klagen sendes til REK nord. Klagen sidera til
19	Den nacionale forskningsetiske komité for medisin og belsefag for endelig vurdering
20	Den nasjonale forskningsetiske konnte for medisin og neiserag for endeng vurdering.
20	
21	Med vennlig hilsen
22	May Dwitt Descruell
23	May bill Rossvoll
24	sekretariatsieder
25	
26	
27	Kopi til:jon.oyvind.odland@uit.no
28	
29	
30	
21	
27	
52	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
12	
43	
44	
45	
46	
47	
48	
49	For peer review only - http://bmjopen.bmj.com/site/about/quidelines.yhtml
50	

LONDON

&TROPICAL

HOOLof

٧E

NE

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT

United Kingdom

Switchboard: +44 (0)20 7636 8636

www.lshtm.ac.uk

26

27

43 44

45

46

47

48

49

50 51

52

53 54

55 56

1

2

3

Dr Titus Divala

LSHTM

9 May 2018

Dear Titus,

Study Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance

LSHTM ethics ref: 15232

Thank you for your application for the above research, which has now been considered by the Interventions Committee.

Observational / Interventions Research Ethics Committee

Confirmation of ethical opinion

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

Conditions of the favourable opinion

Approval is dependent on local ethical approval having been received, where relevant.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

Document Type	File Name	Date	Version
Safety Information	ACT_PackageInsertAzithromycin	14/03/2013	JUNE 2013
Safety Information	ACT_PackageInsertAmoxicillin	21/12/2015	DEC 2015
Sponsor Letter	2018-KEP-077_Sponsor Confirmation_13.03.18	13/03/2018	1
Other	GCP Cert_LSHTM_TDivala_21.03.18	21/03/2018	1
Investigator CV	ACT-CV1_TitusDivala	30/03/2018	1
Investigator CV	ACT-CV2_KatherineFielding	30/03/2018	1
Investigator CV	ACT-CV3_LizCorbett	30/03/2018	1
Information Sheet	ACT-20180330InformedConsentEnglish	30/03/2018	1.0
Information Sheet	ACT-20180330InformedConsentChichewa	30/03/2018	1.0
Protocol / Proposal	ACT-20180330Protocol	30/03/2018	1.0

After ethical review

The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application. These must be submitted to the Committee for review using an Amendment form. Amendments must not be initiated before receipt of written favourable opinion from the committee.

The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project by submitting a Serious Adverse Event form.

An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.

At the end of the study, the CI or delegate must notify the committee using an End of Study form.

All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk

Additional information is available at: www.lshtm.ac.uk/ethics

Yours sincerely,

<u>ethics@lshtm.ac.uk</u> <u>http://www.lshtm.ac.uk/ethics/</u>

BMJ Open

BMJ Open

London School of Hygiene & Tropical Medicine

Keppel Street, London WC1E 7HT

United Kingdom

Switchboard: +44 (0)20 7636 8636

www.lshtm.ac.uk





Observational / Interventions Research Ethics Committee	
Dr Titus Divala LSHTM	•
12/04/2019	
Dear Titus,	
Project Title: RCT investigating if benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis in primary care adult patients outweigh the risk of antimicrobial resistance	
Project ID: 15232	
Thank you for your annual report application for the continuation of your research dated 09/04/2019 12:01, which has now been considered by the Chair on behalf of the Ethics Committee.	
Confirmation of ethical opinion	
This application is approved by the committee for a further year.	
Conditions of the favourable opinion	
Approval is dependent on local ethical approval having been received, where relevant.	
After ethical review	_
Any changes to the application must be submitted to the committee via an Amendment form.	Ens
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reaction (SUSARs) which occur during the project by submitting a SUSAR and Protocol Violation form.	eignei
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.	men
At the end of the study, the CI or delegate must notify the committee using an End of Study form.	It Su
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at http://leo.lshtm.ac.uk.	lper
Additional information is available at: www.lshtm.ac.uk/ethics.	ieu
Yours sincerely,	r (AB
AL A A	ES).
Professor John DH Porter	
ethics@lshtm.ac.uk http://www.lshtm.ac.uk/ethics/	
Improving health worldwide	
hno hno	

APPENDIX 2: TRIAL REGISTRATION—DATA SET

NCT Number	NCT03545373
Title	Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
Acronym	ACT-TB
Status	Recruiting
Study Results	No Results Available
Conditions	Tuberculosis Respiratory Tract Infections Pneumonia
Interventions	Drug: Azithromycin Drug: Amoxicillin
Outcome Measures	Diagnostic accuracy of trial-of-antibiotics: Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 against a mycobacteriology reference standard. Overall clinical benefit of empirical antibiotic treatment in primary care participants with chronic cough: proportion of participants experiencing adverse clinical outcomes Impact of trial-of- antibiotics on antimicrobial resistance Diagnostic accuracy of trial-of-antibiotics including participants who did not produce sputum Economic analysis of use of trial-of-antibiotics
Sponsor/Collaborators	London School of Hygiene and Tropical Medicine University of Malawi College of Medicine
Gender	All
Age	18 Years and older (Adult, Older Adult)
Phases	Phase 3
Enrollment	1875
Funded Bys	Other
Study Type	Interventional
Study Designs	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Diagnostic
Other IDs	15232
Start Date	February 25, 2019
Primary Completion Date	Jun-20
Completion Date	Jun-20
First Posted	June 4, 2018
Results First Posted	
Last Update Posted	August 15, 2019
Locations	University of Malawi College of Medicine, Blantyre, Southern, Malawi
Study Documents	
URL	https://ClinicalTrials.gov/show/NCT03545373

Randomised controlled clinical trial investigating benefits of using response to broad spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primary care adult patients versus risk of antimicrobial resistance (AMR)

Short title: Accuracy and Consequences of using Trial-of-antibiotics for TB diagnosis

Acronym: ACT-TB Study

Trial registration:

Protocol version: 4.0, 27 Jan 2020

Titus H Divala
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
Tel: +44 740 523 1847
Email: titus.divala@lshtm.ac.uk
Katherine L Fielding, Neil French, Derek J Sloan, Elizabeth L Corbett
Marriott Nliwasa, Augustine Choko, Ankur Gupta-Wright, Jennifer Cornic,
Jon Øyvind Odland, Chisomo Msefula, Hendramoorthy Maheswaran
London School of Hygiene & Tropical Medicine is the main research sponsor
for this study. For further information regarding the sponsorship conditions,
please contact the Research Governance and Integrity Office:
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
Tel: +44 207 927 2626
Email: RGIO@lshtm.ac.uk
Helse Nord RHF
Tromsø, Norway; Tel: +47 97065144
Email: Hanne.Husom.Haukland@helse-nord.no
University of Malawi College of Medicine
Private Bag 360
Chichiri, Blantyre, Malawi
Tel: +2651871911
First sile was a directed and only and a start
-

2	
3 4	
5	
6 7	
8	
9	
10	
12	
13 14	
15	
16	
17	
19	
20 21	
22	
23	
24 25	
26	
27 28	
29	
30 21	
32	
33	
34 35	
36	
37 38	
39	
40	
41 42	
43	
44 45	
46	
47 48	
40 49	
50	
51 52	
53	
54 55	
56	
57 50	
58 59	
60	

Table of contents

1	Abl	brevia	ations	6
2	Stu	dy S	ummary	8
3	Intr	oduc	tion	11
	3.1	Bad	ckground	11
	3.2	Svs	stematic literature review	13
	3.3	Pla	nned study	15
	0.0	Det		4.5
	3.4	Rat	lionale for current study	15
	3.4	.1	Accuracy of trial-of-antibiotics	15
	3.4	.2	Antimicrobial resistance and trial-of-antibiotics	16
	3.4	.3		17
	3.4	.4	Important subgroups	18
	3.5	Cho	oice of study interventions	19
	3.6	Nas	sopharyngeal pneumococcus for AMR	20
	3.7	Obj	jectives and outcomes	20
4	Stu	dy de	esign, participants, and statistical approach	22
	4.1	Stu	dy design	22
	4 2	Stu	idv setting	22
	7.2	otu		
	4.3	Sta	ndard of care	22
	4.4	Elig	gibility criteria	24
	4.4	.1	Inclusion Criteria	24
	4.4	.2	Exclusion Criteria	24
	4.5	Inte	erventions	24
	4.5	.1	Name and description of intervention arms	24
	4.5	.2	Legal status of drugs used in intervention arms	24
	4.5	.3	Summary of Product Characteristics	24
	4.5	.4	Drug Storage and Supply	25
	4.5	.5	Preparation and labelling of study drugs	25
	4.5	.6	Known drug reactions (adverse events)	25
	4.5	.7	Concomitant medication and interaction with other therapies	25
	4.5	.8	Trial restrictions	25

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
3
4
5
c
6
7
8
0
9
10
11
10
12
13
14
15
15
16
17
18
10
19
20
21
22
23
24
25
25
26
27
28
20
29
30
31
27
52
33
34
35
22
36
37
38
20
39
40
41
12
42
43
44
45
16
46
47
48
10
50
51
52
52
22
54
55
56
50
57
58
59
<u> </u>
ъU

	4.5	5.9	Assessment of compliance	25
	4.5	5.10	Withdraw of interventions	26
	4.6	Stat	istical approach	26
	4.6	6.1	Primary outcome	26
	4.6	6.2	Secondary outcomes	29
	4.6	6.3	Exploratory outcome	30
	4.6	6.4	Planned subgroup analyses	30
	4.7	San	nple size and power	30
	4.7	7.1	Primary outcome 1: specificity of trial-of-antibiotics versus mycobacteriology	30
	4.7	7.2	Primary outcome 2: Incidence of adverse clinical outcome at Day-29	31
	4.7	7.3	Secondary outcomes	32
	4.7	7.4	Exploratory outcomes	32
_				
5	Pilo	ot stud	dy	33
	5.1	Spe	cific objectives of the pilot study	33
	5.2	Рор	ulation for the pilot study	34
	5.3	Pilo	t study procedures	34
	5.4	Data	a analysis	35
6	5.4 Stu	Data Idy pre	a analysis	35 37
6	5.4 Stu 6.1	Data Idy pro Scre	a analysis ocedures	35 37 37
6	5.4 Stu 6.1	Data Idy pro Scro	a analysis ocedures eening	35 37 37 37
6	5.4 Stu 6.1 6.2	Data Idy pro Scro Info	a analysis ocedures eening rmed consent	35 37 37 37
6	5.4 Stu 6.1 6.2 6.3	Data Idy pro Scro Info Bas	a analysis ocedures eening rmed consent eline procedures	35 37 37 37 37
6	5.4 Stu 6.1 6.2 6.3 6.4	Data Idy pro Scro Info Bas Ass	a analysis ocedures eening rmed consent eline procedures ignment of interventions	35 37 37 37 37 38
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5	Data Idy pro Scro Info Bas Ass Blin	a analysis ocedures eening rmed consent eline procedures ignment of interventions	35 37 37 37 37 38 40
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6	Data Idy pro Scro Info Bas Ass Blin Part	a analysis ocedures eening rmed consent eline procedures ignment of interventions iding	35 37 37 37 37 38 40 40
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6 6.6	Data Idy pro Scro Info Bas Ass Blin Part	a analysis ocedures eening rmed consent eline procedures ignment of interventions ding ticipant follow up Day-8 activities	35 37 37 37 37 38 40 40 41
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6 6.6 6.6	Data Idy pro Scro Info Bas Ass Blin Part 5.1	a analysis	35 37 37 37 37 38 40 41 41
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6 6.6 6.6 6.7	Data Idy pro Scro Info Bas Ass Blin Part 5.1 5.2 Lab	a analysis ocedures eening rmed consent eline procedures ignment of interventions ding ticipant follow up Day-8 activities Day-29 activities oratory methods	35 37 37 37 37 38 40 41 41 41
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6 6.6 6.6 6.7 6.7	Data Idy pro Scro Info Bas Ass Blin Part 5.1 5.2 Lab	a analysis ocedures eening rmed consent eline procedures ignment of interventions ding ticipant follow up Day-8 activities Day-29 activities oratory methods	35 37 37 37 37 38 40 41 41 41 41 42 42
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6 6.6 6.6 6.7 6.7 6.7 6.7	Data Idy pro Scro Info Bas Ass Blin Part 5.1 5.2 Lab 7.1 7.2	a analysis ocedures eening med consent rmed consent eline procedures ignment of interventions ding ticipant follow up Day-8 activities Day-29 activities Day-29 activities Tuberculosis mycobacteriology Urine antigen testing for lipoarabamannan and other MTB antigens	35 37 37 37 37 38 40 41 41 41 41 42 42 42
6	5.4 Stu 6.1 6.2 6.3 6.4 6.5 6.6 6.6 6.6 6.7 6.7 6.7 6.7 6.7	Data Idy pro Scro Info Bas Ass Blin Part 5.1 5.2 Lab 7.1 7.2 7.3	a analysis	35 37 37 37 37 38 40 41 41 41 42 42 42 42

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2
2
3
4
5
6
7
, 0
8
9
10
11
12
12
13
14
15
16
17
17
18
19
20
21
∠ I 22
22
23
24
25
25
20
27
28
29
30
50
31
32
33
34
25
35
36
37
38
20
29
40
41
42
<u>4</u> २
-TJ // /
44
45
46
47
10
40
49
50
51
52
52
22
54
55
56
57
57
20
59
60

6.9	Trial closure4	3
6.10	Summary schedule for study procedures4	.3
7 Saf	ety reporting4	15
7.1	Definitions	5
7.2	DMID grading for AEs4	6
7.3	Grading for expected events4	6
7.4	Causality4	8
7.5	Reporting Procedures	.9
7.5	.1 Non-serious Adverse Events (AEs) 4	19
7.5	.2 Serious Adverse Events (SAEs)	19
8 Eco	onomic evaluation	50
8.1	Objective	60
8.2	Outcomes	60
8.3	Data collection	60
8.4	Data analysis	51
8.5	Missing data5	51
9 Dat	a management	52
9.1	Source Data	52
9.2	Data collection methods	52
9.3	Data management5	52
9.4	Quality control and quality assurance	;3
9.5	Access to data5	;3
10 E	Data monitoring and quality assurance5	54
10.1	Data monitoring5	;4
10.2	Audits and Inspections5	;4
10.3	Data Safety and Monitoring Board (DSMB)5	;4
10.4	Trial Management Group (TMG)5	;4
10.5	Trial Investigational Team5	5

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3	
4	
5	
6	
/	
ð 0	
10	
11	
12	
13	
14	
15	
16	
17	
19	
20	
21	
22	
23	
24	
25 26	
27	
28	
29	
30	
31	
32 33	
34	
35	
36	
37	
38	
39	
40 41	
42	
43	
44	
45	
46	
47 48	
49	
50	
51	
52	
53	
54 55	
56	
57	
58	
59	

1 2

11	Ethics and dissemination
11.1	Risk assessment
11.2	Research ethics approval
11.3	Indemnity57
11.4	Sponsor
11.5	Declaration of interests
11.6	Cost of participation, ancillary and post-trial care57
11.7	Dissemination policy
12	References
13	Appendix 1: Informed consent
14	Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table 62
15	Appendix 3: Package insert for Azithromycin and amoxicillin74

thromycin .

ACASI	Audio Computer Assisted Self-Interview
AE	Adverse Event
AMR	Antimicrobial Resistance
AR	Adverse Reaction
ART	Antiretroviral Therapy
CD4	Cluster of Differentiation 4
CEACs	Cost-Effectiveness Acceptability Curves
COMREC	University of Malawi College of Medicine Research and Ethics Committee
CXR	Chest X-Ray
DMID	Division of Microbiology and Infectious Diseases
DSMB	Data Safety and Monitoring Board
GLM	Generalised Linear Model
HIV	Human Immunodeficiency Virus
HRQoL	Health Quality of Life
LAM	Urine Lipoarabinomannan Assay
LJ	Lowenstein-Jensen
LSHTM	London School of Hygiene & Tropical Medicine
MDA	Mass Drug Administration
MGIT	Mvcobacteria Growth Indicator Tube

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ACT-TB Study Protocol V4.1, 27 Jan 2020
MIB or M.tb	Mycobacterium tuberculosis
NMBs	Net Monetary Benefits
NTM	Non-Tuberculous Mycobacteria
NTP	National Tuberculosis Control Program
NTS	Non-Typhoidal Salmonellae
PCP	Pneumocystis Jiroveci
PLHIV	People Living With HIV
PTB	Pulmonary Tuberculosis
QALY	Quality-Adjusted Life Year
RCT	Randomized Controlled Trial
SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SOC	Standard of Care
STGG	Skim Milk Tryptone Glucose Glycerol
SUSAR	Suspected Unexpected Serious Adverse Reaction
ТВ	Tuberculosis
TMG	Trial Management Group
WHO	World Health Organization
WTP	Willingness to Pay

Title	Randomised controlled clinical tri	al investigating benefits of using response to broad				
	spectrum antibiotics as an exclusion diagnostic for tuberculosis (TB) in primarv care					
	adult patients versus risk of antimicrobial resistance (AMR)					
Design	Three arm (625 per arm) individu	ally randomised (1:1:1), open-label controlled clinical				
	trial investigating standard care diagnostic approach for tuberculosis. The trial will not					
	use any unlicensed products.					
Objective		Outcomes				
Primary						
1. To establi	sh the diagnostic value of trial-of-	Proportion of participants correctly classified as PTB				
antibiotics fo	r excluding pulmonary	negative based on report of improvement of baseline				
tuberculosis	(PTB) in adults with prolonged	symptoms on study Day-8 (i.e. after a trial-of-				
cough (and h	nave a valid sputum test result) at	antibiotics if in azithromycin or amoxicillin arms, or				
primary care	level in Malawi.	without antibiotics if in standard of care arm) against a				
		mycobacteriology reference standard, among				
		participants with a valid result from at least one				
		sputum TB test				
2. To determ	ine the overall clinical benefit of	Proportion of participants experiencing at least one of				
giving empiri	cal antibiotic treatment in primary	the following adverse outcomes by Day 29:				
care particip	ants with chronic cough.	1) death				
		2) hospitalisation				
		3) missed TB diagnosis				
		o) missed ib diagnosis				
Secondary						
	· · · · · · · · · · · · · · · · · · ·					
	te using nasopharyngeal	Proportion of Day 29 nasopharyngeal Streptococcus				
3. To evalua					
3. To evalua Streptococcu	us pneumonia, the effect of a trial-	<i>pneumoniae</i> isolates resistant to commonly used				
3. To evalua Streptococcu of-antibiotics	us pneumonia, the effect of a trial- on selection for antimicrobial	<i>pneumoniae</i> isolates resistant to commonly used antimicrobials.				
3. To evalua Streptococcu of-antibiotics resistance.	us pneumonia, the effect of a trial-	<i>pneumoniae</i> isolates resistant to commonly used antimicrobials.				
 To evalua Streptococcu of-antibiotics resistance. To establi 	us pneumonia, the effect of a trial- on selection for antimicrobial sh the diagnostic value of trial-of-	<i>pneumoniae</i> isolates resistant to commonly used antimicrobials. Proportion of participants correctly classified as PTB				
 To evalua Streptococcu of-antibiotics resistance. To establi antibiotics fo 	us pneumonia, the effect of a trial- on selection for antimicrobial sh the diagnostic value of trial-of- r excluding pulmonary	<i>pneumoniae</i> isolates resistant to commonly used antimicrobials. Proportion of participants correctly classified as PTB negative based on report of improvement of baseline				
 To evalua Streptococcu of-antibiotics resistance. To establi antibiotics fo tuberculosis 	us pneumonia, the effect of a trial- s on selection for antimicrobial sh the diagnostic value of trial-of- r excluding pulmonary (PTB) in primary care presenting	<i>pneumoniae</i> isolates resistant to commonly used antimicrobials. Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-				
 To evalua Streptococcu of-antibiotics resistance. To establi antibiotics fo tuberculosis Malawian ad including the 	us pneumonia, the effect of a trial- s on selection for antimicrobial sh the diagnostic value of trial-of- r excluding pulmonary (PTB) in primary care presenting ults with prolonged cough	pneumoniae isolates resistant to commonly used antimicrobials. Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of- antibiotics if in azithromycin or amoxicillin arms, or				

test (unable to	o submit sputum and those with	randomised participants, with those who could not				
invalid sputum results).		provide sputum or had an invalid sputum result				
		classified as mycobacteriologically negative.				
5. To estimate	e the incremental cost-	Incremental cost per quality adjusted life year				
effectiveness	of trial-of-antibiotics using	gained				
azithromycin	and trial-of-antibiotics using	Total direct medical costs per participant over				
amoxicillin in	comparison to standard of care,	56 days				
and to each c	ther.	Eq-5D utility score				
Exploratory						
Our explorato	ry analyses will be comparisons be	etween the azithromycin and amoxicillin arms for all our				
primary and s	econdary outcomes.					
Population	Adults presenting to primary care	e centres in Malawi reporting cough.				
	Inclusion criteria:					
	 Ambulatory clinic attendees presenting with cough 					
	 Should have been ill for ≥ 14 days 					
	Aged at least 18 years					
	• Reside in Blantyre and willing to return to the same clinic for follow up visits over					
	the entire study period.					
	Exclusion criteria:					
	Self-reported allergy to study medications					
	Acute danger signs defined in national TB treatment guidelines					
	Tuberculosis treatment or	tment or isoniazid preventive therapy in the last 6 months				
	• Treated with antibiotics, o	ther than co-trimoxazole prophylaxis, for the current				
	illness or within the past 14 days					
Treatment	Arm 1 : Azithromycin 500mg once daily for 3 days commencing on randomization day.					
	Arm 2: Amoxicillin 1 g 3 times daily for 5 days commencing on randomization day.					
	Arm 3: Standard of care in current national guidelines for patients presenting with cough					
	and without danger signs (No treatment until re-evaluation with sputum TB test results)					
Duration	We will give treatments on the randomisation day (Day-1) and perform follow up					
	activities on days 8, and 29.					

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

3 Introduction

3.1 Background

Antimicrobial resistance is a growing crisis, becoming in 2016 one of only four health topics ever to be discussed at the United Nations General Assembly.¹⁻⁴ Tuberculosis is the leading global infectious cause of death in adults,⁵ with approximately 10.4 million cases and 1.8 million deaths in 2015.⁶ The high case-fatality rate in part reflects suboptimal diagnostics(Figure 2).⁷⁻¹⁰



Figure 2: method of diagnosis for TB notifications globally (A) and in Blantyre, Malawi (B)

To complement the suboptimal diagnostics, standard diagnostic algorithms in resource-limited settings include a "trial-of-antibiotics" (Figure 3). This is a course of broad-spectrum antibiotics, with negligible *Mycobacterium tuberculosis* activity, given to patients with symptoms such as cough in order to "rule-out" or "rule in" tuberculosis.¹¹⁻¹³ Patients with negative sputum mycobacteriology and responded to antibiotic treatment are considered tuberculosis negative while those who remain symptomatic are deemed likely to have tuberculosis and undergo further evaluations leading on to receiving tuberculosis treatment.



Figure 3: Implementation of trial-of-antibiotics (marked with red boxes) in Malawi TB diagnostic algorithm, National TB control program (NTP)

Approximately 26.5 million course of antibiotics are prescribed in the diagnosis of the 5.3 million smear negative tuberculosis registrations per annum (Figure 4).⁶ This estimate is based on an average of 5 antibiotic courses per sputum-negative treatment initiation, with 2 courses given to the patients before tuberculosis treatment,⁸ and the other 3 courses accounting for patients whose symptoms resolved and tuberculosis was ruled out.¹⁴.

Wilkinson et al¹⁴ prescribed 120 + 74 courses of trial-of-antibiotics to diagnose 40 smear-negative TB patients (a typical ratio of ~1:5).⁸ If generalizable, then for 5.3 million annual smearnegative TB registrations globally ~5 x 5.3 million trial-of-antibiotics courses (26.5 million) will have been prescribed.

Enrolled	280	
TB smear microscopy positive		160
Given trial-of-antibiotics (amoxicillin)	120	
Improved, declared TB negative		46
Given trial-of-antibiotics (erythromycin)	74	
Improved, declared TB negative		34
Treated for smear negative TB	40	
	0000	
vviikinson et.al int J-i uberc Lung Dis. 1	2000	

Figure 4: Quantifying number of trial-of-antibiotics courses prescribed per year using data from Wilkinson et.al and WHO TB Report 2016

Despite this widespread use, there is no randomised controlled trial evidence supporting the diagnostic accuracy of trial-of-antibiotics. There is also a dearth of evidence on their impact on antimicrobial resistance or patient clinical outcomes.

3.2 Systematic literature review

We performed a systematic literature review to determine the sensitivity and specificity of using a trial-of-antibiotics compared to sputum mycobacteriology for diagnosis of PTB. We also wanted to describe how trial-of-antibiotics tits into TB diagnostic algorithms: timing of prescription; type, duration, and number of antibiotic prescriptions; and how response to treatment is measured. We searched MEDLINE, Embase, and Global Health using the Ovid platform to identify studies meeting the following criteria:

2
3
1
4
5
6
7
, 0
0
9
10
11
10
12
13
14
15
16
10
17
18
19
20
20
21
22
23
24
24
25
26
27
-/ 20
20
29
30
31
22
52
33
34
35
26
50
37
38
39
10
40
41
42
43
ΔΔ
45
45
46
47
48
40
49
50
51
52
52
22
54
55
56
50
5/
58
50

60

Population	Adult patients with symptoms suggestive of pulmonary tuberculosis
Intervention	Routinely prescribed broad-spectrum oral antibiotics without MTB activity,
	and given as part of evaluation of pulmonary TB
Outcome	sensitivity and specificity of the intervention in comparison with any
	mycobacteriology test
Study design	Any design with prospective component allows evaluation of the outcome
	of the intervention
Time frame	Studies published after WHO declaration of TB as a 'global emergency'
	(1993)
Language	English, lack of translation capacity

We identified 7,064 articles from a systematic search on MEDLINE, Embase, and Global Health using the Ovid platform. Of these studies, 12 were eligible for narrative synthesis and seven had suitable data for meta-analysis. None of the studies was an RCT and all the observational studies were small and not primarily designed to address the benefits and consequences of trial-of-antibiotics. Unlike our proposed RCT, most of the published work was from hospital setting or in specialised clinics. Most studies used amoxicillin and some studies prescribed a subsequent course of antimicrobials either before or after assessing for improvement. The definition of improvement from baseline clinical state was largely subjective: it was based on self-report, clinical examination, radiological assessment or a combination.

There is no consensus on the sensitivity and specificity of trial-of-antibiotics across studies with estimates ranging from 43% to 91% for sensitivity and 41% to 82% for specificity (shown below).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3
4
5
6
7
, 8
a
10
11
12
12
17
14
15
10
10
10
יקו 20
∠∪ 21
∠ I 22
22
∠⊃ ⊃4
24
25
20
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60

1

Population, Study		Sensiti	ivity, 95%	% CI	Specificity, 95% Cl			
237	Wilkinson et al 1997	0.5	0.37	0.64	0.82	0.76	0.87	
120	Wilkinson et al 2000	0.83	0.71	0.91	0.56	0.44	0.67	
204	Kudjawu et al 2006	0.91	0.83	0.96	0.65	0.56	0.73	
1000	Kamran et al 2006	0.72	0.62	0.8	0.41	0.38	0.44	
264	Soto et al 2011	0.43	0.32	0.55	0.68	0.63	0.72	
439	Soto et al 2013	0.46	0.34	0.58	0.6	0.53	0.66	
440	Padmapriyadarsini et al 2	0.7	0.55	0.8	0.69	0.64	0.73	

We could not identify any RCT, the current literature only has small studies, with trial-of-antibiotics not being the primary focus of investigation in most cases. There is limited data for primary care settings as most of the work was in hospital setting. None of the studies addressed AMR. Therefore, despite widespread use, the approach, the value and consequences of having trial-of-antibiotics in TB diagnostic algorithms, remains to be established.

3.3 Planned study

To address the evidence gaps related to a) accuracy, b) antimicrobial resistance, and c) impact on clinical outcomes), we propose to conduct a randomised controlled clinical trial recruiting adult patients presenting to primary care centres in Blantyre, Malawi with history of cough for at least 2 weeks. After excluding those with danger signs we will randomise participants to receiving or not receiving trial-of-antibiotics (azithromycin or amoxicillin) from Day-1 to determine diagnostic accuracy (specificity) against mycobacteriology reference standard (smear microscopy, Xpert/MTB/RIF and culture).

For secondary outcomes, we will also compare between arms differences in antimicrobial resistance and clinical outcomes (risk of death, hospitalisation, and missed TB diagnosis) at Day-29. To our knowledge this will be the first randomised controlled trial to address these questions in over 20 years of systematic use of trial-of-antibiotics without strong evidence base.

3.4 Rationale for current study

3.4.1 Accuracy of trial-of-antibiotics

BMJ Open

 As an approach that is being used on such a large scale, trial-of-antibiotics should ideally have a strong evidence-base (supported by reference mycobacteriology) of how much diagnostic and/or clinical improvement it brings to the TB diagnostic algorithm.^{15,16} This will be among the most important considerations when deciding whether it is worth the trade-off with potential for AMR. Such evidence could come from an RCT or a well-designed prospective study.¹⁵⁻¹⁷ However, despite being in use for more than 20 years, we have not identified any such clinical trial, and even the observational evidence is highly limited and of insufficient quality and quantity to definitively address the question.

There is also no guidance on antibiotic choice beyond a recommendation to avoid those with antituberculosis activity (like fluoroquinolones). Another key area that lacks clarity is lack of a clear definition for clinical resolution when determining the outcome of trial-of-antibiotics. Clinical resolution is the basis for decisions that follow (i.e. discontinue follow up or proceed Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance can be either intrinsic or acquired. The risk of acquired resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been previously investigated, although previous work has shown that empirical antibiotics can drive rapid emergence of AMR.^{18,19} For example, co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010.²⁰ Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

In our study, the AMR risks of empirical antibiotic prescriptions (azithromycin and amoxicillin arms of the RCT) are justified because of the widespread use of this approach for amoxicillin, and the low potential clinical impact and short-lived effects of use of azithromycin on AMR, given the limited use of macrolides in Malawi. Mathematical modelling work suggests that macrolide resistance can successfully be eliminated by intra-species competition alone (fitness cost) within 5 years of last use.²³

3.4.2 Antimicrobial resistance and trial-of-antibiotics

Antimicrobial resistance relating to antibiotic use during evaluation for suspected tuberculosis has not been investigated before. Previous work has shown that empirical antibiotics can drive rapid emergence of antimicrobial resistance.^{18,19} Co-trimoxazole prophylaxis for HIV-positive patients, introduced in 2005, was followed by near-universal resistance in bloodstream infections by 2010²⁰ also shown in Table 1. Mass drug administration of azithromycin for trachoma control initially reduces nasopharyngeal carriage of *Streptococcus pneumoniae*, but with increased macrolide-resistance 6 months later.^{21,22}

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

We will investigate antimicrobial resistance in nasopharyngeal *S. pneumonia* by randomisation arm and cumulative antibiotic exposure to assess the extent to which brief exposure drives antimicrobial resistance during diagnostic work-up for tuberculosis. An ecological niche for many bacterial species, the upper respiratory tract also presents a convenient window for investigating antimicrobial resistance.²⁴ *S. pneumonia* is the organism of choice not only for being an important cause of respiratory tract infections but also because it often colonises the upper respiratory tract and has well documented laboratory investigation procedures in place.²⁵ As exploratory analyses, we will also assess nasopharygeal colonization and antimicrobial resistance in relation to tuberculosis treatment and HIV status.

Table 1 Resistance patterns of common aetiologies of pneumonia to commonly used antimicrobials in Blantyre, Malawi

		Gram	Gram positive		Gram negative			
0		Streptococcus	Staphylococcu		Haemophilu	Klebsiella	Escherichia	Pseudomona
Organism		pneumoniae	s aureus		s influenzae	pneumoniae	coli	s aeruginosa
Prevalence		15.6%	6.6%		0.9%	4.4%	0.1%	1.5%
	amoxicillin	*	*		58%	100%	94%	100%
	penicillin	21%	*		*	*	*	*
	co-trimoxazole	98%	40%		100%	92%	94%	75%
Resistance	chloramphenicol	21%	2%		92%	48%	61%	100%
percentage	Erythromycin	2%	30%		*	*	*	*
	tetracycline	38%	35%		*	*	*	*
	Ceftriaxone	*	*		0%	90%	30%	100%
	Ciprofloxacin	*	*		NA	705	31%	24%

*not routinely tested

2016 data from hospitalised febrile patients at Queen Elizabeth central hospital (Blantyre, Malawi) as reported by the MLW Clinical research laboratory (unpublished).

3.4.3 Potential benefits of antibiotics

In areas with high HIV prevalence, empirical antibiotics during tuberculosis investigations could be life-saving: mortality immediately before and after tuberculosis diagnosis is high, ^{7,26} and is often secondary to severe bacterial infections.²⁶⁻²⁸ The leading aetiologies of infection and death on tuberculosis treatment as well as among outpatients with tuberculosis-like symptoms are *Streptococcus pneumoniae* and non-typhoidal salmonellae (NTS): both can present with cough (primary cause) or as co-morbidities (super-infections) in patients presenting with active *Mycobacterium tuberculosis* (*M.tb*) disease.²⁶⁻²⁸ If effective treatment of this type of life-threatening primary/super-infections reduces mortality during the diagnostic work-up of suspected TB in people living with HIV (PLHIV), then empirical use of broad-spectrum antibiotics would be indicated for this purpose alone, irrespective of any diagnostic contribution to TB treatment decisions. In this context, azithromycin may be the most effective arm, as Salmonella infections are highly sensitive to azithromycin, but not to amoxicillin.²⁹

3.4.3.1 Measures of clinical benefit of trial-of-antibiotics

In this study, we will investigate the overall clinical benefit of trial-of-antibiotics by comparing the risk of any of death, hospitalisation, and missed TB diagnosis by Day 29. Although all these events are potential consequences of trial-of-antibiotics, grouping them as a single composite endpoint may only appropriately represent the effect of the intervention 1) there are similarities in the importance patients would attach to each of its components and 2) the components occur with similar frequencies in the patient population.³⁰

The impact of antibiotics on hospitalisation and mortality causing illnesses is as described above. Both these outcomes are important with their similarity hinged on the fact that hospitalisation event predicts mortality. In patients with chronic cough, frequencies of mortality and that of hospitalization over a two months period are similar, ranging from 2 to 6%.³¹

TB misdiagnosis becomes a concern because of the potential for misclassification in either direction –false positive or false negative. False positive diagnosis in the context of trial-of-antibiotics would occur when the underlying pathology for the respiratory symptoms is not responding to the antibiotic, which can be secondary to either AMR or the illness not being of bacterial origin. On the other hand, patients would be prone to a false negative result had both TB and a susceptible bacterial infection. If the symptoms were largely driven by the susceptible bacterial infection, their symptoms will improve and would be declared TB negative. TB is a life-threatening illness, missing its diagnosis can therefore lead to death which is more important to an individual patient than taking TB chemotherapy with a false positive TB diagnosis. We will therefore include only missed TB diagnoses in the composite clinical outcome. Unpublished data from Blantyre shows that the frequency of missed TB diagnosis under routine care settings is approximately 5% which is similar to that of death and hospitalisation.

3.4.4 Important subgroups

Response to trial-of-antibiotic- in patients with bacteriologically confirmed tuberculosis (i.e. falsenegatives/low sensitivity from the perspective of TB diagnosis) may relate to multiple superinfections and so this phenomenon may vary by HIV status, since multiple concurrent infections are a hallmark of advanced HIV immunosuppression, and commonly identified in patients with suspected TB in the pre-ART era.^{8,27} More recently, in Malawi, 45% of adults who presented to primary care with prolonged cough (≥2 weeks) were HIV-positive, of whom only ~20% started TB treatment on the basis of positive mycobacteriology.³¹ As such, the benefits and consequences of trial-of-antibiotics may vary by HIV status and by subsequent TB treatment decisions. We will, therefore, include a pre-specified sub-analysis of trial outcomes stratified by HIV and ART status.

3.5 Choice of study interventions

Our trial will compare azithromycin and amoxicillin to standard of care. We propose 2 different antibiotic arms for the following reasons: -

a) Macrolides, including azithromycin, are rarely used in Malawi because of their higher manufacturing costs. However, they do provide a more effective treatment of communityacquired pneumonia than the standard antibiotic by Ministry of Health for trial-of-antibiotic (amoxicillin), because of low levels of acquired macrolide-resistance in bacterial isolates in Malawi,²⁹ reflecting low rates of past exposure to this class of drugs, and also better intrinsic coverage of "bacterial cause of pneumonia including "atypical" intracellular organisms such as *mycoplasma* species.

Although viral pneumonias, *Pneumocystis jiroveci* (PCP) and non-infectious causes of cough will still not be expected to respond to azithromycin, this arm should then provide the highest possible diagnostic discrimination for bacterial vs mycobacterial causes of cough. The starting point of low pre-existing (acquired) resistance will also facilitate investigation of AMR acquired during trial-of-antibiotics. However, the trial will have limited national relevance in Malawi without comparison to an antibiotic in programmatic use.

b) Amoxicillin is low cost option that is still a recommended treatment for community-acquired pneumonia in most settings, including UK, despite potential treatment failure from bacterial pneumonia due to organisms with intrinsic ("atypicals") or acquired (common in gram-negative organisms, and *Staphylococcus aureus*) penicillin resistance.²⁹ This arm reflects the true standard of care (SOC) currently in widespread use in Malawi and many other low-income countries, and so provides data of immediate programmatic relevance and also a starting point to investigate exacerbation of pre-existing AMR pressure. If there is a marked difference between the azithromycin and amoxicillin arms, then there will also be important health economic considerations of relevance to many national TB programmes beyond Malawi.

Azithromycin provides effective treatment for community-acquired pneumonia³²⁻³⁴ and has negligible activity against *M.tb.*^{35,36} As discussed above, macrolides are not commonly used in Malawi. Azithromycin has an excellent safety profile and is used for mass drug administration (MDA) in communities prone to trachoma. Azithromycin used for MDA in Ethiopia reduced inter-current infections^{21,37} and death in children,^{38,39} supporting the safety of using this drug for our trial.⁷

Amoxicillin is the first line treatment for outpatient management of pneumonia in Malawi and is commonly used for trial-of-antibiotics. We anticipate higher specificity for azithromycin than amoxicillin, due to broader coverage of "atypical pneumonia" organisms, and salmonella species, Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

60

but with the 2 antibiotics arms having "equipoise" due to lack of previous head-to-head comparison.²⁷

3.6 Nasopharyngeal pneumococcus for AMR

Streptococcus pneumonia is a major cause of morbidity and mortality in children and adults.^{20,29,40,41} Asymptomatic nasopharyngeal carriage of *S. pneumoniae* is common and a prerequisite for the occurrence and transmission of invasive pneumococcal disease.^{42,43} Since carriage is more common than the invasive *S. pneumoniae* disease it forms a basis for establishing circulating serotypes, resistance patterns, and evaluation of vaccine effectiveness.

The other key advantage is the existence of globally accepted laboratory procedures for assessing and interpreting pneumococcal resistance. Our laboratory (in Malawi-Liverpool Wellcome Trust) has carried out pneumococcal work for decades with outstanding quality assurance reputation.

3.7 Objectives and outcomes

In Table 2 below, we present study objectives together with corresponding outcomes. We have clarified the outcomes with detailed definitions and planned analyses under "statistical approach" section.

Objective Outcome **Primary** 1. To establish the diagnostic value of Proportion of participants correctly classified as PTB trial-of-antibiotics for excluding negative based on report of improvement of baseline pulmonary tuberculosis (PTB) in adults symptoms on study Day-8 (i.e. after a trial-ofwith prolonged cough (and have a valid antibiotics if in azithromycin or amoxicillin arms, or sputum test result) at primary care level without antibiotics if in standard of care arm) against a in Malawi. mycobacteriology reference standard, among participants with a valid result from at least one sputum test 2. To determine the overall clinical Proportion of participants experiencing at least one of benefit of giving empirical antibiotic the following adverse outcomes by Day 29: treatment in primary care participants 1) death 2) hospitalisation with chronic cough. 3) missed TB diagnosis

Table 2: study objectives and outcomes

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Secondary			
Secondary			
3. To evaluate using nasopharyngeal	Proportion of Day 29nasopharyngeal Streptococcus		
Streptococcus pneumonia, the effect of	pneumoniae isolates resistant to any of commonly		
a trial-of-antibiotics on selection for	used antimicrobials.		
antimicrobial resistance.			
4. To establish the diagnostic value of	Proportion of participants correctly classified as PTB		
trial-of-antibiotics for excluding	negative based on report of improvement of baseline		
pulmonary tuberculosis (PTB) in	symptoms on study Day-8 (i.e. after a trial-of-		
primary care presenting Malawian	antibiotics if in azithromycin or amoxicillin arms, or		
adults with prolonged cough including	without antibiotics if in standard of care arm) against a		
those without a successful sputum test	mycobacteriology reference standard, among all		
(unable to submit sputum and those	randomised participants, with those who could not		
with invalid sputum results).	provide sputum or had an invalid sputum result		
0	classified as mycobacteriologically negative.		
5. To estimate the incremental cost-	Incremental cost per quality adjusted life year		
effectiveness of trial-of-antibiotics using	gained		
azithromycin and trial-of-antibiotics	Total direct medical costs per participant over		
using amoxicillin in comparison to	56 days		
standard of care, and to each other.	Eq-5D utility score		
Exploratory			
Our exploratory analyses will be comparis	sons between the azithromycin and amoxicillin arms for		
all our primary and secondary outcomes.			

4 Study design, participants, and statistical approach

4.1 Study design

This is a three arm (625 per arm) individually randomised (1:1:1), open-label controlled clinical trial investigating accuracy and broader clinical, and antimicrobial resistance impact of using trial-ofantibiotics to "rule out" tuberculosis among adults presenting with cough at primary care centres in Malawi.

4.2 Study setting

We will screen adults aged at least 18 presenting to primary care centres in Blantyre, Malawi. Blantyre has an estimated adult HIV prevalence of 12.7% (95% CI: 11.9 to 13.6) and an estimated tuberculosis prevalence of 1,014 per 100,000 (95% CI: 486 to 1,542).⁴⁴

4.3 Standard of care

The standard of care in national guidelines from the NTP for primary care patients presenting with cough and are otherwise well (no danger signs) is to take sputum x 2 for smear microscopy or Xpert and ask them to return for results, typically 3 days - 1 week later (Figure 3 and 5). The Malawi tuberculosis diagnostic algorithm recommends use of broad-spectrum antibiotics as trial-of-antibiotics after negative sputum tests are provided to the patient, if they remain symptomatic.

However, more commonly this algorithm is adapted in the outpatient setting to combine prescription of antibiotics (usually amoxicillin) with sputum collection at the first visit, to save the patient from making separate visits: thus, our amoxicillin arm is the most common standard-of-care in Malawi, while the no-antibiotic arm is the NTP recommended standard-of-care.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



BMJ Open

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ACT-TB Study Protocol V4.1, 27 Jan 2020

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

4.4 Eligibility criteria

We will offer enrolment to patients who satisfy the following inclusion and exclusion criteria.

4.4.1 Inclusion Criteria

- Ambulatory clinic attendees presenting with cough for at least 14 days
- No previous formal consultation for current illness (initial presentation)
- Aged at least 18 years
- Reside in Blantyre and willing to return to the same clinic for follow up visits over the entire study period.

4.4.2 Exclusion Criteria

- Self-reported allergy to study medications
- Danger signs (WHO/Malawi NTP): respiratory rate > 30/min, temperature >39°C, Heart rate >120/minute, confused/agitated, respiratory distress, systolic blood pressure <90 mmHg, inability to walk unassisted
- Treated with antibiotics other than co-trimoxazole prophylaxis within the past 14 days
- TB treatment or Isoniazid preventive therapy within the last 6 months

4.5 Interventions

We will have two active study arms receiving trial-of-antibiotics at enrolment (azithromycin and amoxicillin) and a standard of care arm of no trial-of-antibiotics. In this study, the goal is to investigate the role of these antibiotics as they are used in TB diagnostic algorithms, as "trial-of-antibiotics," to exclude TB in symptomatic patients. The study is likely to be underpowered to detect differences between the 2 antibiotic arms will only be compared for exploratory outcomes.

4.5.1 Name and description of intervention arms

The study will have three arms as follows:

- Arm 1: Immediate trial-of-antibiotics with Azithromycin 500mg once daily for 3 days.
- Arm 2: Immediate trial-of-antibiotics with Amoxicillin 500 mg 3 times daily for 5 days.
- Arm 3: Standard of care

4.5.2 Legal status of drugs used in intervention arms

Both azithromycin and amoxicillin are registered for use in Malawi and United Kingdom, with both Arms 1 and 2 regimens being UK-recommended community-acquired pneumonia treatment.

4.5.3 Summary of Product Characteristics

Appendix 3 includes current versions of package insets for azithromycin and amoxicillin. We will review and update (when applicable) the package inserts annually with each ethics continuing review.

4.5.4 Drug Storage and Supply

 We will procure study products from Durbin PLC (DURBIN PLC 180 Northolt Road South Harrow Middlesex HA2 0LT). Azithromycin will be manufactured by Sandoz limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Amoxicillin will be manufactured by Medopharm private limited or other pharmaceutical companies recognised in United Kingdom where Durbin is based. Both azithromycin and amoxicillin are stable at room temperature. We will therefore ship and store in ambient conditions.

4.5.5 Preparation and labelling of study drugs

Study products will be stored at Malawi Liverpool Wellcome Trust Pharmacy. The pharmacy team will be responsible for packing and labelling.

4.5.6 Known drug reactions (adverse events)

Azithromycin and amoxicillin are already widely used in Malawi and are well tolerated. Rare side effects for azithromycin include nervousness, dermatologic reactions including Stevens–Johnson syndrome, anaphylaxis and prolonged QT interval. Rare side-effects for amoxicillin are mental state changes, light-headedness, photosensitivity and severe allergic reactions.

4.5.7 Concomitant medication and interaction with other therapies

We do not have any restrictions with respect to concomitant medications apart from those listed in the exclusion criteria. We expect some participants to be on HIV antiretroviral drugs and some may subsequently start tuberculosis therapy. Important interactions therefore would be those with HIV antiretroviral drugs and tuberculosis therapy. There is no moderate or major interaction between either azithromycin or amoxicillin with the classes of HIV antiretroviral drugs, tuberculosis therapy, and antimalarial drugs used in Malawi.

4.5.8 Trial restrictions

We do not require participants to have any dietary restrictions. We will also accept co-administration with contraception. Our trial interventions can safely be used in pregnancy, so we will include pregnant women should they be eligible.

4.5.9 Assessment of compliance

On Day-8, we will document self-reported compliance adherence of study products.

4.5.10 Withdraw of interventions

The investigator may also terminate a participant from study product if indicated by an adverse reaction. If a participant stops taking study product either voluntarily or by investigator decision, they will be encouraged to remain in follow up and their data will form part of intention to treat analyses.

4.6 Statistical approach

We will summarise the processes of recruitment including non-eligibility and reasons of exclusion in a CONSORT flow chart. We will describe the study participants by their baseline characteristics which we will report for each arm. We will perform analyses of all our outcomes based on an intention to treat analysis (using the arm patient was randomised to), adjusting for centre. We will make the following comparisons:

- i) azithromycin or amoxicillin versus standard of care
- ii) azithromycin versus standard of care
- iii) amoxicillin versus standard of care

We will perform data cleaning and analysis using Stata release 15 (Stata Corp, College station, Texas, USA).

The following are descriptions of each outcome and corresponding statistical approach. The statistical approach will be expanded in a detailed statistical analysis plan, separate to the protocol, which will be finalised before unblinding the study data.

4.6.1 Primary outcome

The clinical trial has two separately powered, and distinctly assessed primary outcomes, one for diagnostic evaluation (Primary outcome 1: Day 8) and the other for clinical impact (Primary outcome 2: Day 29) of the intervention.

4.6.1.1 Primary outcome 1: Specificity of day 8 symptom change versus mycobacteriology

Investigational test

The investigational test is change in symptoms at Day 8 categorised as: improved or not improved (no change plus worsened) in response to the following question: *on day 1, you reported that you were unwell; compared to that day, has your illness worsened, remained the same, or improved?*

To minimise ascertainment bias in ascertaining this endpoint, the evaluation of improvement of baseline symptoms will be captured using a self-interview platform: Audio Computer Assisted Self-Interview (ACASI). After orientation, the participant will be left alone in the room to interact with the

computer. ACASI on Day-8 will precede all other interaction with research staff and clinical assessment/decision making. We will report ACASI interview outcome as:

- ACASI-test-negative if the participant reports improvement
- ACASI-test-positive if the participant reports no change or worsening.

Reference test

Mycobacteriology reference standard will be defined in participants with at least one specimen with a valid result on days 1 and 8 as:

- **Sputum-test-positive**: if at least one positive smear microscopy, Xpert/MTB/RIF, or MTB culture on sputum samples taken.
- **Sputum-test-negative**: none of the day 1 and day 8 sputum samples are positive on smear microscopy, GeneXpert MTB/RIF, or MTB culture.

To minimise bias, the mycobacteriology will be performed by a high-quality research laboratory in the University of Malawi College of Medicine by staff with no access to participant treatment allocation information or ACASI results.

The diagnostic assessment outcome

 Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 ACASI against a mycobacteriology reference standard (b+d in Figure 6). Using the investigational test and reference test described above, this can be rewritten as: proportion of sputum-test-negative participants who are ACASI-test-negative.

1

Reference Result: any positive smear microscopy, Xpert/MTB/RIF, or <u>MTB Culture</u> from sputum samples collected on Day 1 and Day 8

ว	
2	
د ∡	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
10	
10	
19	
2U	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
31	
25	
22	
30 27	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
22	
54 57	
55	
56	
57	
58	
59	
60	

	visit defines tuderculos	is-lest-positive	
		Sputum-test- positive	Sputum-test- negative
ACASI* Response on Day 8 ACASI test is defined by response to the following question asked using ACASI on Day 8: on day 1, you reported that you were unwell:	ACASI-test-positive (worse or no change)	а	b
compared to that day, has your illness <u>worsened</u> , <u>remained the</u> <u>same</u> , or <u>improved</u> ?	ACASI-test negative (Improved)	C	d
Primary outcome: specificity, cal	culated by d / (b+d)		

*Audio Computer Assisted Self-Interview (ACASI) in which the participant, after a how-to-use test session, responds to the prescribed question on a database-linked android tablet, without any human interaction, and in private.

Figure 6: Ascertainment of diagnostic value of trial-of-antibiotics

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. In pre-specified subgroup analysis, we will estimate the treatment effects stratifying by baseline HIV status. If the GLM model does not converge, we will use logistic regression to estimate the treatment effect using an odds ratio.

Participants without valid sputum mycobacteriology results

Primary analyses will be limited to participants who have at least one valid sputum sample result from all samples collected on visits Day-1 and Day-8. However, in real-life, ~15% fail to produce sputum, we will as a secondary outcome, perform all the analyses described for primary outcome with these participants defined as mycobacteriology negative. Further sensitivity analyses with urine lipoarabamannan antigen (LAM) results will include them in mycobacteriology definition.

4.6.1.2 Primary outcome 2: Clinical benefit of trial-of-antibiotics

Outcome definition

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Proportion of participants experiencing at least one of the following adverse outcomes: death, hospitalisation, and missed TB diagnosis. The definitions of the components of this composite clinical outcome are defined in the table below:

Outcome component	Definition		
death	Proportion of deaths by Day 29		
hospitalisation	Proportion hospitalised for any cause by Day 29		
missed TB diagnosis	Day 29 proportion of participants meeting standard		
	mycobacteriological and radiological TB definitions but		
	incorrectly classified as TB negative and not yet on TB		
	treatment by Day 29.		

Estimation of measures of effect

We will use a generalised linear model (GLM) with identity link to estimate risks differences and the GLM with log link to estimate risk ratios for the three comparisons, adjusting for primary care center. For each comparison, we will report 95% Confidence Intervals and Chi-square p-values. If the outcome is rare or if GLM does not converge, we will use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.2 Secondary outcomes

Outcome definitions

1) Proportion of day 29 nasopharyngeal *Streptococcus pneumoniae* isolates resistant to any of the commonly used antimicrobials.

We will define **AMR positive** as having nasopharyngeal isolates of Streptococcus pneumoniae that are resistant to any of the following commonly used antibiotics: ceftriaxone, amoxycillin, cefoxitin, azithromycin, and erythromycin as determined using disc diffusion technique; and **AMR negative** as either (1) not isolating any Streptococcus pneumoniae or (2) isolating any Streptococcus pneumoniae that is not resistant to any of the assessed antibiotics. For each arm, and at both baseline and day 29, we will report proportion of AMR positive participants. The study outcome will be the proportion of AMR positive participants at day 29.

2) Proportion of participants correctly classified as PTB negative based on report of improvement of baseline symptoms on study Day-8 (i.e. after a trial-of-antibiotics if in azithromycin or amoxicillin arms, or without antibiotics if in standard of care arm) against a mycobacteriology

 reference standard, among all randomised participants, with those who do not have a valid sputum test result classified as mycobacteriologically negative.

Estimation of measures of effect

Our secondary outcomes are anticipated to be rare, we will therefore use logistic regression to model odds and report odds ratios for the following comparisons and their associated report 95% CIs and p-values.

4.6.3 Exploratory outcome

Our exploratory analyses will be comparisons between the **azithromycin** and **amoxicillin** arms for all our primary and secondary outcomes.

4.6.4 Planned subgroup analyses

We will perform subgroup analysis for the primary outcome. The important subgroups based on rationale detailed under section 2.4.4, include HIV status, ART status, and PTB treatment. HIV and ART status will be as documented on Day-1 while PTB treatment will be either as:

- TB treatment commenced based on positive baseline (Day-1 and Day-8) mycobacteriology, or
- TB treatment commenced within 29 days of enrolment in patients with negative Day1 and Day-8 bacteriology.

The 29 days cut off for clinical decision to treat is to ensure that we only capture TB disease that was present at baseline. 29 days is a reasonable because: TB is a slowly progressing disease which if positive at Day-29, must have been incident on Day-1; and in routine care setting it can take over a month from presentation to diagnosis of TB.⁸

4.7 Sample size and power

4.7.1 Primary outcome 1: specificity of day 8 symptom change versus mycobacteriology

We assume that trial-of-antibiotics (in azithromycin arm or in amoxicillin arm) will correctly classify 60% of mycobacteriology negative participants.¹⁴ We have determined that 400 mycobacteriologically negative (true negatives) participants per arm will provide 80% power to detect a 10% difference in proportion of participants correctly classified as negative by amoxicillin arm or by azithromycin arm (60%) versus standard of care arm (50%). See table 3. We assume that 80% of participants randomised will have negative mycobacteriology,³¹ requiring 500 participants to yield the 400 per arm. Assuming that 15% will not be able to produce sputum, and that 5% will not return for Day-8 visit, the sample size is increased to 625 per arm or 1,875 for the whole study.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

For a 2:1 comparison (combining the two antibiotic arms versus the standard of care arm), 305 sputum-test-negative participants per arm will be needed to achieve 80% discriminatory power to detect a 10% difference in specificity. Accounting for TB prevalence, ability to produce and submit sputum, and loss-to-follow up increases the sample size requirement to 472 per arm or 1,416 for the whole study.

Table 3: Power and sample size estimation for primary outcome 1

True negatives (mycobacteriology tests negative participants) b+d	¹ p (negatives correctly classified) d/(b+d)	² effect size	power (X difference between independent proportions)	
320	0.60	0.10	69%	
400	0.60	0.10	80%	
480	0.60	0.10	86%	
¹ specificity with either azithromycin or amoxicillin trial-of-antibiotics arms				
² risk difference (azithromycin arm- standard of care arm)				

4.7.2 Primary outcome 2: Incidence of adverse clinical outcome at Day-29

We will use a pilot study to determine the standard of care risk of at least one of death, hospitalisation, and missed TB diagnosis. The pilot study is described in section 5.0.

For now, we will assume that there is a 10% risk of experiencing this composite adverse outcome in the standard of care arm, and that loss to follow up by Day-29 will be 10%. With the sample size of 625 participants per arm (based on the primary outcome 1 sample size calculation), and alpha of 0.05, we will be able to detect the difference between intervention and standard of care with 80% power, if the risk in intervention arm is 6% or lower (Table 4). This estimate is applicable to the 2:1 comparison of the study arms.

Table 4: Sample size estimation for clinical benefit outcome

Participants per arm <u>based on primary</u>	625
10% loss to follow up by Day-29	562
Outcome risk in standard of care arm	0.10
Desired power	0.80
Alpha	0.05
Required intervention arm risk	0.06

4.7.3 Secondary outcomes

1) Incidence of resistant S. pneumonia on Day-29

Study arms will be compared based proportion of participants with resistant *Streptococcus pneumoniae* on day 29. We assume 10% loss to follow up by Day-29, and the rate of *S. pneumonia* isolation from nasopharyngeal swabs in this population is expected to be ~45% at Day-29. The sample size based on the primary outcome (625 per arm) will provides ~253 *S. pneumonia* isolates/arm. In the standard of care arm, with 10% risk of resistant isolates, this translates into 25 cases. For the intention to treat population (the randomised 625 participants/arm) in the standard of care arm the 21 cases of resistant isolates translate into 4% (25/625) risk. To detect a twofold change in odds of day 29 AMR risk with at least 80% power, alpha of 0.05, and using Pearson's Chi-squared test, we will need at least 431 and 553 participants per arm for the 2:1 and pairwise comparisons respectively.

4.7.4 Exploratory outcomes

We anticipate that our sample size will be enough for hypothesis generation around our exploratory objectives but may not be enough to provide discriminatory power for comparison of outcomes between arms.

5 Pilot study

 This area of research has limited evidence to guide the precise determination of sample size and the practical aspects of the clinical trial making a pilot study an invaluable tool. We have identified the following as key knowledge gaps which require exploration using a pilot study:

- 1) Among the adult patients presenting to primary care centres with cough for at least 2 weeks what proportion gets antibiotics:
 - a. before clinic presentation?
 - **b.** on first clinic visit?
 - c. on follow up clinic visit after mycobacteriology results?
- 2) Following antibiotic treatment, how do patients report their clinical response? What are the best questions to ask patients post-antibiotic treatment to determine if they have improved or not? How best can we deliver these questions via Audio Computer Assisted Self-Interview (ACASI)? How well do these responses correlate with mycobacteriology and radiology?
- 3) What is the best timing for nasopharyngeal swabs for evaluating AMR in patients who receive a course of antibiotics during TB investigations?
- 4) In the standard of care setting, what proportion of adult patients presenting to primary care centres with cough for at least 2 weeks experience the following adverse outcomes (as defined under the clinical benefit composite endpoint)?
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.1 Specific objectives of the pilot study

- 1) To determine the proportion of adults with prolonged cough who
 - a. present to primary care having already had antibiotics for the index clinical complaints.
 - b. receive antibiotics before sputum mycobacteriology results at first presentation
 - c. receive antibiotics after negative mycobacteriology

- 2) To establish an objective way of documenting response to antibiotic treatment using Audio Computer Assisted Self Interview (ACASI). Assessing ACASI responses against clinical signs, outcomes of TB mycobacteriology and chest radiography.
- **3)** To determine:
 - a. the prevalence of Streptococcus pneumonia;
 - b. the prevalence of resistant Streptococcus pneumonia isolates;
 - c. the optimal specimen collection timing for evaluating impact of antibiotic use on prevalence of *Streptococcus pneumonia* isolates resistant to common antibiotics
- 4) To establish standard of care rates of the following adverse clinical outcomes:
 - a. death
 - b. hospitalisation
 - c. missed TB diagnosis
 - d. HIV care loss to follow up
 - e. TB care loss to follow up

5.2 Population for the pilot study

This exploratory study will include up to 400 adult (≥18 years old) patients presenting to primary care centres with cough for at least 14 days. We will exclude patients not meeting the eligibility criteria of the clinical trial.

5.3 Pilot study procedures

The pilot study procedures are outlined in the flow chart below. Following pilot study informed consent, we will use a baseline assessment questionnaire to collect clinical history, and antibiotic use for the index illness prior to the clinic visit. Throughout follow up, we will record all antibiotic use from any source. We will collect sputum samples for mycobacteriology from all participants on Day1 and Day 8.

We will establish HIV and TB diagnosis throughout the study, link participants to care services, and follow their adherence to follow up. For TB we will use a combination of Xpert, smear and culture on Day 1, 8 and whenever symptomatic suggestions of TB arise. We will also perform a chest x-ray on Day 8 and a follow up film on Day 29.

We will collect nasopharyngeal swab samples, for antimicrobial resistance assessment using *Streptococcus pneumonia* culture and sensitivity, on Day 1, Day 8, and Day 29. We will assess change in symptoms and well-being from Day 1 to Day 8, by using various combinations of questions and answers delivered via Audio Computer Assisted Self Interview (ACASI) on Day 8. We

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

will ask participants which sets of questions they found easy to understand. We will also collect clinical information on all study visits including illness events, hospitalisations and vital status.



Pilot study flow diagram, summarizing the study procedures at each visit.

5.4 Data analysis

We will report the proportions of participants who used any antibiotics prior to primary care and during work-up for Tuberculosis. We will determine the best ACASI question and response combinations by participant reported ease of use, and by assessing correlation with clinical findings,

 mycobacteriology and radiological outcomes. The optimal time for assessing AMR will be determined by comparing incidence of resistant Streptococcus pneumonia isolates at days 8 and 29.

We will comparing participants exposed to antibiotics to those not exposed to antibiotics by estimating and reporting relative risk and 95% confidence intervals for:

- 1) Day 8 and Day 29 of resistant Streptococcus pneumonia
- 2) Composite adverse outcome of experiencing any of: death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up tor occite terren ont

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

6 Study procedures

6.1 Screening

 At the designated primary health care centres, study staff will approach patients with symptoms of pulmonary tuberculosis (including cough of any duration, fever, weight loss, and night sweats) with information about the study. Those willing to be screened for eligibility will be assessed against the study inclusion and exclusion criteria.

6.2 Informed consent

We will seek written informed consent (Appendix 1) from all patients who meet eligibility criteria before any trial-specific procedures. Screening for tuberculosis symptoms will not be considered as part of the study procedures, as it is already a fundamental component of the routine clinical assessment and history taking. A member of the study team will hand an informed consent form to a potential participant in their preferred language (Chichewa or English) detailing background, procedures, risks, benefits and participant expectations should they choose to join the study. The consent form will also state that the participant is free to withdraw from the trial at any time for any reason without prejudice to future care, and no obligation to give reason for the withdrawal.

If they choose to join as a study participant, we will then request them to sign two copies of informed consent form. If a potential participant does not know how to read or write, we will perform the informed consent process in the presence of a witness. In such cases, if they agree to participate in the study, we will ask them to sign using a thumb-print in the presence of their witness and a study team member. We will keep one copy of the signed informed consent forms and hand the participant the other copy.

6.3 Baseline procedures

After consenting, we will on the same visit request participants to provide 2 on the spot sputum samples for smear microscopy, Xpert and culture collected at least one hour apart. Those unable to spontaneously produce sputum will be instructed in the physiotherapy manoeuvre of "huffing" (forced expiration technique) for inducing mucus clearance from the airways.

Patients still unable to provide at least one mucoid sputum sample of >1 ml will initially will be given a sputum container and asked to return it the next day. If they do not manage to produce sputum at home, their mycobacteriology results will be treated as missing. We expect ~15% of participants to fall in this category³¹ and have accounted for them in the sample size estimation. For participants who produce less than the needed quantity of sputum, we will process them for the planned tests in the following priority order: 1) Xpert MTB/RIF, 2) MTB culture, 3) smear microscopy. The Xpert MTB/RIF

BMJ Open

is the single most important guide for immediate clinical diagnosis and the MTB culture is the single most accurate reference diagnostic.

We will also collect a urine sample which we will store for subsequent lipoarabamannan antigen detection (LAM); and a nasopharyngeal swab for pneumococcal culture and sensitivity testing to estimate prevalent antimicrobial resistance. We will also perform HIV tests according to the national algorithm, and if positive we will do HIV viral load. After completing all Day-1 visit procedures, we will link the newly tested positive participants to routine HIV care and will document when they start ART (Malawi National Program provides same-Day-ART initiation to all newly-diagnosed or untreated HIV-positive patients). After the sample collections, we will collect the following information:

- Demographic data, including precise geographic locator information using ePAL geolocation software (to aid follow-up). The locator information will also include phone numbers for the participant and for up to 3 family, or friends they nominate as alternative contacts.
- Clinical history including information on tuberculosis symptoms and health care seeking for HIV and tuberculosis care services including ART, cotrimoxazole, isoniazid preventive therapy, and past TB treatment.
- Vital signs including height and weight

After completing all these baseline procedures, we will randomise the participants to the three study arms.

6.4 Assignment of interventions

Step 1: An independent statistician based at LSHTM and without contact with participants or the study staff that see participants, will use the ralloc command in Stata (StataCorp LLC, College Station, Texas USA. Release 15.0) to prepare a random allocation sequence in advance of study recruitment efforts. Randomisation will be 1:1:1 to the three arms of the trial, block-randomised with variable block sizes, and stratified by primary care centre.

Step 2: Each treatment allocation will be printed alongside a randomisation number onto a pdf document.

Step 3: The statistician will email the pdf document to an independent designee within university of Malawi who will print and place the randomisation assignments in envelopes labelled with randomisation numbers. The independent designee will hand the envelopes directly to the study pharmacist who will also receive a shipment of study medications. The pharmacist will store the envelopes in a secure location within the pharmacy.

Step 5: The pharmacist will pre-pack 625 each of protocol doses of azithromycin and amoxycillin without any reference to the allocation sequence. There is no need to refer to the allocation sequence for this step because the dosage for both treatments is the same and the total number of allocation for each treatment is known.

Step 6: At the beginning of each working week and upon request from study site, the study pharmacist will hand to site coordinators of each primary care center, a recruitment-rate-driven daily working stock of 1) the sequentially numbered sealed opaque envelopes containing randomization numbers and corresponding treatment allocations, and 2) study drugs.

Step 7: Study staff from each site will conduct patient eligibility assessments. Patients meeting the quick criteria of age and cough for ≥14 days, will be assigned screening IDs before being taken through the full eligibility criteria and consenting process. Participants will be considered eligible and ready for randomisation after they meet all criteria and sign consent.

Step 8: Upon signing consent, the participant will be taken to the site-coordinators (nurse or clinical officer) who will assign them the next available study ID number and document it on their paper and electronic eligibility checklist and enrolment CRF. The study ID number will be the number on the treatment allocation envelope plus a site-specific code. They will then open the envelope, document the treatment assignment, to the participant's enrolment paper and electronic case report forms as well as on a study card that will be pasted in the participant personal health profile book.

Step 9: The coordinator will double-check to ensure that the enrolment number and the treatment assignment are recorded correctly. They will then record screening date, screening ID, randomisation date, study ID, and randomisation arm on an enrolment log. They will then administer the allocated treatment. Administering study medications will not be considered as prescribing considering that prescription to all eligible participants will have already been done by the study protocol.

Step 10: When the stock of either envelopes or study drugs runs out,, the nurse-coordinators will reorder a from the study pharmacist.

Additional details

All steps of receipt, and utilization of the allocations and study drugs are elaborated in a detailed SOP. The SOP guides implementation of the above plan as far as possible and in line with site conditions.

BMJ Open

The study drugs will be pre-packed blindly without any reference to treatment allocations ensuring that neither the pharmacist nor the nurse-coordinator know the treatment allocations until just before assigning to a participant.

6.5 Blinding

We will mask the treatments as far as possible. The study pharmacist will remain blinded as they will use the randomly- allocated label numbers to prepare and pack the correctly dosed study medications in opaque packaging. Study outcome assessment will occur without reference to study treatment allocation. All laboratory forms for mycobacteriology and nasopharyngeal pneumococcal work will have no reference to participant treatment allocation. On Day-8, assessment of improvement from baseline symptoms will utilize audio computer-assisted self-interview (ACASI) to minimise potential for social-mediated reporting and ascertainment biases (see Procedures Section of the protocol). All clinical endpoints assessment case report forms will bear no reference to treatment arm. However, we will keep participants, research coordinators, and routine care staff unmasked to ensure safety of the participants and allow appropriate patient management decision-making which may be related to the trial interventions.

6.6 Participant follow up

Following enrolment and completion of baseline procedures we will ask participants to return for follow up visits on days 8, and 29. They will be given 1 sputum collection bottle when leaving the clinic on Day-1 to bring with them sputum for mycobacteriology planned for Day-8 ("morning" specimen) followed by collection of one further "spot" sputum on Day-8, 2 sputum samples in total). We will also collect a second urine sample for storage for subsequent LAM antigen testing. Patients unable to produce at least one mucoid sputum sample of >1ml on Day-8 will be assumed for purposes of analysis to be mycobacterially negative for the Day-8 sputum samples. We are performing two sets of sputum examinations (Day-1 and Day-8) for each participant to strengthen the accuracy of the reference standard. Considering that TB progresses very slowly, making a diagnosis on Day-8 is not different from that made on Day-1.

We will advise participants that their sputum TB test results will start becoming available from 48 working hours after collection, but with the last test (MTB culture) taking up to 4 weeks. Patients will be advised that they will not be routinely contacted if positive TB test results become available before their Day-8 appointment (as is standard for outpatient management without danger signs in Malawi), and so will be advised to report promptly back to the clinic (with refund of transportation given) if they experience any clinical deterioration during Days 2 to 7.

In the circumstances where TB treatment is commenced before completion of antibiotics prescribed for trial-of-antibiotics (amoxicillin and azithromycin), we will ask them to carry on with their allocated intervention together with the TB treatment.

6.6.1 Day-8 activities

 On Day-8, the first activity before the participants undergo all other evaluations will be documentation of self-reported improvement of baseline (Day 1) TB symptoms using a pilot-validated set of questions and answer options delivered via Audio Computer Assisted Self Interview (ACASI). We will use ACASI with the goal of eliminating inter-observer variability and patient/interviewer reporting or ascertainment biases. After a "how to use" orientation and testing session, the participant will be left alone in the room to interact with the computer. A pre-recorded interviewer will ask the participant questions related to how their symptoms have changed on that day compared to how they were on Day-1 and will offer categorised voice-recorded responses with touch screen response buttons. The ACASI questionnaire will also include questions about adherence to study arm drugs and any other medical care (including traditional medicine) sought during the previous week.

Other activities for all participants on Day-8 include:

- collection of a second sputum sample for mycobacteriology tests.
- providing participants with Day 1 smear and Xpert results linking those with positive tests, ongoing symptoms and other illnesses with routine care for appropriate management.
- clinical history detailing clinical events since enrolment.
- documentation of any medications including antimicrobials and traditional medicine outside
 the study
- providing a study Day-29 appointment card

For participants with negative Day-1 mycobacteriology results we will perform clinical evaluation after ACASI and will inform the patient that any positive Day-8 sputum mycobacteriology results will be reported actively (via telephone or house visit) as soon as quality-assured results become available (within 48 working hours for microscopy and Xpert). Patients who have not had complete resolution of symptoms will be referred with all available results to routine primary care management.

6.6.2 Day-29 activities

Day-29 will be the final study visit. We will on this visit, collect data on clinical impact of antibiotic treatment and risk of AMR. In line with the second primary endpoint (composite clinical impact), we will document:

- 1) vital status
- 2) hospitalisations
- **3)** identify missed TB diagnosis by using culture results from Day 1 and Day 8 sputum, any chest X-rays performed in follow up, and repeat mycobacteriology if symptomatic
- 4) perform HIV tests for those with unknown status and eligible for routine HIV test.

We will first collect information on clinical events prior to and at the visit and communicate all available sputum culture results and the final reported CXR results.

After collecting the clinical information, we will collect nasopharyngeal swab sample for assessing antimicrobial resistance. To collect the sample, a trained study staff will swab the participants' nasopharynx and place the swab in a tube containing skim milk tryptone glucose glycerol (STGG).

6.7 Laboratory methods

6.7.1 Tuberculosis mycobacteriology

We will process mycobacteriology tests at the Malawi College of Medicine TB laboratory, a reference laboratory located in Blantyre. For sputum samples collected on Day-1, we will perform smear microscopy, Xpert MTB/RIF and MTB culture. For sputum samples collected on Day-8, we will perform smear microscopy and MTB culture. We will use Mycobacteria Growth Indicator Tube (MGIT) and Lowenstein-Jensen (LJ) culture methods for TB culture. Once isolated, we will perform speciation as *Mycobacteria tuberculosis* (MTB) or non-tuberculous mycobacteria (NTM) using MBP84 antigen testing, microscopic cording and, if necessary, morphology and growth characteristics at different temperatures and on solid (LJ) media containing p-nitrobenzoic acid (PNB).

6.7.2 Urine antigen testing for lipoarabamannan and other MTB antigens

Urine will be collected and stored as two 1 ml aliquots at -20°C from each participant on both Day-1 and Day-8 for subsequent mycobacterial antigen testing. No appropriate product is available for immediate use, but we anticipate that a commercial product with sufficiently high analytic accuracy for use in ambulant outpatients (sensitivity and specificity) may become available during the course of, or soon after, the study. If ongoing evaluations of the FIND-sponsored FujiFilm product⁴⁵ meet or exceed pre-specified requirements for clinical utility in the outpatient context, then point-of-care LAM testing at Day-1 and Day-8 will be added to the mycobacteriological definition of TB and patient management as soon as kits have been obtained and evaluated in Malawi.

6.7.3 Antimicrobial resistance testing

We will store swabs in STGG at minus 80°C. At a later stage we will thaw them in batches, and plate them onto selective media and culture colonies consistent with *S. pneumoniae*. We will determine

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Minimal inhibitory concentrations (MICs) using E-test strips (azithromycin and amoxicillin), and Kirby Bauer Disc diffusion testing (azithromycin, rifampicin, tetracycline, ceftriaxone, chloramphenicol, co-trimoxazole, erythromycin and penicillin) and define resistance by EUCAST breakpoints.

We will store isolates and remaining STGG at minus 80°C to allow genotypic characterization, isolation and susceptibility testing of other key respiratory pathogens, FTD 33 respiratory pathogen diagnostic panel, metagenomics analysis, and microarrays to detect multiple carriage and macrolide resistance genes in a broader range of pathogens at a later stage.

6.8 Loss to follow-up

To minimise loss to follow up, we will at enrolment record geolocation information of participants' place of residence using ePAL android app, a high-resolution mapping system validated in Blantyre. We will also record up to 3 contact phone numbers of the participant and their nominated friends and relatives. Should a participant miss a study visit, we will contact them by phone or by visiting them at home to encourage them to attend the study visit before expiry of prescribed visit window.

We anticipate a loss to follow-up of 5% by Day-8, and 10% by Day-29. We have accounted for these assumptions in the sample size calculation. We will not replace participants who discontinue study participation or study treatment regardless of reason for withdrawal or discontinuation or the time either of these occurs.

6.9 Trial closure

We will consider the trial closed after completing follow up of the last enrolled participant, and upon recording all mycobacteriology laboratory reports. Antimicrobial resistance lab work will continue beyond trial closure. The trial may be terminated early by the trial steering committee upon recommendation of the DSMB. The halting rule for a trial arm is an unacceptable high level of deaths assessed using an alpha determined at the first DSMB meeting.

6.10 Summary schedule for study procedures

In Table 5 below, we have summarised all key study procedures over the study period.

2	
2	
5	
4	
5	
6	
7	
, 0	
0	
9	
10	
11	
12	
12	
15	
14	
15	
16	
17	
10	
18	
19	
20	
21	
22	
<u>~~</u>))	
23	
24	
25	
26	
27	
20	
20	
29	
30	
31	
32	
22	
22	
34	
35	
36	
37	
20	
38	
39	
40	
41	
42	
42	
43	
44	
45	
46	
47	
10	
40	
49	
50	
51	
52	
52	
55	
54	
55	
56	
57	
50	
20	
59	
60	

	STUDY PERIOD			
	Enrolment	Follow up		ow up
TIMEPOINT**	Day-1	Day-8		Day-29
ENROLMENT:				
Eligibility screen	Х			
Informed consent	х			
Allocation	x			
INTERVENTIONS:				
Azithromycin	x			
Amoxicillin	x			
Standard of care	x			
ASSESSMENTS:				
Demographics	X			
History of antibiotic use	Х	x		×
*History & examination	X	x		x
**Sputum collection	Х	X		
Urine for TB LAM test	Х	x		
Nasopharyngeal swab	х		\bigcirc	x
HIV test and CD4 count	х			х
Linking to routine care	х	х		×
¹ ACASI		Х		
***Clinical events		х		x
Update contact & address		х		x
*For symptomatic participants, Da before they leave the clinic. Ches	*For symptomatic participants, Day-8 sputum mycobacteriology should be fast-tracked to inform care before they leave the clinic. Chest X-ray should be performed and interpreted in real-time.			
**Give sputum bottles at end of D mycobacteriology at any time of t	**Give sputum bottles at end of Day-1 visit for submission on Day-8. Also collect sputum and perform mycobacteriology at any time of the study when clinically indicated			
***Illnesses, clinic visits, radiological outcomes, new HIV diagnosis, new TB diagnosis, death, hospitalisation, missed TB diagnosis, HIV care loss to follow up, and TB care loss to follow up ¹ Audio Computer Assisted Self-Interview for documenting change of symptoms on Day- 8 versus Day-1				

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ACT-TB Study Protocol V4.1, 27 Jan 2020

7 Safety reporting

7.1 Definitions

Term	Definition
Adverse Event (AE)	Any untoward medical occurrence in a participant to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product.
	An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP), whether or not considered related to the IMP.
Adverse Reaction (AR)	Any untoward and unintended response in a participant to an investigational medicinal product which is related to any dose administered to that participant.
	The phrase "response to an investigational medicinal product" means that a causal relationship between a trial medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out.
	All cases judged by either the reporting medically qualified professional or the Sponsor as having a reasonable suspected causal relationship to the trial medication qualify as adverse reactions.
Serious Adverse Event (SAE)	 A serious adverse event is any untoward medical occurrence that: Results in death Is life-threatening Requires inpatient hospitalisation or prolongation of existing hospitalisation Results in persistent or significant disability/incapacity Consists of a congenital anomaly or birth defect
	Other 'important medical events' may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences.
Serious Adverse Reaction (SAR)	An adverse event that is both serious and, in the opinion of the reporting investigator, believed with reasonable probability to be due to one of the trial treatments, based on the information provided.
Suspected Unexpected Serious Adverse Reaction (SUSAR)	A serious adverse reaction, the nature and severity of which is not consistent with the information about the medicinal product in question set out:
	 In the case of a product with a marketing authorisation, in the summary of product characteristics (SmPC) for that product.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

7.2 DMID grading for AEs

We will adopt the events grading criteria prepared by the Division of Microbiology and Infectious Diseases (DMID) of the USA National Institutes of Health as shown in the table below.

1 MILD	2 MODERATE	3 SEVERE	4 LIFE-THREATENING
Transient or mild discomfort (< 48 hours); no medical intervention required	Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention required	Marked limitation in activity, some assistance usually required; medical intervention required, hospitalizations possible	Extreme limitation in activity, significant assistance required; significant medical intervention required, hospitalization probable

7.3 Grading for expected events

The following table provides guidance for grading known important or frequent side effects of azithromycin (based on the AE grading criteria provided in the BREATHE Trial Protocol, also investigating azithromycin) and amoxicillin graded on the DMID scale. All events not mentioned here or in Appendix 2, will be graded using the DMID grading for AEs table presented above.

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE- THREATENING
Side-effects	1	2	3	4
Acute Allergic Reaction	Localized urticaria (wheals) with no medical intervention indicated	Localized urticaria with intervention indicated OR Mild angioedema with no intervention indicated	Generalized urticaria OR Angioedema with intervention indicated OR Symptoms of mild bronchospasm	Acute anaphylaxis OR Life-threatening bronchospasm OR Laryngeal oedema
Rash Specify type, if applicable	Localized rash	Diffuse rash OR Target lesions	Diffuse rash AND Vesicles or limited number of bullae or superficial ulcerations of mucous membrane limited to one site	Extensive or generalized bullous lesions OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Stevens-Johnson syndrome OR Toxic epidermal necrolysis
Mental state changes	mild anxiety or depression	moderate anxiety or depression; therapy required;	severe mood changes requiring therapy; or suicidal ideation;	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE- THREATENING
Photosensitivity	Painless erythema covering <10% body surface area	change in normal routine Tender Erythema covering 10 - 30% body surface area	or aggressive ideation Erythema covering >30% body surface area and erythema with blistering, requiring intervention	Life-threatening consequences; urgent intervention indicated
Arrhythmia (by ECG or physical examination) Specify type, if applicable	No symptoms AND No intervention indicated	No symptoms AND Non-urgent intervention indicated	Non-life- threatening symptoms AND Non-urgent intervention indicated	Life-threatening arrhythmia OR Urgent intervention indicated
Prolonged QTc Interval	0.45 to 0.47 seconds	> 0.47 to 0.50 seconds	 > 0.50 seconds OR ≥ 0.06 seconds above baseline 	Life-threatening consequences (e.g., Torsade de pointes, other associated serious ventricular dysrhythmia)
Diarrhea ≥ 1 year of age	Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline per 24-hour period	Persistent episodes of unformed to watery stools OR Increase of 4 to 6 stools over baseline per 24-hour period	Increase of ≥ 7 stools per 24- hour period OR IV fluid replacement indicated	Life-threatening consequences (e.g., hypotensive shock)
Tinnitus	Symptoms causing no or minimal interference with usual social & functional activities with intervention not indicated	Symptoms causing greater than minimal interference with usual social & functional activities with intervention indicated	Symptoms causing inability to perform usual social & functional activities	NA
Nausea	Transient (< 24 hours) or intermittent AND No or minimal	Persistent nausea resulting in decreased oral intake for 24 to 48 hours	Persistent nausea resulting in minimal oral intake for > 48 hours OR Rehydration	Life-threatening consequences (e.g., hypotensive shock)

	1 MILD	2 MODERATE	3 SEVERE	4 LIFE- THREATENING
	interference with oral intake		indicated (e.g., IV fluids)	
Vomiting	Transient or intermittent AND No or minimal interference with oral intake	Frequent episodes with no or mild dehydration	Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated (e.g., IV fluids)	Life-threatening consequences (e.g. hypotensive shock)
Laboratory	1	2	3	4
ALT or SGPT, High	1.25 to < 2.5 x ULN	2.5 to < 5.0 x ULN	5.0 to < 10.0 x ULN	≥ 10.0 x ULN
Report only one				
Creatinine Clearance or eGFR, Low <i>Report only one</i>	NA	< 90 to 60 ml/min or ml/min/1.73 m2 OR 10 to < 30% decrease from baseline	< 60 to 30 ml/min or ml/min/1.73 m2 OR ≥ 30 to < 50% decrease from baseline	< 30 ml/min or ml/min/1.73 m2 OR ≥ 50% decrease from baseline or dialysis needed

7.4 Causality

When reporting on serious adverse events, the trial investigator will state whether they believe that the event is causally associated with any of the trial treatments and the strength of the causal relationship. They will also state whether the adverse event was expected and what if any action was taken.

Relationship	Description
Unrelated	There is no evidence of any causal relationship
Unlikely	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatment).
Possible	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g. the participant's clinical condition, other concomitant treatments).
Probable	There is evidence to suggest a causal relationship and the influence of other factors is unlikely.

Definitely	There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.
Not assessable	There is insufficient or incomplete evidence to make a clinical judgement of the causal relationship.

7.5 Reporting Procedures

7.5.1 Non-serious Adverse Events (AEs)

Adverse events will be ascertained from patient follow-up visits or reports from relatives or guardian if patient cannot be contacted for follow-up. Study clinicians will be responsible for recording of details of the event including a description of the event, date of onset, severity, assessment of relatedness to trial interventions. Adverse events will be recorded in case report forms and uploaded into the study database.

7.5.2 Serious Adverse Events (SAEs)

All serious adverse events (SAEs) will be recorded on the relevant study CRFs and reported immediately to the Principal Investigator who will ensure that they are compiled in aggregate form and reported to COMREC and the DSMB once every 6 months. The DSMB will review SAE reports at their 6 monthly meetings and issue recommendations which will be shared with ethics committees. Events relating to a pre-existing condition or any planned hospitalisations for elective treatment of a pre-existing condition will not be reported as SAEs.

8 Economic evaluation

8.1 Objective

The objective of the economic evaluation is to undertake a cost-utility analysis to estimate the incremental cost-effectiveness of trial-of-antibiotics using azithromycin and trial-of-antibiotics using amoxicillin in comparison to standard of care, and to each other. We will systematically compare costs and consequences associated with the interventions.

8.2 Outcomes

We will perform a within trial comparison of the three treatment arms to estimate the incremental cost per quality-adjusted life year (QALY) gained for the azithromycin or amoxicillin arm in comparison to standard of care. Costs will be estimated from the Malawian Ministry of Health perspective. Health outcomes will be quantified in QALYs, estimated from participants' responses to the Chichewa version of the EQ-5D-3L, a Health quality of life (HRQoL) measure.^{46,47} We will adopt a time horizon matching the length of participant follow-up to achieve the within trial evaluation.

8.3 Data collection

The health economic data collection will be undertaken alongside planned clinical data collections. We will administer the Chichewa version of the EQ-5D-3L to all trial participants at baseline (Day1), Day 8 and Day 29. The Chichewa EQ-5D-3L was prepared in accordance with international and EuroQoL guidelines. The EQ-5D uses a descriptive system and a visual analogue scale (VAS). HRQoL on the day of response is defined using the descriptive system in terms of the following dimensions: 1) mobility, 2)self care, 3)usual activities, 4)pain/discomfort, and 5) anxiety or depression. The responses are then split into the following ordinal levels: 1) no problems; 2) some or moderate problems; and 3) severe or extreme problems.

The EQ-5D has 243 health states to which each response is allocated and converted to an EQ-5D utility score using a tariff. Tariff sets are derived from national surveys and currently no Malawian EQ-5D tariff exists. Zimbabwe, a setting similar to Malawi, has EQ-5D tariff set. In this study, we will use the Zimbabwean set to derive EQ-5D utility scores⁴⁸ an acceptable practice considering the similarities in how the two populations value health.⁴⁹ The EQ-5D utility scores in the Zimbabwean tariff, range from 1.0 (which means no problems in the five dimensions) to -0.29 (defined as severe problems in all five dimension).

We will capture all healthcare resources used by trial participants from recruitment into the trial till Day 29. This will be undertaken on Day 1, Day 8 and Day 29. Healthcare resources will be translated into direct medical costs using previously estimated costs^{47,50,51} and the wider literature.

BMJ Open

Drug prices will be based on International market prices.⁵² The health resource use questionnaire will at a minimum capture:

- Outpatient clinic visits
- Days of inpatient hospital care
- Medications
- Investigations and procedures

8.4 Data analysis

Our primary analysis will focus on direct intervention and the broader healthcare costs. We will define direct intervention costs as the costs associated with the application of the interventions. We will plot health state values measured by the EQ-5D-3L against time assuming that the health states reported at each time point are linearly connected. We will estimate QALYs associated with participant health profile by area under the plotted curve as calculated using the trapezium rule.

We will use a range of analytical methods depending on whether baseline covariates (EQ-5D utility values) are balanced between the trial arms or not. If they are balanced, we can obtain unbiased cost-effectiveness estimates by using non-parametric bootstrap approaches; if imbalance exists regression methods will be the approach of choice.

We will explore a range of estimators and undertake model diagnostics to determine the optimal model because the distributions of costs and QALYs are commonly skewed, often bimodal, or truncated. We will estimate mean costs and outcomes for each intervention together with respective mean incremental cost-effectiveness ratio. We will for each estimate report respective measures of uncertainty (standard errors and confidence intervals). We will also estimate the net monetary benefits (NMBs) for a range of different willingness to pay (WTP) thresholds. To identify the optimal intervention at different WTP thresholds, we will construct cost-effectiveness acceptability curves (CEACs) based on the NMB framework.

8.5 Missing data

For each participant we will collect complete data as far as possible but in cases of missing values, a common occurrence in trials, we will perform additional analyses to explore the impact of and account for the missingness.

ACT-TB Study Protocol V4.1, 27 Jan 2020

9 Data management

9.1 Source Data

We will consider a document as source if it is where data were first recorded, and from which we obtained participants' case report forms (CRF) data. These will include hospital records, health center records, participant health passport, laboratory and pharmacy records, diaries, radiographs, and correspondence. We will consider CRF entries as source data if the CRF is the site of the original recording.

We will on all study-specific documents, other than study ID code list, the signed consent forms household locator form and, refer to the participant by their trial participant identification number, not by name. We will keep study ID code list, consent and locator forms separate from the rest of the participant file to avoid linkage between participant name and the study ID.

9.2 Data collection methods

We will collect data using standardised, pre-tested CRFs in two forms:

- programmed into android tablets using Open Data Kit (ODK) platform (opendatakit.org) with paper back-ups.
- optical mark recognition readable forms read and extracted using TELEFORM system (Cardiff Software, Inc., Vista, CA), an optical-character-recognition software.

9.3 Data management

Any participants' identifiable data collected by the Study Coordination Centre will be stored securely and their confidentiality protected in accordance with the Data Protection Act 1998.

To ensure data security and maintenance of participant confidentiality, we will take several strict measures. All the study data collection tablets and computers will be encrypted, password protected and stored in a fireproof lockable cabinet inside a locked room. The principal investigator, study coordinator and data manager will be responsible for the maintenance of the tablets as well as all other computers, and their security from viruses and theft. All users will check in with the study coordinator and sign for data entry tablets every time they are taken out to for data entry and upon return. Whenever not in use, the devices will be kept in their locked cabinet.

We will keep all paper records in a locked space only be accessible to the principal investigator, coinvestigators and delegated study staff. Study databases will be encrypted, password protected and will be stored on dedicated servers within the University of Malawi College of Medicine. We will keep all electronic and paper records securely for up to 10 years after the end of the trial in accordance with LSHTM Records Retention & Disposal Schedule guidelines.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

9.4 Quality control and quality assurance

We will apply quality control at each stage of data handling in accordance with GCP requirements to ensure that all data are reliable and have been processed correctly. We will manual review all paper CRFs for completeness, accuracy and legibility before scanning. Our ODK data entry system will include automatic pre-programmed real-time data validation. The TELEFORM system will also have pre-programmed automatic data validation capabilities. We will perform data quality assurance (QA) on a random 10% of all participant files. The QA process will involve examining database entries and for paper source documents, verification of database entries and source.

9.5 Access to data

We will upon request, provide direct access to authorised representatives from the Sponsor, host institution and the regulatory authorities to allow smooth running of trial-related monitoring, audits and inspections.

10 Data monitoring and quality assurance

10.1 Data monitoring

Site monitoring for safety will be conducted to ensure human subject protection. The study will be monitored just before commencing enrolment, then once every 6 months by a monitoring team from the University of Malawi College of Medicine. The objective will be to ensure that study procedures, study products administration, and data collection processes are of high quality and meet ethical and regulatory guidelines. The regular monitoring will focus on the following areas: 1) protocol adherence, 2) informed consent documentation, 3) trial endpoints, 4) treatment discontinuation, 5) regulatory documents, 6) compare source documents and case report forms for accuracy, and 7) documentation practices in general.

10.2 Audits and Inspections

The study will be subject audit by the London School of Hygiene & Tropical Medicine under their remit as sponsor, the Study Coordination Centre and other regulatory bodies to ensure adherence to GCP.

10.3 Data Safety and Monitoring Board (DSMB)

We will set up a DSMB before commencing trial activities. The DSMB will provide independent review of the study conduct, progress and findings. It will comprise 3 members including a chairperson who will be responsible for collating and communicating the views of the DSMB. The DSMB will consist of an independent statistician and two clinicians, at least one of them a physician, with research experience and expertise in the management of tuberculosis and HIV in Africa. The proposed data safety monitoring plan will be discussed in a teleconference including the DSMB members and the key investigators prior to the study starting.

The proposed meeting schedule is 6 monthly. Two weeks before a 6 monthly DSMB meeting, the study team will prepare a report covering study progress, study approvals, any obstacles, and recruitment statistics, adverse events, withdrawals and trial outcome measures. The DSMB will, through its chairperson, provide written feedback to the principal investigator who will be responsible for passing it on to ethics committees.

10.4 Trial Management Group (TMG)

A Trial Management Group (TMG) will be appointed and will be responsible for overseeing the progress of the trial. The day-to-Day-management of the trial will be co-ordinated through the University of Malawi College of Medicine.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

10.5 Trial Investigational Team

Our investigational team includes expertise in diagnosis and management of TB; clinical evaluation of TB diagnostics; design and conduct of large randomised controlled trials; laboratory TB and AMR diagnostics; data management and analysis.

Chief investigator

 Dr Titus H Divala: the chief investigator and PhD student will be responsible for protocol development, coordination and conduct of the trial, governance, data management, data analysis and results dissemination. Dr Divala is a clinician with a career interest in clinical trials. Apart from medical training, he holds MPH and Masters of Science in epidemiology and preventive medicine. He has managed two large GCP, US-NIH-funded clinical trials, one of which was IND as the local PI supervising over 40 study staff at two sites in different cities. He has worked as a clinician for over 8 years in Malawi, a period when identifying TB cases and putting them on treatment was a daily job. This topic therefore falls in area of great personal interest above and beyond the potential benefit it has towards improving patient care in Malawi and all low and middle-income countries where 95% of the TB burden lies, where this approach is the standard.

Co-investigators and members of PhD supervisory team

<u>Prof Katherine L Fielding</u>: a seasoned TB statistician and clinical trialist, and PhD supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

<u>Prof Elizabeth L Corbett</u>: a seasoned TB clinical epidemiologist and PhD co-supervisor for the CI, will be responsible for protocol development, conduct of the study, and data dissemination.

Co-investigators and members of PhD advisory committee

Dr Derek J Sloan: clinician with detailed local clinical and research experience, will be responsible for protocol development, trial implementation and data dissemination.

<u>Prof Neil French</u>: a seasoned pneumococcal expert, will be responsible for protocol development, oversee all aspects of AMR work, and data dissemination.

Collaborators

<u>Dr Marriott Nliwasa</u>: clinician, with experience conducting studies in the study setting. He will be support the conduct of the study, linkage with the national program, and data dissemination.

<u>Mr Augustine Choko</u>: statistician, with expertise and experience in using ACASI. He will support ACASI development, data management and development of analysis plan.

Dr Ankur Gupta-Wright: clinician, will provide clinical input in protocol development and clinical consultation support to research coordinators during study implementation..

<u>Dr Jennifer Cornick</u>: microbiologist, will be support protocol development, and AMR laboratory methods and analysis, and data dissemination.

<u>Prof Jon Øyvind Odland</u>: Epidemiologist and honorary professor at University of Malawi College of Medicine, responsible for seeking ethical approvals from the funder appointed ethics committee.

11 Ethics and dissemination

We will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki and in full conformity with relevant regulations and with the ICH Guidelines for Good Clinical Practice E6 (R2) of November 2016.

11.1 Risk assessment

This is a low risk study as it is using already licensed antibiotics with good safety profile in a population defined by national clinical guidelines as clinically stable and not requiring other intervention but TB investigations. Our work complements standard of care by bringing in detailed TB diagnostics. In our study, the standard of care equivalent of the antibiotics we will prescribed on Day-1 to those randomised to either azithromycin or amoxicillin arms, are in standard of care prescribed on Day-8 only to mycobacteriology negative symptomatic patients (similar to the no antibiotic or standard of care arm of our trial). So, participants randomised to no antibiotic at Day-1 will not be receiving inadequate care but the recommended standard management of withholding antibiotics until after the TB results are available (Figure 1). To maintain participant safety and continuity of their care while on study interventions, we will not blind routine care clinical team and they will be free to manage the participants on their clinical judgement and national guidelines.

11.2 Research ethics approval

We will seek ethical approval for the trial protocol, informed consent forms, participant information sheet, any advertising material, and amendments to any of these documents, from the University of Malawi College of Medicine Research and Ethics Committee (COMREC), the LSHTM Research Ethics Committee, and Regional Committee for Health and Research Ethics, NTNU-Midt, Norway (on behalf of the funder). We will seek regulatory approval from the Malawi Pharmacy, Medicines, and Poisons Board (PMPB). Every year when the trial is active, we will seek continuous ethical review and approval before expiry of previous year's approval. In the event of an amendment, the changes will only be implemented upon ethical and regulatory approval.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

11.3 Indemnity

London School of Hygiene & Tropical Medicine holds Public Liability ("negligent harm") and Clinical Trial ("non-negligent harm") insurance policies which apply to this trial.

11.4 Sponsor

London School of Hygiene & Tropical Medicine will act as the main sponsor for this study. Delegated responsibilities will be assigned locally.

11.5 Declaration of interests

The study team declares that they have no conflict of interest in conducting this clinical trial.

11.6 Cost of participation, ancillary and post-trial care

During the study, participant will benefit from frequent interaction with clinical study staff and associated optimised management of illnesses. There are minimal risks including discomfort associated with collection of nasopharygeal samples, and side-effects of study interventions. We will reimburse participant transport for attending study visits.

11.7 Dissemination policy

This work will form part of a PhD thesis for Titus Divala, which he will submit to the London School of Hygiene & Tropical Medicine (LSHTM). All publications and presentations relating to the study will be authorised by the Trial Management Group. The first publication of the trial results will be in the name of the Trial Management Group, if this does not conflict with the journal's policy. If there are named authors, these will include at least the trial's Chief Investigator, Statistician and Trial Coordinator.

Members of the TMG and the DSMB will be listed and contributors will be cited by name if published in a journal where this does not conflict with the journal's policy

12	References
14	
1.	Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ. Understanding the mechanisms and drivers of antimicrobial resistance. <i>The Lancet</i> 2016: 387 (10014): 176-87.
2.	World Health Organization. The evolving threat of antimicrobial resistance: options for action: Geneva: World Health Organization: 2012.
3.	World Health Organization. Antimicrobial resistance: global report on surveillance: World Health Organization; 2014.
4.	Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. <i>The Lancet</i> 2016; 387 (10014): 168-75
5.	Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. <i>Infectious disease reports</i> 2016: 8 (2): 6570.
6.	World Health Organization, Global tuberculosis report 2016, 2016.
7.	Nliwasa M, MacPherson P, Mukaka M, Mdolo A, Mwapasa M, Kaswaswa K, Msefula C, Chipungu G, Mwandumba H, Corbett E. High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. <i>The international journal</i>
8.	Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. <i>The Lancet</i> 2007; 369 (9578): 2042-9.
9.	Corbett E, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality [State of the art series. Active case finding/screening. Number 5 in the series]. <i>The international journal of tuberculosis and lung disease</i> 2013: 17 (0): 1125-38
10.	Siddiqi K, Lambert M-L, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. <i>The Lancet infectious diseases</i> 2003; 3 (5); 288-96.
11.	Ghana Health Service. Guidelines for the Clinical Management of TB and HIV Co-infection in Ghana. In: Department DCaP, editor. Accra; 2007.
12.	Ministry of Health. Malawi National TB Programme Manual In: Programme NT, editor. 8 ed. Lilongwe; 2016.
13.	National Department of Health. South Africa National Tuberculosis Management Guidelines 2014. In: Coordination TDS, editor. Pretoria; 2014.
14.	Wilkinson D, Newman W, Reid A, Squire S, Sturm A, Gilks C. Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence. <i>The International Journal of Tuberculosis and Lung Disease</i> 2000; 4 (6): 513-8.
15.	Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. <i>Annals of internal medicine</i> 2011; 155 (8): 529-36.
16.	Rychetnik L, Frommer M, Hawe P, Shiell A. Criteria for evaluating evidence on public health interventions. <i>Journal of Epidemiology & Community Health</i> 2002; 56 (2): 119-27.
17.	Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Jr., Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, Group GW. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. <i>BMJ</i> 2008; 336 (7653): 1106-10
18.	Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nature medicine 2004: 10 (12s): S122.
19.	Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. <i>The Lancet</i> 2005; 365 (9459): 579-87.
20.	Everett DB, Mukaka M, Denis B, Gordon SB, Carrol ED, van Oosterhout JJ, Molyneux EM, Molyneux M, French N, Heyderman RS. Ten years of surveillance for invasive

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

3		Ct
<u>ј</u>		Streptococci
5		prophylaxis i
6	21.	Coles CL, M
7		Mass distrib
0		azithromycin
0		treatment. C
9	22.	Mitià O. Hou
10		Grice T Mas
11		Medicine 201
12	22	Mehor MC
13	23.	
14		TM, Porco T
15		from the field
16	24.	Man WH, de
17		gatekeeper t
18	25.	Satzke C, Tu
19		Restrepo AM
20		respiratory c
21		World Health
22		165 70
23	26	100-79. Coin KD An
24	20.	Cain KP, An
25		Sattayawuth
26		who have tu
20	27.	Bedell RA, A
28		Heyderman
20		bloodstream
30		Malawi. <i>PLo</i>
31	28.	Schleicher G
32		Mycobacteri
33		pneumonia.
34		8.
35	29.	Musicha P. 0
36	20.	Gordon MA
37		resistance in
38		a surveilland
30	20	Montori V/M
10	50.	NOTION VIVI,
40 41		Diyani D, An
42	04	
42	31.	Niiwasa M, N
43		Msefula C, S
45		Amplification
46		Malawi. Plos
40	32.	Lubell Y, Tu
48		acquired infe
40 40		Medicine & I
50	33.	Phua J, Dea
51		pneumonia:
52		237.
52	34	Lim W Smit
55	U 11	pneumonia o
54		2015: thoray
55	35	Van der Daa
50	55.	dor Mort TO
50		
50		
22		40 (2): 444-5
00		

1

Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi. *PloS one* 2011; **6**(3): e17765.

- 21. Coles CL, Mabula K, Seidman JC, Levens J, Mkocha H, Munoz B, Mfinanga SG, West S. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. *Clinical Infectious Diseases* 2013; **56**(11): 1519-26.
- 22. Mitjà O, Houinei W, Moses P, Kapa A, Paru R, Hays R, Lukehart S, Godornes C, Bieb SV, Grice T. Mass treatment with single-dose azithromycin for yaws. *New England Journal of Medicine* 2015; **372**(8): 703-10.
- 23. Maher MC, Alemayehu W, Lakew T, Gaynor BD, Haug S, Cevallos V, Keenan JD, Lietman TM, Porco TC. The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. *PLoS One* 2012; **7**(1): e29407.
- 24. Man WH, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol* 2017; **15**(5): 259-70.
- Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* 2013; **32**(1): 165-79.
- 26. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK. Causes of death in HIV-infected persons who have tuberculosis, Thailand. *Emerging infectious diseases* 2009; **15**(2): 258.
 - 27. Bedell RA, Anderson ST, Van Lettow M, Åkesson A, Corbett EL, Kumwenda M, Chan AK, Heyderman RS, Zachariah R, Harries AD. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. *PLoS One* 2012; **7**(6): e39347.
- Schleicher G, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. *The International Journal of Tuberculosis and Lung Disease* 2003; **7**(12): 1207-8.
- 29. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, Kennedy N, Mallewa J, Gordon MA, Msefula CL, Heyderman RS, Everett DB, Feasey NA. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. *The Lancet Infectious Diseases* 2017; **17**(10): 1042-52.
- Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E. Validity of composite end points in clinical trials. *Bmj* 2005; **330**(7491): 594-6.
- 31. Nliwasa M, MacPherson P, Chisala P, Kamdolozi M, Khundi M, Kaswaswa K, Mwapasa M, Msefula C, Sohn H, Flach C. The sensitivity and specificity of Loop-Mediated Isothermal Amplification (LAMP) assay for Tuberculosis diagnosis in adults with chronic cough in Malawi. *PloS one* 2016; **11**(5): e0155101.
- 32. Lubell Y, Turner P, Ashley EA, White NJ. Susceptibility of bacterial isolates from communityacquired infections in sub-Saharan Africa and Asia to macrolide antibiotics. *Tropical Medicine & International Health* 2011; **16**(10): 1192-205.
- 33. Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. Severe community-acquired pneumonia: timely management measures in the first 24 hours. *Critical Care* 2016; **20**(1): 237.
- 34. Lim W, Smith D, Wise M, Welham S. British Thoracic Society community acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. *Thorax* 2015: thoraxjnl-2015-206881.
- 35. van der Paardt A-F, Wilffert B, Akkerman OW, de Lange WC, van Soolingen D, Sinha B, van der Werf TS, Kosterink JG, Alffenaar J-WC. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. *European Respiratory Journal* 2015;
 46(2): 444-55.

1		
2		
3	36.	Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. In vitro and in vivo activities of
4		macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother
5		2005 49 (4) 1447-54
6	37	Frv Δ Iba H Lietman T Chaudhary IP Bhatta R Elliott I Hyde T Schuchat Δ Gaynor B
7	57.	Dewell S. Adverse and beneficial accordant effects of mass treatment with exitbromycin to
8		Dowell S. Adverse and beneficial secondary effects of mass frequencies 2000; 25(4): 205
9		eliminale bindness due lo trachoma in Nepal. <i>Clinical infectious diseases</i> 2002; 35 (4): 395-
10		402.
11	38.	Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ,
12		Emerson P. Effect of mass distribution of azithromycin for trachoma control on overall
13		mortality in Ethiopian children: a randomized trial. <i>Jama</i> 2009; 302 (9): 962-8.
14	39.	Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC,
15		Emerson PM Lietman TM. Childhood mortality in a cohort treated with mass azithromycin
16		for trachoma Clin Infect Dis 2011: 52(7): 883-8
10	40	Muchar DM Thornor AP. Community acquired pnoumonia. N Engl / Mod 2014: 371 (17):
1/	40.	Acto on
10		
19	41.	Gordon SB, Chaponda M, Walsh AL, Whitty CJ, Gordon MA, Machili CE, Gilks CF, Boeree
20		MJ, Kampondeni S, Read RC, Molyneux ME. Pneumococcal disease in HIV-infected
21		Malawian adults: acute mortality and long-term survival. <i>AIDS</i> 2002; 16 (10): 1409-17.
22	42.	Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that
23		control pneumococcal carriage. PLoS pathogens 2017; 13(12): e1006665.
24	43.	Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, Pebody R, George R,
25		Solution A Edmunds J Gav N Kayhty H Miller E Antibody responses to nasopharyngeal
26		carriage of Streptococcus pneumoniae in adults: a longitudinal household study. <i>Unfect Dis</i>
27		2005: 102 (3): 387 03
28	11	2003, 192(3). 307-93. National Tubaraulasia Control programma, Malawi Nationwida Tubaraulasia Dravalanaa
29	44.	Survey 45th Union World Conference on Lung Locith Develope Spein 2014
30	45	Survey. 45 th Union world Conference on Lung Health. Barcelona, Spain, 2014.
31	45.	Global Health Innovative Technology Fund. Highly Sensitive POC TB-LAW Rapid Diagnostic
32		Test. 2017. https://www.ghitfund.org/impact/portfolio/awpdetail/detail/78 (accessed 28 Feb
33		2018).
34	46.	EuroQol G. EuroQola new facility for the measurement of health-related quality of life.
35		Health policy (Amsterdam, Netherlands) 1990; 16 (3): 199.
36	47.	Maheswaran H, Petrou S, MacPherson P, Choko AT, Kumwenda F, Lalloo DG, Clarke A,
37		Corbett EL. Cost and quality of life analysis of HIV self-testing and facility-based HIV testing
38		and counselling in Blantvre, Malawi, BMC medicine 2016; 14(1); 34.
39	48	Jelsma J Hansen K De Weerdt W De Cock P Kind P How do Zimbabweans value health
40		states? Population health metrics 2003: 1(1): 11
41	<u>1</u> 0	Drummond ME, Sculpher MT, Clayton K, Stoddart GL, Torrance GW, Methods for the
42	40.	economic evaluation of health care programmes: Oxford university press: 2015
43	50	Mehoewaran H. Detrou S. MacDharpen D. Kumwanda F. Lallas DC. Carbett FL. Clarke A
44	50.	Maneswaran H, Petrou S, MacPherson P, Kuniwenda F, Lando DG, Corbett EL, Clarke A.
45		Economic costs and health-related quality of life outcomes of HIV treatment after self-and
46		facility-based HIV testing in a cluster randomized trial. Journal of acquired immune
47		deficiency syndromes (1999) 2017; 75 (3): 280.
-7 /18	51.	Maheswaran H, Petrou S, Cohen D, MacPherson P, Kumwenda F, Lalloo DG, Corbett EL,
40 40		Clarke A. Economic costs and health-related quality of life outcomes of hospitalised patients
47 50		with high HIV prevalence: A prospective hospital cohort study in Malawi. PLOS ONE 2018:
50		13 (3): e0192991.
51	52	Frve JE International Medical Products price indicator quide: Management Sciences for
52 52	02.	Health 2015
55		
54		
55		
56		
5/		
58		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

13 Appendix 1: Informed consent

Included as a separate document on headed pages.

to beet eview only

14 Appendix 2: Division of Microbiology and Infectious Diseases (DMID) adult toxicity table

TABLE VERSION: November 2007

ABBREVIATIONS: Abbreviations utilized in the Table:

ULN = Upper Limit of Normal LLN = Lower Limit of Normal R_x = Therapy	Req = Required
---	----------------

Mod = Moderate IV = Intravenous ADL = Activities of Daily Living Dec = Decreased

ESTIMATING SEVERITY GRADE

For abnormalities NOT found elsewhere in the Toxicity Tables use the scale below to estimate grade of severity:

GRADE 1 Mild Transient or mild discomfort

(< 48 hours); no medical intervention/therapy required

GRADE 2 Moderate Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required

GRADE 3SevereMarked limitation in activity, some assistance usually required;medical intervention/therapy required, hospitalizations possible

GRADE 4 Life-threatening Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable

SERIOUS OR LIFE-THREATENING AEs

ANY clinical event deemed by the clinician to be serious or life-threatening should be considered a grade 4 event. Clinical events considered to be serious or life-threatening include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, severe depression.

COMMENTS REGARDING THE USE OF THIS TABLE

- Standardized and commonly used toxicity tables (Division of AIDS, NCI's Common Toxicity Criteria (CTC), and World Health Organization (WHO)) have been adapted for use by the Division of Microbiology and Infectious Diseases (DMID) and modified to better meet the needs of participants in DMID trials.
- For parameters not included in the following Toxicity Tables, sites should refer to the "Guide for Estimating Severity Grade" located above.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ACT-TB Study Protocol V4.1, 27 Jan 2020

- Criteria are generally grouped by body system.
- Some protocols may have additional protocol specific grading criteria, which will supersede the use of these tables for specified criteria.

HEMATOLOGY				
	Grade 1	Grade 2	Grade 3	Grade 4
Hemoglobin	9.5 - 10.5 gm/d L	8.0 - 9.4gm/dL	6.5 - 7.9 gm/d L	< 6.5 gm/dL
Absolute Neutrophil Count	1000-1500/ mm ³	750-999/ mm ³	500-749/ mm ³	<500/ mm ³
Platelets	75,000-	50,000-	20,000-49,999/	<20,000/ mm ³
	99,999/ mm³	74,999/ mm³	mm ³	
WBCs	11,000-13,000/	13,000-	15,000-	>30,000 or
	mm ³	15,000 / mm³	30,000/ mm³	<1,000 / mm³
% Polymorphonuclear	> 80%	90 – 95%	>95%	
Leucocytes + Band Cells				
Abnormal Fibrinogen	Low:	Low:	Low:	Fibrinogen
	100-200 mg/dL	<100 mg/dL	< 50 mg/dL	associated with
		4		gross bleeding
	High:	High:		
	400-600 mg/dL	>600 mg/dL		coagulation
Fibrin Split Product	20-40 mcg/ ml	41-50 mcg/ ml	51-60 mcg/ ml	> 60 mcg/ ml
Prothrombin Time (PT)	1.01 - 1.25 x ULN	1.26-1.5 x ULN	1.51 -3.0 x ULN	>3 x ULN
Activated Partial	1.01 -1.66 x ULN	1.67 - 2.33 x	2.34 - 3 x ULN	> 3 x ULN
Thromboplastin (APPT)		ULN		
Methemoglobin	5.0 - 9.9 %	10.0 - 14.9 %	15.0 - 19.9%	> 20.0 %

	Grade 1	Grade 2	Grade 3	Grade 4
Hyponatremia	130-135 mEq/ L	123-129	116-122 mEq/ L	< 116 mEq/ L
		mEa/ I		abnormal
		4/ _		sodium <i>with</i>
				mental
				status change
	~			or seizures
Hypernatremia	146-150 mEq/ L	151-157 mEq/	158-165 mEq/ L	> 165 mEq/ L
		L		abnormal
				sodium <i>with</i>
				mental
				status change
				or seizures
Hypokalemia	3.0 - 3.4 mEq/ L	2.5 - 2.9 mEq/	2.0 - 2.4 mEq/ L	< 2.0 mEq/ L
		L .	or intensive	abnormal
			replacement	potassium <i>wi</i>
			therapy or	paresis ileus
		1 7	hospitalization	life-threatenir
			required	arrhythmia
			0,	
Hyperkalemia	5.6 - 6.0 mEq/ L	6.1 - 6.5 mEq/	6.6 - 7.0 mEq/l	> 7.0 mEq/ L
		L		abnormal
				potassium <i>wi</i>
				life-threatenir
				arrhythmia
Hypoglycemia	55-64 mg/dL	40-54 mg/dL	30-39 mg/dL	<30 mg/d L o
				abnormal
				glucose <i>with</i>
				mental

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

				status changes
				or coma
Hyperglycemia	116 - 160 mg/dL	161- 250	251 - 500 mg/dL	> 500 mg/d L or
(nonfasting and no prior		ma/d l		abnormal
diabatas)				glucose <i>with</i>
ulabeles				ketoacidosis or
				seizures
Hypocalcemia (corrected	8.4 - 7.8 mg/dL	7.7 - 7.0 mg/dL	6.9 - 6.1 mg/dL	< 6.1 mg/dL or
for albumin)				abnormal
				calcium <i>with</i> life
				threatening
				arrhythmia or
				tetany
Hypercalcemia (correct for	10.6 - 11.5 mg/d	11.6 - 12.5	12.6 - 13.5 mg/d L	> 13.5 mg/dL or
albumin)	L	ma/d l		abnormal
				calcium <i>with</i> life
		4.		threatening
		O,		arrhythmia
Hypomagnesemia	1.4 - 1.2 mEq/ L	1.1 - 0.9 mEq/	0.8 - 0.6 mEq/ L	< 0.6 mEq/ L or
		L		abnormal
				magnesium <i>with</i>
			2/	life-threatening
			1	arrhythmia
Hypophosphatemia	2.0 - 2.4 mg/dL	1.5 -1.9 mg/dL	1.0 -1.4 mg/dL	< 1.0 mg/dL or
		or	intensive therapy	abnormal
		replacement	or hospitalization	phosphate <i>with</i>
		Rx required	required	life-threatenina
				arrhythmia
Hyperbilirubinemia (when	1.1 - <1.25 x ULN	1.25 - <1.5 x	1.5 – 1.75 x ULN	> 1.75 x ULN
accompanied by any				

increase in other liver				
function test)				
Hyperbilirubinemia (when	1.1 - <1.5 x ULN	1.5 - <2.0 x	2.0 – 3.0 x ULN	> 3.0 x ULN
other liver function are in		ULN		
the normal range)				
BUN	1.25 - 2.5 x ULN	2.6 - 5 x ULN	5.1 - 10 x ULN	> 10 x ULN
Hyperuricemia (uric acid)	7.5 – 10.0 mg/dL	10.1 – 12.0	12.1 – 15.0 mg/d	>15.0 mg/d L
		mg/d L	L	
Creatinine	1.1 - 1.5 x ULN	1.6 - 3.0 x ULN	3.1 - 6 x ULN	> 6 x ULN or
				dialysis required
EN ZYMES				
	Grade 1	Grade 2	Grade 3	Grade 4
AST (SGOT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	l 3.0 – 8.0 x ULN	> 8 x ULN
ALT (SGPT)	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
GGT	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
Alkaline Phosphatase	1.1 - <2.0 x ULN	2.0 – <3.0 x ULN	13.0 – 8.0 x ULN	> 8 x ULN
Amylase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
Lipase	1.1 - 1.5 x ULN	1.6 - 2.0 x ULN	2.1 - 5.0 x ULN	> 5.1 x ULN
URINALYSIS				
	Grade 1	Grade 2	Grade 3	Grade 4
Proteinuria	1+	2-3+	4+	nephrotic
	or	or	or	syndrome
	200 mg - 1 gm	1- 2 gm	2-3.5 gm loss/day	or
	loss/day	loss/day		> 3.5 gm

ACT-TB Study Protocol V4.1, 27 Jan 2020

loss/day

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	
4	
5	
6	
7	
/ 0	
0	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
27	
22	
27	
24 25	
22	
0C 7C	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	
60	

	-	•		
Hematuria	microscopic only	gross, no clots	gross, with or	obstructive or
	<10 rbc/hpf	>10 rbc/hpf	without clots, OR	required
			red blood cell	transfusion
			casts	
CARDIOVASCULAR		<u> </u>	1	<u> </u>
	Grade 1	Grade 2	Grade 3	Grade 4
Cardiac Rhythm		asymptomatic,	recurrent/persiste	unstable
			nt;	
(\mathbf{D}	transient signs,	symptomatic Rx	dysrythmia;
		no	required	hospitalization
	6	Rx required		and treatment
		lotroquirou		
	Ó.			required
Hypertension	transient increase	recurrent,	acute treatment	end organ
	$> 20 \text{ mm}/\text{Hg} \cdot \text{po}$	chronic	required:	damage or
	treatment	increase	outnatient	hospitalization
		> 20mm/ Ha.	treatment or	
				required
		/treatment	hospitalization	
		required	possible	
		(
Hypotension	transient	symptoms due	requires IV fluids;	mean arterial
	orthostatic	to orthostatic	no hospitalization	pressure
	hypotension with	hypotension or	required	<60mm/ Hg or
	heart rate	BP decreased		end organ
	increased by <20	by <20 mm ⊟g		damage or
	beat/min or	sysiolic,		shock; requires
	decreased by <10	with oral fluid		hospitalization
	mm Hg systolic	treatment		and vasopressor
	BP, No treatment			treatment
	required			
	1	1		

Pericarditis	minimal effusion	mild/ moderate asymptomatic effusion, no treatment	symptomatic effusion; pain; EKG changes	tamponade; pericardiocentes is or surgery required
Hemorrhage, Blood Loss	microscopic/occul t	mild, no transfusion	gross blood loss; 1-2 units transfused	massive blood loss; > 3 units transfused
RESPIRATORY				
C	Grade 1	Grade 2	Grade 3	Grade 4
Cough	transient- no treatment	persistent cough; treatment responsive	Paroxysmal cough; uncontrolled with treatment	
Bronchospasm, Acute	transient; no treatment; 70% - 80% FEV ₁ of peak flow	requires treatment; normalizes with bronchodilator; FEV ₁ 50% - 70% (of peak flow)	no normalization with bronchodilator; FEV ₁ 25% - 50% of peak flow; or retractions present	cyanosis: FEV ₁ < 25% of peak flow or intubation necessary
Dyspnea	dyspnea on exertion	dyspnea with normal activity	dyspnea at rest	dyspnea requiring Oxygen therapy
GASTROINTESTINAL	I	I	I	J
	Grade 1	Grade 2	Grade 3	Grade 4

ACT-TB Study Protocol V4.1, 27 Jan 2020

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2
2
<u></u>
4
5
6
7
/
8
9
10
11
12
12
13
14
15
16
17
10
18
19
20
21
22
22 22
23
24
25
26
27
27
28
29
30
31
32
22
33
34
35
36
37
20
38
39
40
41
42
-⊤∠ ∕\?
43
44
45
46
47
10
40
49
50
51
52
53
- J-J
54
55
56
57
52
50
59
60

Nausea	mild or transient;	moderate	no significant	hospitalization
	maintains	discomfort;	intake; requires IV	required;
	reasonable intake	intake	flu ids	
		decreased		
		significantly:		
		some activity		
		limited		
		IIIIIIICEU		
Vomiting	1 episode in 24	2-5 episodes in	>6 episodes in 24	physiologic
	hours	24 hours	hours or needing	consequences
			IV fluids	requiring
				hospitalization
				or requiring
				parenteral
				nutrition
Constipation	requiring stool	requiring	obstipation	obstruction or
	softener or	laxatives	requiring manual	toxic megacolon
	dietary		evacuation or	
	modification	10	enema	
Diarrhea	mild or transient;	moderate or	>7 loose	hypotensive
	3-4 loose	persistent; 5-7	stools/day	shock or
	stools/Day-or mild	loose	or bloody	physiologic
	otoolo, Day of mild	stools/Day-or	diarrhea: or	consequences
	diarrhea last < 1	diarrhea	orthostatic	requiring
	week	lasting >1	hypotension or	hospitalization
		week	electrolyte	
			imbalance or >2L	
			IV fluids required	
Oral Discomfort/Dysphagia	mild discomfort;	some limits on	eating/talking very	unable to drink
	no difficulty	eating/drinking	limited; unable to	flu ids; requires
	swallowing		swallow solid	IV fluids
			foods	
NEUROLOGICAL	l		l	

	Grade 1	Grade 2	Grade 3	Grade 4
Neuro-Cerebellar	slight incoordination	intention tremor,	locomotor ataxia	incapacitated
	is	slurred speech; nystagmus		
Psychiatric	mild anxiety or depression	moderate anxiety or depression; therapy required; change in normal routine	severe mood changes requiring therapy; or suicidal ideation; or aggressive ideation	acute psychosis requiring hospitalization; or suicidal gesture/attempt or hallucinations
Muscle Strength	subjective weakness no objective symptoms/ signs	mild objective signs/symptom s no decrease in function	objective weakness function limited	paralysis
Paresthesia (burning, tingling, etc.)	mild discomfort; no treatment required	moderate discomfort; non-narcotic analgesia required	severe discomfort; or narcotic analgesia required with symptomatic improvement	incapacitating; or not responsive to narcotic analgesia
Neuro-sensory	mild impairment in sensation (decreased sensation, e.g., vibratory, pinprick, hot/cold in great toes) in	moderate impairment (mod decreased sensation, e.g., vibratory, pinprick, hot/cold to	severe impairment (decreased or loss of sensation to knees or wrists) or loss of sensation of at	sensory loss involves limbs and trunk; paralysis; or seizures

ACT-TB Study Protocol V4.1, 27 Jan 2020

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	focal area or	ankles) and/or	least mod degree	
	symmetrical	joint position or	in multiple	
	distribution; or	mild	different body	
	change in taste,	impairment	areas (i.e., upper	
	smell, vision	that	and lower	
	and/or hearing	is not	e xtremities)	
		symmetrical		
MUSCULOSKELATEL		I		<u> </u>
Q	Grade 1	Grade 2	Grade 3	Grade 4
Arthralgia (joint pain)	mild pain not	moderate pain,	severe pain; pain	disabling pain
	interfering with	analgesics	and/or analgesics	
	function	and/or pain	interfering with	
		interfering with	activities of daily	
		function but	living	
		not with		
		activities		
		of daily living		
Arthritis	mild pain with	moderate pain	severe pain with	permanent
	inflammation,	with	inflammation,	and/or disabling
	erythema or joint	inflammation,	erythema or joint	joint
				distruction
	swelling – but not	erythema or	swelling –and	
	interfering with	joint swelling –	interfering with	
	function	interfering with	activities of daily	
		function, but	living	
		not with		
		activities of		
		daily living		
			1	1

ACT-TB Study Protocol V4.1, 27 Jan 2020

	limitation of activity	tenderness (at other than injection site) or with moderate impairment of activity	tenderness with marked impairment of activity	myonecrosis
SKIN]		
	Grade 1	Grade 2	Grade 3	Grade 4
Mucocutaneous	erythema;	diffuse,	vesiculation or	exfoliative
	pruritus	maculo-		
		papular		
		rash, dry	moist	dermatitis,
		desquamation	desquamation or	mucous
			ulceration	membrane
		4		involvement or erythema,
		(0	multiforme or
				suspected
			1	Stevens-
				Johnson or
				necrosis
				requiring
				surgery
Induration	< 15mm	15-30 mm	>30mm	
Erythema	< 15mm	15-30 mm	>30mm	
	4.4.5	15.00 mana	>20mm	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2
3
4
5
5
6
7
8
9
10
11
12
12
13
14
15
16
17
18
19
20
∠∪ ว1
21
22
23
24
25
26
27
27
28
29
30
31
32
33
31
24 27
35
36
37
38
39
40
41
ר גר
+∠ ∡⊃
45
44
45
46
47
48
49
50
50
21
52
53
54
55
56
57
50
50
59
60

Rash at Injection Site	< 15mm	15-30 mm	>30mm	
, ,				
Pruritus	slight itching at	moderate	itching over entire	
	injection site	itching at	body	
		injection		
		extremity		
SYSTEMIC			<u> </u>	1
	Grade 1	Grade 2	Grade 3	Grade 4
Allergic Reaction	pruritus without	localized	generalized	anaphylaxis
	rash	urticaria	urticaria;	
			angioedema	
Headache	mild, no treatme	nttransient,	severe; responds	intractable;
	required	moderate;	to initial narcotic	requires
		treatment	therapy	repeated
		required		narcotic therapy
		lequired		
Fever: oral	37.7 - 38.5 C or	38.6 - 39.5 C	39.6 - 40.5 C or	> 40 C or
	100.0 - 101.5 F	or 101.6 -	103 - 105 F	> 105 F
		102.9 F		
Fatigue	normal activity	normal activity	normal activity	unable to care
	reduced < 48	decreased 25-	decreased > 50%	for self
	hours	50% > 48	can't work	
		hours	2	

15 Appendix 3: Package insert for Azithromycin and amoxicillin

Included as separate attachments.

for beet teries only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



3

4

5 6

7 8

9 10

11

12

13

14

15 16 17

18

35

53 54 55

PARTICIPANT INFORMATION SHEET

Participant information sheet



What is the benefit and unintended consequences of using antibiotic treatment as a way of excluding tuberculosis disease in patients with cough?

Introduction

We would like to invite you to take part in a research study. Joining the study is entirely up to you. Before you Protected decide, you need to understand why the research is being done and what it would involve. One of our team will go through this information sheet with you, and answer any questions you may have. Ask questions if anything you read is not clear or you would like more information. Please feel free to talk to others about the study if you wish. Take time to decide whether or not to take part.

What is the purpose of the study?

19 Tuberculosis (TB) is a disease that causes a long illness and cough with sputum. Although curable TB is 20 difficult to detect. When they fail to detect TB after testing sputum, clinicians give antibiotic treatment that can 21 cure all other causes of TB symptoms but not TB. In this approach, TB is considered ruled out if patient gets 22 better and it is considered likely if they do not get better. The goal of this research study is to develop 23 understanding of how well the antibiotics help distinguish TB patients from those who do not have it, whether 24 giving antibiotics carries other health benefits, and whether it leads to development of disease causing 25 26 organisms which are resistant to drugs. 27

28 We will learn about this by comparing a group of patients given antibiotics on the first day of the study to 29 another group not given antibiotics. There will be two groups receiving antibiotics as follows: 1) Azithromycin 30 taken as one tablet once a day for 3 days, and 2) Amoxicillin 4 capsules taken three times a day for 5 days. The 31 group you will go into, out of the three, will be decided by chance so you can fall into any group. 32

33 What will be involved if I accept to participate in the study? 34

We are considering you for participation in this study because you told us that you have a cough. Any patient 36 37 who has been coughing for at least 2 weeks, is at least 18 years, and lives within Blantyre, is eligible to 38 participate in this study if they do not have signs consistent with serious illness. Apart from you, we will recruit 39 1,874 other individuals. 40

41 Study activities will be performed the first day, at 1 week (Day 8), and at one month (Day 29). At each of these 42 study visits, we will ask you questions about your contact details, your health, use of medications, and any 43 illnesses or hospitalisations you may have had in between study visits. We will also document relevant details 44 45 from your health passport and other clinical documentation you may have. 46

47 On Day 1 and at 1 week, we will ask you to submit sputum and urine samples for TB tests. If you are not able to 48 give sputum on Day 1, we will give you containers so that you can bring them the following morning. Some of 49 the sputum TB tests results will become available after 7 days and we will pass them to health center clinicians 50 who will make a plan for your care, the other results may take up to 4 weeks so you will get them at the 1 month 51 visit. Urine TB test results will not be available for your clinical care. 52

21-May-2019

A copy of this informed consent document to be offered to the participant

56 Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-57 antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi 58 Version & Date: 3.0/28 Feb 2019

59 Principal Investigator: Dr Titus H Divala

ref: LSHTM 15232: COMREC P.04/18/238 Participant Information SheeFor peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 4 60

BMJ Open



We will also do an HIV test. If the results are confirmed to be HIV positive we will do a viral load test, and at the end of the study activities on Day 1, we will link you to HIV management team here at the health center who will start you on treatment. Should we make a diagnosis of TB or HIV at any other point during the study, we will link you with the responsible health center team for treatment services.

On day 1 and at 1-month visit, we will swab the back of the inside of your nose as shown in this picture to collect germs that live there. We will test the germs for drug resistance. Results of this test are not relevant to your care.

Page 121

1

2

3

4 5 6

7

8

9

10

18

19

21

51 52

11 On 1-week visit, we will ask you to report how your health has 12 changed in comparison to how you were on day 1. These 13 questions will be read to you by a computer and you will answer 14 15 them by choosing various options which it will display during the 16 interview. 17

The 1 month visit will be the final study visit where we will also

provide you with results for TB culture and ask if you have TB symptoms. If you are in HIV or TB care, we 20 will ask how your follow up is going. The appointment with you at 1 months is very important because it will help you to know the results of the TB tests and it will also help us know the status of your health. 22

23 The number of clinic visits you will make for this study is at least three. Here we count Day 1, one visit after 24 25 one week, and another visit at one month. If you have not been able to come here for any of the visits, we will 26 remind you by phone call or we will use the permission and information you will give us to visit you at your 27 home. The first visit will take about 60 minutes and the later visits will take about 30 minutes each. 28

29 Will there be any risks involved in this study? 30

31 This study is a low risk study. There are no risks involved in submitting sputum or urine for the study. You 32 may feel some discomfort during swabbing of the back of the nose and during blood collection for HIV and 33 Azithromycin and amoxicillin are already widely used in Malawi and rarely cause viral load tests. 34 35 problems. Rare side effects for azithromycin include feeling nervousness, skin reactions and disturbance of 36 heart function. Rare side-effects for amoxicillin are mental state changes, feeling light-headed, and reactions to 37 sunlight. 38

39 The London School of Hygiene and Tropical Medicine holds insurance policies which apply to this study. If 40 you experience harm or injury as a result of taking part in this study, you may be eligible to claim 41 compensation. 42

43 Will there be any benefits in this study? 44 45

46 The key benefit of this study is that you will have access to a more detailed TB evaluation process than usual. 47 This will help you know if you have TB and to have the opportunity to start TB treatment. The study is also 48 beneficial to health care providers because it will address important questions about use of antibiotics during the 49 TB diagnostic process. ollege OI leaicine 50

53 Will the findings in the study be confidential? 54

21-Mav-2019

55 A copy of this informed consent document to be offered to the participant 56 Study title: Randomised controlled clinical trial of diagnostic value, clinical benefits and unintended consequences of using trial-of-57 antibiotics to evaluate ambulatory adults with prolonged cough for tuberculosis in Malawi 58 Version & Date: 3.0/28 Feb2019

59 Principal Investigator: Dr Titus H Divala

REC ref: LSHTM 15232; COMREC P.04/18/238 Participant Information SheefFor peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 2 of 4 60



122 of 134 BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, AI training, and similar technologies

Your identity in this study will be treated as confidential. The results of the study, including laboratory or any other data, may be published for scientific purposes but will not give your name or include any identifiable references to you. Information about TB test result and HIV test results will be recorded using an identification number. However, any records or data obtained as a result of your participation in this study may be used by LSHTM who are sponsoring this study, regulators of health research (COMREC), or by members of the research team. These records will be kept in a locked space in the University of Malawi College of Medicine. Information and samples collected in this study will be retained for up to 10 years after the end of the trial, according to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent.

According to our institution recommendations. These collected samples and other information may also be used for future studies if you give us that consent. **Can I withdraw from the study anytime and will this affect my treatment?**You are free to choose whether or not to participate in this study. While we would like you to participate in the study to the very end, withdrawing at any point is an option that is freely available to you without any penalty or loss of any entitled benefits. You will be provided with any significant new findings developed during the course of this study that may relate to or influence your willingness to continue participation. **What are the financial benefits of participating in this study?**There will be no payment given to you for participating in the study. The study will provide at least MK8,000 as compensation for your costs of attending the study visits. We will give this money in instalments on scheduled study visits. **Is this study approved by an ethics committee?**The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee, and the College of Medicine Research Ethics Committee (COMREC). **Who do you ask if you have questions regarding the study?**

If you have any questions concerning participation in this study, please feel free to ask me. Alternatively, you can contact the following people by phone or post:

	Name	Telephone	Postal address
Study investigators	Dr Titus Divala	0999478376	Helse Nord Tuberculosis Initiative University of Malawi College of
	Dr Marriott	0888681948	Medicine
	Nliwasa		Private Bag 360, Chichiri, Blantyre 3, Malawi
COMREC			
	Administrative	01 877 245	University of Malawi College of
	officer, COMREC	01 877 291	Medicine por over by
	Secretariat		Private Bag 360, Chichiri, Blantyre 3, Malawi
		-	21-May-2019
Study title: Randomised cont intibiotics to evaluate ambula Principal Investigator: Dr T Participant Information Sheet	A copy of this informed c crolled clinical trial of diagno atory adults with prolonged Version & itus H Divala For peer review only - http	onsent document stic value, clinical b cough for tuberculo Date: 3.0/28 Feb20 p://bmjopen.bmj.c	to be offered to the participant enefits and unintended consequences of using trial-of- osis in Malawi 19 REC ref: LSHTM 15232; COMREC P.04/18/2381 om/site/about/guidelines.xhtml Page 3 of 4

Page 123 of 134 ACT

2 3 4

5



What is the benefit and unintended consequences of using antibiotics treatments as a way of excluding tuberculosis disease in patients with cough?

Patient declaration

Statement		In	itial or
		th	umbprir
		ea	ich box
I confirm that I have read the above	e information sheet for the above named study	. I have had	
the opportunity to consider the info	ormation, ask questions and have these answere	ed	
satisfactorily.			
OR			
I have had the information explained	ed to by study personnel in a language that I un	nderstand. I	
have had the opportunity to consid	er the information, ask questions and have thes	se answered	
satisfactorily.			
I understand that my participation i	is voluntary and that I am free to withdraw at a	iny time	
without giving any reason, without	t my medical care or legal rights being affected	the study may	
i understand that relevant sections	of my incurcal notes and data collected during	the study may	
Medicine and COMREC where it	is relevant to my taking part in this research	I give	
nermission for these individuals to	have access to my records	1 5110	
I understand that data about me ma	by be shared via a public data repository or by	sharing directly	
with other researchers and that I w	yill not be identifiable from this information		
and that I w			
I understand that the tissue sample	collected from me will be used to support othe	er research in	
the future, and may be shared anon	nymously with other researchers, for their ethic	ally-approved	
projects			
I agree to take part in the above nat	med study		
8 1			
0 1			
Printed name of narticinant	Signature/thumb print of participant	Date	
Printed name of participant	Signature/thumb print of participant	Date	
Printed name of participant	Signature/thumb print of participant	Date	
Printed name of participant	Signature/thumb print of participant	Date	
Printed name of participant Printed name of impartial witnes	Signature/thumb print of participant Signature of impartial witness*	Date	
Printed name of participant Printed name of impartial witnes	Signature/thumb print of participant Signature of impartial witness* Udv information accurately. to	Date	and was
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to	Date Date , a	and was
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applied)	Date Date, a eely given their cons ble	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Signature of impartial witness* Udy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical	Date Date , a cely given their cons ble).	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Udy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical	Date Date, a cely given their cons ble).	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my know participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Indy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical	Date Date	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a	Signature/thumb print of participant Signature of impartial witness* Idy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical sent Signature of staff obtaining consent	Date Date , a eely given their cons ble). Date	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons **	Signature/thumb print of participant Signature/thumb print of participant Ss* Signature of impartial witness* udy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical sent Signature of staff obtaining consent	Date Date 	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participant should be someone the part	Signature/thumb print of participant Signature/thumb print of participant ss* Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant in participant in the impartial witness of signature and the impartial witness of signature of signature and the impartial witness of signature of signature and the impartial witness of signature of signature of signature and the impartial witness of signature	Date Date , a cely given their cons ble). Date Date Date Date	and was sent to
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in	Signature/thumb print of participant Signature/thumb print of participant Ss* Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant place of signature and the impartial witness should go ahead and stated and	Date Date , a cely given their cons ble). Date Date name but cannot sign for th and sign in designated space	and was sent to nem. Instea
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in	Signature/thumb print of participant Signature/thumb print of participant ss* Signature of impartial witness* udy information accurately to ledge by, the participant and that he/she has freabove named impartial witness (where applical sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant replace of signature and the impartial witness should go ahead and the impartial witness should go and the impartial wi	Date Date	and was sent to nem. Instea e.
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in A copy of the	Signature/thumb print of participant Signature/thumb print of participant Signature of impartial witness* Output of the participant and that he/she has free above named impartial witness (where applicat sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant place of signature and the impartial witness should go ahead a sis informed consent document to be offered to the participant	Date Date , a cely given their cons ble). Date Date ticipant	and was sent to nem. Instea
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in A copy of thi Study title: Randomised controlled clinical antibilaties to avaluate ambulatery adults of	Signature/thumb print of participant Signature of impartial witness* ady information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant place of signature and the impartial witness should go ahead and the impartial witness and th	Date Date , a cely given their cons ble). Date name but cannot sign for th and sign in designated space ticipant onsequences of using tria	and was sent to nem. Instea e.
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part Iliterate participants should use thumbprint in A copy of thi Study title: Randomised controlled clinical antibiotics to evaluate ambulatory adults wi	Signature/thumb print of participant Signature of impartial witness* udy information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applical sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant place of signature and the impartial witness should go ahead a is informed consent document to be offered to the participant trial of diagnostic value, clinical benefits and unintended contended cough for tuberculosis in Malawi Version & Date: 3.0/28 Feb2019	Date Date	and was sent to nem. Instea e. al-of-
Printed name of participant Printed name of impartial witnes I attest that I have explained the stu understood to the best of my knowl participate* in the presence of the a Printed name of staff obtaining cons *Impartial witness should be someone the part illiterate participants should use thumbprint in A copy of thi Study title: Randomised controlled clinical antibiotics to evaluate ambulatory adults wi Principal Investigator: Dr Titus H Divala	Signature/thumb print of participant Signature/thumb print of participant Signature of impartial witness* Ady information accurately to ledge by, the participant and that he/she has free above named impartial witness (where applicat sent Signature of staff obtaining consent ticipant trusts. The impartial witness can write the participant place of signature and the impartial witness should go ahead is informed consent document to be offered to the part trial of diagnostic value, clinical benefits and unintended c ith prolonged cough for tuberculosis in Malawi Version & Date: 3.0/28 Feb2019 REC ref: LSHTM 1	Date Date , a cely given their consecution Date Date Date Date Date Date Date Date	and was sent to nem. Instea al-of- /2381


PARTICIPANT INFORMATION SHEET



Chikalata chofotokozera ofuna kutenga nawo mbali

Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufifuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Chiyambi

1

2

3 4

5 6

7 8

9 10

11

12

13

14

15 16

17

18 19

20 21

22

23

24

25 26

27

28

29

30

31

32 33

34 35

36

37

38

39

40 41

42 43 44

45

46

47

48 49

50

51

52 53

54 55

56

57 58

59

60

Tikukukupemphani kuti mutenge nawo mbali mu kafukufuku. Ndi chifuniro chanu kulowa mu kafukufukuyu. Musanapange chiganizo, mukuyenera kumvetsa chifukwa chimene kafukufukuyu akuchitikira komanso zimene zitadzachitike. M'modzi mwa anthu a gulu logwira ntchito mu kafukufuku awerenga chikalatachi pamodzi ndi inu, ndipo ayankha mafunso ena aliwonse amene mungakhale nawo. Funsani mafunso ngati simukumvetsa zomwe mwawerenga kapena ngati mukufuna uthenga owonjezera. Muli omasuka kulankhula ndi ena zokhudza kafukufukuyu ngati mukufuna. Ganizani mofatsa musanavomereze kutenga nawo mbali kapena ayi.

Kodi cholinga cha kafukufukuyu ndi chiyani?

Chifuwa chachikulu (TB) ndi matenda amene munthu amkhala chidwalire kwa nthawi yaitali. Odwalayo, amapanga makhololo. Ngakhale chili chochizika, chifuwa chachikulu ndi chovuta kuchipeza. Pamene njira zoyeza makholoro zalephera kupeza chifuwa chachikulu, achipatala amapereka mankhwala opha tizirombo toyambitsa matenda amene angathane ndi zonse zimene zimayambitsa zizindikiro za matenda ofanana ndi chifuwa chachikulu. Ngati odwala apeza bwino ndi njira imeneyi amaganiziridwa kuti alibe matenda a chifuwa chachikulu koma ngati sanapeze bwino amaganiziridwa kuti ali ndi chifuwa chachikulu. Cholinga cha kafukufuku ameneyu ndi kufuna kumvetsa za m'mene mankhwala amenewa amathandizira kusiyanitsa odwala matenda a chifuwa chachikulu ndi amene alibe matendawa, ngati mankhwalawa ali ndi phindu lina kwa odwala, komanso ngati kupereka mankhwalawa kukubweretsa tizirombo tosamva makhwala.

Tiphunzira zimenezi pakusiyanitsa gulu la anthu odwala amene apatsidwa mankhwala opha tizirombo toyambitsa matenda patsiku loyamba la kafukufukuyu ndi gulu lina limene silinapatsidwe mankhwalawa. Pakhala magulu awiri olandira mankhwala opha tizirombo motere: 1) Azitrhomycin omwedwa pilisi imodzi kamodzi patsiku kwa masiku atatu, komanso 2) Amoxicillin makapusolo anayi omwedwa katatu patsiku kwa masiku asanu. Gulu limene mulowe, mwa magulu atatuwa, lisankhidwa mwa mayere choncho mukhoza kupezeka mu gulu lina lirilonse.

Kodi chidzachitike ndi chiyani ngati ndingavomereze kutenga nawo mbali mu kafukufukuyu?

Tikukupemphani kuti mutenge nawo mbali mu kafukufukuyu chifukwa mwatiuza kuti muli ndi chifuwa. Odwala wina aliyense amene wakhala akukhosomola kwa masabata osachepera awiri, ali ndi zaka zosachepera 18, ndipo amakhala mu Blantyre muno, atha kutenga nawo mbali mu kafukufukuyu ngati alibe zizindikiro zosonyeza kudwalika kwambiri. Kupatula inu, tilemba anthu ena okwanira 1,874.

Zochitika za kafukufukuyu zidzapangidwa patsiku loyamba, pa sabata imodzi (Tsiku 8), ndi pamwezi umodzi (Tsiku 29). Pa masiku a kafukufuku onsewa, tidzakufunsani mafunso okhudzana ndi m'mene tingalumikizirane nanu, thanzi lanu, kagwiritsidwe ntchito ka mankhwala, ndi matenda ena aliwonse kapena kugonekedwa mu chipatala komwe kungakuchitikireni. Tidzalembahso/zinthulzofunikira

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: ԹՇՇֈեսջ ի Divala only - http://bmjopen.bmj.com/sitePaSouf/JSHJCH14523RtmpMREC P.04/18/238 Chikalata chofotokozera ofuna kutenga nawo mbali Page 1 of 5



kuchokera mu bukhu lanu la kuchipatala komanso zolembedwa zina za chipatala zimene mungakhale nazo.

Patsiku loyamba ndi pakutha pasabata yoyamba, tidzakufunsani kuti mupereke makhololo komanso mkodzo pofuna kuyeza matenda a chifuwa chachikulu. Ngati simungakwanitse kupereka makhololo patsiku loyamba, tidzakupatsani mabotolo kuti mudzawabweretse m'mawa wa tsiku lotsatira. Zotsatira zina za makhololo zidzatuluka pakutha pa masiku asanu ndi awiri ndipo tidzazipereka kwa matodolo a chipatala chino kuti akuthandizeni, zotsatira zina zidzatenga pafupi-fupi masabata anayi choncho mudzazilandira pa ulendo wa pamwezi umodzi. Zotsatira zanu zoyesa mikodzo ku matenda a chifuwa chachikulu sizidzakhalapo ku nkhani ya chisamaliro chanu cha kuchipatala.

Tidzayezanso kachirombo ka HIV. Ngati zotsatirazi zasonyeza kuti muli ndi kachirombo ka HIV tidzayeza kuchuluka kwa tizirombo ta HIV, komanso kukutumizani kolandilira chithandizo chamatendawa. Ngati tingakupezeni kuti muli ndi matenda a chifuwa chachikulu kapena kachirombo ka HIV panthawi ina iliyonse mkati mwa kafukufukuyu, tidzakutumizani kolandilira zithandizo zamatendawa pompano pachipatala.

Patsiku loyamba komanso pa ulendo wa mwezi woyamba, tidzapukuta kumbuyo kwa mkati mwa mphuno mwanu ngati m'mene zikuonekera pachithunzichi kuti titenge tizirombo timene timakhala m'menemo. Tidzayeza tizirombo timeneti kuti tione ngati tikumva mankhwala. Zotsatira zimenezi sizidzagwiritsidwa ntchito kuchisamaliro chanu chaku chipatala.

Pa ulendo wa sabata yoyamba, tidzakupemphani kuti mutiuze m'mene thanzi lanu lasinthira kuyerekeza ndi

m'mene munaliri patsiku loyamba. Mafunso amenewa adzawerengedwa kwa inu kudzera pa makina a kompyuta ndipo mudzawayankha pakusankha mayankho angapo amene makinawa adzawonetse panthawi yomwe azidzafunsa.

Ulendo wa pa mwezi umodzi udzakhala wotsiriza umene tidzakupatseninso zotsatira za zoyesa za matenda a chifuwa chachikulu komanso tidzakufunsani ngati muli ndi zizindikiro za matenda a chifuwa chachikulu. Ngati panthawiyi mudzakhale kuti mukulandira Thandizo la HIV kapena TB, tidzakufuna kudziwa kuti zikuyenda bwanji. Kukumana ndi inu patatha mwezi umodzi ndikofunikira kwambiri chifukwa zidzakuthandizirani kuti mudziwe zotsatira za zoyeza za matenda a chifuwa chachikulu ndipo zidzatithandiziranso kudziwa zam'mene thanzi lanu liliri.

Maulendo a kuchipatala amene mudzayende a kafukufukuyu ndiwosachepera atatu. Pamenepa tikuwerenga tsiku loyamba, ulendo umodzi pakutha pa sabata imodzi, ndi ulendo umodzi pa mwezi umodzi. Ngati simunakwanitse kubwera kuno pa ulendo wina uliwonse tidzakukumbutsani pokuyimbirani lamya kapena tidzagwiritsa ntchito chilorezo ndi uthenga umene mudzatipatse kuti tikuyendereni kunyumba kwanu. Patsiku loyamba tidzakhala nanu kwa mphindi makumi asanu ndi imodzi, pamene paasiku ena onse, tidzakhala nanu kwa mphindi makumi atatu.

Kodi padzakhala ziopsezo zina zilizonse zochitika mu kafukufukayu?May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Chikalata chofotokozera ofuna kutenga nawo mbali Page 2 of 5







Kupanga nawo kafukufukuyu sikuika moyo wanu pa chiopsyezo chochuluka. Palibe chiopsezo pa kupereka makhololo kapena mikozo mu kafukufukuyu. Mukhoza kusamva bwino panthawi yopukuta kumbuyo kwa mphuno komanso panthawi yotenga magazi oyeza za kachirombo ka HIV ndi kuchuluka kwa tizirombo toyambitsa matendawa. Azithromycin ndi amoxicillin ndi mankhwala oti akhala akugwiritsidwa ntchito kwa nthawi yayitali m'Malawi ndipo sikweni-kweni kuyambitsa mavuto. Patalipatali azithromycin amapangitsa kumva nthumazi, ziwengo, komanso kusokonekera kwa kagwiridwe ntchito ka mtima. Patali-patali amoxicillin amapangitsa kusakhazikika mmanganizo, kumva chizungulire, komanso kutuluka ziwengo munthu akakhala padzuwa.

A London School of Hygiene ndi Tropical Medicine ali ndi thumba landalama zachipukuta misozi lokhudzana ndi kafukufukuyu. Ngati mwapweteka kapena kuvulala chifukwa chotenga nawo mbali mu kafukufukuyu, mudzakhale omasuka kupempha chipukuta misonzi.

Kodi padzakhala zopindula zina zilizonse mu kafukufukuyu?

Chopindulitsa chodziwika cha kafukufukuyu ndi chakuti mudzakhala ndi mwayi oyezedwa matenda a chifuwa chachikulu mozama kuposa m'mene zimakhalira nthawi zonse. Zimenezi zidzakuthandizirani kudziwa ngati muli ndi matenda a chifuwa chachikulu komanso kukhala ndi mwayi oyamba kulandira thandizo la mankhwala a chifuwa chachikulu. Kafukufukuyu ndi opindindulitsanso kwa opereka chisamaliro cha kuchipatala chifukwa adzayankha mafunso ofunikira okhudzana ndi kagwiritsidwe ntchito ka mankhwala opha tizirombo toyambitsa matenda panthawi ya ndondomeko yoyeza matenda a chifuwa chachikulu.

Kodi zotsatira za mukafukufukuyu zidzakhala za chinsinsi?

Chizindikiritso chanu mu kafukufukuyu chidzatengedwa kukhala cha chinsinsi. Zotsatira za kafukufukuyu, zikhoza kudzasindikizidwa ndi cholinga cha sayansi koma dzina lanu kapena chizindikiritso chilichonse chokhudzana ndi inu chidzabisidwa. Uthenga okhudza zotsatira zoyesa matenda achifuwa chachikulu kapena HIV zidzalembedwa pogwiritsa ntchito nambala yanu yakafukufuku. Komabe, zina zomwe mungatifotokozere zitha kudzagwiritsidwa ntchito ndi amene ali oyang'anira za kafukufuku wa zaumoyo (COMREC) komanso LSHTM. kapena ndi mamembala a gulu la kafukufukuyu. Zolembedwazi zidzasungidwa mumalo otsekedwa bwino ku sukulu ya ukachenjede ya Malawi College of Medicine. Uthenga ndi zoyesa zotengedwa mu kafukufukuyu zidzassungidwa kwa zaka pafupi-fupi khumi (10) pakutha pakuyesaku, malingana ndi ndondomeko ya bungwe lathu. Zoyesa zotengedwazi ndi mauthenga ena zikhoza kugwiritsidwanso ntchito pa kafukufuku wamtsogolo ngati mutatipatsa chilolezo chimenecho.

Kodi ndikhoza kusiya kafukufukuyu nthawi ina iliyonse ndipo zimenezi zingadzakhudze thandizo langa la mankhwala?

Muli ndi ufulu kusankha kutenga nawo mbali kapena kusatenga nawo mbali mu kafukufukuyu. Ngakhale tingakonde kuti mutenge nawo mbali mu kafukufukuyu mpaka ku mapeto, kutuluka nthawi iliyonse mukafukufuku ndi chisankho chanu popanda chilango chilli chonse kapena kuluza kulandira thandizo lililonse lomwe mukuyenera kulandira. Munthawi yakafukufukuyu, tidzakudziwitsani patati 21-May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Dr Titus H Divala For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Chikalata chofotokozera ofuna kutenga nawo mbali Page 3 of 5



Page 127 of 13 patuluka mauthenga ena a sayansi ofotokoza zinthu zimene zingakupangitseni kuti mulingalirenso 2 zachisamkho chanu chotenga nawo mbali. 3 4 Kodi pali phindu la ndalama lotani pakutenga nawo mbali mu kafukufukuyu? 5 6 Sipadzakhala kupatsidwa malipiro chifukwa chotenga nawo mbali mukafukufukuyu. Ndalama yomwe 7 8 tidzakupatseni ndi yokwana MK8,000. Ndalamayi tizikupatsani pangonopango pamasiku anu 9 akafukufuku.. 10 11 Kodi kafukufukuyu ndiwovomerezeka ndi komiti yowona za ufulu wa anthu mukafukufuku? 12 13 Kafukufukuyu wavomerezedwa ndi London School of Hygiene & Tropical Medicine Research Ethics 14 Committee, ndi College of Medicine Research Ethics Committee (COMREC). 15 16 Kodi mungafunse ndani ngati muli ndi mafunso okhudzana ndi kafukufukuyu? 17 18 Ngati muli ndi mafunso ena aliwonse okhudza kutenga nawo mbali mukafukufukuyu, chonde khalani 19 20 omasuka kundifunsa. Munjira ina, mukhoza kulumikizana ndi anthu otsatirawa pa lamya kapena 21 polemba kalata kumakeyala awa: 22 23 Telephone **Postal address** Name 24 Dzina Lamya Adilesi 25 26 **Study investigators** Dr Titus Divala 0999478376 Helse Nord Tuberculosis Initiative 27 Akulu-akulu 28 University of Malawi College of 29 akafukufuku Medicine 30 Dr Marriott 0888681948 Private Bag 360, Chichiri, 31 Nliwasa Blantyre 3, Malawi 32 **COMREC** 33 01 877 245 University of Malawi College of Administrative 34 01 877 291 officer. COMREC Medicine 35 Private Bag 360, Chichiri, 36 Secretariat 37 Blantyre 3, Malawi 38 39 40 41 42 43 44 45 46 Approved by College of Medicine 47 48 49 50

21-May-2019

Mpatseni otenga nawo mbali chikalata chimodzi kuti chikhale chake

Dzina la kafukufuku: Kodi kugwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira kufufuza chifuwa chachikulu kuli ndi phindu kapena kuipa kotani?

51 52

53 54 55

56

57 58

59

60

Version & Date: 3.0/28 Feb 2019

Mkulu wakafukufuku: Pr Titus H Divala Chikalata chofotokozera ofuna kutenga nawo mbali Page 4 o Page 4 of 5



MEDICINE Kodi pali phindu lotani komanso zotsatira zosayembekezereka zotani pogwiritsa ntchito mankhwala opha tizirombo toyambitsa matenda ngati njira yothana ndi matenda a chifuwa chachikulu mu anthu amene ali ndi chifuwa?

Chitsimikizo cha odwala

 Lembani mubokosi liri kumanjali mawu oyamba adzina lanu kapena dindani ndi chala

ngati mukuvomereza		
Mfundo yachitsimikizo		
Ndikutsimikiza kuti ndawerenga	chikalata cha uthenga wa kafukufuku amene watchulidwa	
m'mwambamu. Ndakhala ndi my	vavi woganizira za uthengawu, kufunsa mafunso komanso	
ndavankhidwa mokhutira.		
KAPFNA		
Ndafatakazeredwa uthengawa nd	i akafukufuku mu chilankhulo chimene ndikuchimvetsa . Ndakhal	0
ndi muavi waganizira za uthanga	n akarukuruku mu cimankiruro cimitene nurkucimirvetsa. Nuakira	a
ndi iliwayi woganizita za utilenga	uwu, Kufunisa mafuniso Komanso ndayankindwa mokinutifa.	
Ndikumvetsa kuti kutenga nawo i	mbali kwanga ndikosakakamizidwa ndipo ndili ndi utulu kusiya	
panthawi ina iliyonse popanda ku	pereka chifukwa china chilichonse, popanda kukhudza chisamalir	0
cha kuchipatala kapena ufulu war	iga.	
Ndikumvetsa kuti magawo ofunil	kira a zolembedwa zanga za ku chipatala komanso mu	
kafukufukuyu kuwonedwa ndi an	thu ovomerezeka aku LSHTM, University of Malawi College of	
Medicine komanso COMREC, pa	umene kuli kofunika kutenga nawo mbali mukafukufukuyu.	
Ndikupereka chilolezo kwa anthu	amenewa kuti athe kuwona za zolembedwa zanga.	
Ndikumvetsa kuti zomwe atolere	akafukufuku zokhudza ine zikhoza kugawilidwa kwa anthu ena	T
opanga kakafukufuku, ndipo kuti	sipadzakhala chizindikiro chilichonse chosonyeza kuti zinachoker	a
kwa ine.		
Ndikumvetsa kuti zoveza za mthu	ipi mwanga zimene zidzatengedwe kwa ine zidzagwiritsidwa	
ntchito kuthandizira kafukufuku y	vina mtsogolo, ndipo zikhoza kudzagawidwa mwachinsinsi ndi	
akafukufuku ena na ntchito yawa	vovomerezeka ndi malamulo aowona zakafukufuku	
Ndilawomorozo latongo nowo m	bali mu kafukufuku amana watahulidwa namwambayu	
Nulkuvometeza kutenga nawo m	Jan mu kalukuluku amene watenunuwa Jamwamuayu.	
	I J	
Drine la wotange newo mbali S	wini/shidinda sha shala sha watanga mbali. Tsiku	
Dzina la wotenga nawo mbali Sa	ayini/chidindo cha chala cha wotenga mbali Tsiku	
Dzina la wotenga nawo mbali Sa	ayini/chidindo cha chala cha wotenga mbali Tsiku	
Dzina la wotenga nawo mbali Sa	ayini/chidindo cha chala cha wotenga mbali Tsiku	
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali*	ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku	
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali*	ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku	
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u	ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamyeka monga mwakudziwa kwar	ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb	ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa nga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kut bali imene yatchulidwa pamwambapa (ngati kuli koyenera).	, 1
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1 , i ate
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb	Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa nga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kut pali imene yatchulidwa pamwambapa (ngati kuli koyenera).	, r , r i ate
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mhoni yopanda mbali ilawanakara kuthala	ayini/chidindo cha chala cha wotenga mbali Tsiku ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa nga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kut bali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Tsiku wakhulupiridwa ndi munthu ofina kutaraa nawa mukafulufukuya Mhari ikhara hulu	, r , i atc
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ddikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mb Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1 i ate
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ddikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala yazina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asavin	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1 , 1 i ate ba
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Diamonda mbali Ndikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali Diamonda mbali Dzina la wotenga chilolezo * *Mboni yopanda mbali ikuyenekera kukhala zizina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa aga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kut bali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Sayini ya wotenga chilolezo Sayini ya wotenga chilolezo Sayini ya muthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulem ufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku e ndi chidindo cha chala chake ndipo mboni isayine dzina ndi sayin, panalo ambone.	, 1
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ddikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oter	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa aga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kut bali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Tsiku yokhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulem ufukuyo koma singasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku e ndi chidindo cha chala chake ndipo mboni isayine dzina noi sayine dzi	, 1 i ate
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Dkikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala yazina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oten Dzina la kafukufuku: Kodi kugwiritsa ntch	Ayini/chidindo cha chala cha wotenga mbali Tsiku Ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ddikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala yazina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oten Dzina la kafukufuku: Kodi kugwiritsa ntok kufufuza chifuwa chachikulu kuli ndi phind	ayini/chidindo cha chala cha wotenga mbali Tsiku ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, 1
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ddikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oter Dzina la kafukufuku: Kodi kugwiritsa ntch kufufuza chifuwa chachikulu kuli ndi phind	ayini/chidindo cha chala cha wotenga mbali Tsiku ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku sayini ya mboni yopanda mbali Tsiku thenga wa kafukufukuyu molondola kwa	, r i ate
Dzina la wotenga nawo mbali Sa Dzina la mboni yopanda mbali* Ddikutsimikiza kuti ndafotokoza za u zinamveka monga mwakudziwa kwar mbali* pamaso pa mboni yopanda mbali* Dzina la wotenga chilolezo *Mboni yopanda mbali ikuyenekera kukhala y dzina la munthu ofuna kutenga nawo mukafuk ngati samatha kuwerenga ndi kulemba, asayin Mpatseni oter Dzina la kafukufuku: Kodi kugwiritsa ntof kufufuza chifuwa chachikulu kuli ndi phind	ayini/chidindo cha chala cha wotenga mbali Tsiku ayini/chidindo cha chala cha wotenga mbali Tsiku Sayini ya mboni yopanda mbali Tsiku staga ndi, wotenga nawo mbali komanso kuti apereka chilolezo chawo kuti ali imene yatchulidwa pamwambapa (ngati kuli koyenera). Sayini ya wotenga chilolezo Sayini ya wotenga chilolezo Tsiku yokhulupiridwa ndi munthu ofuna kutenga nawo mukafukufukuyo. Mboni ikhoza kulem ufukuyo koma siingasayine mmalo mwake. Munthu ofuna kutenga nawo mukafukufuku e ndi chidindo cha chala chake ndipo mboni iso ine dzina di so ini, papalo ambone. nga nawo mbali chikalata chimodzi kuti chikhale chake nito mankhwala opha tizirombo toyambitsa matenda ena ngati njira yothandizira u kapena kuipa kotani? Version & Date: 3.0/28 Feb 2019 Nersion & Date: 3.0/28 Feb 2019 aka kata (functiona kutenga hari conta) (finctiona kutenga kut	, n i ate

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	<u>#1</u>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	30
Protocol version	<u>#3</u>	Date and version identifier	1
Funding	<u>#4</u>	Sources and types of financial, material, and other support	26
	For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

U	0		54
			BMJ Open: first published
	Protected by copyright, includ		as 10.1136/bmjopen-2019-033999
•	ing for uses related to text and da	Enseignement Superieur	on 25 March 2020. Downloaded fr
	ta mining, Al training	(ABES) .	om http://bmjopen.bi
	, and similar techn		nj.com/ on June 11
	ologies.		, 2025 at Agend
			ce Bibliographique de l

1 2 3 4 5	Roles and responsibilities: contributorship	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	26
6 7 8 9 10 11 12	Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	26
13 14 15 16 17 18 19 20 21 22	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	26
22 23 24 25 26 27 28 29 30 31	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	21
32 33	Introduction			
34 35 36 37 38 39 40 41 42	Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
43 44 45 46 47	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	4, 8, 22
48 49	Objectives	<u>#7</u>	Specific objectives or hypotheses	5, 10
50 51 52 53 54 55 56 57 58 59	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	5, 6
5 9 60	F	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6	Methods: Participants, interventions, and outcomes		
7 8 9 10 11 12 13	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
14 15 16 17 18 19 20	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
21 22 23 24 25	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
26 27 28 29 30 31 32 33	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
35 36 37 38 39 40	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
41 42 43 44	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial
45 46 47 48 49 50 51 52 53 54 55 56 57 58	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
59 60	Fo	or peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2019-033999 on 25 March 2020. Downloaded from http://bmjopen.bmj.com/ on June 11, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1 2 3 4 5 6 7 8	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
9 10 11 12 13 14 15 16	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
17 18 19 20	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size
21 22	Methods:		
23	Assignment of		
24	interventions (for		
25 26 27	controlled trials)		
28 20	Allocation: sequence	<u>#16a</u>	Method of generating the allocation sequence
30	generation		(eg, computer-generated random numbers),
31 22			and list of any factors for stratification. To
33			reduce predictability of a random sequence,
34			details of any planned restriction (eq, blocking)
35 36			should be provided in a separate document that
37			is unavailable to those who enrol participants or
38			assign interventions
39 40			assign interventions
41	Allocation	<u>#16b</u>	Mechanism of implementing the allocation
42 43	concealment		sequence (eq, central telephone; sequentially
44	mechanism		numbered, opaque, sealed envelopes).
45			describing any steps to conceal the sequence
46 47			until interventions are assigned
48			
49 50	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who
51	implementation		will enrol participants, and who will assign
52			participants to interventions
55 54			
55	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to
оо 57			interventions (eg, trial participants, care
58			
59 60	Fo	r peer rev	/iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2			providers, outcome assessors, data analysts), and how
3 4 5 6 7 8 9	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial
10 11 12	Methods: Data		
12	collection,		
14 15 16	analysis		
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
32 33 34 35 36 37 38 39	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
40 41 42 43 44 45 46 47 48 40	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
49 50 51 52 53 54 55	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
56 57 58 59 60	Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2 3 4 5 6 7	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	19
, 8 9 10	Methods: Monitoring			
11 12 13 14 15 16 17 18 19 20 21 22 22 23	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	21 21
24 25 26 27 28 29 30	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	P30, appendix ser related to text
31 32 33 34 35 36 27	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	P30, appendix data (protocol) an nining, A
37 38 39 40 41 42	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	P30, appendix fraining (protocol) and si
43 44 45 46	Ethics and dissemination			nilar tech
47 48 49	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	22 22
50 51 52 53 54 55 56 57 58 59 59	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	22

1 2 3 4 5	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	30 appendix (consent)
6 7 8 9 10	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	30 appendix (consent)
11 12 13 14 15 16 17	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	30 appendix (consent) by copyrig
18 19 20 21 22	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	ht, including fo
23 24 25 26 27 28 29	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	30, appendix s (protocol) f to tex
30 31 32 33 34	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	30, appendix and data (protocol) data min
55 36 37 38 39 40 41 42 43 44 43 44 45 46	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	ing, Al training, and similar tech
47 48 49	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	25, and 28 og appendix (protocol)
50 51 52 53 54 55	Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	25, and 28 appendix (protocol)
56 57 58	Appendices			
59 60		For peer rev	/iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtm	I

Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	30 appendix (consent)
Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	30 appendix (consent/protocol)
Notes: • The SPIRIT chec CC-BY-ND 3.0. ⁻¹ https://www.good Penelope.ai	cklist is d This chec dreports.o	istributed under the terms of the Creative Commor cklist was completed on 01. September 2019 using ord/, a tool made by the EQUATOR Network in col	hs Attribution License laboration with
	For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtm	ıl